<html lang="en" class="js"><head><link rel="preload" href="/static/fonts/HardingText-Regular-Web-cecd90984f.woff2" as="font" type="font/woff2" crossorigin=""><script async="" src="https://scripts.webcontentassessor.com/scripts/93dabb8d80079a87fec7bb6f67b807fce90e1688f8957ad7ad152bfd58ea01c2"></script><script type="text/javascript" async="" src="https://pagead2.googlesyndication.com/tag/js/gpt.js"></script><script async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-MRVXSHQ"></script><script type="text/javascript" src="https://www.nature.com/IuEShZpVDqqtW0E8tduG6Z1fNJ3bJ36BmInyU-FyvDOdJqAXDVsZFRaKpV0otfLqkc3M5P20qv2wgK7zqMkhmQ=="></script><script src="https://cmp.nature.com/production_live/en/consent-bundle-8-85.js" onload="initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')"></script>
    <title>RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer | Nature Medicine</title>
    
        
<link rel="alternate" type="application/rss+xml" href="https://www.nature.com/nm.rss">


    
        

        <script id="save-data-connection-testing">
            function hasConnection() {
                return navigator.connection || navigator.mozConnection || navigator.webkitConnection || navigator.msConnection;
            }

            function createLink(src) {
                var preloadLink = document.createElement("link");
                preloadLink.rel = "preload";
                preloadLink.href = src;
                preloadLink.as = "font";
                preloadLink.type = "font/woff2";
                preloadLink.crossOrigin = "";
                document.head.insertBefore(preloadLink, document.head.firstChild);
            }

            var connectionDetail = {
                saveDataEnabled: false,
                slowConnection: false
            };

            var connection = hasConnection();
            if (connection) {
                connectionDetail.saveDataEnabled = connection.saveData;
                if (/\slow-2g|2g/.test(connection.effectiveType)) {
                    connectionDetail.slowConnection = true;
                }
            }

            if (!(connectionDetail.saveDataEnabled || connectionDetail.slowConnection)) {
                createLink("/static/fonts/HardingText-Regular-Web-cecd90984f.woff2");
            } else {
                document.documentElement.classList.add('save-data');
            }
        </script>
    

<link rel="preconnect" href="https://cmp.nature.com" crossorigin="">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="applicable-device" content="pc,mobile">
<meta name="viewport" content="width=device-width,initial-scale=1.0,maximum-scale=5,user-scalable=yes">
<meta name="360-site-verification" content="5a2dc4ab3fcb9b0393241ffbbb490480">

<script data-test="dataLayer">
    window.dataLayer = [{"content":{"category":{"contentType":"article","legacy":{"webtrendsPrimaryArticleType":"research","webtrendsSubjectTerms":"colorectal-cancer;predictive-markers;tumour-biomarkers","webtrendsContentCategory":null,"webtrendsContentCollection":null,"webtrendsContentGroup":"Nature Medicine","webtrendsContentGroupType":null,"webtrendsContentSubGroup":"Article","status":null}},"article":{"doi":"10.1038/s41591-022-01976-z"},"attributes":{"cms":null,"deliveryPlatform":"oscar","copyright":{"open":true,"legacy":{"webtrendsLicenceType":"http://creativecommons.org/licenses/by/4.0/"}}},"contentInfo":{"authors":["Elena Elez","Javier Ros","Jose Fernández","Guillermo Villacampa","Ana Belén Moreno-Cárdenas","Carlota Arenillas","Kinga Bernatowicz","Raquel Comas","Shanshan Li","David Philip Kodack","Roberta Fasani","Ariadna Garcia","Javier Gonzalo-Ruiz","Alejandro Piris-Gimenez","Paolo Nuciforo","Grainne Kerr","Rossana Intini","Aldo Montagna","Marco Maria Germani","Giovanni Randon","Ana Vivancos","Ron Smits","Diana Graus","Raquel Perez-Lopez","Chiara Cremolini","Sara Lonardi","Filippo Pietrantonio","Rodrigo Dienstmann","Josep Tabernero","Rodrigo A. Toledo"],"publishedAt":1662940800,"publishedAtString":"2022-09-12","title":"RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer","legacy":null,"publishedAtTime":null,"documentType":"aplusplus","subjects":"Colorectal cancer,Predictive markers,Tumour biomarkers"},"journal":{"pcode":"nm","title":"nature medicine","volume":"28","issue":"10","id":41591,"publishingModel":"Hybrid Access"},"authorization":{"status":true},"features":[{"name":"furtherReadingSection","present":true}],"collection":null},"page":{"category":{"pageType":"article"},"attributes":{"template":"mosaic","featureFlags":[{"name":"nature-onwards-journey","active":false}],"testGroup":null},"search":null},"privacy":{},"version":"1.0.0","product":null,"session":null,"user":null,"backHalfContent":true,"country":"BR","hasBody":true,"uneditedManuscript":false,"twitterId":["o3xnx","o43y9","o3ef7"],"baiduId":"d38bce82bcb44717ccc29a90c4b781ea","japan":false}];
    window.dataLayer.push({
        ga4MeasurementId: 'G-ERRNTNZ807',
        ga360TrackingId: 'UA-71668177-1',
        twitterId: ['3xnx', 'o43y9', 'o3ef7'],
        baiduId: 'd38bce82bcb44717ccc29a90c4b781ea',
        ga4ServerUrl: 'https://collect.nature.com',
        imprint: 'nature'
    });
</script>

<script>
    (function(w, d) {
        w.config = w.config || {};
        w.config.mustardcut = false;

        
        if (w.matchMedia && w.matchMedia('only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)').matches) {
            w.config.mustardcut = true;
            d.classList.add('js');
            d.classList.remove('grade-c');
            d.classList.remove('no-js');
        }
    })(window, document.documentElement);
</script>
 



     
    
    
        
    
    <style>@media only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark) {  .c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card--major .c-card__title,.c-card__title,.u-h2,.u-h3,h2,h3{font-weight:700;-webkit-font-smoothing:antialiased;font-family:Harding,Palatino,serif;letter-spacing:-.0117156rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card__title,.u-h3,h3{font-size:1.25rem;line-height:1.4rem}.c-reading-companion__figure-title,.u-h4,h4{font-weight:700;-webkit-font-smoothing:antialiased;line-height:1.4rem}html{line-height:1.15;text-size-adjust:100%;box-sizing:border-box;font-size:100%;height:100%;overflow-y:scroll}body{background:#eee;color:#222;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.125rem;line-height:1.76;margin:0;min-height:100%}details,main{display:block}h1{font-size:2em;margin:.67em 0}a,sup{vertical-align:baseline}a{background-color:transparent;color:#069;overflow-wrap:break-word;text-decoration:underline;text-decoration-skip-ink:auto;word-break:break-word}b{font-weight:bolder}sup{font-size:75%;line-height:0;position:relative;top:-.5em}img{border:0;height:auto;max-width:100%;vertical-align:middle}button,input,select{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=submit],button{-webkit-appearance:button}[type=checkbox]{box-sizing:border-box;padding:0}summary{display:list-item}[hidden]{display:none}button{border-radius:0;cursor:pointer;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}h1{font-weight:700;-webkit-font-smoothing:antialiased;font-family:Harding,Palatino,serif;font-size:2rem;letter-spacing:-.0390625rem;line-height:2.25rem}.c-card--major .c-card__title,.u-h2,.u-h3,h2{font-family:Harding,Palatino,serif;letter-spacing:-.0117156rem}.c-card--major .c-card__title,.u-h2,h2{font-weight:700;-webkit-font-smoothing:antialiased;font-size:1.5rem;line-height:1.6rem}.u-h3{font-size:1.25rem}.c-card__title,.c-reading-companion__figure-title,.u-h3,.u-h4,h4,h5,h6{font-weight:700;-webkit-font-smoothing:antialiased;line-height:1.4rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card__title,h3{font-family:Harding,Palatino,serif;font-size:1.25rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,h3{font-weight:700;-webkit-font-smoothing:antialiased;letter-spacing:-.0117156rem;line-height:1.4rem}.c-reading-companion__figure-title,.u-h4,h4{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.125rem;letter-spacing:-.0117156rem}input+label{padding-left:.5em}nav ol,nav ul{list-style:none none}p:empty{display:none}.sans-serif{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.article-page{background:#fff}.c-article-header{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;margin-bottom:40px}.c-article-identifiers{color:#6f6f6f;display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3;list-style:none;margin:0 0 8px;padding:0}.c-article-identifiers__item{border-right:1px solid #6f6f6f;list-style:none;margin-right:8px;padding-right:8px}.c-article-identifiers__item:last-child{border-right:0;margin-right:0;padding-right:0}.c-article-title{font-size:1.5rem;line-height:1.25;margin:0 0 16px}@media only screen and (min-width:768px){.c-article-title{font-size:1.875rem;line-height:1.2}}.c-article-author-list{display:inline;font-size:1rem;list-style:none;margin:0 8px 0 0;padding:0;width:100%}.c-article-author-list__item{display:inline;padding-right:0}.c-article-author-list svg{margin-left:4px}.c-article-author-list__show-more{display:none;margin-right:4px}.c-article-author-list__button,.js .c-article-author-list__item--hide,.js .c-article-author-list__show-more{display:none}.js .c-article-author-list--long .c-article-author-list__show-more,.js .c-article-author-list--long+.c-article-author-list__button{display:inline}@media only screen and (max-width:539px){.js .c-article-author-list__item--hide-small-screen{display:none}.js .c-article-author-list--short .c-article-author-list__show-more,.js .c-article-author-list--short+.c-article-author-list__button{display:inline}}#uptodate-client,.js .c-article-author-list--expanded .c-article-author-list__show-more{display:none!important}.js .c-article-author-list--expanded .c-article-author-list__item--hide-small-screen{display:inline!important}.c-article-author-list__button,.c-button-author-list{background:#ebf1f5;border:4px solid #ebf1f5;border-radius:20px;color:#666;font-size:.875rem;line-height:1.4;padding:2px 11px 2px 8px;text-decoration:none}.c-article-author-list__button svg,.c-button-author-list svg{margin:1px 4px 0 0}.c-article-author-list__button:hover,.c-button-author-list:hover{background:#069;border-color:transparent;color:#fff}.c-article-info-details{font-size:1rem;margin-bottom:8px;margin-top:16px}.c-article-info-details__cite-as{border-left:1px solid #6f6f6f;margin-left:8px;padding-left:8px}.c-article-metrics-bar{display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3}.c-article-metrics-bar__wrapper{margin:16px 0}.c-article-metrics-bar__item{align-items:baseline;border-right:1px solid #6f6f6f;margin-right:8px}.c-article-metrics-bar__item:last-child{border-right:0}.c-article-metrics-bar__count{font-weight:700;margin:0}.c-article-metrics-bar__label{color:#626262;font-style:normal;font-weight:400;margin:0 10px 0 5px}.c-article-metrics-bar__details{margin:0}.c-article-main-column{font-family:Harding,Palatino,serif;margin-right:8.6%;width:60.2%}@media only screen and (max-width:1023px){.c-article-main-column{margin-right:0;width:100%}}.c-article-extras{float:left;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;width:31.2%}@media only screen and (max-width:1023px){.c-article-extras{display:none}}.c-article-associated-content__container .c-article-associated-content__title,.c-article-section__title{border-bottom:2px solid #d5d5d5;font-size:1.25rem;margin:0;padding-bottom:8px}@media only screen and (min-width:768px){.c-article-associated-content__container .c-article-associated-content__title,.c-article-section__title{font-size:1.5rem;line-height:1.24}}.c-article-associated-content__container .c-article-associated-content__title{margin-bottom:8px}.c-article-body p{margin-bottom:24px;margin-top:0}.c-article-section{clear:both}.c-article-section__content{margin-bottom:40px;padding-top:8px}@media only screen and (max-width:1023px){.c-article-section__content{padding-left:0}}.c-article-authors-search{margin-bottom:24px;margin-top:0}.c-article-authors-search__item,.c-article-authors-search__title{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.c-article-authors-search__title{color:#626262;font-size:1.05rem;font-weight:700;margin:0;padding:0}.c-article-authors-search__item{font-size:1rem}.c-article-authors-search__text{margin:0}.c-code-block{border:1px solid #eee;font-family:monospace;margin:0 0 24px;padding:20px}.c-code-block__heading{font-weight:400;margin-bottom:16px}.c-code-block__line{display:block;overflow-wrap:break-word;white-space:pre-wrap}.c-article-share-box__no-sharelink-info{font-size:.813rem;font-weight:700;margin-bottom:24px;padding-top:4px}.c-article-share-box__only-read-input{border:1px solid #d5d5d5;box-sizing:content-box;display:inline-block;font-size:.875rem;font-weight:700;height:24px;margin-bottom:8px;padding:8px 10px}.c-article-share-box__button--link-like{background-color:transparent;border:0;color:#069;cursor:pointer;font-size:.875rem;margin-bottom:8px;margin-left:10px}.c-article-editorial-summary__container{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem}.c-article-editorial-summary__container .c-article-editorial-summary__content p:last-child{margin-bottom:0}.c-article-editorial-summary__container .c-article-editorial-summary__content--less{max-height:9.5rem;overflow:hidden}.c-article-editorial-summary__container .c-article-editorial-summary__button{background-color:#fff;border:0;color:#069;font-size:.875rem;margin-bottom:16px}.c-article-editorial-summary__container .c-article-editorial-summary__button.active,.c-article-editorial-summary__container .c-article-editorial-summary__button.hover,.c-article-editorial-summary__container .c-article-editorial-summary__button:active,.c-article-editorial-summary__container .c-article-editorial-summary__button:hover{text-decoration:underline;text-decoration-skip-ink:auto}.c-article-associated-content__container .c-article-associated-content__collection-label{font-size:.875rem;line-height:1.4}.c-article-associated-content__container .c-article-associated-content__collection-title{line-height:1.3}.c-context-bar{box-shadow:0 0 10px 0 rgba(51,51,51,.2);position:relative;width:100%}.c-context-bar__title{display:none}.c-reading-companion{clear:both;min-height:389px}.c-reading-companion__sticky{max-width:389px}.c-reading-companion__scroll-pane{margin:0;min-height:200px;overflow:hidden auto}.c-reading-companion__tabs{display:flex;flex-flow:row nowrap;font-size:1rem;list-style:none;margin:0 0 8px;padding:0}.c-reading-companion__tabs>li{flex-grow:1}.c-reading-companion__tab{background-color:#eee;border:1px solid #d5d5d5;border-image:initial;border-left-width:0;color:#069;font-size:1rem;padding:8px 8px 8px 15px;text-align:left;width:100%}.c-reading-companion__tabs li:first-child .c-reading-companion__tab{border-left-width:1px}.c-reading-companion__tab--active{background-color:#fff;border-bottom:1px solid #fff;color:#222;font-weight:700}.c-reading-companion__sections-list{list-style:none;padding:0}.c-reading-companion__figures-list,.c-reading-companion__references-list{list-style:none;min-height:389px;padding:0}.c-reading-companion__references-list--numeric{list-style:decimal inside}.c-reading-companion__sections-list{margin:0 0 8px;min-height:50px}.c-reading-companion__section-item{font-size:1rem;padding:0}.c-reading-companion__section-item a{display:block;line-height:1.5;overflow:hidden;padding:8px 0 8px 16px;text-overflow:ellipsis;white-space:nowrap}.c-reading-companion__figure-item{border-top:1px solid #d5d5d5;font-size:1rem;padding:16px 8px 16px 0}.c-reading-companion__figure-item:first-child{border-top:none;padding-top:8px}.c-reading-companion__reference-item{border-top:1px solid #d5d5d5;font-size:1rem;padding:8px 8px 8px 16px}.c-reading-companion__reference-item:first-child{border-top:none}.c-reading-companion__reference-item a{word-break:break-word}.c-reading-companion__reference-citation{display:inline}.c-reading-companion__reference-links{font-size:.813rem;font-weight:700;list-style:none;margin:8px 0 0;padding:0;text-align:right}.c-reading-companion__reference-links>a{display:inline-block;padding-left:8px}.c-reading-companion__reference-links>a:first-child{display:inline-block;padding-left:0}.c-reading-companion__figure-title{display:block;margin:0 0 8px}.c-reading-companion__figure-links{display:flex;justify-content:space-between;margin:8px 0 0}.c-reading-companion__figure-links>a{align-items:center;display:flex}.c-reading-companion__figure-full-link svg{height:.8em;margin-left:2px}.c-reading-companion__panel{border-top:none;display:none;margin-top:0;padding-top:0}.c-cod,.c-reading-companion__panel--active{display:block}.c-cod{font-size:1rem;width:100%}.c-cod__form{background:#ebf0f3}.c-cod__prompt{font-size:1.125rem;line-height:1.3;margin:0 0 24px}.c-cod__label{display:block;margin:0 0 4px}.c-cod__row{display:flex;margin:0 0 16px}.c-cod__row:last-child{margin:0}.c-cod__input{border:1px solid #d5d5d5;border-radius:2px;flex-basis:75%;flex-shrink:0;margin:0;padding:13px}.c-cod__input--submit{background-color:#069;border:1px solid #069;color:#fff;flex-shrink:1;margin-left:8px;transition:background-color .2s ease-out 0s,color .2s ease-out 0s}.c-cod__input--submit-single{flex-basis:100%;flex-shrink:0;margin:0}.c-cod__input--submit:focus,.c-cod__input--submit:hover{background-color:#fff;color:#069}.c-pdf-download__link .u-icon{padding-top:2px}.c-pdf-download{display:flex;margin-bottom:16px;max-height:48px}@media only screen and (min-width:540px){.c-pdf-download{max-height:none}}@media only screen and (min-width:1024px){.c-pdf-download{max-height:48px}}.c-pdf-download__link{display:flex;flex:1 1 0%}.c-pdf-download__link:hover{text-decoration:none}.c-pdf-download__text{padding-right:4px}@media only screen and (max-width:539px){.c-pdf-download__text{text-transform:capitalize}}@media only screen and (min-width:540px){.c-pdf-download__text{padding-right:8px}}.c-context-bar--sticky .c-pdf-download{display:block;margin-bottom:0;white-space:nowrap}@media only screen and (max-width:539px){.c-pdf-download .u-sticky-visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}}.c-pdf-container{display:flex;justify-content:flex-end}@media only screen and (max-width:539px){.c-pdf-container .c-pdf-download{display:flex;flex-basis:100%}}.c-pdf-container .c-pdf-download+.c-pdf-download{margin-left:16px}.c-article-extras .c-pdf-container .c-pdf-download{width:100%}.c-article-extras .c-pdf-container .c-pdf-download+.c-pdf-download{margin-left:0}@media only screen and (min-width:540px){.c-context-bar--sticky .c-pdf-download__link{align-items:center;flex:1 1 183px}}@media only screen and (max-width:320px){.c-context-bar--sticky .c-pdf-download__link{padding:16px}}.article-page--commercial .c-article-main-column .c-pdf-button__container .c-pdf-download{display:none}@media only screen and (max-width:1023px){.article-page--commercial .c-article-main-column .c-pdf-button__container .c-pdf-download{display:block}}.c-recommendations-column-switch .c-meta{margin-top:auto}.c-article-recommendations-card__meta-type,.c-meta .c-meta__item:first-child{font-weight:700}.c-article-metrics__heading a,.c-article-metrics__posts .c-card__title a{color:inherit}.c-article-metrics__posts .c-card__title{font-size:1.05rem}.c-article-metrics__posts .c-card__title+span{color:#6f6f6f;font-size:1rem}p{overflow-wrap:break-word;word-break:break-word}.c-ad{text-align:center}@media only screen and (min-width:320px){.c-ad{padding:8px}}.c-ad--728x90{background-color:#ccc;display:none}.c-ad--728x90 .c-ad__inner{min-height:calc(1.5em + 94px)}@media only screen and (min-width:768px){.js .c-ad--728x90{display:none}.js .u-show-following-ad+.c-ad--728x90{display:block}}.c-ad__label{color:#333;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;font-weight:400;line-height:1.5;margin-bottom:4px}.app-author-list{color:#6f6f6f;font-family:inherit;font-size:1rem;line-height:inherit;list-style:none;margin:0;padding:0}.app-author-list>li,.c-breadcrumbs>li,.c-footer__links>li,.js .app-author-list,.u-list-comma-separated>li,.u-list-inline>li{display:inline}.app-author-list>li:not(:first-child):not(:last-child):before{content:", "}.app-author-list>li:not(:only-child):last-child:before{content:" & "}.app-author-list--compact{font-size:.875rem;line-height:1.4}.app-author-list--truncated>li:not(:only-child):last-child:before{content:" ... "}.js .app-author-list__hide{display:none;visibility:hidden}.js .app-author-list__hide:first-child+*{margin-block-start:0}.c-meta{color:inherit;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;line-height:1.4;list-style:none;margin:0;padding:0}.c-meta--large{font-size:1rem}.c-meta--large .c-meta__item{margin-bottom:8px}.c-meta__item{display:inline-block;margin-bottom:4px}.c-meta__item:not(:last-child){border-right:1px solid #d5d5d5;margin-right:4px;padding-right:4px}@media only screen and (max-width:539px){.c-meta__item--block-sm-max{display:block}.c-meta__item--block-sm-max:not(:last-child){border-right:none;margin-right:0;padding-right:0}}@media only screen and (min-width:1024px){.c-meta__item--block-at-lg{display:block}.c-meta__item--block-at-lg:not(:last-child){border-right:none;margin-right:0;padding-right:0}}.c-meta__type{font-weight:700;text-transform:none}.c-skip-link{background:#069;bottom:auto;color:#fff;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;padding:8px;position:absolute;text-align:center;transform:translateY(-100%);z-index:9999}@media (prefers-reduced-motion:reduce){.c-skip-link{transition:top .3s ease-in-out 0s}}@media print{.c-skip-link{display:none}}.c-skip-link:link{color:#fff}.c-status-message{align-items:center;box-sizing:border-box;display:flex;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;position:relative;width:100%}.c-card__summary>p:last-child,.c-status-message :last-child{margin-bottom:0}.c-status-message--boxed{background-color:#fff;border:1px solid #eee;border-radius:2px;line-height:1.4;padding:16px}.c-status-message__heading{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;font-weight:700}.c-status-message__icon{fill:currentcolor;display:inline-block;flex:0 0 auto;height:1.5em;margin-right:8px;transform:translate(0);vertical-align:text-top;width:1.5em}.c-status-message__icon--top{align-self:flex-start}.c-status-message--info .c-status-message__icon{color:#003f8d}.c-status-message--boxed.c-status-message--info{border-bottom:4px solid #003f8d}.c-status-message--error .c-status-message__icon{color:#c40606}.c-status-message--boxed.c-status-message--error{border-bottom:4px solid #c40606}.c-status-message--success .c-status-message__icon{color:#00b8b0}.c-status-message--boxed.c-status-message--success{border-bottom:4px solid #00b8b0}.c-status-message--warning .c-status-message__icon{color:#edbc53}.c-status-message--boxed.c-status-message--warning{border-bottom:4px solid #edbc53}.c-breadcrumbs{color:#000;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;list-style:none;margin:0;padding:0}.c-breadcrumbs__link{color:#666}svg.c-breadcrumbs__chevron{margin:4px 4px 0;fill:#888;height:10px;width:10px}@media only screen and (max-width:539px){.c-breadcrumbs .c-breadcrumbs__item{display:none}.c-breadcrumbs .c-breadcrumbs__item:last-child,.c-breadcrumbs .c-breadcrumbs__item:nth-last-child(2){display:inline}}.c-card{background-color:transparent;border:0;box-shadow:none;display:flex;flex-direction:column;font-size:14px;min-width:0;overflow:hidden;padding:0;position:relative}.c-card--no-shape{background:0 0;border:0;box-shadow:none}.c-card__image{display:flex;justify-content:center;overflow:hidden;padding-bottom:56.25%;position:relative}@supports (aspect-ratio:1/1){.c-card__image{padding-bottom:0}}.c-card__image img{left:0;min-height:100%;min-width:100%;position:absolute}@supports ((-o-object-fit:cover) or (object-fit:cover)){.c-card__image img{height:100%;object-fit:cover;width:100%}}.c-card__body{flex:1 1 auto;padding:16px}.c-card--no-shape .c-card__body{padding:0}.c-card--no-shape .c-card__body:not(:first-child){padding-top:16px}.c-card__title{letter-spacing:-.01875rem;margin-bottom:8px;margin-top:0}[lang=de] .c-card__title{hyphens:auto}.c-card__summary{line-height:1.4}.c-card__summary>p{margin-bottom:5px}.c-card__summary a{text-decoration:underline}.c-card__link:not(.c-card__link--no-block-link):before{bottom:0;content:"";left:0;position:absolute;right:0;top:0}.c-card--flush .c-card__body{padding:0}.c-card--major{font-size:1rem}.c-card--dark{background-color:#29303c;border-width:0;color:#e3e4e5}.c-card--dark .c-card__title{color:#fff}.c-card--dark .c-card__link,.c-card--dark .c-card__summary a{color:inherit}.c-header{background-color:#fff;border-bottom:5px solid #000;font-size:1rem;line-height:1.4;margin-bottom:16px}.c-header__row{padding:0;position:relative}.c-header__row:not(:last-child){border-bottom:1px solid #eee}.c-header__split{align-items:center;display:flex;justify-content:space-between}.c-header__logo-container{flex:1 1 0px;line-height:0;margin:8px 24px 8px 0}.c-header__logo{transform:translateZ(0)}.c-header__logo img{max-height:32px}.c-header__container{margin:0 auto;max-width:1280px}.c-header__menu{align-items:center;display:flex;flex:0 1 auto;flex-wrap:wrap;font-weight:700;gap:8px 8px;line-height:1.4;list-style:none;margin:0 -8px;padding:0}@media print{.c-header__menu{display:none}}@media only screen and (max-width:1023px){.c-header__menu--hide-lg-max{display:none;visibility:hidden}}.c-header__menu--global{font-weight:400;justify-content:flex-end}.c-header__menu--global svg{display:none;visibility:hidden}.c-header__menu--global svg:first-child+*{margin-block-start:0}@media only screen and (min-width:540px){.c-header__menu--global svg{display:block;visibility:visible}}.c-header__menu--journal{font-size:.875rem;margin:8px 0 8px -8px}@media only screen and (min-width:540px){.c-header__menu--journal{flex-wrap:nowrap;font-size:1rem}}.c-header__item{padding-bottom:0;padding-top:0;position:static}.c-header__item--pipe{border-left:2px solid #eee;padding-left:8px}.c-header__item--padding{padding-bottom:8px;padding-top:8px}@media only screen and (min-width:540px){.c-header__item--dropdown-menu{position:relative}}@media only screen and (min-width:1024px){.c-header__item--hide-lg{display:none;visibility:hidden}}@media only screen and (max-width:767px){.c-header__item--hide-md-max{display:none;visibility:hidden}.c-header__item--hide-md-max:first-child+*{margin-block-start:0}}.c-header__link{align-items:center;color:inherit;display:inline-flex;gap:4px 4px;padding:8px;white-space:nowrap}.c-header__link svg{transition-duration:.2s}.c-header__show-text{display:none;visibility:hidden}.has-tethered .c-header__heading--js-hide:first-child+*{margin-block-start:0}@media only screen and (min-width:540px){.c-header__show-text{display:inline;visibility:visible}}.c-header__dropdown{background-color:#000;border-bottom:1px solid #2f2f2f;color:#eee;font-size:.875rem;line-height:1.2;padding:16px 0}@media print{.c-header__dropdown{display:none}}.c-header__heading{display:inline-block;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.25rem;font-weight:400;line-height:1.4;margin-bottom:8px}.c-header__heading--keyline{border-top:1px solid;border-color:#2f2f2f;margin-top:16px;padding-top:16px;width:100%}.c-header__list{display:flex;flex-wrap:wrap;gap:0 16px;list-style:none;margin:0 -8px}.c-header__flush{margin:0 -8px}.c-header__visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.c-header__search-form{margin-bottom:8px}.c-header__search-layout{display:flex;flex-wrap:wrap;gap:16px 16px}.c-header__search-layout>:first-child{flex:999 1 auto}.c-header__search-layout>*{flex:1 1 auto}.c-header__search-layout--max-width{max-width:720px}.c-header__search-button{align-items:center;background-color:transparent;background-image:none;border:1px solid #fff;border-radius:2px;color:#fff;cursor:pointer;display:flex;font-family:sans-serif;font-size:1rem;justify-content:center;line-height:1.15;margin:0;padding:8px 16px;position:relative;text-decoration:none;transition:all .25s ease 0s,color .25s ease 0s,border-color .25s ease 0s;width:100%}.u-button svg,.u-button--primary svg{fill:currentcolor}.c-header__input,.c-header__select{border:1px solid;border-radius:3px;box-sizing:border-box;font-size:1rem;padding:8px 16px;width:100%}.c-header__select{-webkit-appearance:none;background-image:url("data:image/svg+xml,%3Csvg height='16' viewBox='0 0 16 16' width='16' xmlns='http://www.w3.org/2000/svg'%3E%3Cpath d='m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z' fill='%23333' fill-rule='evenodd' transform='matrix(0 1 -1 0 11 3)'/%3E%3C/svg%3E");background-position:right .7em top 50%;background-repeat:no-repeat;background-size:1em;box-shadow:0 1px 0 1px rgba(0,0,0,.04);display:block;margin:0;max-width:100%;min-width:150px}@media only screen and (min-width:540px){.c-header__menu--journal .c-header__item--dropdown-menu:last-child .c-header__dropdown.has-tethered{left:auto;right:0}}@media only screen and (min-width:768px){.c-header__menu--journal .c-header__item--dropdown-menu:last-child .c-header__dropdown.has-tethered{left:0;right:auto}}.c-header__dropdown.has-tethered{border-bottom:0;border-radius:0 0 2px 2px;left:0;position:absolute;top:100%;transform:translateY(5px);width:100%;z-index:1}@media only screen and (min-width:540px){.c-header__dropdown.has-tethered{transform:translateY(8px);width:auto}}@media only screen and (min-width:768px){.c-header__dropdown.has-tethered{min-width:225px}}.c-header__dropdown--full-width.has-tethered{padding:32px 0 24px;transform:none;width:100%}.has-tethered .c-header__heading--js-hide{display:none;visibility:hidden}.has-tethered .c-header__list--js-stack{flex-direction:column}.has-tethered .c-header__item--keyline,.has-tethered .c-header__list~.c-header__list .c-header__item:first-child{border-top:1px solid #d5d5d5;margin-top:8px;padding-top:8px}.c-header__item--snid-account-widget{display:flex}.c-header__container{padding:0 4px}.c-header__list{padding:0 12px}.c-header__menu .c-header__link{font-size:14px}.c-header__item--snid-account-widget .c-header__link{padding:8px}.c-header__menu--journal{margin-left:0}@media only screen and (min-width:540px){.c-header__container{padding:0 16px}.c-header__menu--journal{margin-left:-8px}.c-header__menu .c-header__link{font-size:16px}.c-header__link--search{gap:13px 13px}}.u-button{align-items:center;background-color:transparent;background-image:none;border:1px solid #069;border-radius:2px;color:#069;cursor:pointer;display:inline-flex;font-family:sans-serif;font-size:1rem;justify-content:center;line-height:1.3;margin:0;padding:8px;position:relative;text-decoration:none;transition:all .25s ease 0s,color .25s ease 0s,border-color .25s ease 0s;width:auto}.u-button--primary{background-color:#069;background-image:none;border:1px solid #069;color:#fff}.u-button--full-width{display:flex;width:100%}.u-display-none{display:none}.js .u-js-hide,.u-hide{display:none;visibility:hidden}.u-hide:first-child+*{margin-block-start:0}.u-visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}@media print{.u-hide-print{display:none}}@media only screen and (min-width:1024px){.u-hide-at-lg{display:none;visibility:hidden}.u-hide-at-lg:first-child+*{margin-block-start:0}}.u-clearfix:after,.u-clearfix:before{content:"";display:table}.u-clearfix:after{clear:both}.u-color-open-access{color:#b74616}.u-float-left{float:left}.u-icon{fill:currentcolor;display:inline-block;height:1em;transform:translate(0);vertical-align:text-top;width:1em}.u-full-height{height:100%}.u-list-reset{list-style:none;margin:0;padding:0}.u-container{margin:0 auto;max-width:1280px;padding:0 16px}.u-justify-content-space-between{justify-content:space-between}.u-mt-32{margin-top:32px}.u-mb-8{margin-bottom:8px}.u-mb-16{margin-bottom:16px}.u-mb-24{margin-bottom:24px}.u-mb-32{margin-bottom:32px}.c-nature-box svg+.c-article__button-text,.u-ml-8{margin-left:8px}.u-pa-16{padding:16px}html *,html :after,html :before{box-sizing:inherit}.c-article-section__title,.c-article-title{font-weight:700}.c-card__title{line-height:1.4em}.c-article__button{background-color:#069;border:1px solid #069;border-radius:2px;color:#fff;display:flex;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;line-height:1.4;margin-bottom:16px;padding:13px;transition:background-color .2s ease-out 0s,color .2s ease-out 0s}.c-article__button,.c-article__button:hover{text-decoration:none}.c-article__button--inverted,.c-article__button:hover{background-color:#fff;color:#069}.c-article__button--inverted:hover{background-color:#069;color:#fff}.c-header__link{text-decoration:inherit}.grade-c-hide{display:block}.c-nature-box{background-color:#fff;border:1px solid #d5d5d5;border-radius:2px;box-shadow:0 0 5px 0 rgba(51,51,51,.1);line-height:1.3;margin-bottom:24px;padding:16px 16px 3px}.c-nature-box__text{font-size:1rem;margin-bottom:16px}.c-nature-box--access-to-pdf{display:none}@media only screen and (min-width:1024px){.c-nature-box--mobile{display:none}}.c-nature-box .c-pdf-download{margin-bottom:16px!important}.c-nature-box--version{background-color:#eee}.c-nature-box__wrapper{transform:translateZ(0)}.c-nature-box__wrapper--placeholder{min-height:165px}.c-pdf-download__link{padding:13px 24px} } </style>




    
        <link data-test="critical-css-handler" data-inline-css-source="critical-css" rel="stylesheet" href="/static/css/enhanced-article-nature-branded-1dd982e2cc.css" media="only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)" onload="this.media='only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)';this.onload=null">
    
    <noscript>
        <link rel="stylesheet" type="text/css" href="/static/css/enhanced-article-nature-branded-1dd982e2cc.css" media="only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)">
    </noscript>

<link rel="stylesheet" type="text/css" href="/static/css/article-print-c9121fecab.css" media="print">
    



<link rel="apple-touch-icon" sizes="180x180" href="/static/images/favicons/nature/apple-touch-icon-f39cb19454.png">
<link rel="icon" type="image/png" sizes="48x48" href="/static/images/favicons/nature/favicon-48x48-b52890008c.png">
<link rel="icon" type="image/png" sizes="32x32" href="/static/images/favicons/nature/favicon-32x32-3fe59ece92.png">
<link rel="icon" type="image/png" sizes="16x16" href="/static/images/favicons/nature/favicon-16x16-951651ab72.png">
<link rel="manifest" href="/static/manifest.json" crossorigin="use-credentials">
<link rel="mask-icon" href="/static/images/favicons/nature/safari-pinned-tab-69bff48fe6.svg" color="#000000">
<link rel="shortcut icon" href="/static/images/favicons/nature/favicon.ico">
<meta name="msapplication-TileColor" content="#000000">
<meta name="msapplication-config" content="/static/browserconfig.xml">
<meta name="theme-color" content="#000000">
<meta name="application-name" content="Nature">


<script>
    (function () {
        if ( typeof window.CustomEvent === "function" ) return false;
        function CustomEvent ( event, params ) {
            params = params || { bubbles: false, cancelable: false, detail: null };
            var evt = document.createEvent( 'CustomEvent' );
            evt.initCustomEvent( event, params.bubbles, params.cancelable, params.detail );
            return evt;
        }

        CustomEvent.prototype = window.Event.prototype;

        window.CustomEvent = CustomEvent;
    })();
</script>



<!-- Google Tag Manager -->
<script data-test="gtm-head">
    window.initGTM = function() {
        if (window.config.mustardcut) {
            (function (w, d, s, l, i) {
                w[l] = w[l] || [];
                w[l].push({'gtm.start': new Date().getTime(), event: 'gtm.js'});
                var f = d.getElementsByTagName(s)[0],
                        j = d.createElement(s),
                        dl = l != 'dataLayer' ? '&l=' + l : '';
                j.async = true;
                j.src = 'https://www.googletagmanager.com/gtm.js?id=' + i + dl;
                f.parentNode.insertBefore(j, f);
            })(window, document, 'script', 'dataLayer', 'GTM-MRVXSHQ');
        }
    }
</script>
<!-- End Google Tag Manager -->

    <script>
    (function(w,d,t) {
        function cc() {
            var h = w.location.hostname;
            if (h.indexOf('preview-www.nature.com') > -1) return;

            var e = d.createElement(t),
                    s = d.getElementsByTagName(t)[0];

            if (h.indexOf('nature.com') > -1) {
                if (h.indexOf('test-www.nature.com') > -1) {
                    e.src = 'https://cmp.nature.com/production_live/en/consent-bundle-8-85.js';
                    e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')");
                } else {
                    e.src = 'https://cmp.nature.com/production_live/en/consent-bundle-8-85.js';
                    e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')");
                }
            } else {
                e.src = '/static/js/cookie-consent-es5-bundle-cb57c2c98a.js';
                e.setAttribute('data-consent', h);
            }
            s.insertAdjacentElement('afterend', e);
        }

        cc();
    })(window,document,'script');
</script>


<script id="js-position0">
    (function(w, d) {
        w.idpVerifyPrefix = 'https://verify.nature.com';
        w.ra21Host = 'https://wayf.springernature.com';
        var moduleSupport = (function() {
            return 'noModule' in d.createElement('script');
        })();

        if (w.config.mustardcut === true) {
            w.loader = {
                index: 0,
                registered: [],
                scripts: [
                    
                        {src: '/static/js/global-article-es6-bundle-c8a573ca90.js', test: 'global-article-js', module: true},
                        {src: '/static/js/global-article-es5-bundle-d17603b9e9.js', test: 'global-article-js', nomodule: true},
                        {src: '/static/js/shared-es6-bundle-e9d2061c95.js', test: 'shared-js', module: true},
                        {src: '/static/js/shared-es5-bundle-1cbf3a8b56.js', test: 'shared-js', nomodule: true},
                        {src: '/static/js/header-150-es6-bundle-5bb959eaa1.js', test: 'header-150-js', module: true},
                        {src: '/static/js/header-150-es5-bundle-994fde5b1d.js', test: 'header-150-js', nomodule: true}
                    
                ].filter(function (s) {
                    if (s.src === null) return false;
                    if (moduleSupport && s.nomodule) return false;
                    return !(!moduleSupport && s.module);
                }),

                register: function (value) {
                    this.registered.push(value);
                },

                ready: function () {
                    if (this.registered.length === this.scripts.length) {
                        this.registered.forEach(function (fn) {
                            if (typeof fn === 'function') {
                                setTimeout(fn, 0); 
                            }
                        });
                        this.ready = function () {};
                    }
                },

                insert: function (s) {
                    var t = d.getElementById('js-position' + this.index);
                    if (t && t.insertAdjacentElement) {
                        t.insertAdjacentElement('afterend', s);
                    } else {
                        d.head.appendChild(s);
                    }
                    ++this.index;
                },

                createScript: function (script, beforeLoad) {
                    var s = d.createElement('script');
                    s.id = 'js-position' + (this.index + 1);
                    s.setAttribute('data-test', script.test);
                    if (beforeLoad) {
                        s.defer = 'defer';
                        s.onload = function () {
                            if (script.noinit) {
                                loader.register(true);
                            }
                            if (d.readyState === 'interactive' || d.readyState === 'complete') {
                                loader.ready();
                            }
                        };
                    } else {
                        s.async = 'async';
                    }
                    s.src = script.src;
                    return s;
                },

                init: function () {
                    this.scripts.forEach(function (s) {
                        loader.insert(loader.createScript(s, true));
                    });

                    d.addEventListener('DOMContentLoaded', function () {
                        loader.ready();
                        var conditionalScripts;
                        
                            conditionalScripts = [
                                {match: 'div[data-pan-container]', src: '/static/js/pan-zoom-es6-bundle-464a2af269.js', test: 'pan-zoom-js',  module: true },
                                {match: 'div[data-pan-container]', src: '/static/js/pan-zoom-es5-bundle-98fb9b653b.js', test: 'pan-zoom-js',  nomodule: true },
                                {match: 'math,span.mathjax-tex', src: '/static/js/math-es6-bundle-23597ae350.js', test: 'math-js', module: true},
                                {match: 'math,span.mathjax-tex', src: '/static/js/math-es5-bundle-6532c6f78b.js', test: 'math-js', nomodule: true}
                            ];
                        

                        if (conditionalScripts) {
                            conditionalScripts.filter(function (script) {
                                return !!document.querySelector(script.match) && !((moduleSupport && script.nomodule) || (!moduleSupport && script.module));
                            }).forEach(function (script) {
                                loader.insert(loader.createScript(script));
                            });
                        }
                    }, false);
                }
            };
            loader.init();
        }
    })(window, document);
</script><script id="js-position1" data-test="global-article-js" defer="" src="/static/js/global-article-es6-bundle-c8a573ca90.js"></script><script id="js-position2" data-test="shared-js" defer="" src="/static/js/shared-es6-bundle-e9d2061c95.js"></script><script id="js-position3" data-test="header-150-js" defer="" src="/static/js/header-150-es6-bundle-5bb959eaa1.js"></script>










<meta name="robots" content="noarchive">
<meta name="access" content="Yes">


<link rel="search" href="https://www.nature.com/search">
<link rel="search" href="https://www.nature.com/opensearch/opensearch.xml" type="application/opensearchdescription+xml" title="nature.com">
<link rel="search" href="https://www.nature.com/opensearch/request" type="application/sru+xml" title="nature.com">





    
    <script type="application/ld+json">{"mainEntity":{"headline":"RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer","description":"Anti-BRAF/EGFR therapy was recently approved for the treatment of metastatic BRAFV600E colorectal cancer (mCRCBRAF-V600E). However, a large fraction of patients do not respond, underscoring the need to identify molecular determinants of treatment response. Using whole-exome sequencing in a discovery cohort of patients with mCRCBRAF-V600E treated with anti-BRAF/EGFR therapy, we found that inactivating mutations in RNF43, a negative regulator of WNT, predict improved response rates and survival outcomes in patients with microsatellite-stable (MSS) tumors. Analysis of an independent validation cohort confirmed the relevance of RNF43 mutations to predicting clinical benefit (72.7% versus 30.8%; P = 0.03), as well as longer progression-free survival (hazard ratio (HR), 0.30; 95% confidence interval (CI), 0.12–0.75; P = 0.01) and overall survival (HR, 0.26; 95% CI, 0.10–0.71; P = 0.008), in patients with MSS-RNF43mutated versus MSS-RNF43wild-type tumors. Microsatellite-instable tumors invariably carried a wild-type-like RNF43 genotype encoding p.G659fs and presented an intermediate response profile. We found no association of RNF43 mutations with patient outcomes in a control cohort of patients with MSS-mCRCBRAF-V600E tumors not exposed to anti-BRAF targeted therapies. Overall, our findings suggest a cross-talk between the MAPK and WNT pathways that may modulate the antitumor activity of anti-BRAF/EGFR therapy and uncover predictive biomarkers to optimize the clinical management of these patients. The presence of inactivating mutations in RNF43, a negative regulator of WNT, in tumor cells predicts improved response rates and survival outcomes in patients with metastatic BRAFV600E colorectal cancer treated with anti-BRAF/EGFR therapy.","datePublished":"2022-09-12T00:00:00Z","dateModified":"2022-09-12T00:00:00Z","pageStart":"2162","pageEnd":"2170","license":"http://creativecommons.org/licenses/by/4.0/","sameAs":"https://doi.org/10.1038/s41591-022-01976-z","keywords":["Colorectal cancer","Predictive markers","Tumour biomarkers","Biomedicine","general","Cancer Research","Metabolic Diseases","Infectious Diseases","Molecular Medicine","Neurosciences"],"image":["https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig1_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig2_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig3_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig4_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig5_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig6_HTML.png"],"isPartOf":{"name":"Nature Medicine","issn":["1546-170X","1078-8956"],"volumeNumber":"28","@type":["Periodical","PublicationVolume"]},"publisher":{"name":"Nature Publishing Group US","logo":{"url":"https://www.springernature.com/app-sn/public/images/logo-springernature.png","@type":"ImageObject"},"@type":"Organization"},"author":[{"name":"Elena Elez","url":"http://orcid.org/0000-0002-4653-6324","affiliation":[{"name":"Vall d’Hebron University Hospital, Vall d’Hebron Barcelona Hospital Campus","address":{"name":"Medical Oncology Department, Vall d’Hebron University Hospital, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain","@type":"PostalAddress"},"@type":"Organization"},{"name":"Vall d’Hebron Barcelona Hospital Campus","address":{"name":"Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain","@type":"PostalAddress"},"@type":"Organization"}],"email":"meelez@vhio.net","@type":"Person"},{"name":"Javier Ros","url":"http://orcid.org/0000-0002-8137-5415","affiliation":[{"name":"Vall d’Hebron University Hospital, Vall d’Hebron Barcelona Hospital Campus","address":{"name":"Medical Oncology Department, Vall d’Hebron University Hospital, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain","@type":"PostalAddress"},"@type":"Organization"},{"name":"Vall d’Hebron Barcelona Hospital Campus","address":{"name":"Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain","@type":"PostalAddress"},"@type":"Organization"},{"name":"Università degli Studi della Campania Luigi Vanvitelli","address":{"name":"Oncologia Medica, Dipartimento di Medicina di Precisione, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Jose Fernández","affiliation":[{"name":"Vall d’Hebron Barcelona Hospital Campus","address":{"name":"Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Guillermo Villacampa","affiliation":[{"name":"Vall d’Hebron Barcelona Hospital Campus","address":{"name":"Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Ana Belén Moreno-Cárdenas","affiliation":[{"name":"Vall d’Hebron Barcelona Hospital Campus","address":{"name":"Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Carlota Arenillas","affiliation":[{"name":"Vall d’Hebron Barcelona Hospital Campus","address":{"name":"Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain","@type":"PostalAddress"},"@type":"Organization"},{"name":"Institute of Health Carlos III (ISCIII)","address":{"name":"Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Institute of Health Carlos III (ISCIII), Madrid, Spain","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Kinga Bernatowicz","url":"http://orcid.org/0000-0001-9166-1709","affiliation":[{"name":"Vall d’Hebron Barcelona Hospital Campus","address":{"name":"Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Raquel Comas","affiliation":[{"name":"Vall d’Hebron Barcelona Hospital Campus","address":{"name":"Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Shanshan Li","affiliation":[{"name":"Erasmus MC-University Medical Center","address":{"name":"Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, the Netherlands","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"David Philip Kodack","affiliation":[{"name":"Novartis Institutes for BioMedical Research","address":{"name":"Novartis Institutes for BioMedical Research, Cambridge, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Roberta Fasani","affiliation":[{"name":"Vall d’Hebron Barcelona Hospital Campus","address":{"name":"Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Ariadna Garcia","affiliation":[{"name":"Vall d’Hebron Barcelona Hospital Campus","address":{"name":"Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Javier Gonzalo-Ruiz","url":"http://orcid.org/0000-0003-4342-3815","affiliation":[{"name":"Vall d’Hebron Barcelona Hospital Campus","address":{"name":"Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Alejandro Piris-Gimenez","affiliation":[{"name":"Vall d’Hebron Barcelona Hospital Campus","address":{"name":"Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Paolo Nuciforo","url":"http://orcid.org/0000-0003-1380-0990","affiliation":[{"name":"Vall d’Hebron Barcelona Hospital Campus","address":{"name":"Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Grainne Kerr","affiliation":[{"name":"Novartis Institutes for Biomedical Research, Novartis","address":{"name":"Oncology Department, Novartis Institutes for Biomedical Research, Novartis, Basel, Switzerland","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Rossana Intini","affiliation":[{"name":"Veneto Institute of Oncology IRCCS","address":{"name":"Department of Oncology, Veneto Institute of Oncology IRCCS, Padova, Italy","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Aldo Montagna","affiliation":[{"name":"Veneto Institute of Oncology IRCCS","address":{"name":"Department of Oncology, Veneto Institute of Oncology IRCCS, Padova, Italy","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Marco Maria Germani","affiliation":[{"name":"Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Department of Trans-lational Research and New Technologies in Medicine, University of Pisa","address":{"name":"Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Department of Trans-lational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Giovanni Randon","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori","address":{"name":"Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Ana Vivancos","affiliation":[{"name":"Vall d’Hebron Barcelona Hospital Campus","address":{"name":"Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Ron Smits","url":"http://orcid.org/0000-0001-6798-3206","affiliation":[{"name":"Erasmus MC-University Medical Center","address":{"name":"Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, the Netherlands","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Diana Graus","affiliation":[{"name":"Novartis Institutes for Biomedical Research, Novartis","address":{"name":"Oncology Department, Novartis Institutes for Biomedical Research, Novartis, Basel, Switzerland","@type":"PostalAddress"},"@type":"Organization"},{"name":"Ridgeline Discovery","address":{"name":"Ridgeline Discovery, Basel, Switzerland","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Raquel Perez-Lopez","affiliation":[{"name":"Vall d’Hebron Barcelona Hospital Campus","address":{"name":"Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain","@type":"PostalAddress"},"@type":"Organization"},{"name":"Vall d’Hebron University Hospital, Vall d’Hebron Barcelona Hospital Campus","address":{"name":"Radiology Department, Vall d’Hebron University Hospital, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Chiara Cremolini","affiliation":[{"name":"Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Department of Trans-lational Research and New Technologies in Medicine, University of Pisa","address":{"name":"Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Department of Trans-lational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Sara Lonardi","url":"http://orcid.org/0000-0002-7593-8138","affiliation":[{"name":"Veneto Institute of Oncology IRCCS","address":{"name":"Department of Oncology, Veneto Institute of Oncology IRCCS, Padova, Italy","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Filippo Pietrantonio","url":"http://orcid.org/0000-0002-8530-8420","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori","address":{"name":"Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Rodrigo Dienstmann","affiliation":[{"name":"Vall d’Hebron Barcelona Hospital Campus","address":{"name":"Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Josep Tabernero","url":"http://orcid.org/0000-0002-2495-8139","affiliation":[{"name":"Vall d’Hebron University Hospital, Vall d’Hebron Barcelona Hospital Campus","address":{"name":"Medical Oncology Department, Vall d’Hebron University Hospital, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain","@type":"PostalAddress"},"@type":"Organization"},{"name":"Vall d’Hebron Barcelona Hospital Campus","address":{"name":"Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain","@type":"PostalAddress"},"@type":"Organization"},{"name":"Institute of Health Carlos III (ISCIII)","address":{"name":"Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Institute of Health Carlos III (ISCIII), Madrid, Spain","@type":"PostalAddress"},"@type":"Organization"},{"name":"UVic-UCC, IOB-Quirón","address":{"name":"UVic-UCC, IOB-Quirón, Barcelona, Spain","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Rodrigo A. Toledo","affiliation":[{"name":"Vall d’Hebron Barcelona Hospital Campus","address":{"name":"Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain","@type":"PostalAddress"},"@type":"Organization"},{"name":"Institute of Health Carlos III (ISCIII)","address":{"name":"Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Institute of Health Carlos III (ISCIII), Madrid, Spain","@type":"PostalAddress"},"@type":"Organization"}],"email":"rtoledo@vhio.net","@type":"Person"}],"isAccessibleForFree":true,"@type":"ScholarlyArticle"},"@context":"https://schema.org","@type":"WebPage"}</script>




    
    
    


    
    <link rel="canonical" href="https://www.nature.com/articles/s41591-022-01976-z">
    
    
    <meta name="journal_id" content="41591">
    <meta name="dc.title" content="RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer">
    <meta name="dc.source" content="Nature Medicine 2022 28:10">
    <meta name="dc.format" content="text/html">
    <meta name="dc.publisher" content="Nature Publishing Group">
    <meta name="dc.date" content="2022-09-12">
    <meta name="dc.type" content="OriginalPaper">
    <meta name="dc.language" content="En">
    <meta name="dc.copyright" content="2022 The Author(s)">
    <meta name="dc.rights" content="2022 The Author(s)">
    <meta name="dc.rightsAgent" content="journalpermissions@springernature.com">
    <meta name="dc.description" content="Anti-BRAF/EGFR therapy was recently approved for the treatment of metastatic BRAFV600E colorectal cancer (mCRCBRAF-V600E). However, a large fraction of patients do not respond, underscoring the need to identify molecular determinants of treatment response. Using whole-exome sequencing in a discovery cohort of patients with mCRCBRAF-V600E treated with anti-BRAF/EGFR therapy, we found that inactivating mutations in RNF43, a negative regulator of WNT, predict improved response rates and survival outcomes in patients with microsatellite-stable (MSS) tumors. Analysis of an independent validation cohort confirmed the relevance of RNF43 mutations to predicting clinical benefit (72.7% versus 30.8%; P = 0.03), as well as longer progression-free survival (hazard ratio (HR), 0.30; 95% confidence interval (CI), 0.12–0.75; P = 0.01) and overall survival (HR, 0.26; 95% CI, 0.10–0.71; P = 0.008), in patients with MSS-RNF43mutated versus MSS-RNF43wild-type tumors. Microsatellite-instable tumors invariably carried a wild-type-like RNF43 genotype encoding p.G659fs and presented an intermediate response profile. We found no association of RNF43 mutations with patient outcomes in a control cohort of patients with MSS-mCRCBRAF-V600E tumors not exposed to anti-BRAF targeted therapies. Overall, our findings suggest a cross-talk between the MAPK and WNT pathways that may modulate the antitumor activity of anti-BRAF/EGFR therapy and uncover predictive biomarkers to optimize the clinical management of these patients. The presence of inactivating mutations in RNF43, a negative regulator of WNT, in tumor cells predicts improved response rates and survival outcomes in patients with metastatic BRAFV600E colorectal cancer treated with anti-BRAF/EGFR therapy.">
    <meta name="prism.issn" content="1546-170X">
    <meta name="prism.publicationName" content="Nature Medicine">
    <meta name="prism.publicationDate" content="2022-09-12">
    <meta name="prism.volume" content="28">
    <meta name="prism.number" content="10">
    <meta name="prism.section" content="OriginalPaper">
    <meta name="prism.startingPage" content="2162">
    <meta name="prism.endingPage" content="2170">
    <meta name="prism.copyright" content="2022 The Author(s)">
    <meta name="prism.rightsAgent" content="journalpermissions@springernature.com">
    <meta name="prism.url" content="https://www.nature.com/articles/s41591-022-01976-z">
    <meta name="prism.doi" content="doi:10.1038/s41591-022-01976-z">
    <meta name="citation_pdf_url" content="https://www.nature.com/articles/s41591-022-01976-z.pdf">
    <meta name="citation_fulltext_html_url" content="https://www.nature.com/articles/s41591-022-01976-z">
    <meta name="citation_journal_title" content="Nature Medicine">
    <meta name="citation_journal_abbrev" content="Nat Med">
    <meta name="citation_publisher" content="Nature Publishing Group">
    <meta name="citation_issn" content="1546-170X">
    <meta name="citation_title" content="RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer">
    <meta name="citation_volume" content="28">
    <meta name="citation_issue" content="10">
    <meta name="citation_publication_date" content="2022/10">
    <meta name="citation_online_date" content="2022/09/12">
    <meta name="citation_firstpage" content="2162">
    <meta name="citation_lastpage" content="2170">
    <meta name="citation_article_type" content="Article">
    <meta name="citation_fulltext_world_readable" content="">
    <meta name="citation_language" content="en">
    <meta name="dc.identifier" content="doi:10.1038/s41591-022-01976-z">
    <meta name="DOI" content="10.1038/s41591-022-01976-z">
    <meta name="size" content="188497">
    <meta name="citation_doi" content="10.1038/s41591-022-01976-z">
    <meta name="citation_springer_api_url" content="http://api.springer.com/xmldata/jats?q=doi:10.1038/s41591-022-01976-z&amp;api_key=">
    <meta name="description" content="Anti-BRAF/EGFR therapy was recently approved for the treatment of metastatic BRAFV600E colorectal cancer (mCRCBRAF-V600E). However, a large fraction of patients do not respond, underscoring the need to identify molecular determinants of treatment response. Using whole-exome sequencing in a discovery cohort of patients with mCRCBRAF-V600E treated with anti-BRAF/EGFR therapy, we found that inactivating mutations in RNF43, a negative regulator of WNT, predict improved response rates and survival outcomes in patients with microsatellite-stable (MSS) tumors. Analysis of an independent validation cohort confirmed the relevance of RNF43 mutations to predicting clinical benefit (72.7% versus 30.8%; P = 0.03), as well as longer progression-free survival (hazard ratio (HR), 0.30; 95% confidence interval (CI), 0.12–0.75; P = 0.01) and overall survival (HR, 0.26; 95% CI, 0.10–0.71; P = 0.008), in patients with MSS-RNF43mutated versus MSS-RNF43wild-type tumors. Microsatellite-instable tumors invariably carried a wild-type-like RNF43 genotype encoding p.G659fs and presented an intermediate response profile. We found no association of RNF43 mutations with patient outcomes in a control cohort of patients with MSS-mCRCBRAF-V600E tumors not exposed to anti-BRAF targeted therapies. Overall, our findings suggest a cross-talk between the MAPK and WNT pathways that may modulate the antitumor activity of anti-BRAF/EGFR therapy and uncover predictive biomarkers to optimize the clinical management of these patients. The presence of inactivating mutations in RNF43, a negative regulator of WNT, in tumor cells predicts improved response rates and survival outcomes in patients with metastatic BRAFV600E colorectal cancer treated with anti-BRAF/EGFR therapy.">
    <meta name="dc.creator" content="Elez, Elena">
    <meta name="dc.creator" content="Ros, Javier">
    <meta name="dc.creator" content="Fernández, Jose">
    <meta name="dc.creator" content="Villacampa, Guillermo">
    <meta name="dc.creator" content="Moreno-Cárdenas, Ana Belén">
    <meta name="dc.creator" content="Arenillas, Carlota">
    <meta name="dc.creator" content="Bernatowicz, Kinga">
    <meta name="dc.creator" content="Comas, Raquel">
    <meta name="dc.creator" content="Li, Shanshan">
    <meta name="dc.creator" content="Kodack, David Philip">
    <meta name="dc.creator" content="Fasani, Roberta">
    <meta name="dc.creator" content="Garcia, Ariadna">
    <meta name="dc.creator" content="Gonzalo-Ruiz, Javier">
    <meta name="dc.creator" content="Piris-Gimenez, Alejandro">
    <meta name="dc.creator" content="Nuciforo, Paolo">
    <meta name="dc.creator" content="Kerr, Grainne">
    <meta name="dc.creator" content="Intini, Rossana">
    <meta name="dc.creator" content="Montagna, Aldo">
    <meta name="dc.creator" content="Germani, Marco Maria">
    <meta name="dc.creator" content="Randon, Giovanni">
    <meta name="dc.creator" content="Vivancos, Ana">
    <meta name="dc.creator" content="Smits, Ron">
    <meta name="dc.creator" content="Graus, Diana">
    <meta name="dc.creator" content="Perez-Lopez, Raquel">
    <meta name="dc.creator" content="Cremolini, Chiara">
    <meta name="dc.creator" content="Lonardi, Sara">
    <meta name="dc.creator" content="Pietrantonio, Filippo">
    <meta name="dc.creator" content="Dienstmann, Rodrigo">
    <meta name="dc.creator" content="Tabernero, Josep">
    <meta name="dc.creator" content="Toledo, Rodrigo A.">
    <meta name="dc.subject" content="Colorectal cancer">
    <meta name="dc.subject" content="Predictive markers">
    <meta name="dc.subject" content="Tumour biomarkers">
    <meta name="citation_reference" content="citation_journal_title=Nat. Rev. Clin. Oncol.; citation_title=Precision oncology in metastatic colorectal cancer—from biology to medicine; citation_author=F Nicolantonio; citation_volume=18; citation_publication_date=2021; citation_pages=506-525; citation_doi=10.1038/s41571-021-00495-z; citation_id=CR1">
    <meta name="citation_reference" content="citation_journal_title=Clin. Colorectal Cancer; citation_title=Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer; citation_author=V Morris; citation_volume=13; citation_publication_date=2014; citation_pages=164-171; citation_doi=10.1016/j.clcc.2014.06.001; citation_id=CR2">
    <meta name="citation_reference" content="citation_journal_title=Lancet Oncol.; citation_title=FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study; citation_author=C Cremolini; citation_volume=16; citation_publication_date=2015; citation_pages=1306-1315; citation_doi=10.1016/S1470-2045(15)00122-9; citation_id=CR3">
    <meta name="citation_reference" content="citation_journal_title=Cancer Cell; citation_title=Clinical sequencing defines the genomic landscape of metastatic colorectal cancer; citation_author=R Yaeger; citation_volume=33; citation_publication_date=2018; citation_pages=125-136; citation_doi=10.1016/j.ccell.2017.12.004; citation_id=CR4">
    <meta name="citation_reference" content="citation_journal_title=Cell; citation_title=Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer; citation_author=KA Hoadley; citation_volume=173; citation_publication_date=2018; citation_pages=291-304; citation_doi=10.1016/j.cell.2018.03.022; citation_id=CR5">
    <meta name="citation_reference" content="citation_journal_title=Nature; citation_title=Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors; citation_author=BK Koo; citation_volume=488; citation_publication_date=2012; citation_pages=665-669; citation_doi=10.1038/nature11308; citation_id=CR6">
    <meta name="citation_reference" content="citation_journal_title=Cell; citation_title=Wnt/β-catenin signaling, disease, and emerging therapeutic modalities; citation_author=R Nusse, H Clevers; citation_volume=169; citation_publication_date=2017; citation_pages=985-999; citation_doi=10.1016/j.cell.2017.05.016; citation_id=CR7">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Vemurafenib in multiple nonmelanoma cancers with BRAFV600 mutations; citation_author=DM Hyman; citation_volume=373; citation_publication_date=2015; citation_pages=726-736; citation_doi=10.1056/NEJMoa1502309; citation_id=CR8">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Inhibition of mutated, activated BRAF in metastatic melanoma; citation_author=KT Flaherty; citation_volume=363; citation_publication_date=2010; citation_pages=809-819; citation_doi=10.1056/NEJMoa1002011; citation_id=CR9">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Survival in BRAFV600-mutant advanced melanoma treated with vemurafenib; citation_author=JA Sosman; citation_volume=366; citation_publication_date=2012; citation_pages=707-714; citation_doi=10.1056/NEJMoa1112302; citation_id=CR10">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Oncol.; citation_title=PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors; citation_author=S Kopetz; citation_volume=28; citation_publication_date=2010; citation_pages=3534; citation_doi=10.1200/jco.2010.28.15_suppl.3534; citation_id=CR11">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Oncol.; citation_title=Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer; citation_author=S Kopetz; citation_volume=33; citation_publication_date=2015; citation_pages=4032-4038; citation_doi=10.1200/JCO.2015.63.2497; citation_id=CR12">
    <meta name="citation_reference" content="citation_journal_title=Nature; citation_title=Unresponsiveness of colon cancer to BRAFV600E inhibition through feedback activation of EGFR; citation_author=A Prahallad; citation_volume=483; citation_publication_date=2012; citation_pages=100-103; citation_doi=10.1038/nature10868; citation_id=CR13">
    <meta name="citation_reference" content="citation_journal_title=Cancer Discov.; citation_title=EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib; citation_author=RB Corcoran; citation_volume=2; citation_publication_date=2012; citation_pages=227-235; citation_doi=10.1158/2159-8290.CD-11-0341; citation_id=CR14">
    <meta name="citation_reference" content="citation_journal_title=Cancer Discov.; citation_title=A phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic BRAF-mutant colorectal cancer; citation_author=R Geel; citation_volume=7; citation_publication_date=2017; citation_pages=610-619; citation_doi=10.1158/2159-8290.CD-16-0795; citation_id=CR15">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Oncol.; citation_title=Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406); citation_author=S Kopetz; citation_volume=39; citation_publication_date=2021; citation_pages=285-294; citation_doi=10.1200/JCO.20.01994; citation_id=CR16">
    <meta name="citation_reference" content="citation_journal_title=Cancer Discov.; citation_title=Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations; citation_author=LG Ahronian; citation_volume=5; citation_publication_date=2015; citation_pages=358-367; citation_doi=10.1158/2159-8290.CD-14-1518; citation_id=CR17">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Encorafenib, binimetinib, and cetuximab in BRAFV600E-mutated colorectal cancer; citation_author=S Kopetz; citation_volume=381; citation_publication_date=2019; citation_pages=1632-1643; citation_doi=10.1056/NEJMoa1908075; citation_id=CR18">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Oncol.; citation_title=Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAFV600E-mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON colorectal cancer study; citation_author=E Cutsem; citation_volume=37; citation_publication_date=2019; citation_pages=1460-1469; citation_doi=10.1200/JCO.18.02459; citation_id=CR19">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Oncol.; citation_title=Encorafenib plus cetuximab as a new standard of care for previously treated BRAFV600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study; citation_author=J Tabernero; citation_volume=39; citation_publication_date=2021; citation_pages=273-284; citation_doi=10.1200/JCO.20.02088; citation_id=CR20">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Oncol.; citation_title=Molecular correlates of clinical benefit in previously treated patients (pts) with BRAFV600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study; citation_author=S Kopetz; citation_volume=39; citation_publication_date=2021; citation_pages=3513; citation_doi=10.1200/JCO.2021.39.15_suppl.3513; citation_id=CR21">
    <meta name="citation_reference" content="citation_journal_title=Eur. J. Cancer; citation_title=RECIST 1.1—standardisation and disease-specific adaptations: perspectives from the RECIST Working Group; citation_author=LH Schwartz; citation_volume=62; citation_publication_date=2016; citation_pages=138-145; citation_doi=10.1016/j.ejca.2016.03.082; citation_id=CR22">
    <meta name="citation_reference" content="citation_journal_title=Cancer Discov.; citation_title=The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data; citation_author=E Cerami; citation_volume=2; citation_publication_date=2012; citation_pages=401-404; citation_doi=10.1158/2159-8290.CD-12-0095; citation_id=CR23">
    <meta name="citation_reference" content="citation_journal_title=Sci. Signal.; citation_title=Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal; citation_author=J Gao; citation_volume=6; citation_publication_date=2013; citation_pages=pl1; citation_doi=10.1126/scisignal.2004088; citation_id=CR24">
    <meta name="citation_reference" content="citation_journal_title=Cell; citation_title=Universal patterns of selection in cancer and somatic tissues; citation_author=I Martincorena; citation_volume=171; citation_publication_date=2017; citation_pages=1029-1041; citation_doi=10.1016/j.cell.2017.09.042; citation_id=CR25">
    <meta name="citation_reference" content="citation_journal_title=Sci. Rep.; citation_title=The most common RNF43 mutant G659Vfs*41 is fully functional in inhibiting Wnt signaling and unlikely to play a role in tumorigenesis; citation_author=J Tu; citation_volume=9; citation_publication_date=2019; citation_doi=10.1038/s41598-019-54931-3; citation_id=CR26">
    <meta name="citation_reference" content="citation_journal_title=Cancer Res.; citation_title=The functional landscape of patient-derived RNF43 mutations predicts sensitivity to Wnt inhibition; citation_author=J Yu; citation_volume=80; citation_publication_date=2020; citation_pages=5619-5632; citation_doi=10.1158/0008-5472.CAN-20-0957; citation_id=CR27">
    <meta name="citation_reference" content="citation_journal_title=Oncogene; citation_title=Commonly observed RNF43 mutations retain functionality in attenuating Wnt/β-catenin signaling and unlikely confer Wnt-dependency onto colorectal cancers; citation_author=S Li; citation_volume=39; citation_publication_date=2020; citation_pages=3458-3472; citation_doi=10.1038/s41388-020-1232-5; citation_id=CR28">
    <meta name="citation_reference" content="citation_journal_title=Ann. Oncol.; citation_title=Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up; citation_author=E Cutsem, A Cervantes, B Nordlinger, D Arnold; citation_volume=25; citation_publication_date=2014; citation_pages=iii1-iii9; citation_doi=10.1093/annonc/mdu260; citation_id=CR29">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Oncol.; citation_title=Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen; citation_author=E Cutsem; citation_volume=30; citation_publication_date=2012; citation_pages=3499-3506; citation_doi=10.1200/JCO.2012.42.8201; citation_id=CR30">
    <meta name="citation_reference" content="citation_journal_title=Lancet Oncol.; citation_title=Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study; citation_author=J Tabernero; citation_volume=16; citation_publication_date=2015; citation_pages=499-508; citation_doi=10.1016/S1470-2045(15)70127-0; citation_id=CR31">
    <meta name="citation_reference" content="citation_journal_title=Clin. Cancer Res.; citation_title=BRAF-mutant transcriptional subtypes predict outcome of combined BRAF, MEK, and EGFR blockade with dabrafenib, trametinib, and panitumumab in patients with colorectal cancer; citation_author=G Middleton; citation_volume=26; citation_publication_date=2020; citation_pages=2466-2476; citation_doi=10.1158/1078-0432.CCR-19-3579; citation_id=CR32">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Invest.; citation_title=Wnt signaling suppresses MAPK-driven proliferation of intestinal stem cells; citation_author=Z Kabiri; citation_volume=128; citation_publication_date=2018; citation_pages=3806-3812; citation_doi=10.1172/JCI99325; citation_id=CR33">
    <meta name="citation_reference" content="citation_journal_title=Nat. Commun.; citation_title=A phospho-switch controls RNF43-mediated degradation of Wnt receptors to suppress tumorigenesis; citation_author=T Tsukiyama; citation_volume=11; citation_publication_date=2020; citation_doi=10.1038/s41467-020-18257-3; citation_id=CR34">
    <meta name="citation_reference" content="citation_journal_title=eLife; citation_title=RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy; citation_author=T Radaszkiewicz; citation_volume=10; citation_publication_date=2021; citation_pages=e65759; citation_doi=10.7554/eLife.65759; citation_id=CR35">
    <meta name="citation_reference" content="citation_journal_title=Front. Cell Dev. Biol.; citation_title=How to inactivate human ubiquitin E3 ligases by mutation; citation_author=C Garcia-Barcena, N Osinalde, J Ramirez, U Mayor; citation_volume=8; citation_publication_date=2020; citation_pages=39; citation_doi=10.3389/fcell.2020.00039; citation_id=CR36">
    <meta name="citation_reference" content="citation_journal_title=Clin. Cancer Res.; citation_title=Exome sequencing of plasma DNA portrays the mutation landscape of colorectal cancer and discovers mutated VEGFR2 receptors as modulators of antiangiogenic therapies; citation_author=RA Toledo; citation_volume=24; citation_publication_date=2018; citation_pages=3550-3559; citation_doi=10.1158/1078-0432.CCR-18-0103; citation_id=CR37">
    <meta name="citation_reference" content="citation_journal_title=Ann. Oncol.; citation_title=Longitudinal whole-exome sequencing of cell-free DNA for tracking the co-evolutionary tumor and immune evasion dynamics: longitudinal data from a single patient; citation_author=RK Hastings; citation_volume=32; citation_publication_date=2021; citation_pages=681-684; citation_doi=10.1016/j.annonc.2021.02.007; citation_id=CR38">
    <meta name="citation_reference" content="citation_journal_title=Eur. J. Cancer; citation_title=Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer; citation_author=G Randon; citation_volume=161; citation_publication_date=2022; citation_pages=90-98; citation_doi=10.1016/j.ejca.2021.11.018; citation_id=CR39">
    <meta name="citation_reference" content="citation_journal_title=F1000Res; citation_title=Sarek: a portable workflow for whole-genome sequencing analysis of germline and somatic variants; citation_author=M Garcia; citation_volume=9; citation_publication_date=2020; citation_pages=63; citation_doi=10.12688/f1000research.16665.2; citation_id=CR40">
    <meta name="citation_author" content="Elez, Elena">
    <meta name="citation_author_institution" content="Medical Oncology Department, Vall d’Hebron University Hospital, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain">
    <meta name="citation_author_institution" content="Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain">
    <meta name="citation_author" content="Ros, Javier">
    <meta name="citation_author_institution" content="Medical Oncology Department, Vall d’Hebron University Hospital, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain">
    <meta name="citation_author_institution" content="Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain">
    <meta name="citation_author_institution" content="Oncologia Medica, Dipartimento di Medicina di Precisione, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy">
    <meta name="citation_author" content="Fernández, Jose">
    <meta name="citation_author_institution" content="Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain">
    <meta name="citation_author" content="Villacampa, Guillermo">
    <meta name="citation_author_institution" content="Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain">
    <meta name="citation_author" content="Moreno-Cárdenas, Ana Belén">
    <meta name="citation_author_institution" content="Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain">
    <meta name="citation_author" content="Arenillas, Carlota">
    <meta name="citation_author_institution" content="Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain">
    <meta name="citation_author_institution" content="Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Institute of Health Carlos III (ISCIII), Madrid, Spain">
    <meta name="citation_author" content="Bernatowicz, Kinga">
    <meta name="citation_author_institution" content="Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain">
    <meta name="citation_author" content="Comas, Raquel">
    <meta name="citation_author_institution" content="Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain">
    <meta name="citation_author" content="Li, Shanshan">
    <meta name="citation_author_institution" content="Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, the Netherlands">
    <meta name="citation_author" content="Kodack, David Philip">
    <meta name="citation_author_institution" content="Novartis Institutes for BioMedical Research, Cambridge, USA">
    <meta name="citation_author" content="Fasani, Roberta">
    <meta name="citation_author_institution" content="Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain">
    <meta name="citation_author" content="Garcia, Ariadna">
    <meta name="citation_author_institution" content="Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain">
    <meta name="citation_author" content="Gonzalo-Ruiz, Javier">
    <meta name="citation_author_institution" content="Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain">
    <meta name="citation_author" content="Piris-Gimenez, Alejandro">
    <meta name="citation_author_institution" content="Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain">
    <meta name="citation_author" content="Nuciforo, Paolo">
    <meta name="citation_author_institution" content="Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain">
    <meta name="citation_author" content="Kerr, Grainne">
    <meta name="citation_author_institution" content="Oncology Department, Novartis Institutes for Biomedical Research, Novartis, Basel, Switzerland">
    <meta name="citation_author" content="Intini, Rossana">
    <meta name="citation_author_institution" content="Department of Oncology, Veneto Institute of Oncology IRCCS, Padova, Italy">
    <meta name="citation_author" content="Montagna, Aldo">
    <meta name="citation_author_institution" content="Department of Oncology, Veneto Institute of Oncology IRCCS, Padova, Italy">
    <meta name="citation_author" content="Germani, Marco Maria">
    <meta name="citation_author_institution" content="Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Department of Trans-lational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy">
    <meta name="citation_author" content="Randon, Giovanni">
    <meta name="citation_author_institution" content="Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy">
    <meta name="citation_author" content="Vivancos, Ana">
    <meta name="citation_author_institution" content="Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain">
    <meta name="citation_author" content="Smits, Ron">
    <meta name="citation_author_institution" content="Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, the Netherlands">
    <meta name="citation_author" content="Graus, Diana">
    <meta name="citation_author_institution" content="Oncology Department, Novartis Institutes for Biomedical Research, Novartis, Basel, Switzerland">
    <meta name="citation_author_institution" content="Ridgeline Discovery, Basel, Switzerland">
    <meta name="citation_author" content="Perez-Lopez, Raquel">
    <meta name="citation_author_institution" content="Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain">
    <meta name="citation_author_institution" content="Radiology Department, Vall d’Hebron University Hospital, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain">
    <meta name="citation_author" content="Cremolini, Chiara">
    <meta name="citation_author_institution" content="Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Department of Trans-lational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy">
    <meta name="citation_author" content="Lonardi, Sara">
    <meta name="citation_author_institution" content="Department of Oncology, Veneto Institute of Oncology IRCCS, Padova, Italy">
    <meta name="citation_author" content="Pietrantonio, Filippo">
    <meta name="citation_author_institution" content="Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy">
    <meta name="citation_author" content="Dienstmann, Rodrigo">
    <meta name="citation_author_institution" content="Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain">
    <meta name="citation_author" content="Tabernero, Josep">
    <meta name="citation_author_institution" content="Medical Oncology Department, Vall d’Hebron University Hospital, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain">
    <meta name="citation_author_institution" content="Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain">
    <meta name="citation_author_institution" content="Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Institute of Health Carlos III (ISCIII), Madrid, Spain">
    <meta name="citation_author_institution" content="UVic-UCC, IOB-Quirón, Barcelona, Spain">
    <meta name="citation_author" content="Toledo, Rodrigo A.">
    <meta name="citation_author_institution" content="Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain">
    <meta name="citation_author_institution" content="Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Institute of Health Carlos III (ISCIII), Madrid, Spain">
    <meta name="access_endpoint" content="https://www.nature.com/platform/readcube-access">
    <meta name="twitter:site" content="@naturemedicine">
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:image:alt" content="Content cover image">
    <meta name="twitter:title" content="RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer">
    <meta name="twitter:description" content="Nature Medicine - The presence of inactivating mutations in RNF43, a negative regulator of WNT, in tumor cells predicts improved response rates and survival outcomes in patients with metastatic...">
    <meta name="twitter:image" content="https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig1_HTML.png">
    

    
    
    <meta property="og:url" content="https://www.nature.com/articles/s41591-022-01976-z">
    <meta property="og:type" content="article">
    <meta property="og:site_name" content="Nature">
    <meta property="og:title" content="RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer - Nature Medicine">
    <meta property="og:description" content="The presence of inactivating mutations in RNF43, a negative regulator of WNT, in tumor cells predicts improved response rates and survival outcomes in patients with metastatic BRAFV600E colorectal cancer treated with anti-BRAF/EGFR therapy.">
    <meta property="og:image" content="https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig1_HTML.png">
    

    <script>
        window.eligibleForRa21 = 'false'; 
    </script>
<style type="text/css">.cc-banner{background-color:#01324b;border:none!important;bottom:0;box-sizing:border-box;color:#fff!important;left:0;line-height:1.3;margin:auto 0 0;max-width:100%;outline:0;overflow:visible;padding:0;position:fixed;right:0;width:100%;z-index:99999}.cc-banner::backdrop{background-color:#0000004d}.cc-banner *{color:inherit!important}.cc-banner:focus{box-shadow:none;outline:0}.cc-banner a{color:#fff!important;text-decoration:underline}.cc-banner a:active,.cc-banner a:focus,.cc-banner a:hover{color:inherit;text-decoration:none}.cc-banner a:focus{outline:3px solid #08c!important}.cc-banner h2,.cc-banner h3,.cc-banner h4,.cc-banner h5,.cc-banner h6{font-family:sans-serif;font-style:normal;font-weight:700;margin:0 0 .5em}.cc-banner .cc-h2,.cc-banner h2{font-size:18px}.cc-banner .cc-h3,.cc-banner h3{font-size:16px}.cc-banner .cc-h4,.cc-banner .cc-h5,.cc-banner .cc-h6,.cc-banner h4,.cc-banner h5,.cc-banner h6{font-size:14px}.cc-banner .cc-button{font-size:16px}.cc-banner__content{background-color:#01324b;display:flex;flex-direction:column;margin:0 auto;max-height:90vh;max-width:100%;padding:16px;position:relative}.cc-banner__content:focus{outline:0}@media (min-width:680px){.cc-banner__content{padding:12px}}@media (min-width:980px){.cc-banner__content{max-height:60vh;padding-bottom:20px;padding-top:20px}}@media (min-width:1320px){.cc-banner__content{padding-bottom:40px;padding-top:40px}}.cc-banner__container{display:flex;flex-direction:column;margin:auto;max-width:1320px;overflow:auto}.cc-banner__title{background:none!important;border:0;flex-shrink:0;font-size:18px!important;font-size:22px!important;font-weight:700!important;letter-spacing:normal;margin:0 0 12px!important;padding:0}@media (min-width:680px){.cc-banner__title{font-size:24px!important;margin:0 0 16px!important}}@media (min-width:1320px){.cc-banner__title{font-size:26px!important;margin:0 0 24px!important}}.cc-banner__body{display:flex;flex-direction:column;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif!important;overflow-x:hidden;overflow-y:auto;padding:3px 3px 16px}@media (min-width:980px){.cc-banner__body{flex-direction:row}}.cc-banner__policy p{font-size:16px!important;margin:0;max-width:none;padding:0}.cc-banner__policy p:not(:last-child){margin:0 0 16px}@media (min-width:980px){.cc-banner__policy p:not(:last-child){margin:0 0 24px}}.cc-banner__policy p a{font-size:16px!important;font-weight:700}.cc-banner__footer{box-shadow:none;flex-shrink:0;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif !important!important;margin:0;padding:12px 0 3px 3px;position:relative}@media (min-width:380px){.cc-banner__footer{align-items:stretch;display:flex;flex-wrap:wrap}}@media (min-width:680px){.cc-banner__footer{box-shadow:none;flex-wrap:nowrap;width:40%}}.cc-banner__footer .cc-banner__button{flex:1 1 auto;font-weight:700;overflow:hidden;padding:.5em 1em;width:100%}@media (min-width:680px){.cc-banner__footer .cc-banner__button{max-width:275px}}.cc-banner__footer .cc-banner__button:not(:last-child){margin-bottom:12px}@media (min-width:680px){.cc-banner__footer .cc-banner__button:not(:last-child){margin-bottom:0;margin-right:16px}}@media (min-width:980px){.cc-banner__footer .cc-banner__button:not(:last-child){margin-right:24px}}@media (min-width:680px){html[dir=rtl] .cc-banner__footer .cc-banner__button:not(:last-child){margin-left:16px!important;margin-right:0!important}}@media (min-width:980px){html[dir=rtl] .cc-banner__footer .cc-banner__button:not(:last-child){margin-left:24px!important;margin-right:0!important}}.cc-banner__button-preferences{padding-left:0;padding-right:0}@media (min-width:380px){.cc-banner__button-preferences{flex:0 0 auto;margin:auto}}@media (min-width:680px){.cc-banner__button-preferences{margin:0}}@media (min-width:380px) and (max-width:680px){.cc-banner__button-break{display:block}}@media (min-width:680px){.cc-banner--is-tcf .cc-banner__footer{width:auto}}@media (min-width:980px){.cc-banner--is-tcf .cc-banner__footer{padding-right:48px;width:66%}}.cc-banner--is-tcf .cc-banner__stacks-intro{font-size:16px!important}.cc-banner--is-tcf .cc-banner__stacks{margin:16px 0 0}@media (min-width:980px){.cc-banner--is-tcf .cc-banner__stacks{display:flex;flex:0 0 33%;flex-direction:column;margin:0 0 0 48px;overflow:auto}}.cc-banner--is-tcf .cc-banner__stacks-intro{font-size:16px;margin:0 0 12px}.cc-banner--is-tcf .cc-banner__stacks-details{padding:0 3px}.cc-banner--is-tcf .cc-banner .cc-details{border-color:#fff3!important}.cc-box{border-radius:10px;padding:12px}.cc-box--info{background-color:#eff6fb}.cc-box--light{background-color:#faf9f6}.cc-button{border:2px solid #0000;border-radius:32px!important;color:inherit;cursor:pointer;font-size:14px;font-weight:700!important;left:auto;line-height:1.2;margin:0;padding:.5em 1em;right:auto;text-transform:none!important;transition:all .2s}@media (min-width:680px){.cc-button{font-size:14px;padding:.75em 1em}}.cc-button--sm{font-size:12px;padding:2px 8px!important}.cc-button--primary{background-color:#025e8d!important;border-color:#025e8d!important;color:#fff!important}.cc-button--primary:focus{outline:3px solid #08c}.cc-button--primary:focus,.cc-button--primary:hover,.cc-button--secondary{background-color:#fff!important;border-color:#025e8d!important;color:#025e8d!important}.cc-button--secondary:focus{background-color:#025e8d!important;border-color:#fff!important;color:#fff!important;outline:3px solid #08c!important}.cc-button--secondary:hover{background-color:#025e8d!important;border-color:#025e8d!important;color:#fff!important}.cc-button--secondary:active{border:2px solid #01324b!important}.cc-button--secondary.cc-button--contrast{border-color:#fff!important}.cc-button--secondary.cc-button--contrast:hover{background-color:initial!important;color:#fff!important}.cc-button--tertiary{background-color:#f0f7fc!important;background-image:none;border:2px solid #f0f7fc;color:#025e8d!important;text-decoration:underline!important;text-underline-offset:.25em}.cc-button--tertiary:focus{outline:3px solid #08c!important}.cc-button--tertiary:hover{text-decoration-thickness:.25em}.cc-button--tertiary:active{color:#013c5b}.cc-button--link{background-color:initial!important;border-color:#0000!important;border-radius:0!important;color:inherit!important;padding:0!important;text-decoration:underline!important;width:inherit!important}.cc-button--link:focus{outline:3px solid #08c}.cc-button--link:hover{background-color:initial!important;box-shadow:none;text-decoration:none}.cc-button--text{border-radius:0;padding:0}.cc-button--details{padding-right:24px!important;position:relative;width:auto}.cc-button--details:after,.cc-button--details:before{background-color:currentColor;content:"";position:absolute;transition:transform .25s ease-out}.cc-button--details:before{height:10px;margin-top:-5px;right:12px;top:50%;width:2px}.cc-button--details:after{height:2px;margin-top:-1px;right:8px;top:50%;width:10px}.cc-button--details.cc-active:before{transform:rotate(90deg);transform-origin:center}.cc-button--details.cc-active:after{display:none}.cc-details{border-bottom:1px solid #0000001a;padding:12px 0;position:relative;width:100%}.cc-details__summary{align-items:center;display:flex;font-size:14px;font-weight:700;list-style-type:none}.cc-details__summary:focus,.cc-details__summary:focus-visible{outline:3px solid #08c!important;will-change:auto}.cc-details__title{align-items:baseline;display:flex}.cc-details__title h2,.cc-details__title h3,.cc-details__title h4,.cc-details__title h5{line-height:1.4;margin:0!important;padding:0!important}.cc-details__title svg{flex-shrink:0;height:auto;margin-right:8px;position:relative;top:-1px;transition:all .2s;width:auto}.cc-details[open] .cc-details__title svg{top:2px;transform:rotate(90deg)}.cc-details__switch{margin-left:auto}.cc-details__section{padding:16px 0 0 18px}.cc-details__section p{margin:0}.cc-details__section p:not(:last-child){margin-bottom:12px}details summary::-webkit-details-marker{display:none}.cc-radio{align-items:center;display:flex;position:relative}.cc-radio *{cursor:pointer}.cc-radio__input{height:22px;left:0;position:absolute;top:0;width:22px}.cc-radio__input:focus{outline:none}.cc-radio__label{color:inherit;font-size:14px;font-weight:700;line-height:23px;margin:0;padding-left:28px}.cc-radio__label:after,.cc-radio__label:before{background-color:#fff;content:"";display:block;position:absolute;transition:transform .25s ease-out}.cc-radio__label:before{border:1px solid #777;border-radius:50%;height:22px;left:0;top:0;width:22px}.cc-radio__label:after{border:7px solid #025e8d;border-radius:50%;height:0;left:4px;opacity:0;top:4px;width:0}.cc-radio__input:focus+.cc-radio__label:before{box-shadow:0 0 0 2px #08c;outline:none}.cc-radio__label--hidden{display:none}.cc-radio__input:checked+.cc-radio__label:after{opacity:1}.cc-radio__input:disabled{cursor:default}.cc-radio__input:disabled+.cc-radio__label{cursor:default;opacity:.5}.cc-switch *{cursor:pointer}.cc-switch{align-items:center;display:flex;line-height:1}.cc-switch__label{cursor:pointer;display:inline-block;font-size:14px;font-weight:700;margin:0;-webkit-user-select:none;user-select:none}.cc-switch__input[type=checkbox]{-webkit-appearance:none;appearance:none;background-color:#fff!important;background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='rgba(0, 0, 0, 0.25)'/%3E%3C/svg%3E")!important;background-position:0!important;background-repeat:no-repeat!important;border:1px solid #777!important;border-radius:16px!important;height:18px!important;margin:0 8px 0 0!important;transition:background-position .2s ease-in-out!important;width:32px!important}.cc-switch__input[type=checkbox]:focus{background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='%2380b3cc'/%3E%3C/svg%3E")!important}.cc-switch__input[type=checkbox]:checked{background-color:#025e8d!important;background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='%23fff'/%3E%3C/svg%3E")!important;background-position:100%!important}.cc-switch__input[type=checkbox]:checked~.cc-switch__label>.cc-switch__text-off,.cc-switch__input[type=checkbox]:not(:checked)~.cc-switch__label>.cc-switch__text-on{display:none}.cc-switch__input[type=checkbox]:hover{cursor:pointer;outline:none}.cc-switch__input[type=checkbox]:focus-visible{cursor:pointer;outline:3px solid #fc0}.cc-switch__input[type=checkbox]:checked:before{background-color:none!important;color:#0000!important}html[dir=rtl] .cc-switch__input[type=checkbox]{margin-left:8px!important;margin-right:0!important}.cc-list>ul,ul.cc-list{list-style-type:disc;margin-left:0;padding-left:0}.cc-list>ul>li,ul.cc-list>li{margin-left:1em}.cc-list>ul>li:not(:last-child),ul.cc-list>li:not(:last-child){margin-bottom:4px}.cc-list__title{margin-bottom:8px!important}.cc-list--inline>ul,ul.cc-list--inline{display:flex;flex-wrap:wrap;list-style-type:none}.cc-list--inline>ul>li,ul.cc-list--inline>li{margin:0 .5em .5em 0}.cc-overlay{background-color:#0000004d;z-index:99998}.cc-overlay,.cc-preferences{bottom:0;left:0;position:fixed;right:0;top:0}.cc-preferences{background-color:#050a14f2!important;border:0;box-sizing:border-box;color:#111;font-family:sans-serif!important;line-height:1.4;margin:auto;max-height:100vh;overflow:auto;padding:0;z-index:100000}.cc-preferences:focus{outline:none}.cc-preferences *,.cc-preferences :after,.cc-preferences :before{box-sizing:inherit!important}.cc-preferences h2,.cc-preferences h3,.cc-preferences h4,.cc-preferences h5,.cc-preferences h6{font-family:sans-serif;font-style:normal;font-weight:700;margin:0 0 .5em}.cc-preferences .cc-h2,.cc-preferences h2{font-size:18px}.cc-preferences .cc-h3,.cc-preferences h3{font-size:16px}.cc-preferences .cc-h4,.cc-preferences .cc-h5,.cc-preferences .cc-h6,.cc-preferences h4,.cc-preferences h5,.cc-preferences h6{font-size:14px}.cc-preferences a{color:#025e8d;text-decoration:underline}.cc-preferences a:hover{color:inherit;text-decoration:none}.cc-preferences h3{background:none;color:#111;padding:0;text-transform:none}dialog.cc-preferences{background-color:initial}dialog.cc-preferences::backdrop{background-color:#000000e6}.cc-preferences__dialog{display:flex;flex-direction:column;margin:auto;max-height:100vh;max-width:860px;padding:12px;position:relative}.cc-preferences__dialog>:last-child{border-bottom-left-radius:10px;border-bottom-right-radius:10px}@media (min-width:980px){.cc-preferences__dialog{padding:16px}}.cc-preferences__close{background:#0000!important;border:1px solid #ececec;border-radius:50%;color:#111!important;cursor:pointer;font-family:Times New Roman,serif;font-size:40px;height:40px;left:auto;line-height:1;margin-top:-20px;padding:0!important;position:absolute;right:20px;top:50%;width:40px}.cc-preferences__close:focus{outline:3px solid #08c}.cc-preferences__close-label{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.cc-preferences__header{background:#fff!important;border-bottom:1px solid #0000001a;border-top-left-radius:10px;border-top-right-radius:10px;padding:16px;position:relative;text-align:center}.cc-preferences__title{background:none!important;color:#111!important;font-family:sans-serif!important;font-size:18px!important;font-weight:700!important;margin:0!important;padding:0 16px 0 0!important}@media (min-width:480px){.cc-preferences__title{padding-right:0!important}}@media (min-width:980px){.cc-preferences__title{font-size:22px!important}}.cc-preferences__body{background:#fff!important;flex:1 1 auto;min-height:200px;overflow-x:hidden;overflow-y:auto;padding:16px}.cc-preferences__footer{background:#fff!important;border-top:1px solid #d0d0d0;box-shadow:0 0 5px 0 #0003;margin-bottom:0;padding:12px;position:relative}@media (min-width:480px){.cc-preferences__footer{align-items:stretch;display:flex}}.cc-preferences__footer>.cc-button{display:block;width:100%}@media (min-width:480px){.cc-preferences__footer>.cc-button{flex:1 1 auto}}@media (min-width:980px){.cc-preferences__footer>.cc-button{flex-basis:auto}}@media (min-width:480px){.cc-preferences__footer>.cc-button:not(:first-child){margin-left:12px}}.cc-preferences__footer>.cc-button:not(:last-child){margin-bottom:8px}@media (min-width:480px){.cc-preferences__footer>.cc-button:not(:last-child){margin-bottom:0}}.cc-preferences__categories{list-style:none;margin:0;padding:0}.cc-preferences__category:not(:last-child){border-bottom:1px solid #0000001a;margin-bottom:12px;padding-bottom:12px}.cc-preferences__category-description{font-size:14px;margin:0 0 8px;padding:0}.cc-preferences__category-footer{align-items:center;display:flex;justify-content:space-between}.cc-preferences__status{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.cc-preferences__controls{display:flex;margin:0}.cc-preferences__controls>:not(:last-child){margin-right:12px}.cc-preferences__always-on{font-size:14px;font-weight:700;padding-left:26px;position:relative}.cc-preferences__always-on:before{background:#0000!important;border:solid;border-top-color:#0000;border-width:0 0 4px 4px;content:"";display:block;height:10px;left:0;position:absolute;top:2px;transform:rotate(-45deg);width:18px}.cc-preferences__details{background-color:#eff6fb!important;border-radius:10px;font-size:14px;margin:12px 0 0;padding:12px}.cc-preferences__cookie-list,.cc-preferences__provider-list{list-style:none;margin:0;padding:0}.cc-preferences__provider-list{columns:170px}.cc-preferences__cookie-title{font-size:1em;font-style:normal;font-weight:400;margin:0}.cc-preferences__cookie-description{font-size:1em;margin:0 0 8px}.cc-preferences__cookie-domain,.cc-preferences__cookie-lifespan{border-left:1px solid #999;color:#666;margin-left:8px;padding-left:4px}body.cc-has-preferences-open{overflow:hidden;position:relative}.cc-table{border-collapse:collapse;width:100%}.cc-table tbody tr{border-top:1px solid #0000001a}.cc-table td,.cc-table th{font-size:14px;padding:4px 8px;vertical-align:top}.cc-table+.cc-table{margin-top:8px}.cc-table--purposes td:first-child,.cc-table--purposes th:first-child{width:70%}@media (min-width:680px){.cc-table--purposes td:first-child,.cc-table--purposes th:first-child{width:80%}}.cc-table--purposes td:last-child,.cc-table--purposes th:last-child{padding-left:8px;width:40%}@media (min-width:680px){.cc-table--purposes td:last-child,.cc-table--purposes th:last-child{width:30%}}.cc-tabs,.cc-tabs>ul{background-color:#faf9f6;display:flex;list-style:none;margin:0;padding:0}.cc-tabs__panel{border-top:1px solid #ececec;margin-top:-1px}.cc-tabs__button{background-color:initial;border:0;border-left:1px solid #0000;border-right:1px solid #0000;color:#111;font-size:16px;font-weight:700;margin:0;padding:15px 16px 12px;position:relative}.cc-tabs__button:before{background-color:initial;content:"";display:block;height:3px;left:0;position:absolute;top:0;width:100%}.cc-tabs__button.cc-active{background-color:#fff;border-color:#025e8d #ececec #ececec;color:#111}.cc-tabs__button.cc-active:before{background-color:#025e8d}.cc-tabs__content{background-color:#fff;display:none;font-size:14px;padding:16px}.cc-tabs__section:not(:first-child){padding-top:24px}.cc-tcf{font-size:14px;margin-top:16px}.cc-tcf__list{list-style:none;margin:0;padding:0}.cc-vendor-count{color:#666;font-size:16px;margin:0 0 8px}.cc-hide{display:none!important}.cc-show{display:block!important}.cc-external-link{background-color:#ececec;background-image:url("data:image/svg+xml;base64,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");background-position:right 8px center;background-repeat:no-repeat;background-size:10px auto;border-radius:3px;box-shadow:0 1px 0 #0003;color:#111!important;display:inline-block;font-size:12px;padding:4px 26px 4px 8px;text-decoration:none!important}.cc-external-link:hover{text-decoration:underline!important}.cc-m-0{margin:0!important}.cc-grey{color:#666}</style><script async="" type="text/javascript" src="https://injections.readcube.com/nature/inject.fa744f3f.js"></script></head>
<body class="article-page"><dialog class="cc-banner" data-cc-banner="" data-nosnippet="" aria-labelledby="cc-banner-label" open="">
		<div class="cc-banner__content" autofocus="" tabindex="-1">
			<div class="cc-banner__container">
				<div class="cc-banner__header">
					<h2 class="cc-banner__title" id="cc-banner-label">Your privacy, your choice</h2>
				</div>
				<div class="cc-banner__body">
					<div class="cc-banner__policy">
						<p>We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.</p><p>By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.</p><p>See our <a href="https://www.nature.com/info/privacy" data-cc-action="privacy">privacy policy</a> for more information on the use of your personal data.</p><p><button type="button" data-cc-action="preferences" class="cc-button cc-button--link cc-button--text">Manage preferences</button> for further information and to change your choices.</p>
					</div>
					
				</div>
				<div class="cc-banner__footer">
					
			<button data-cc-action="accept" class="cc-button cc-button--secondary cc-button--contrast cc-banner__button cc-banner__button-accept">Accept all cookies</button>
			
		
				</div>
			</div>
		</div>
	</dialog>

<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-MRVXSHQ"
                  height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>



<div class="position-relative cleared z-index-50 background-white" data-test="top-containers">
    <a class="c-skip-link" href="#content">Skip to main content</a>



<div class="c-grade-c-banner u-hide">
    <div class="c-grade-c-banner__container">
        
        <p>Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
            the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
            Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
            and JavaScript.</p>

    </div>
</div>

    

    

    
    
        <div class="u-hide u-show-following-ad"></div>

    <aside class="c-ad c-ad--728x90" style="display: none !important;">
        <div class="c-ad__inner" data-container-type="banner-advert">
            <p class="c-ad__label">Advertisement</p>
            
        
            
    <div id="div-gpt-ad-top-1" class="div-gpt-ad advert leaderboard js-ad text-center hide-print grade-c-hide" data-ad-type="top" data-test="top-ad" data-pa11y-ignore="" data-gpt="" data-gpt-unitpath="/285/medicine.nature.com/article" data-gpt-sizes="728x90" data-gpt-targeting="type=article;pos=top;artid=s41591-022-01976-z;doi=10.1038/s41591-022-01976-z;subjmeta=1504,1857,1885,2423,308,53,631,67,692;kwrd=Colorectal+cancer,Predictive+markers,Tumour+biomarkers">
        <noscript>
            <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/285/medicine.nature.com/article&amp;sz=728x90&amp;c=-1477804517&amp;t=pos%3Dtop%26type%3Darticle%26artid%3Ds41591-022-01976-z%26doi%3D10.1038/s41591-022-01976-z%26subjmeta%3D1504,1857,1885,2423,308,53,631,67,692%26kwrd%3DColorectal+cancer,Predictive+markers,Tumour+biomarkers">
                <img data-test="gpt-advert-fallback-img"
                     src="//pubads.g.doubleclick.net/gampad/ad?iu=/285/medicine.nature.com/article&amp;sz=728x90&amp;c=-1477804517&amp;t=pos%3Dtop%26type%3Darticle%26artid%3Ds41591-022-01976-z%26doi%3D10.1038/s41591-022-01976-z%26subjmeta%3D1504,1857,1885,2423,308,53,631,67,692%26kwrd%3DColorectal+cancer,Predictive+markers,Tumour+biomarkers"
                     alt="Advertisement"
                     width="728"
                     height="90"></a>
        </noscript>
    </div>

        
    
        </div>
    </aside>


    <header class="c-header" id="header" data-header="" data-track-component="nature-150-split-header" style="border-color:#e40428">
        <div class="c-header__row">
            <div class="c-header__container">
                <div class="c-header__split">
                    
                    
                    <div class="c-header__logo-container">
                        
                        <a href="/nm" data-track="click" data-track-action="home" data-track-label="image">
                            <picture class="c-header__logo">
                                <source srcset="https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg" media="(min-width: 875px)">
                                <img src="https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg" height="32" alt="Nature Medicine">
                            </picture>
                        </a>
                    
                    </div>
                    
                    <ul class="c-header__menu c-header__menu--global">
                        <li class="c-header__item c-header__item--padding c-header__item--hide-md-max">
                            <a class="c-header__link" href="https://www.nature.com/siteindex" data-test="siteindex-link" data-track="click" data-track-action="open nature research index" data-track-label="link">
                                <span>View all journals</span>
                            </a>
                        </li>
                        <li class="c-header__item c-header__item--padding c-header__item--pipe">
                            <a class="c-header__link c-header__link--search" href="javascript:;" data-header-expander="" data-test="search-link" data-track="click" data-track-action="open search tray" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                <svg role="img" aria-hidden="true" focusable="false" height="22" width="22" viewBox="0 0 18 18" xmlns="http://www.w3.org/2000/svg"><path d="M16.48 15.455c.283.282.29.749.007 1.032a.738.738 0 01-1.032-.007l-3.045-3.044a7 7 0 111.026-1.026zM8 14A6 6 0 108 2a6 6 0 000 12z"></path></svg><span>Search</span>
                            </a><div id="search-menu" class="c-header__dropdown c-header__dropdown--full-width has-tethered u-js-hide" data-track-component="nature-150-split-header" hidden="">
    <div class="c-header__container">
        <h2 class="c-header__visually-hidden">Search</h2>
        <form class="c-header__search-form" action="/search" method="get" role="search" autocomplete="off" data-test="inline-search">
            <label class="c-header__heading" for="keywords">Search articles by subject, keyword or author</label>
            <div class="c-header__search-layout c-header__search-layout--max-width">
                <div>
                    <input type="text" required="" class="c-header__input" id="keywords" name="q" value="">
                </div>
                <div class="c-header__search-layout">
                    <div>
                        <label for="results-from" class="c-header__visually-hidden">Show results from</label>
                        <select id="results-from" name="journal" class="c-header__select">
                            
                                
                                    <option value="" selected="">All journals</option>
                                    <option value="nm">This journal</option>
                                
                            
                        </select>
                    </div>
                    <div>
                        <button type="submit" class="c-header__search-button">Search</button>
                    </div>
                </div>

            </div>
        </form>

        <div class="c-header__flush">
            <a class="c-header__link" href="/search/advanced" data-track="click" data-track-action="advanced search" data-track-label="link">
                Advanced search
            </a>
        </div>

        <h3 class="c-header__heading c-header__heading--keyline">Quick links</h3>
        <ul class="c-header__list">
            <li><a class="c-header__link" href="/subjects" data-track="click" data-track-action="explore articles by subject" data-track-label="link">Explore articles by subject</a></li>
            <li><a class="c-header__link" href="/naturecareers" data-track="click" data-track-action="find a job" data-track-label="link">Find a job</a></li>
            <li><a class="c-header__link" href="/authors/index.html" data-track="click" data-track-action="guide to authors" data-track-label="link">Guide to authors</a></li>
            <li><a class="c-header__link" href="/authors/editorial_policies/" data-track="click" data-track-action="editorial policies" data-track-label="link">Editorial policies</a></li>
        </ul>
    </div>
</div>
                        </li>
                        <li class="c-header__item c-header__item--padding c-header__item--snid-account-widget c-header__item--pipe">
                            
                                <a class="c-header__link eds-c-header__link" id="identity-account-widget" data-track="click_login" data-track-context="header" href="https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41591-022-01976-z"><span class="eds-c-header__widget-fragment-title">Log in</span></a>
                            
                        </li>
                    </ul>
                </div>
            </div>
        </div>
        
            <div class="c-header__row">
                <div class="c-header__container" data-test="navigation-row">
                    <div class="c-header__split">
                        <ul class="c-header__menu c-header__menu--journal">
                            
                                <li class="c-header__item c-header__item--dropdown-menu" data-test="explore-content-button">
                                    <a href="javascript:;" class="c-header__link" data-header-expander="" data-test="menu-button--explore" data-track="click" data-track-action="open explore expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                        <span><span class="c-header__show-text">Explore</span> content</span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                    </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="Explore-content" data-test="Explore-content" id="explore" data-track-component="nature-150-split-header" hidden="">
            <div class="c-header__container">
                <h2 id="Explore-content" class="c-header__heading c-header__heading--js-hide">Explore content</h2>
                <ul class="c-header__list c-header__list--js-stack">
                    
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/research-articles" data-track="click" data-track-action="research articles" data-track-label="link" data-test="explore-nav-item">
                                    Research articles
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/reviews-and-analysis" data-track="click" data-track-action="reviews &amp; analysis" data-track-label="link" data-test="explore-nav-item">
                                    Reviews &amp; Analysis
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/news-and-comment" data-track="click" data-track-action="news &amp; comment" data-track-label="link" data-test="explore-nav-item">
                                    News &amp; Comment
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/podcast" data-track="click" data-track-action="podcasts" data-track-label="link" data-test="explore-nav-item">
                                    Podcasts
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/current-issue" data-track="click" data-track-action="current issue" data-track-label="link" data-test="explore-nav-item">
                                    Current issue
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/collections" data-track="click" data-track-action="collections" data-track-label="link" data-test="explore-nav-item">
                                    Collections
                                </a>
                            </li>
                        
                    
                </ul>
                <ul class="c-header__list c-header__list--js-stack">
                    
                        <li class="c-header__item">
                            <a class="c-header__link" href="https://www.facebook.com/Nature-Medicine-193691346949/" data-track="click" data-track-action="facebook" data-track-label="link">Follow us on Facebook
                            </a>
                        </li>
                    
                    
                        <li class="c-header__item">
                            <a class="c-header__link" href="https://twitter.com/naturemedicine" data-track="click" data-track-action="twitter" data-track-label="link">Follow us on Twitter
                            </a>
                        </li>
                    
                    
                    
                        <li class="c-header__item c-header__item--hide-lg">
                            <a class="c-header__link" href="https://www.nature.com/my-account/alerts/subscribe-journal?list-id=5" rel="nofollow" data-track="nav_sign_up_for_alerts" data-track-action="Sign up for alerts" data-track-external="" data-track-label="link (mobile dropdown)">Sign up for alerts<svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill="#fff"></path></svg>
                            </a>
                        </li>
                    
                    
                        <li class="c-header__item c-header__item--hide-lg">
                            <a class="c-header__link" href="https://www.nature.com/nm.rss" data-track="click" data-track-action="rss feed" data-track-label="link">
                                <span>RSS feed</span>
                            </a>
                        </li>
                    
                </ul>
            </div>
        </nav>
                                </li>
                            
                            
                                <li class="c-header__item c-header__item--dropdown-menu">
                                    <a href="javascript:;" class="c-header__link" data-header-expander="" data-test="menu-button--about-the-journal" data-track="click" data-track-action="open about the journal expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                        <span>About <span class="c-header__show-text">the journal</span></span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                    </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="About-the-journal" id="about-the-journal" data-test="about-the-journal" data-track-component="nature-150-split-header" hidden="">
                <div class="c-header__container">
                    <h2 id="About-the-journal" class="c-header__heading c-header__heading--js-hide">About the journal</h2>
                    <ul class="c-header__list c-header__list--js-stack">
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/aims" data-track="click" data-track-action="aims &amp; scope" data-track-label="link">
                                    Aims &amp; Scope
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/journal-information" data-track="click" data-track-action="journal information" data-track-label="link">
                                    Journal Information
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/journal-impact" data-track="click" data-track-action="journal metrics" data-track-label="link">
                                    Journal Metrics
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editors" data-track="click" data-track-action="about the editors" data-track-label="link">
                                    About the Editors
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/research-cross-journal-editorial-team" data-track="click" data-track-action="research cross-journal editorial team" data-track-label="link">
                                    Research Cross-Journal Editorial Team
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/reviews-cross-journal-editorial-team" data-track="click" data-track-action="reviews cross-journal editorial team" data-track-label="link">
                                    Reviews Cross-Journal Editorial Team
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/statistics-advisory-panel" data-track="click" data-track-action="statistical advisory panel" data-track-label="link">
                                    Statistical Advisory Panel
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/our-publishing-models" data-track="click" data-track-action="our publishing models" data-track-label="link">
                                    Our publishing models
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editorial-values-statement" data-track="click" data-track-action="editorial values statement" data-track-label="link">
                                    Editorial Values Statement
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editorial-policies" data-track="click" data-track-action="editorial policies" data-track-label="link">
                                    Editorial Policies
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/content" data-track="click" data-track-action="content types" data-track-label="link">
                                    Content Types
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/web-feeds" data-track="click" data-track-action="web feeds" data-track-label="link">
                                    Web Feeds
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/contact" data-track="click" data-track-action="contact" data-track-label="link">
                                    Contact
                                </a>
                            </li>
                        
                    </ul>
                </div>
            </nav>
                                </li>
                                
                                    <li class="c-header__item c-header__item--dropdown-menu" data-test="publish-with-us-button">
                                        <a href="javascript:;" class="c-header__link c-header__link--dropdown-menu" data-header-expander="" data-test="menu-button--publish" data-track="click" data-track-action="open publish with us expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                            <span>Publish <span class="c-header__show-text">with us</span></span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                        </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="Publish-with-us-label" id="publish-with-us" data-test="publish-with-us" data-track-component="nature-150-split-header" hidden="">
                <div class="c-header__container">
                    <h2 id="Publish-with-us-label" class="c-header__heading c-header__heading--js-hide">Publish with us</h2>
                    <ul class="c-header__list c-header__list--js-stack">
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/submission-guidelines" data-track="click" data-track-action="submission guidelines" data-track-label="link">
                                    Submission Guidelines
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/for-reviewers" data-track="click" data-track-action="for reviewers" data-track-label="link">
                                    For Reviewers
                                </a>
                            </li>
                        
                        
                            <li class="c-header__item">
                                <a class="c-header__link" data-test="nature-author-services" data-track="nav_language_services" data-track-context="header publish with us dropdown menu" data-track-action="manuscript author services" data-track-label="link manuscript author services" href="https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&amp;utm_medium=Website_Nature&amp;utm_campaign=Platform+Experimentation+2022&amp;utm_id=PE2022">
                                    Language editing services
                                </a>
                            </li>
                        
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/open-access-funding" data-test="funding-eligibility-link" data-track="click_explore_funding" data-track-context="header publish with us" data-track-action="funding eligibility">Open access funding</a>
                            </li>
                        
                        
                            <li class="c-header__item c-header__item--keyline">
                                <a class="c-header__link" href="https://mts-nmed.nature.com/cgi-bin/main.plex" data-track="click_submit_manuscript" data-track-context="submit link in Nature header dropdown menu" data-track-action="submit manuscript" data-track-label="link (publish with us dropdown menu)" data-track-external="" data-gtm-criteo="submit-manuscript">Submit manuscript<svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m15 0c1.1045695 0 2 .8954305 2 2v5.5c0 .27614237-.2238576.5-.5.5s-.5-.22385763-.5-.5v-5.5c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-9v3c0 1.1045695-.8954305 2-2 2h-3v10c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h7.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-7.5c-1.1045695 0-2-.8954305-2-2v-10.17157288c0-.53043297.21071368-1.0391408.58578644-1.41421356l3.82842712-3.82842712c.37507276-.37507276.88378059-.58578644 1.41421356-.58578644zm-.5442863 8.18867991 3.3545404 3.35454039c.2508994.2508994.2538696.6596433.0035959.909917-.2429543.2429542-.6561449.2462671-.9065387-.0089489l-2.2609825-2.3045251.0010427 7.2231989c0 .3569916-.2898381.6371378-.6473715.6371378-.3470771 0-.6473715-.2852563-.6473715-.6371378l-.0010428-7.2231995-2.2611222 2.3046654c-.2531661.2580415-.6562868.2592444-.9065605.0089707-.24295423-.2429542-.24865597-.6576651.0036132-.9099343l3.3546673-3.35466731c.2509089-.25090888.6612706-.25227691.9135302-.00001728zm-.9557137-3.18867991c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm-8.5-3.587-3.587 3.587h2.587c.55228475 0 1-.44771525 1-1zm8.5 1.587c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill="#fff"></path></svg>
                                </a>
                            </li>
                        
                    </ul>
                </div>
            </nav>
                                    </li>
                                
                            
                            
                        </ul>
                        <ul class="c-header__menu c-header__menu--hide-lg-max">
                            
                                <li class="c-header__item" data-test="alert-link">
                                    <a class="c-header__link" href="https://journal-alerts.springernature.com/subscribe?journal_id=41591" rel="nofollow" data-track="nav_sign_up_for_alerts" data-track-action="Sign up for alerts" data-track-label="link (desktop site header)" data-track-external="">
                                        <span>Sign up for alerts</span><svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill="#222"></path></svg>
                                    </a>
                                </li>
                            
                            
                                <li class="c-header__item c-header__item--pipe">
                                    <a class="c-header__link" href="https://www.nature.com/nm.rss" data-track="click" data-track-action="rss feed" data-track-label="link">
                                            <span>RSS feed</span>
                                    </a>
                                </li>
                            
                        </ul>
                    </div>
                </div>
            </div>
        
    </header>


    
    
        <nav class="u-mb-16" aria-label="breadcrumbs">
            <div class="u-container">
                <ol class="c-breadcrumbs" itemscope="" itemtype="https://schema.org/BreadcrumbList">
                    <li class="c-breadcrumbs__item" id="breadcrumb0" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:nature"><span itemprop="name">nature</span></a><meta itemprop="position" content="1">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb1" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/nm" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:nature medicine"><span itemprop="name">nature medicine</span></a><meta itemprop="position" content="2">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb2" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/nm/articles?type=article" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:articles"><span itemprop="name">articles</span></a><meta itemprop="position" content="3">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb3" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem">
                                    <span itemprop="name">article</span><meta itemprop="position" content="4"></li>
                </ol>
            </div>
        </nav>
    



    

</div>


<div class="u-container u-mt-32 u-mb-32 u-clearfix" id="content" data-component="article-container" data-container-type="article">
    <main class="c-article-main-column u-float-left js-main-column" data-track-component="article body">
        
            
                <div class="c-context-bar u-hide" id="js-enable-context-bar" data-test="context-bar" data-context-bar="" aria-hidden="true">
                    <div class="c-context-bar__container u-container" data-track-context="sticky banner">
                        <div class="c-context-bar__title">
                            <i>RNF43</i> mutations predict response to anti-BRAF/EGFR combinatory therapies in <i>BRAF</i><sup>V600E</sup> metastatic colorectal cancer
                        </div>
                        
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-022-01976-z.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                    </div>
                </div>
            
        
        <article lang="en">
            
                <div class="c-pdf-button__container u-mb-16 u-hide-at-lg js-context-bar-sticky-point-mobile">
                    <div class="c-pdf-container" data-track-context="article body">
                        
                            
                                
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-022-01976-z.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                            
                        
                    </div>
                </div>
            
            <div class="c-article-header">
                <header>
                    <ul class="c-article-identifiers" data-test="article-identifier">
                        
        <li class="c-article-identifiers__item" data-test="article-category">Article</li>
    
        <li class="c-article-identifiers__item">
            <a href="https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research" data-track="click" data-track-action="open access" data-track-label="link" class="u-color-open-access" data-test="open-access">Open access</a>
        </li>
    
    

                        <li class="c-article-identifiers__item">Published: <time datetime="2022-09-12">12 September 2022</time></li>
                    </ul>

                    <h1 class="c-article-title" data-test="article-title" data-article-title=""><i>RNF43</i> mutations predict response to anti-BRAF/EGFR combinatory therapies in <i>BRAF</i><sup>V600E</sup> metastatic colorectal cancer</h1>
                    <ul class="c-article-author-list c-article-author-list--long js-no-scroll" data-test="authors-list" data-component-authors-activator="authors-list"><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Elena-Elez-Aff1-Aff2" data-author-popup="auth-Elena-Elez-Aff1-Aff2" data-author-search="Elez, Elena" data-corresp-id="c1" data-track-context="researcher popup with no profile" data-track-index="1_30">Elena Elez<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-mail-medium"></use></svg></a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-4653-6324"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-4653-6324</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Javier-Ros-Aff1-Aff2-Aff3" data-author-popup="auth-Javier-Ros-Aff1-Aff2-Aff3" data-author-search="Ros, Javier" data-track-context="researcher popup with no profile" data-track-index="2_30">Javier Ros</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-8137-5415"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-8137-5415</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff2" tabindex="-1">2</a>,<a href="#Aff3" tabindex="-1">3</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Jose-Fern_ndez-Aff2" data-author-popup="auth-Jose-Fern_ndez-Aff2" data-author-search="Fernández, Jose" data-track-context="researcher popup with no profile" data-track-index="3_30">Jose Fernández</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Guillermo-Villacampa-Aff2" data-author-popup="auth-Guillermo-Villacampa-Aff2" data-author-search="Villacampa, Guillermo" data-track-context="researcher popup with no profile" data-track-index="4_30">Guillermo Villacampa</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Ana_Bel_n-Moreno_C_rdenas-Aff2" data-author-popup="auth-Ana_Bel_n-Moreno_C_rdenas-Aff2" data-author-search="Moreno-Cárdenas, Ana Belén" data-track-context="researcher popup with no profile" data-track-index="5_30">Ana Belén Moreno-Cárdenas</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Carlota-Arenillas-Aff2-Aff4" data-author-popup="auth-Carlota-Arenillas-Aff2-Aff4" data-author-search="Arenillas, Carlota" data-track-context="researcher popup with no profile" data-track-index="6_30">Carlota Arenillas</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a>,<a href="#Aff4" tabindex="-1">4</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Kinga-Bernatowicz-Aff2" data-author-popup="auth-Kinga-Bernatowicz-Aff2" data-author-search="Bernatowicz, Kinga" data-track-context="researcher popup with no profile" data-track-index="7_30">Kinga Bernatowicz</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0001-9166-1709"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0001-9166-1709</a></span><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Raquel-Comas-Aff2" data-author-popup="auth-Raquel-Comas-Aff2" data-author-search="Comas, Raquel" data-track-context="researcher popup with no profile" data-track-index="8_30">Raquel Comas</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Shanshan-Li-Aff5" data-author-popup="auth-Shanshan-Li-Aff5" data-author-search="Li, Shanshan" data-track-context="researcher popup with no profile" data-track-index="9_30">Shanshan Li</a><sup class="u-js-hide"><a href="#Aff5" tabindex="-1">5</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-David_Philip-Kodack-Aff6" data-author-popup="auth-David_Philip-Kodack-Aff6" data-author-search="Kodack, David Philip" data-track-context="researcher popup with no profile" data-track-index="10_30">David Philip Kodack</a><sup class="u-js-hide"><a href="#Aff6" tabindex="-1">6</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Roberta-Fasani-Aff2" data-author-popup="auth-Roberta-Fasani-Aff2" data-author-search="Fasani, Roberta" data-track-context="researcher popup with no profile" data-track-index="11_30">Roberta Fasani</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Ariadna-Garcia-Aff2" data-author-popup="auth-Ariadna-Garcia-Aff2" data-author-search="Garcia, Ariadna" data-track-context="researcher popup with no profile" data-track-index="12_30">Ariadna Garcia</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Javier-Gonzalo_Ruiz-Aff2" data-author-popup="auth-Javier-Gonzalo_Ruiz-Aff2" data-author-search="Gonzalo-Ruiz, Javier" data-track-context="researcher popup with no profile" data-track-index="13_30">Javier Gonzalo-Ruiz</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0003-4342-3815"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-4342-3815</a></span><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Alejandro-Piris_Gimenez-Aff2" data-author-popup="auth-Alejandro-Piris_Gimenez-Aff2" data-author-search="Piris-Gimenez, Alejandro" data-track-context="researcher popup with no profile" data-track-index="14_30">Alejandro Piris-Gimenez</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Paolo-Nuciforo-Aff2" data-author-popup="auth-Paolo-Nuciforo-Aff2" data-author-search="Nuciforo, Paolo" data-track-context="researcher popup with no profile" data-track-index="15_30">Paolo Nuciforo</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0003-1380-0990"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-1380-0990</a></span><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Grainne-Kerr-Aff7" data-author-popup="auth-Grainne-Kerr-Aff7" data-author-search="Kerr, Grainne" data-track-context="researcher popup with no profile" data-track-index="16_30">Grainne Kerr</a><sup class="u-js-hide"><a href="#Aff7" tabindex="-1">7</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Rossana-Intini-Aff8" data-author-popup="auth-Rossana-Intini-Aff8" data-author-search="Intini, Rossana" data-track-context="researcher popup with no profile" data-track-index="17_30">Rossana Intini</a><sup class="u-js-hide"><a href="#Aff8" tabindex="-1">8</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Aldo-Montagna-Aff8" data-author-popup="auth-Aldo-Montagna-Aff8" data-author-search="Montagna, Aldo" data-track-context="researcher popup with no profile" data-track-index="18_30">Aldo Montagna</a><sup class="u-js-hide"><a href="#Aff8" tabindex="-1">8</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Marco_Maria-Germani-Aff9" data-author-popup="auth-Marco_Maria-Germani-Aff9" data-author-search="Germani, Marco Maria" data-track-context="researcher popup with no profile" data-track-index="19_30">Marco Maria Germani</a><sup class="u-js-hide"><a href="#Aff9" tabindex="-1">9</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Giovanni-Randon-Aff10" data-author-popup="auth-Giovanni-Randon-Aff10" data-author-search="Randon, Giovanni" data-track-context="researcher popup with no profile" data-track-index="20_30">Giovanni Randon</a><sup class="u-js-hide"><a href="#Aff10" tabindex="-1">10</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Ana-Vivancos-Aff2" data-author-popup="auth-Ana-Vivancos-Aff2" data-author-search="Vivancos, Ana" data-track-context="researcher popup with no profile" data-track-index="21_30">Ana Vivancos</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Ron-Smits-Aff5" data-author-popup="auth-Ron-Smits-Aff5" data-author-search="Smits, Ron" data-track-context="researcher popup with no profile" data-track-index="22_30">Ron Smits</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0001-6798-3206"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0001-6798-3206</a></span><sup class="u-js-hide"><a href="#Aff5" tabindex="-1">5</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Diana-Graus-Aff7-Aff13" data-author-popup="auth-Diana-Graus-Aff7-Aff13" data-author-search="Graus, Diana" data-track-context="researcher popup with no profile" data-track-index="23_30">Diana Graus</a><sup class="u-js-hide"><a href="#Aff7" tabindex="-1">7</a></sup><sup class="u-js-hide">&nbsp;<a href="#nAff13" tabindex="-1">nAff13</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Raquel-Perez_Lopez-Aff2-Aff11" data-author-popup="auth-Raquel-Perez_Lopez-Aff2-Aff11" data-author-search="Perez-Lopez, Raquel" data-track-context="researcher popup with no profile" data-track-index="24_30">Raquel Perez-Lopez</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a>,<a href="#Aff11" tabindex="-1">11</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Chiara-Cremolini-Aff9" data-author-popup="auth-Chiara-Cremolini-Aff9" data-author-search="Cremolini, Chiara" data-track-context="researcher popup with no profile" data-track-index="25_30">Chiara Cremolini</a><sup class="u-js-hide"><a href="#Aff9" tabindex="-1">9</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Sara-Lonardi-Aff8" data-author-popup="auth-Sara-Lonardi-Aff8" data-author-search="Lonardi, Sara" data-track-context="researcher popup with no profile" data-track-index="26_30">Sara Lonardi</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-7593-8138"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-7593-8138</a></span><sup class="u-js-hide"><a href="#Aff8" tabindex="-1">8</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Filippo-Pietrantonio-Aff10" data-author-popup="auth-Filippo-Pietrantonio-Aff10" data-author-search="Pietrantonio, Filippo" data-track-context="researcher popup with no profile" data-track-index="27_30">Filippo Pietrantonio</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-8530-8420"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-8530-8420</a></span><sup class="u-js-hide"><a href="#Aff10" tabindex="-1">10</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Rodrigo-Dienstmann-Aff2" data-author-popup="auth-Rodrigo-Dienstmann-Aff2" data-author-search="Dienstmann, Rodrigo" data-track-context="researcher popup with no profile" data-track-index="28_30">Rodrigo Dienstmann</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Josep-Tabernero-Aff1-Aff2-Aff4-Aff12" data-author-popup="auth-Josep-Tabernero-Aff1-Aff2-Aff4-Aff12" data-author-search="Tabernero, Josep" data-track-context="researcher popup with no profile" data-track-index="29_30">Josep Tabernero</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-2495-8139"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-2495-8139</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff2" tabindex="-1">2</a>,<a href="#Aff4" tabindex="-1">4</a>,<a href="#Aff12" tabindex="-1">12</a></sup> &amp; </li><li class="c-article-author-list__show-more" aria-label="Show all 30 authors for this article" title="Show all 30 authors for this article">…</li><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Rodrigo_A_-Toledo-Aff2-Aff4" data-author-popup="auth-Rodrigo_A_-Toledo-Aff2-Aff4" data-author-search="Toledo, Rodrigo A." data-corresp-id="c2" data-track-context="researcher popup with no profile" data-track-index="30_30">Rodrigo A. Toledo<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-mail-medium"></use></svg></a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a>,<a href="#Aff4" tabindex="-1">4</a></sup>&nbsp;</li></ul><button aria-expanded="false" class="c-article-author-list__button"><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-down-medium"></use></svg><span>Show authors</span></button>

                    

                    <p class="c-article-info-details" data-container-section="info">
                        
    <a data-test="journal-link" href="/nm" data-track="click" data-track-action="journal homepage" data-track-category="article body" data-track-label="link"><i data-test="journal-title">Nature Medicine</i></a>

                        <b data-test="journal-volume"><span class="u-visually-hidden">volume</span>&nbsp;28</b>,&nbsp;<span class="u-visually-hidden">pages </span>2162–2170 (<span data-test="article-publication-year">2022</span>)<a href="#citeas" class="c-article-info-details__cite-as u-hide-print" data-track="click" data-track-action="cite this article" data-track-label="link">Cite this article</a>
                    </p>
                    
        <div class="c-article-metrics-bar__wrapper u-clear-both">
            <ul class="c-article-metrics-bar u-list-reset">
                
                    <li class=" c-article-metrics-bar__item" data-test="access-count">
                        <p class="c-article-metrics-bar__count">20k <span class="c-article-metrics-bar__label">Accesses</span></p>
                    </li>
                
                
                    <li class="c-article-metrics-bar__item" data-test="citation-count">
                        <p class="c-article-metrics-bar__count">74 <span class="c-article-metrics-bar__label">Citations</span></p>
                    </li>
                
                
                    
                        <li class="c-article-metrics-bar__item" data-test="altmetric-score">
                            <p class="c-article-metrics-bar__count">81 <span class="c-article-metrics-bar__label">Altmetric</span></p>
                        </li>
                    
                
                <li class="c-article-metrics-bar__item">
                    <p class="c-article-metrics-bar__details"><a href="/articles/s41591-022-01976-z/metrics" data-track="click" data-track-action="view metrics" data-track-label="link" rel="nofollow">Metrics <span class="u-visually-hidden">details</span></a></p>
                </li>
            </ul>
        </div>
    
                    
                </header>

                
    

                
    
    

    
    

                
            </div>

        <div class="c-article-body">
            <section aria-labelledby="Abs1" data-title="Abstract" lang="en"><div class="c-article-section" id="Abs1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Abs1">Abstract</h2><div class="c-article-section__content" id="Abs1-content"><p>Anti-BRAF/EGFR therapy was recently approved for the treatment of metastatic <i>BRAF</i><sup>V600E</sup> colorectal cancer (mCRC<sup>BRAF-V600E</sup>). However, a large fraction of patients do not respond, underscoring the need to identify molecular determinants of treatment response. Using whole-exome sequencing in a discovery cohort of patients with mCRC<sup>BRAF-V600E</sup> treated with anti-BRAF/EGFR therapy, we found that inactivating mutations in <i>RNF43</i>, a negative regulator of WNT, predict improved response rates and survival outcomes in patients with microsatellite-stable (MSS) tumors. Analysis of an independent validation cohort confirmed the relevance of <i>RNF43</i> mutations to predicting clinical benefit (72.7% versus 30.8%; <i>P</i> = 0.03), as well as longer progression-free survival (hazard ratio (HR), 0.30; 95% confidence interval (CI), 0.12–0.75; <i>P</i> = 0.01) and overall survival (HR, 0.26; 95% CI, 0.10–0.71; <i>P</i> = 0.008), in patients with MSS-<i>RNF43</i><sup>mutated</sup> versus MSS-<i>RNF43</i><sup>wild-type</sup> tumors. Microsatellite-instable tumors invariably carried a wild-type-like <i>RNF43</i> genotype encoding p.G659fs and presented an intermediate response profile. We found no association of <i>RNF43</i> mutations with patient outcomes in a control cohort of patients with MSS-mCRC<sup>BRAF-V600E</sup> tumors not exposed to anti-BRAF targeted therapies. Overall, our findings suggest a cross-talk between the MAPK and WNT pathways that may modulate the antitumor activity of anti-BRAF/EGFR therapy and uncover predictive biomarkers to optimize the clinical management of these patients.</p></div></div></section>

            
                
            

            
                
                    
        
            <section aria-labelledby="inline-recommendations" data-title="Inline Recommendations" class="c-article-recommendations" data-track-component="inline-recommendations">
                <h3 class="c-article-recommendations-title" id="inline-recommendations">Similar content being viewed by others</h3>
                <div class="c-article-recommendations-list">
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41591-024-03235-9/MediaObjects/41591_2024_3235_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s41591-024-03235-9?fromPaywallRec=false" data-track="select_recommendations_1" data-track-context="inline recommendations" data-track-action="click recommendations inline - 1" data-track-label="10.1038/s41591-024-03235-9">Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                         <span class="c-article-meta-recommendations__access-type">Open access</span>
                                         <span class="c-article-meta-recommendations__date">23 September 2024</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41467-022-33172-5/MediaObjects/41467_2022_33172_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s41467-022-33172-5?fromPaywallRec=false" data-track="select_recommendations_2" data-track-context="inline recommendations" data-track-action="click recommendations inline - 2" data-track-label="10.1038/s41467-022-33172-5">ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                         <span class="c-article-meta-recommendations__access-type">Open access</span>
                                         <span class="c-article-meta-recommendations__date">19 September 2022</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41416-020-01147-2/MediaObjects/41416_2020_1147_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s41416-020-01147-2?fromPaywallRec=false" data-track="select_recommendations_3" data-track-context="inline recommendations" data-track-action="click recommendations inline - 3" data-track-label="10.1038/s41416-020-01147-2">Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/− binimetinib or alpelisib
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                         <span class="c-article-meta-recommendations__access-type">Open access</span>
                                         <span class="c-article-meta-recommendations__date">18 November 2020</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                </div>
            </section>
        
            <script>
                window.dataLayer = window.dataLayer || [];
                window.dataLayer.push({
                    recommendations: {
                        recommender: 'semantic',
                        model: 'specter',
                        policy_id: 'NA',
                        timestamp: 1749514033,
                        embedded_user: 'null'
                    }
                });
            </script>
        
    
                
                
                <div class="main-content">
                    
                        <section data-title="Main"><div class="c-article-section" id="Sec1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec1">Main</h2><div class="c-article-section__content" id="Sec1-content"><p>The﻿ criteria to match patients with cancer with the most effective therapies relies on the identification of molecular tumor dependencies that can be targeted with available treatments<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 1" title="Di Nicolantonio, F. et al. Precision oncology in metastatic colorectal cancer—from biology to medicine. Nat. Rev. Clin. Oncol. 18, 506–525 (2021)." href="/articles/s41591-022-01976-z#ref-CR1" id="ref-link-section-d68499825e947">1</a></sup>. The <i>BRAF</i><sup>V600E</sup> mutation is found in approximately 10% of patients with metastatic colorectal cancer (mCRC), and its clinical presentation is often associated with a predominance of right-sided proximal tumors, high prevalence of microsatellite instability (MSI; near 30%), refractoriness to standard-of-care therapies and an unfavorable prognosis (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig7">1a</a>)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 2" title="Morris, V. et al. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin. Colorectal Cancer 13, 164–171 (2014)." href="/articles/s41591-022-01976-z#ref-CR2" id="ref-link-section-d68499825e958">2</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 3" title="Cremolini, C. et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 16, 1306–1315 (2015)." href="/articles/s41591-022-01976-z#ref-CR3" id="ref-link-section-d68499825e961">3</a></sup><sub>.</sub> Compared to mCRC<sup>BRAF-wild-type</sup>, <i>BRAF</i><sup>V600E</sup> tumors (hereafter referred to as mCRC<sup>BRAF-V600E</sup>) also associate with specific molecular features, including a low frequency of <i>APC</i> mutations and a high rate of mutations in the tumor suppressor gene <i>RNF43</i> (refs. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 4" title="Yaeger, R. et al. Clinical sequencing defines the genomic landscape of metastatic colorectal cancer. Cancer Cell 33, 125–136 (2018)." href="/articles/s41591-022-01976-z#ref-CR4" id="ref-link-section-d68499825e982">4</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 5" title="Hoadley, K. A. et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell 173, 291–304 (2018)." href="/articles/s41591-022-01976-z#ref-CR5" id="ref-link-section-d68499825e985">5</a></sup>), a RING E3 ubiquitin ligase involved in suppression of the WNT–β-catenin pathway through promoting the degradation of FZD/WNT receptors<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 6" title="Koo, B. K. et al. Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature 488, 665–669 (2012)." href="/articles/s41591-022-01976-z#ref-CR6" id="ref-link-section-d68499825e989">6</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 7" title="Nusse, R. &amp; Clevers, H. Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell 169, 985–999 (2017)." href="/articles/s41591-022-01976-z#ref-CR7" id="ref-link-section-d68499825e992">7</a></sup>.</p><p>BRAF<sup>V600E</sup> ATP-competitive kinase inhibitors were designed and clinically tested for the treatment of BRAF<sup>V600E</sup>-driven tumors, thus achieving variable outcomes depending on tumor type<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 8" title="Hyman, D. M. et al. Vemurafenib in multiple nonmelanoma cancers with BRAFV600 mutations. N. Engl. J. Med. 373, 726–736 (2015)." href="/articles/s41591-022-01976-z#ref-CR8" id="ref-link-section-d68499825e1003">8</a></sup>. In particular, patients with melanoma harboring <i>BRAF</i><sup>V600E</sup> mutations have been demonstrated to derive marked benefit from BRAF inhibitor monotherapy (up to 70% objective response rate (ORR)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 9" title="Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809–819 (2010)." href="/articles/s41591-022-01976-z#ref-CR9" id="ref-link-section-d68499825e1011">9</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 10" title="Sosman, J. A. et al. Survival in BRAFV600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707–714 (2012)." href="/articles/s41591-022-01976-z#ref-CR10" id="ref-link-section-d68499825e1014">10</a></sup>), while, in stark contrast, patients with <i>BRAF</i><sup>V600E</sup>-mutant CRC receiving the same treatment experienced little clinical benefit<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 8" title="Hyman, D. M. et al. Vemurafenib in multiple nonmelanoma cancers with BRAFV600 mutations. N. Engl. J. Med. 373, 726–736 (2015)." href="/articles/s41591-022-01976-z#ref-CR8" id="ref-link-section-d68499825e1023">8</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 11" title="Kopetz, S. et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J. Clin. Oncol. 28, 3534 (2010)." href="/articles/s41591-022-01976-z#ref-CR11" id="ref-link-section-d68499825e1026">11</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="Kopetz, S. et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J. Clin. Oncol. 33, 4032–4038 (2015)." href="/articles/s41591-022-01976-z#ref-CR12" id="ref-link-section-d68499825e1029">12</a></sup>. Preclinical studies uncovered an intricate molecular circuitry in CRC<sup>BRAF-V600E</sup> leading to rapid compensatory activation of the epidermal growth factor receptor (EGFR) that likely hampered the clinical outcomes of these patients<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Prahallad, A. et al. Unresponsiveness of colon cancer to BRAFV600E inhibition through feedback activation of EGFR. Nature 483, 100–103 (2012)." href="/articles/s41591-022-01976-z#ref-CR13" id="ref-link-section-d68499825e1035">13</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 14" title="Corcoran, R. B. et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227–235 (2012)." href="/articles/s41591-022-01976-z#ref-CR14" id="ref-link-section-d68499825e1038">14</a></sup>. These key findings set the rationale for the design of clinical trials targeting both BRAF and EGFR, with or without additional targeted therapies (that is, MEK, ERK or PIK3CA inhibitors) that generally achieved improved clinical outcomes as compared to previous standard-of-care treatments<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="Kopetz, S. et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J. Clin. Oncol. 33, 4032–4038 (2015)." href="/articles/s41591-022-01976-z#ref-CR12" id="ref-link-section-d68499825e1042">12</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="van Geel, R. et al. A phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic BRAF-mutant colorectal cancer. Cancer Discov. 7, 610–619 (2017)." href="#ref-CR15" id="ref-link-section-d68499825e1045">15</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Kopetz, S. et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406). J. Clin. Oncol. 39, 285–294 (2021)." href="#ref-CR16" id="ref-link-section-d68499825e1045_1">16</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17" title="Ahronian, L. G. et al. Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer Discov. 5, 358–367 (2015)." href="/articles/s41591-022-01976-z#ref-CR17" id="ref-link-section-d68499825e1048">17</a></sup>.</p><p>The clinical outcomes of patients with mCRC<sup>BRAF-V600E</sup> treated with the triplet regimen of encorafenib, cetuximab and binimetinib were assessed in the phase 3 BEACON CRC trial (<a href="https://clinicaltrials.gov/ct2/show/NCT02928224">NCT02928224</a>). The study showed that combinatorial blockade of BRAF and EGFR, with or without concomitant MEK inhibition, achieved improved ORR (26% with the triplet and 20% with the doublet therapy versus 2% in the control arm) and extended overall survival (OS) and progression-free survival (PFS)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Kopetz, S. et al. Encorafenib, binimetinib, and cetuximab in BRAFV600E-mutated colorectal cancer. N. Engl. J. Med. 381, 1632–1643 (2019)." href="/articles/s41591-022-01976-z#ref-CR18" id="ref-link-section-d68499825e1064">18</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 19" title="Van Cutsem, E. et al. Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAFV600E-mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON colorectal cancer study. J. Clin. Oncol. 37, 1460–1469 (2019)." href="/articles/s41591-022-01976-z#ref-CR19" id="ref-link-section-d68499825e1067">19</a></sup>. These results warranted approval of the doublet therapy as a new standard therapy for CRC<sup>BRAF-V600E</sup> by the US Food and Drug Administration and European Medicines Agency<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Tabernero, J. et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAFV600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J. Clin. Oncol. 39, 273–284 (2021)." href="/articles/s41591-022-01976-z#ref-CR20" id="ref-link-section-d68499825e1073">20</a></sup>. While the responses documented are unprecedented for patients with mCRC<sup>BRAF-V600E</sup>, these still compare unfavorably with the higher response rates observed in <i>BRAF</i>-mutant metastatic melanomas treated with anti-BRAF therapy<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 9" title="Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809–819 (2010)." href="/articles/s41591-022-01976-z#ref-CR9" id="ref-link-section-d68499825e1083">9</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 10" title="Sosman, J. A. et al. Survival in BRAFV600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707–714 (2012)." href="/articles/s41591-022-01976-z#ref-CR10" id="ref-link-section-d68499825e1086">10</a></sup> and display a high degree of heterogeneity, which underscores the need for a deeper understanding of factors modulating treatment response that can optimize the clinical management of patients<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 1" title="Di Nicolantonio, F. et al. Precision oncology in metastatic colorectal cancer—from biology to medicine. Nat. Rev. Clin. Oncol. 18, 506–525 (2021)." href="/articles/s41591-022-01976-z#ref-CR1" id="ref-link-section-d68499825e1090">1</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 21" title="Kopetz, S. et al. Molecular correlates of clinical benefit in previously treated patients (pts) with BRAFV600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study. J. Clin. Oncol. 39, 3513 (2021)." href="/articles/s41591-022-01976-z#ref-CR21" id="ref-link-section-d68499825e1093">21</a></sup>.</p><p>Herein we sought to explore genetic biomarkers with a predictive value that can contribute to refining the stratification of patients with mCRC<sup>BRAF-V600E</sup> treated with anti-BRAF/EGFR combinatorial therapy. We applied whole-exome sequencing (WES) and/or targeted gene sequencing on baseline tumor and/or plasma cell-free DNA (cfDNA) samples from a large cohort of patients with mCRC<sup>BRAF-V600E</sup> treated with anti-BRAF/EGFR therapy, as well as from a control cohort of patients with mCRC<sup>BRAF-V600E</sup> receiving standard chemotherapies and antiangiogenic agents (and not exposed to anti-BRAF), and integrated these data with clinical correlates of response and survival. Our findings identified molecular subtypes based on microsatellite-stable (MSS)/MSI status and <i>RNF43</i> alterations and uncovered the predictive value of <i>RNF43</i> mutations as a biomarker of clinical outcome, including increased ORR, PFS and OS, to anti-BRAF/EGFR ± combinatorial therapies. Specifically, our data show that patients with MSS-mCRC<sup>BRAF-V600E</sup> tumors harboring loss-of-function mutations in <i>RNF43</i> respond favorably to anti-BRAF/EGFR combinatorial therapy, whereas those with functional <i>RNF43</i> derived limited benefit from this regimen (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig1">1</a>).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-1" data-title="Study design."><figure><figcaption><b id="Fig1" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 1: Study design.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-022-01976-z/figures/1" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig1_HTML.png?as=webp"><img aria-describedby="Fig1" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig1_HTML.png" alt="figure 1" loading="lazy" width="685" height="519"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-1-desc"><p>A total of 166 patients with mCRC<sup>BRAF-V600E</sup> were included in the study from discovery (<i>n</i> = 46), validation (<i>n</i> = 52) and control (<i>n</i> = 68) cohorts. WES of germline DNA, baseline tumor DNA and/or baseline plasma cfDNA from 28 patients was performed. Targeted NGS was used to assess <i>RNF43</i> tumor mutation status for the 18 remaining patients from the discovery cohort and all tumors from the validation and control cohorts. Genomic profiles and MSS/MSI-<i>RNF43</i> molecular subtypes were compared with clinical response data (ORR, mPFS and mOS) using dNdScv maximum-likelihood unbiased mutation enrichment analysis<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 25" title="Martincorena, I. et al. Universal patterns of selection in cancer and somatic tissues. Cell 171, 1029–1041 (2017)." href="/articles/s41591-022-01976-z#ref-CR25" id="ref-link-section-d68499825e1154">25</a></sup>. In vitro assays were used to assess the functional impact of <i>RNF43</i> mutations detected in patient samples (see more in Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig6">6</a>).</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-022-01976-z/figures/1" data-track-dest="link:Figure1 Full size image" aria-label="Full size image figure 1" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div></div></div></section><section data-title="Results"><div class="c-article-section" id="Sec2-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec2">Results</h2><div class="c-article-section__content" id="Sec2-content"><h3 class="c-article__sub-heading" id="Sec3">Description of patient cohorts treated with anti-BRAF/EGFR</h3><p>A total of 98 patients with mCRC<sup>BRAF-V600E</sup> treated with anti-BRAF/EGFR ± combinatorial therapies in clinical trials or who received such therapies through a compassionate use program were included in the current study (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig1">1</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig7">1b</a>). The discovery cohort was composed of 46 patients from the Vall d’Hebron University Hospital (Barcelona, Spain) prospectively included from 2013 to 2021, and the validation cohort comprised 52 patients from three academic hospitals from Italy (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; University Hospital of Pisa, Pisa, Italy; Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy).</p><p>In the discovery cohort, 28 patients (61%) were female, with a median age at diagnosis of 61 years (range, 33–82 years), 31 patients (67%) had right-sided tumors, 34 patients (74%) had more than one metastatic site, and 37 patients (80%) had MSS and 9 patients (20%) had MSI tumors. In total, 35 patients (76%) received anti-BRAF/EGFR-based combinations as second- or third-line therapy, 6 patients (13%) received this as first-line therapy and 5 patients (11%) received this beyond third-line therapy. The number of patients who received the doublet combination was 29 (63%), and 17 patients (37%) received the triplet combination. The ORR by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1; ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Schwartz, L. H. et al. RECIST 1.1—standardisation and disease-specific adaptations: perspectives from the RECIST Working Group. Eur. J. Cancer 62, 138–145 (2016)." href="/articles/s41591-022-01976-z#ref-CR22" id="ref-link-section-d68499825e1195">22</a></sup>) was 44% (20/45 patients, one patient was not evaluable for response). The number of patients with MSI tumors who received immunotherapy after targeted therapy was 3 (7%). The <i>RNF43</i> mutation frequency was 43% (20/46) in the overall discovery cohort, 100% (9/9, all G659fs) in MSI tumors and 30% (11/37) in MSS tumors (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01976-z#MOESM1">1</a> and Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig2">2a</a>).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-2" data-title="Clinical responses to BRAF/EGFR inhibition according to MSS/MSI and RNF43 status."><figure><figcaption><b id="Fig2" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 2: Clinical responses to BRAF/EGFR inhibition according to MSS/MSI and <i>RNF43</i> status.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-022-01976-z/figures/2" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig2_HTML.png?as=webp"><img aria-describedby="Fig2" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig2_HTML.png" alt="figure 2" loading="lazy" width="685" height="229"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-2-desc"><p><b>a</b>,<b>b</b>, Waterfall plots representing best observed response in the mCRC<sup>BRAF-V600E</sup> discovery cohort (<i>n</i> = 44) (<b>a</b>) and validation cohort (<i>n</i> = 42) (<b>b</b>), measured as percentage best change from baseline according to RECIST 1.1 criteria<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Schwartz, L. H. et al. RECIST 1.1—standardisation and disease-specific adaptations: perspectives from the RECIST Working Group. Eur. J. Cancer 62, 138–145 (2016)." href="/articles/s41591-022-01976-z#ref-CR22" id="ref-link-section-d68499825e1244">22</a></sup> (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-022-01976-z#Sec9">Methods</a>). Colors refer to molecular subtypes: MSS-<i>RNF43</i><sup>wild-type</sup> tumors (yellow), MSS-<i>RNF43</i><sup>mutated</sup> tumors (blue) and MSI-<i>RNF43</i><sup>mutated</sup> tumors (gray).</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-022-01976-z/figures/2" data-track-dest="link:Figure2 Full size image" aria-label="Full size image figure 2" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>In the validation cohort, 31 patients (60%) were female, with a median age at diagnosis of 62 years (range, 38–80 years), 40 patients (77%) had right-sided tumors, 33 patients (63%) had more than one metastatic site, and 39 patients (75%) had MSS and 13 patients (25%) had MSI tumors. Overall, 33 (63%) patients received anti-BRAF/EGFR-based combinations as second-line therapy, and 19 patients (37%) received this as third-line therapy. The number of patients who received the doublet combination was 29 (56%), and 23 patients (44%) received the triplet combination. The ORR by RECIST 1.1 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Schwartz, L. H. et al. RECIST 1.1—standardisation and disease-specific adaptations: perspectives from the RECIST Working Group. Eur. J. Cancer 62, 138–145 (2016)." href="/articles/s41591-022-01976-z#ref-CR22" id="ref-link-section-d68499825e1275">22</a></sup>) was 27% (14/51 patients, one patient was not evaluable for response). Six patients (12%) with MSI tumors received immunotherapy after targeted therapy. The <i>RNF43</i> mutation frequency was 44% (23/52) in the overall validation cohort, 92% (12/13, G659fs) in MSI tumors and 28% (11/39) in MSS tumors (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01976-z#MOESM1">1</a> and Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig2">2b</a>).</p><h3 class="c-article__sub-heading" id="Sec4">Biomarkers of response to anti-BRAF/EGFR in MSS-mCRC<sup>BRAF-V600E</sup>
                        </h3><p>WES analysis detected mutations in several cancer-related genes previously reported to be implicated in mCRC<sup>BRAF-V600E</sup> tumors, such as <i>APC</i>, <i>TP53</i>, <i>ARID1A</i>, <i>PIK3CA</i>, <i>FBXW7</i> and <i>RNF43</i>, among others (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01976-z#MOESM1">2</a>). In general, the mutation frequencies of the discovery cohort were comparable to those observed in The Cancer Genome Atlas (TCGA) CRC tumors carrying the <i>BRAF</i><sup>V600E</sup> mutation from the PanCancer Atlas<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23" title="Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012)." href="/articles/s41591-022-01976-z#ref-CR23" id="ref-link-section-d68499825e1327">23</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 24" title="Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013)." href="/articles/s41591-022-01976-z#ref-CR24" id="ref-link-section-d68499825e1330">24</a></sup> (<i>n</i> = 46; Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01976-z#MOESM1">2</a>). Unbiased maximum-likelihood analysis of WES mutational data from responders (partial response (PR) and complete response (CR)) versus nonresponders (stable disease (SD) and progressive disease (PD)) using dNdScv<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 25" title="Martincorena, I. et al. Universal patterns of selection in cancer and somatic tissues. Cell 171, 1029–1041 (2017)." href="/articles/s41591-022-01976-z#ref-CR25" id="ref-link-section-d68499825e1341">25</a></sup> identified the <i>RNF43</i> gene as a top candidate gene associated with ORR (<i>P</i> values and <i>q</i> values &lt;0.001; Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig8">2a,b</a>). Other candidate genes were identified, but we focused on <i>RNF43</i> because of its high mutation frequency and implications in CRC biology. <i>RNF43</i> mutations were detected in both tumor-derived and plasma cfDNA-derived DNA samples (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig9">3a–c</a>).</p><p>The mutation rate of <i>RNF43</i> in the discovery cohort (20/46, 43%) was consistent with the rate reported in the TCGA PanCancer Atlas for CRC<sup>BRAF-V600E</sup> (refs. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23" title="Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012)." href="/articles/s41591-022-01976-z#ref-CR23" id="ref-link-section-d68499825e1375">23</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 24" title="Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013)." href="/articles/s41591-022-01976-z#ref-CR24" id="ref-link-section-d68499825e1378">24</a></sup>; 21/46, 46%). To test the potential association between <i>RNF43</i> mutations and ORR, we analyzed data from the whole discovery series including WES and next-generation sequencing (NGS) panel data from 45 evaluable patients with mCRC<sup>BRAF-V600E</sup>. ORR in the whole <i>RNF43</i><sup>mutated</sup> subgroup, including MSS and MSI tumors, was 63% (12/19), which was significantly superior to the ORR of 31% achieved in patients with <i>RNF43</i><sup>wild-type</sup> status (8/26; <i>P</i> = 0.03; Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig10">4a</a>). The accuracy of <i>RNF43</i> mutations alone for predicting response to treatment was 67% (sensitivity, 60%; specificity, 72%; positive predictive value (PPV), 63%; negative predictive value (NPV), 69%; Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig10">4g</a>). In line with findings in the BEACON trial, patients with MSS and MSI CRC<sup>BRAF-V600E</sup> achieved similar ORRs (50% (4/8) versus 43% (16/37); <i>P</i> = 1; Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig10">4b</a>), and the predictive accuracy of MSS/MSI status alone was 44% (sensitivity, 80%; specificity, 16%; PPV, 43%; NPV, 50%; Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig10">4g</a>).</p><p>We next classified tumor samples according to three molecular subtypes: MSS-<i>RNF43</i><sup>wild-type</sup>, MSS-<i>RNF43</i><sup>mutated</sup> and MSI-<i>RNF43</i><sup>mutated</sup>. The ORR of the MSS-<i>RNF43</i><sup>mutated</sup> subtype was significantly higher than those of the MSS-<i>RNF43</i><sup>wild-type</sup> and MSI-<i>RNF43</i><sup>mutated</sup> subtypes (73% versus 31% and 50%, respectively; <i>P</i> = 0.03) (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig2">2a</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig10">4c</a>). In agreement, accuracy for prediction of response combining MSS/MSI + <i>RNF43</i> mutation status was 67% (sensitivity, 40%; specificity, 88%; PPV, 73%; NPV, 65%; Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig10">4g</a>).</p><h3 class="c-article__sub-heading" id="Sec5">Validation of MSS/MSI-<i>RNF43</i> status and clinical response</h3><p>To explore the generalizability of the results obtained in the discovery set, we sought to validate the predictive value of <i>RNF43</i> mutations in an external independent cohort of patients treated with anti-BRAF/EGFR ± combinatorial therapies as second- or third-line therapy (<i>n</i> = 52). Overall, the ORR in the validation cohort was 27% (95% confidence interval (CI), 16.3–42%; 14/51 patients) with a median PFS (mPFS) of 4.4 months (95% CI, 4.1–5.9 months) and a median OS (mOS) of 8.5 months (95% CI, 6.9–14.2 months) (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01976-z#MOESM1">1</a>). Consistent with the results in the discovery cohort, patients in the MSS-<i>RNF43</i><sup>mutated</sup> subtype in the validation cohort also achieved a significatively higher ORR compared to those in the MSS-<i>RNF43</i><sup>wild-type</sup> and MSI-<i>RNF43</i><sup>mutated</sup> subtypes (54% versus 21% and 18%, respectively; <i>P</i> = 0.02; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig2">2b</a> and Extended Data Figs. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig10">4d–f</a> and <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig11">5a–d</a>).</p><p>We next evaluated whether the observed increased ORR was a surrogate for improved outcomes measured by PFS and OS. The mPFS in the MSS-<i>RNF43</i><sup>mutated</sup> subtype was 10.1 months (hazard ratio (HR), 0.36; 95% CI, 0.16–0.81), 4.1 months in the MSS-<i>RNF43</i><sup>wild-type</sup> subtype and 4.4 months (HR, 0.74; 95% CI, 0.36–1.50) in the MSI-<i>RNF43</i><sup>mutated</sup> subtype (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig3">3a,b</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig12">6a,b</a>). The MSS-<i>RNF43</i><sup>mutated</sup> subtype also showed a trend toward better OS compared to the MSS-<i>RNF43</i><sup>wild-type</sup> subtype (mOS of 13.6 versus 7 months; <i>P</i> = 0.07; HR, 0.46; 95% CI, 0.20–1.08; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig3">3c,d</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig12">6c,d</a>). In multivariate analysis, the MSS-<i>RNF43</i><sup>mutated</sup> subtype maintained an independent association with OS (HR, 0.26; 95% CI, 0.10–0.71; <i>P</i> = 0.008) after adjusting for imbalance in prognostic factors such as age and metastatic site (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig4">4a,b</a>). Despite having a short PFS in response to anti-BRAF/EGFR therapies, patients with MSI-<i>RNF43</i><sup>mutated</sup> status did not show a significantly lower mOS when compared to those with MSS-<i>RNF43</i><sup>mutated</sup> status, most likely because of the positive impact of the treatment with immune-checkpoint inhibitors administered in six patients (12%) with MSI after progression on anti-BRAF/EGFR therapy (HR, 0.38; 95% CI, 0.09–1.48; <i>P</i> = 0.16; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig4">4b</a>).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-3" data-title="Survival analysis of patients undergoing BRAF/EGFR inhibition according to MSS/MSI and RNF43 status."><figure><figcaption><b id="Fig3" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 3: Survival analysis of patients undergoing BRAF/EGFR inhibition according to MSS/MSI and <i>RNF43</i> status.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-022-01976-z/figures/3" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig3_HTML.png?as=webp"><img aria-describedby="Fig3" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig3_HTML.png" alt="figure 3" loading="lazy" width="685" height="522"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-3-desc"><p><b>a</b>,<b>b</b>, Kaplan–Meier curves representing PFS of patients with <i>RNF43</i><sup>wild-type</sup> (<i>n</i> = 29) and <i>RNF43</i><sup>mutated</sup> (<i>n</i> = 23) tumors (<b>a</b>) and combined <i>RNF43</i> and MSS/MSI status (MSS-<i>RNF43</i><sup>wild-type</sup> (<i>n</i> = 28), MSS-<i>RNF43</i><sup>mutated</sup> (<i>n</i> = 11) and MSI-<i>RNF43</i><sup>mutated</sup> (<i>n</i> = 12)) (<b>b</b>). <b>c</b>,<b>d</b>, OS of patients with <i>RNF43</i><sup>wild-type</sup> (<i>n</i> = 29) and <i>RNF43</i><sup>mutated</sup> (<i>n</i> = 23) tumors (<b>c</b>) and combined <i>RNF43</i> and MSS/MSI status (MSS-<i>RNF43</i><sup>wild-type</sup> (<i>n</i> = 28), MSS-<i>RNF43</i><sup>mutated</sup> (<i>n</i> = 11) and MSI-<i>RNF43</i><sup>mutated</sup> (<i>n</i> = 12)) (<b>d</b>). Cox models were used to obtain HRs with 95% CIs, and the two-sided log-rank test was used for statistical comparisons without adjustment for multiplicity. Colors indicate molecular subtypes: <i>RNF43</i><sup>wild-type</sup> tumors with or without MSS (yellow), <i>RNF43</i><sup>mutated</sup> tumors with or without MSS (blue) and MSI-<i>RNF43</i><sup>mutated</sup> tumors (gray). Significant values are shown in bold. m, months; NR, not reported; Ref., reference.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-022-01976-z/figures/3" data-track-dest="link:Figure3 Full size image" aria-label="Full size image figure 3" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-4" data-title="Univariate and multivariate Cox regression models."><figure><figcaption><b id="Fig4" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 4: Univariate and multivariate Cox regression models.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-022-01976-z/figures/4" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig4_HTML.png?as=webp"><img aria-describedby="Fig4" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig4_HTML.png" alt="figure 4" loading="lazy" width="685" height="755"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-4-desc"><p><b>a</b>,<b>b</b>, Analysis performed in the validation cohort (<i>n</i> = 52) for PFS (<b>a</b>) and OS (<b>b</b>). Univariate HRs along with 95% CIs are represented for each prognostic factor. <i>P</i> values were estimated by means of the two-sided log-rank test in the univariate analysis and by means of the Cox model in the multivariate analysis (two-sided). Significant values are shown in bold. ECOG, Eastern Cooperative Oncology Group performance; ICI, immune checkpoint inhibitor.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-022-01976-z/figures/4" data-track-dest="link:Figure4 Full size image" aria-label="Full size image figure 4" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>We also sought to explore whether, in addition to their power to predict response, the MSS/MSI-<i>RNF43</i> molecular subtypes could anticipate refractoriness to anti-BRAF/EGFR ± combinatorial therapies. Of the 16 patients with refractory mCRC<sup>BRAF-V600E</sup> in the discovery and validation cohorts with PD as the best observed response, 13 (13/16, 81%) were MSS-<i>RNF43</i><sup>wild-type</sup>, 3 (3/16, 19%) were MSI-<i>RNF43</i><sup>mutated</sup> and none (0/16, 0%) were MSS-<i>RNF43</i><sup>mutated</sup>. Strikingly, none of the 22 patients with MSS-<i>RNF43</i><sup>mutated</sup> status in the two cohorts had PD as the best response (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig11">5d</a>).</p><h3 class="c-article__sub-heading" id="Sec6">Predictive value of <i>RNF43</i> mutations in MSS-mCRC<sup>BRAF-V600E</sup>
                        </h3><p>To further confirm the value of <i>RNF43</i> mutations in predicting response to treatment in patients with MSS-mCRC<sup>BRAF-V600E</sup> tumors, we aggregated data from 68 sex- and age-matched patients treated in four different hospitals (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig13">7a–e</a>). All patients received standard-of-care chemotherapies and antiangiogenic agents that did not involve anti-BRAF therapy. The median age at diagnosis was 60.5 years (range, 30–80 years); 68% of patients had right-sided tumors. With regard to MSS/MSI-<i>RNF43</i> status, 22% of patients were MSS-<i>RNF43</i><sup>mutated</sup> and 78% were MSS-<i>RNF43</i><sup>wild-type</sup>, similar to the discovery and validation MSS tumor cohorts (29% and 71%, respectively) (Extended Data ﻿Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig13">7a–c</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01976-z#MOESM1">1</a>). Moreover, the MSS discovery/validation and control cohorts presented with similar <i>RNF43</i> mutation frequencies (29% (22/76) and 22% (15/68), respectively) (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig13">7b,c</a>) as well as <i>RNF43</i> mutation localization patterns (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig13">7d,e</a>). Among 68 patients treated in the second- and third-line setting, those in the MSS-<i>RNF43</i><sup>mutated</sup> subgroup achieved an mPFS of 1.3 months as compared to 1.6 months in the MSS-<i>RNF43</i><sup>wild-type</sup> population (HR, 0.85; 95% CI, 0.40–1.79; <i>P</i> = 0.67). Similarly, we found no differences in mOS after the start of second-line therapy (5 months in patients with MSS-<i>RNF43</i><sup>mutated</sup> tumors and 5.7 months in patients with MSS-<i>RNF43</i><sup>wild-type</sup> tumors; HR, 0.93; 95% CI, 0.30–2.83; <i>P</i> = 0.89) (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig5">5a–d</a>). To corroborate these findings, we also evaluated mPFS in the first-line setting for the entire control cohort and found no significant differences in the MSS-<i>RNF43</i><sup>mutated</sup> versus MSS-<i>RNF43</i><sup>wild-type</sup> population (4.5 months versus 3.9 months, respectively; HR, 0.64; 95% CI, 0.36–1.15; <i>P</i> = 0.13) (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig14">8a–d</a>). Altogether, these data suggest that <i>RNF43</i> mutations have no prognostic relevance in patients with MSS-mCRC<sup>BRAF-V600E</sup> in our cohort and support their predictive value in response to anti-BRAF/EGFR combinatorial therapies in this clinical setting. Conversely, the predictive value of <i>RNF43</i> mutations seen in MSS tumors was not observed in MSI tumors.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-5" data-title="Predictive value of MSS/MSI-RNF43 status."><figure><figcaption><b id="Fig5" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 5: Predictive value of MSS/MSI-<i>RNF43</i> status.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-022-01976-z/figures/5" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig5_HTML.png?as=webp"><img aria-describedby="Fig5" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig5_HTML.png" alt="figure 5" loading="lazy" width="685" height="549"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-5-desc"><p><b>a</b>–<b>d</b>, Kaplan–Meier curves representing PFS (<b>a</b>) and OS (<b>b</b>) for patients with mCRC<sup>BRAF-V600E</sup> undergoing anti-BRAF/EGFR therapy in the validation cohort (anti-BRAF/EGFR as second or third line, <i>n</i> = 39) and PFS (<b>c</b>) and OS (<b>d</b>) in patients in the control cohort not exposed to BRAF inhibition (<i>n</i> = 67 second and third treatment lines; Extended Data Fig.<a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig13">7</a>﻿). Cox models were used to obtain HRs with 95% CIs, and the two-sided log-rank test was used for statistical comparisons without adjustment for multiplicity. Colors refer to molecular subtypes: MSS-<i>RNF43</i><sup>wild-type</sup> (yellow) and MSS-<i>RNF43</i><sup>mutated</sup> (blue). Significant values are shown in bold.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-022-01976-z/figures/5" data-track-dest="link:Figure5 Full size image" aria-label="Full size image figure 5" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><h3 class="c-article__sub-heading" id="Sec7">Molecular profiles of <i>RNF43</i> mutations in mCRC<sup>BRAF-V600E</sup>
                        </h3><p>To better understand the underlying molecular features of MSS-<i>RNF43</i><sup>mutated</sup> CRC<sup>BRAF-V600E</sup> tumors, we next classified and characterized the observed <i>RNF43</i> somatic mutations occurring in patients from both the discovery and validation cohorts. <i>RNF43</i> mutations were identified in 21 of 22 (95%) MSI tumors and 22 of 76 (29%) MSS tumors. In addition to the different frequencies, the location and functional nature of the <i>RNF43</i> mutations were fundamentally distinct in MSI and MSS tumors (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig6">6a</a>). All MSI <i>RNF43</i>-mutated tumors carried a hotspot mutation encoding p.G659fs*41 at the C-terminal, which is caused by a DNA slippage error at the seven-guanine repeat region, typical in MSI tumors lacking full DNA repair machinery, and classified as moderate loss of function with retained wild-type-like functional properties<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 26" title="Tu, J. et al. The most common RNF43 mutant G659Vfs*41 is fully functional in inhibiting Wnt signaling and unlikely to play a role in tumorigenesis. Sci. Rep. 9, 18557 (2019)." href="/articles/s41591-022-01976-z#ref-CR26" id="ref-link-section-d68499825e1984">26</a></sup>. Conversely, the mutations occurring in MSS tumors were not recurrent and spanned the N-terminal domain of the protein, including the extracellular (EC), protease-associated (PA), transmembrane (TM), RING finger (RING) and DVL2-binding (DVL) domains. We identified 7 missense mutations in these domains and 16 that led to protein truncations predicted to cause loss of function<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 27" title="Yu, J. et al. The functional landscape of patient-derived RNF43 mutations predicts sensitivity to Wnt inhibition. Cancer Res. 80, 5619–5632 (2020)." href="/articles/s41591-022-01976-z#ref-CR27" id="ref-link-section-d68499825e1988">27</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Li, S. et al. Commonly observed RNF43 mutations retain functionality in attenuating Wnt/β-catenin signaling and unlikely confer Wnt-dependency onto colorectal cancers. Oncogene 39, 3458–3472 (2020)." href="/articles/s41591-022-01976-z#ref-CR28" id="ref-link-section-d68499825e1991">28</a></sup> (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig6">6a,b</a>). To validate the biological impact of the <i>RNF43</i> missense mutations detected in the MSS-mCRC<sup>BRAF-V600E</sup> tumors of our patients, we performed luciferase reporter assays<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 27" title="Yu, J. et al. The functional landscape of patient-derived RNF43 mutations predicts sensitivity to Wnt inhibition. Cancer Res. 80, 5619–5632 (2020)." href="/articles/s41591-022-01976-z#ref-CR27" id="ref-link-section-d68499825e2004">27</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Li, S. et al. Commonly observed RNF43 mutations retain functionality in attenuating Wnt/β-catenin signaling and unlikely confer Wnt-dependency onto colorectal cancers. Oncogene 39, 3458–3472 (2020)." href="/articles/s41591-022-01976-z#ref-CR28" id="ref-link-section-d68499825e2007">28</a></sup>. Compared to wild-type <i>RNF43</i>, six of seven (86%) of the <i>RNF43</i> mutations analyzed (encoding I48T, A73V, A169T, H292Y, R296H and W302R substitutions) behaved as loss-of-function variants (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig6">6c,d</a>). The corresponding inactivated RNF43 mutants lost the capacity to ubiquitinate and degrade FZD/WNT receptors, resulting in an accumulation of these receptors on the cell membrane and in high WNT signal levels in the luciferase reporter assays (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig6">6c–e</a>). Because of this effect, <i>RNF43</i> loss-of-function mutations are also referred to as ‘WNT-hyperactivating’ mutations<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Tu, J. et al. The most common RNF43 mutant G659Vfs*41 is fully functional in inhibiting Wnt signaling and unlikely to play a role in tumorigenesis. Sci. Rep. 9, 18557 (2019)." href="#ref-CR26" id="ref-link-section-d68499825e2027">26</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Yu, J. et al. The functional landscape of patient-derived RNF43 mutations predicts sensitivity to Wnt inhibition. Cancer Res. 80, 5619–5632 (2020)." href="#ref-CR27" id="ref-link-section-d68499825e2027_1">27</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Li, S. et al. Commonly observed RNF43 mutations retain functionality in attenuating Wnt/β-catenin signaling and unlikely confer Wnt-dependency onto colorectal cancers. Oncogene 39, 3458–3472 (2020)." href="/articles/s41591-022-01976-z#ref-CR28" id="ref-link-section-d68499825e2030">28</a></sup>.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-6" data-title="Functional analysis of RNF43 mutations."><figure><figcaption><b id="Fig6" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 6: Functional analysis of <i>RNF43</i> mutations.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-022-01976-z/figures/6" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig6_HTML.png?as=webp"><img aria-describedby="Fig6" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig6_HTML.png" alt="figure 6" loading="lazy" width="685" height="338"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-6-desc"><p><b>a</b>, Distinct localization and functional impact of <i>RNF43</i> mutations among patients with mCRC<sup>BRAF-V600E</sup> treated with anti-BRAF/EGFR therapy according to MSS/MSI and <i>RNF43</i> molecular status (<i>n</i> = 98). MSI CRCs (<i>n</i> = 21) carried a mutation encoding G659fs, while MSS CRCs were divided into MSS-<i>RNF43</i><sup>mutated</sup> (<i>n</i> = 22) and MSS-<i>RNF43</i><sup>wild-type</sup> (<i>n</i> = 54) tumors. Numbers indicate the amino acid residue in the RNF43 protein sequence. The MSS-<i>RNF43</i><sup>mutated</sup> subtype harbored mutations mainly in the RNF43 N-terminal domain. Colors indicate the effect of the mutation on protein function: loss of function (LOF) (red), moderate loss of function (yellow) and normal function (blue); symbols reflect MSS/MSI status (circle and triangle, respectively) and the presence of a compound mutation (discontinuous border). <b>b</b>, Illustration of the ‘cross-brace’ topology of the RING domain containing a highly conserved sequence of cysteine–histidine residues that coordinates two atoms of zinc and four hydrophobic residues that are involved in binding to E2 (canonical sequence, CX<sub>2</sub>CX<sub>(9–39)</sub>CX<sub>(1–3)</sub>HX<sub>(2–3)</sub>CX<sub>2</sub>CX<sub>(4–48)</sub>CX<sub>2</sub>C). Figure adapted from ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 36" title="Garcia-Barcena, C., Osinalde, N., Ramirez, J. &amp; Mayor, U. How to inactivate human ubiquitin E3 ligases by mutation. Front. Cell Dev. Biol. 8, 39 (2020)." href="/articles/s41591-022-01976-z#ref-CR36" id="ref-link-section-d68499825e2104">36</a></sup>, Frontiers Media (CC BY 4.0 license). Mutations encoding H292Y, R296H and W302R in the RING domain of RNF43 are circled in red, while the mutation encoding M313R is located right outside the RING protein domain and likely for this reason did not affect RNF43’s ubiquitinase function. The four conserved residues are shown in blue. <b>c</b>, Western blot quantification of Flag-tagged RNF43 protein ectopically expressed in the HEK293T cell line; β-actin, loading control. This experiment was repeated twice obtaining the same protein expression levels. <b>d</b>, In vitro luciferase reporter assays representing levels of β-catenin activation (<i>y</i> axis) upon ectopic expression of RNF43 mutants (<i>x</i> axis) in HEK293T cells, following stimulation with Wnt3A conditioned medium (CM). One representative experiment is shown. The assay was performed three times with basically identical results. The statistical significance of all mutants relative to wild-type protein was obtained using a two-sided Student’s <i>t</i>-test (**<i>P</i> &lt; 0.01, ***<i>P</i> &lt; 0.001, ****<i>P</i> &lt; 0.0001; NS, not significant). Empty vector (EV) and EV + WNT (control conditions) are shown in gray, <i>RNF43</i> alterations that behaved as loss-of-function variants are shown in red and wild-type protein and the M313R variant are shown in blue. <b>e</b>, Graphical representation of the impact of <i>RNF43</i> mutations (1) in impairing the ubiquitinase activity of the protein (2), resulting in the accumulation of FZD/WNT receptors in the cell membrane (3). Ub, ubiquitin.</p><p><a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01976-z#MOESM3">Source data</a></p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-022-01976-z/figures/6" data-track-dest="link:Figure6 Full size image" aria-label="Full size image figure 6" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>Mutations detected in other genes of the WNT pathway, such as <i>APC</i> and <i>CTNNB1</i>, are shown in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01976-z#MOESM1">1</a> and did not correlate with ORR (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig15">9a,b</a>). Moreover, no correlation was observed of β-catenin protein expression levels and localization with response to anti-BRAF/EGFR ± combinatorial therapies, MSS/MSI status or <i>RNF43</i> mutation status in 33 mCRC<sup>BRAF-V600E</sup> tumors from the discovery cohort (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig15">9c,d</a>).</p></div></div></section><section data-title="Discussion"><div class="c-article-section" id="Sec8-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec8">Discussion</h2><div class="c-article-section__content" id="Sec8-content"><p>mCRC<sup>BRAF-V600E</sup> represents an entity of its own with particular phenotypic features and with crucial implications in terms of prognosis<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 2" title="Morris, V. et al. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin. Colorectal Cancer 13, 164–171 (2014)." href="/articles/s41591-022-01976-z#ref-CR2" id="ref-link-section-d68499825e2190">2</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 3" title="Cremolini, C. et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 16, 1306–1315 (2015)." href="/articles/s41591-022-01976-z#ref-CR3" id="ref-link-section-d68499825e2193">3</a></sup>. Hence, there is a critical need for new clinical–biological insights that can lead to therapeutic improvements and the identification of new biomarkers of response. However, identification of biomarkers in this patient population, as well as development of new therapeutic strategies, has been challenging in this particular tumor type, given its underrepresentation in randomized clinical trials due to its low frequency (up to 12% of mCRC) and the high tumor burden and poor clinical conditions that impair inclusion of these patients in clinical trials<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 29" title="Van Cutsem, E., Cervantes, A., Nordlinger, B. &amp; Arnold, D. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 25, iii1–iii9 (2014)." href="/articles/s41591-022-01976-z#ref-CR29" id="ref-link-section-d68499825e2197">29</a></sup>. Indeed, some of the current recommendations for standard-of-care treatments are based on subgroup analyses of phase 3 clinical trials<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 3" title="Cremolini, C. et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 16, 1306–1315 (2015)." href="/articles/s41591-022-01976-z#ref-CR3" id="ref-link-section-d68499825e2201">3</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 30" title="Van Cutsem, E. et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 30, 3499–3506 (2012)." href="/articles/s41591-022-01976-z#ref-CR30" id="ref-link-section-d68499825e2204">30</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 31" title="Tabernero, J. et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 16, 499–508 (2015)." href="/articles/s41591-022-01976-z#ref-CR31" id="ref-link-section-d68499825e2207">31</a></sup>. On the other hand, despite the meaningful clinical activity observed in clinical trials evaluating BRAF inhibitor-based combinations, not all patients respond the same, and some responses are relatively short. This disparity in terms of treatment benefit highlights the biological heterogeneity of mCRC<sup>BRAF-V600E</sup> and justifies better molecular characterization to optimize treatment outcomes.</p><p>Through pursuing an unbiased genomic analysis of responders versus nonresponders, we detected a strong signal in the <i>RNF43</i> locus in association with clinical outcome in response to anti-BRAF/EGFR-based therapies that was confirmed in a validation cohort (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig3">3a–d</a>) but not observed in a sex- and age-matched control cohort of patients receiving standard chemotherapy ± antiangiogenic agents (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig5">5a–d</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig14">8a–d</a>). Our study uncovers a previously unknown value of <i>RNF43</i> mutations, occurring in 29% of MSS-mCRC<sup>BRAF-V600E</sup> tumors, in predicting response and clinical outcome. In contrast to patients with MSI mCRC, the patient population with MSS-mCRC<sup>BRAF-V600E</sup> currently lacks biomarkers to guide treatment decision-making. Although previous analyses had associated tumor-based transcription subtypes with response<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 32" title="Middleton, G. et al. BRAF-mutant transcriptional subtypes predict outcome of combined BRAF, MEK, and EGFR blockade with dabrafenib, trametinib, and panitumumab in patients with colorectal cancer. Clin. Cancer Res. 26, 2466–2476 (2020)." href="/articles/s41591-022-01976-z#ref-CR32" id="ref-link-section-d68499825e2236">32</a></sup>, our study reports a potential genomic prediction biomarker to anti-BRAF/EGFR-based combinations in the patient population with mCRC<sup>BRAF-V600E</sup>. Specifically, we found that within the MSS group, which represents 70% of patients with mCRC<sup>BRAF-V600E</sup>, the occurrence of a <i>RNF43</i> mutation was associated with improved ORR and, importantly, longer PFS and OS with anti-BRAF/EGFR strategies (Figs. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig2">2a,b</a>, <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig3">3a–d</a>﻿ and <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig5">5a–d</a> and Extended Data Figs. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig10">4a–g</a> and <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig5">5a–f</a>).</p><p>Overall, this finding has two main implications. First, incorporating <i>RNF43</i> mutation as a routine biomarker could contribute to defining the optimal treatment sequence in patients with MSS-mCRC<sup>BRAF-V600E</sup> according to their predicted response profile. Second, it uncovers a cross-talk between MAPK and RNF43–WNT pathways in the antitumor activity of BRAF/EGFR-targeting therapy, which might be exploited as a future potential therapeutic target.</p><p>The mechanistic basis underlying the clinical success of concomitant BRAF/EGFR inhibition builds upon preclinical evidence of a rapid feedback compensation for EGFR mediated by the activation of CRAF or by the transactivation of CRAF–BRAF heterodimers<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Prahallad, A. et al. Unresponsiveness of colon cancer to BRAFV600E inhibition through feedback activation of EGFR. Nature 483, 100–103 (2012)." href="/articles/s41591-022-01976-z#ref-CR13" id="ref-link-section-d68499825e2274">13</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 14" title="Corcoran, R. B. et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227–235 (2012)." href="/articles/s41591-022-01976-z#ref-CR14" id="ref-link-section-d68499825e2277">14</a></sup>. Our findings underscoring the potential role of RNF43 in modulating response to anti-BRAF/EGFR therapy point to an interplay between the MAPK and WNT signaling pathways in MSS-mCRC<sup>BRAF-V600E</sup> tumors. Specifically, our in vitro experiments show that most <i>RNF43</i> mutations detected in MSS tumors of responding patients have a loss-of-function effect, which contrasts with <i>RNF43</i> mutations described in MSI tumors, where the protein retains its function<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 26" title="Tu, J. et al. The most common RNF43 mutant G659Vfs*41 is fully functional in inhibiting Wnt signaling and unlikely to play a role in tumorigenesis. Sci. Rep. 9, 18557 (2019)." href="/articles/s41591-022-01976-z#ref-CR26" id="ref-link-section-d68499825e2289">26</a></sup>. In our patient datasets, loss of RNF43 would impair degradation of WNT/FZD receptors, leading to activation of the WNT pathway. While the molecular intricacies through which the MAPK and WNT pathways cross-talk to modulate the antitumor activity of this treatment combination need to be studied in detail, our clinical findings are consistent with preclinical studies describing a role for WNT activation in antagonizing MAPK-driven proliferation to preserve an equilibrium with differentiation of intestinal stem cells<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 33" title="Kabiri, Z. et al. Wnt signaling suppresses MAPK-driven proliferation of intestinal stem cells. J. Clin. Invest. 128, 3806–3812 (2018)." href="/articles/s41591-022-01976-z#ref-CR33" id="ref-link-section-d68499825e2294">33</a></sup>. It is therefore plausible to speculate that a similar mechanism of RNF43 loss-dependent WNT activation may be restraining MAPK signaling in MSS mCRC tumors and synergizing with pharmacological blockade of the pathway. Of note, we found no correlation of response with the presence of <i>APC</i> or <i>CTNNB1</i> mutations or β-catenin protein expression or localization in mCRC<sup>BRAF-V600E</sup> tumors (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig15">9a–d</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01976-z#MOESM1">1</a>), suggesting that noncanonical WNT pathways<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 34" title="Tsukiyama, T. et al. A phospho-switch controls RNF43-mediated degradation of Wnt receptors to suppress tumorigenesis. Nat. Commun. 11, 4586 (2020)." href="/articles/s41591-022-01976-z#ref-CR34" id="ref-link-section-d68499825e2313">34</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 35" title="Radaszkiewicz, T. et al. RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy. eLife 10, e65759 (2021)." href="/articles/s41591-022-01976-z#ref-CR35" id="ref-link-section-d68499825e2316">35</a></sup>, rather than canonical (β-catenin-dependent) signaling, might be involved in modulation of anti-BRAF/EGFR activity.</p><p>Despite our study representing, to our knowledge, the largest genetic biomarker analysis to date on this patient population, the overall number of patients remains limited owing to the rarity of <i>BRAF</i><sup>V600E</sup> mutation in mCRC and the difficulties in accessing clinically annotated cohorts with comprehensive genomic profiling. Furthermore, while our genomic analyses uncover a robust association of <i>RNF43</i> mutations with clinical outcome, the inherent heterogeneity of our real-world patient cohorts receiving treatment in four different hospitals and undergoing molecular profiling with different multigene panels represents another limitation to be addressed in prospective, standardized biomarker studies. The lack of randomized data represents a constraint for analysis of the predictive versus prognostic role of <i>RNF43</i> mutations. In this regard, our efforts to identify control patients exposed to chemotherapies and antiangiogenic agents during the same time period and at the same hospitals that contributed data for the discovery and validation cohorts are the best mitigation available, also taking into account that similar NGS platforms were used for molecular stratification. Finally, despite our in vitro analysis supporting a loss-of-function effect of most <i>RNF43</i> mutations detected in MSS tumors from responding patients, the mechanistic basis for how altered WNT signaling modulates MAPK pathway activation in response to anti-BRAF/EGFR agents remains to be fully elucidated.</p><p>In summary, <i>RNF43</i> mutations represent a new biomarker that warrants further validation for its potential to help prioritize anti-EGFR/BRAF combinations in selected patients with mCRC<sup>BRAF-V600E</sup> who are more likely to derive benefit and identify those patients for whom alternative treatment approaches are needed. Future research should explore incorporating this biomarker in routine testing along with <i>BRAF</i> and MSS/MSI status and evaluate their integration with other transcriptomic, microbiome or microenvironmental indicators for optimizing the clinical management of this heterogeneous and complex disease.</p></div></div></section><section data-title="Methods"><div class="c-article-section" id="Sec9-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec9">Methods</h2><div class="c-article-section__content" id="Sec9-content"><h3 class="c-article__sub-heading" id="Sec10">Predictive and prognostic value analysis</h3><p>To assess the predictive value of <i>RNF43</i> status, we aggregated the clinical and genetic data of 68 patients from four different cohorts (hospitals participating in the present work) treated with standard-of-care regimens only (no exposure to anti-BRAF therapies) whose tumors harbored <i>BRAF</i><sup>V600E</sup> mutation and with information on the status of MSI and <i>RNF43</i> mutations. These patients received in total 135 chemotherapy regimens with or without antiangiogenic drugs during the first, second or third line of therapy. To control for potential confounding factors, we excluded (1) treatments in the first line and (2) patients whose tumors were MSI and who received anti-PD1/PD-L1 therapies during the disease course. A total of 67 treatment lines (second and third line) in patients with MSS were analyzed. To compare the prognosis of patients with MSS-<i>RNF43</i><sup>mutated</sup> and MSS-<i>RNF43</i><sup>wild-type</sup> tumors, PFS and OS endpoints were estimated using the Kaplan–Meier method. Mixed-effects Cox models considering patient ID as a random effect, to adjust for the intra-patient variability in patients with more than one line of therapy, were used to obtain HRs with 95% CIs (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01976-z#MOESM1">1</a>).</p><h3 class="c-article__sub-heading" id="Sec11">Ethics committee approval</h3><p>The study was approved by each investigational site’s institutional review board/ethics committee: Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; Veneto Institute of Oncology IRCCS, Padova, Italy; Azienda Ospedaliero-Universitaria Pisana, University of Pisa, Pisa, Italy; and Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. The research was conducted in accordance with the Declaration of Helsinki and local data protection laws. All patients were provided with written informed consent before enrollment. All data provided are anonymized in line with applicable laws and regulations.</p><h3 class="c-article__sub-heading" id="Sec12">Radiological response evaluation</h3><p>All cases were reviewed by board-certified radiologists with experience in oncology imaging and clinical trials. Radiological response for each patient was classified following the principles of RECIST 1.1 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Schwartz, L. H. et al. RECIST 1.1—standardisation and disease-specific adaptations: perspectives from the RECIST Working Group. Eur. J. Cancer 62, 138–145 (2016)." href="/articles/s41591-022-01976-z#ref-CR22" id="ref-link-section-d68499825e2398">22</a></sup>): CR (disappearance of the lesion or reduction in the short axis to &lt;10 mm in the case of a pathological lymph node), PR (a decrease by at least 30% in the long axis for visceral or soft tissue disease and the short axis for pathological lymph nodes), PD (an increase of at least 20% in the long axis in the case of visceral or soft tissue disease and the short axis in the case of pathological lymph nodes) or SD (when the lesion did not fulfill the criteria for PR or PD). As is commonly the case in clinical practice for aggressive tumors, some patients included in the study had no image available due to evident progression as per rapid clinical deterioration, increase in the levels of tumor markers in plasma (CEA) and progression of nontarget disease. These patients were considered to have clinical PD.</p><h3 class="c-article__sub-heading" id="Sec13">DNA extraction</h3><p>DNA extraction from tumor samples was performed with the automated system Maxwell 16 FFPE plus LEV DNA purification kit (Promega), and quality and concentration were measured with a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific). cfDNA was extracted from 1 ml of plasma using the QIAamp Circulating Nucleic Acid Kit (Qiagen), based on the manufacturer’s recommendations, and quantified using the highly sensitive kit for the Qubit, dsDNA HS (High Sensitivity) Assay Kit (Thermo Fisher Scientific).</p><h3 class="c-article__sub-heading" id="Sec14">WES</h3><p>WES was performed in 55 baseline biological samples available at VHIO’s sample biobank (19 germline DNA, 22 tumor DNA, 5 patient-derived xenograft DNA and 9 plasma cfDNA) from 28 patients from the discovery cohort. Genomic libraries were prepared using 10–15 ng of cfDNA and the ThruPLEX DNA or Plasma-seq Kit (Rubicon Genomics; now commercialized as the SMARTer ThruPLEX plasma-seq kit by Takara Bio)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 37" title="Toledo, R. A. et al. Exome sequencing of plasma DNA portrays the mutation landscape of colorectal cancer and discovers mutated VEGFR2 receptors as modulators of antiangiogenic therapies. Clin. Cancer Res. 24, 3550–3559 (2018)." href="/articles/s41591-022-01976-z#ref-CR37" id="ref-link-section-d68499825e2419">37</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 38" title="Hastings, R. K. et al. Longitudinal whole-exome sequencing of cell-free DNA for tracking the co-evolutionary tumor and immune evasion dynamics: longitudinal data from a single patient. Ann. Oncol. 32, 681–684 (2021)." href="/articles/s41591-022-01976-z#ref-CR38" id="ref-link-section-d68499825e2422">38</a></sup>. Quality control of libraries was carried out in TapeStation (Agilent), and amplified profiles of ~300 base pairs were considered for downstream analysis. Capture of the genomic coding regions for WES was performed using the SureSelect Human All Exon V5 or V6 kit (Agilent), with a target sequencing output of 12 Gb (100×) for genomic DNA and 36 Gb (300×) for tumor and cfDNA. Sequencing was carried out on a HiSeq or NovaSeq Illumina sequencing platform.</p><h3 class="c-article__sub-heading" id="Sec15">NGS cancer gene panel</h3><p>Tumor samples from the discovery cohort that did not have WES data (<i>n</i> = 18) and from the validation (<i>n</i> = 52) and control (<i>n</i> = 68) cohorts were genetically analyzed using a VHIO in-house NGS test of 430 cancer genes or a Foundation Medicine or Caris Life Sciences commercial NGS platform<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 39" title="Randon, G. et al. Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer. Eur. J. Cancer 161, 90–98 (2022)." href="/articles/s41591-022-01976-z#ref-CR39" id="ref-link-section-d68499825e2443">39</a></sup>.</p><h3 class="c-article__sub-heading" id="Sec16">Bioinformatics</h3><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec17">Data processing and analysis (WES)</h4><p>The WES samples (FASTQ files) were processed using sarek (v2.7.1)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 40" title="Garcia, M. et al. Sarek: a portable workflow for whole-genome sequencing analysis of germline and somatic variants. F1000Res 9, 63 (2020)." href="/articles/s41591-022-01976-z#ref-CR40" id="ref-link-section-d68499825e2459">40</a></sup>. Briefly, the following steps were performed: quality filtering and adaptor trimming with TrimGalore; alignment to the reference genome with BWA; marking of duplicates with GATK4 MarkDuplicates; recalibration of scores with GATK4 BaseRecalibrator and ApplyBSQR; and computing of pileups with SAMtools. Variant calling was performed using four different tools: Mutect2, Strelka2, MSIsensor and Control-FREEC (tumor-only and pair mode). Filtering of the variants generated by Mutect2 was conducted using GATK4 GetPileupSummaries, CalculateContamination and FilterMutectCalls. Annotation of the variants was performed using snpEff. MultipleQC and statistics were generated using FastQC, Qualimap, SAMtools, VCFtools and MultiQC. We used a public Panel of Normals (PON) obtained from the public repository of GATK at gs://gatk-best-practices/somatic-hg38/1000g_pon.hg38.vcf.gz and a BED file containing all the genomic intervals of the kits used to generate the WES samples. Mutect2 variants corresponding to the tumor-only samples were refiltered with GATK4 FilterMutectCalls using a value of 10 for the parameter ‘-max-events-in-region’. These variants were subsequently reannotated with snpEff with the same genome reference, version and settings that were used in the processing pipeline. The generated mutational data were subsequently summarized, postprocessed, filtered and validated for downstream analysis.</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec18">Mutational enrichment analysis</h4><p>Two different analyses were performed on the discovery cohort to determine which genes were enriched for somatic mutations in the responder and nonresponder groups. In the first analysis, we summarized the number of mutations, accumulated mutated allele frequency and number of samples/patients per gene. In the second analysis, we computed somatic enrichment <i>P</i> values and <i>q</i> values for each group using dNdScv<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 25" title="Martincorena, I. et al. Universal patterns of selection in cancer and somatic tissues. Cell 171, 1029–1041 (2017)." href="/articles/s41591-022-01976-z#ref-CR25" id="ref-link-section-d68499825e2477">25</a></sup> (GRCh38). This tool models the background mutation rate of each gene by combining local information (synonymous mutations in the gene) and global information (nonsynonymous mutations in the gene and other covariates) and controlling for the sequence composition of the gene and mutational signatures<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 25" title="Martincorena, I. et al. Universal patterns of selection in cancer and somatic tissues. Cell 171, 1029–1041 (2017)." href="/articles/s41591-022-01976-z#ref-CR25" id="ref-link-section-d68499825e2481">25</a></sup>.</p><h3 class="c-article__sub-heading" id="Sec19">Functional classification of <i>RNF43</i> mutations</h3><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec20">Functional classification derived from previous in vitro and in vivo studies</h4><p>To initially assess the potential biological consequences of the identified <i>RNF43</i> mutations, we applied a recently developed functional classification derived from in vitro and in vivo studies<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Tu, J. et al. The most common RNF43 mutant G659Vfs*41 is fully functional in inhibiting Wnt signaling and unlikely to play a role in tumorigenesis. Sci. Rep. 9, 18557 (2019)." href="#ref-CR26" id="ref-link-section-d68499825e2505">26</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Yu, J. et al. The functional landscape of patient-derived RNF43 mutations predicts sensitivity to Wnt inhibition. Cancer Res. 80, 5619–5632 (2020)." href="#ref-CR27" id="ref-link-section-d68499825e2505_1">27</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Li, S. et al. Commonly observed RNF43 mutations retain functionality in attenuating Wnt/β-catenin signaling and unlikely confer Wnt-dependency onto colorectal cancers. Oncogene 39, 3458–3472 (2020)." href="/articles/s41591-022-01976-z#ref-CR28" id="ref-link-section-d68499825e2508">28</a></sup>. Accordingly, <i>RNF43</i> mutations can be classified as (1) wild-type like, (2) activators of the WNT–β-catenin pathway or (3) hyperactivators of the WNT–β-catenin pathway<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Tu, J. et al. The most common RNF43 mutant G659Vfs*41 is fully functional in inhibiting Wnt signaling and unlikely to play a role in tumorigenesis. Sci. Rep. 9, 18557 (2019)." href="#ref-CR26" id="ref-link-section-d68499825e2515">26</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Yu, J. et al. The functional landscape of patient-derived RNF43 mutations predicts sensitivity to Wnt inhibition. Cancer Res. 80, 5619–5632 (2020)." href="#ref-CR27" id="ref-link-section-d68499825e2515_1">27</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Li, S. et al. Commonly observed RNF43 mutations retain functionality in attenuating Wnt/β-catenin signaling and unlikely confer Wnt-dependency onto colorectal cancers. Oncogene 39, 3458–3472 (2020)." href="/articles/s41591-022-01976-z#ref-CR28" id="ref-link-section-d68499825e2518">28</a></sup>. Mechanistically, wild-type-like mutants maintain their capability to repress the WNT–β-catenin pathway and activators lose their ubiquitinase function, leading to an increased abundance of FZD/WNT receptors in the cellular membrane and activation of the WNT–β-catenin pathway, while hyperactivators exert a dominant-negative effect on the wild-type protein, completely blocking ubiquitination of FZD/WNT receptors and thereby leading to extremely high levels of WNT–β-catenin pathway activation<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Tu, J. et al. The most common RNF43 mutant G659Vfs*41 is fully functional in inhibiting Wnt signaling and unlikely to play a role in tumorigenesis. Sci. Rep. 9, 18557 (2019)." href="#ref-CR26" id="ref-link-section-d68499825e2522">26</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Yu, J. et al. The functional landscape of patient-derived RNF43 mutations predicts sensitivity to Wnt inhibition. Cancer Res. 80, 5619–5632 (2020)." href="#ref-CR27" id="ref-link-section-d68499825e2522_1">27</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Li, S. et al. Commonly observed RNF43 mutations retain functionality in attenuating Wnt/β-catenin signaling and unlikely confer Wnt-dependency onto colorectal cancers. Oncogene 39, 3458–3472 (2020)." href="/articles/s41591-022-01976-z#ref-CR28" id="ref-link-section-d68499825e2525">28</a></sup>.</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec21">Luciferase reporter assays with <i>RNF43</i> mutation expression vectors</h4><p>To further demonstrate the biological impact of the identified <i>RNF43</i> missense mutations, we performed luciferase reporter assays with ectopic expression of the <i>RNF43</i> mutants. Flag-tagged <i>RNF43</i> mutation expression plasmids were generated using the New England Biolabs Q5 Mutagenesis Kit<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 27" title="Yu, J. et al. The functional landscape of patient-derived RNF43 mutations predicts sensitivity to Wnt inhibition. Cancer Res. 80, 5619–5632 (2020)." href="/articles/s41591-022-01976-z#ref-CR27" id="ref-link-section-d68499825e2550">27</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Li, S. et al. Commonly observed RNF43 mutations retain functionality in attenuating Wnt/β-catenin signaling and unlikely confer Wnt-dependency onto colorectal cancers. Oncogene 39, 3458–3472 (2020)." href="/articles/s41591-022-01976-z#ref-CR28" id="ref-link-section-d68499825e2553">28</a></sup>. All plasmids were full-length sequence verified.</p><p>HEK293T cells were used for the assays, cultured in DMEM (Gibco) supplemented with 10% (vol/vol) FBS (Gibco). Cells were cultured in a humidified incubator maintained at 37 °C with 5% CO<sub>2</sub>. Cells tested negative for mycoplasma based on the real-time PCR method at Eurofins GATC-Biotech (Konstanz, Germany). Identity of the HEK293T cells was confirmed by the Erasmus Molecular Diagnostics Department, using PowerPlex-16 STR genotyping (Promega). For the β-catenin reporter assays, HEK293T cells were seeded in 24-well plates and transfected with 100 ng WRE Wnt/β-catenin reporter, 100 ng RNF43 expression plasmid (wild-type RNF43, mutant RNF43 or empty vector) and 10 ng CMV-Renilla expression plasmid, using Lipofectamine 2000 (Thermo Fisher Scientific) as transfection reagent. L-Wnt3A or L-control conditioned medium (diluted 30-fold in normal growth medium) was added after 16 h. Cells were lysed in passive lysis buffer (Promega) 48 h after transfection. Next, the firefly and <i>Renilla</i> luciferase activity was measured with the Dual-Luciferase Reporter Assay System (Promega) using a LumiStar Optima luminescence counter (BMG LabTech). β-catenin reporter activity was measured in triplicate. All β-catenin reporter values were normalized to the value obtained for cells with empty vector exposed to L-control conditioned medium, which was arbitrarily set to 1. One representative experiment is shown. The assay was performed three times with basically identical results. Proper expression of Flag-tagged RNF43 was analyzed using fluorescent western blotting as described below.</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec22">Immunoblotting analysis</h4><p>Immunoblotting was carried out using standard methods. HEK293T cells transfected with RNF43 were lysed in 2× Laemmli sample buffer with 0.1 M dithiothreitol and heated for 10 min at 95 °C. Proteins were separated by 10% SDS–PAGE and then transferred to an Immobilon-P PVDF membrane (MilliporeSigma). The membrane was blocked for 1 h with Odyssey Blocking Buffer (LI-COR Biosciences) at room temperature and incubated overnight with primary antibodies at 4 °C. After washing three times with 0.05% Tween-20 in TBS (TBST) buffer for 10 min, the membrane was incubated for 1 h with IRDye 680 Goat Anti-Mouse (1:10,000; LI 926-68070, LI-COR Biosciences) and then washed three times with TBST for 10 min. The membrane was scanned on the Odyssey Infrared Imaging System (LI-COR Biosciences). Primary antibodies used were mouse anti-FLAG (1:1,000; F1804, Sigma-Aldrich) and mouse anti-β-actin (1:1,000; sc-47778, Santa Cruz).</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec23">Immunostaining of β-catenin in CRC<sup>BRAF-V600E</sup> tumors</h4><p>Immunohistochemical analysis was performed using a primary antibody against human β-catenin (prediluted, Beta-Catenin Mouse Monoclonal Antibody, clone 14, 760-4242, Cell Marque) in Benchmark ULTRA (Ventana Medical Systems). Labeling was performed using ULTRA Cell Conditioning 1 (ULTRACC1) (950-224, Roche) antigen retrieval buffer for 64 min at 95 °C, followed by incubation with primary antibody for 32 min at 36 °C and detection with the Ventana UltraView Universal DAB Detection Kit (760-500, Roche). Immunohistochemistry was scored semiquantitatively by one pathologist (R.F.) using an H-score (for the cytoplasm, membrane and nucleus separately). H-score was obtained by multiplying the proportion of cells showing cytoplasmic, membrane or nuclear staining and the intensity of staining (0, no staining; 1, weak; 2, moderate; 3, strong).</p><h4 class="c-article__sub-heading c-article__sub-heading--small" id="Sec24">Statistical analysis</h4><p>A descriptive analysis of all included variables in the study was performed. Continuous variables were expressed as the median and interquartile range, and categorical variables were expressed as absolute values and percentages. ORR was estimated in all subgroups based on RECIST version 1.1 criteria along with 95% CIs, and Fisher’s exact test was used to assess statistical significance. Accuracy, sensitivity, specificity, and PPV and NPV were calculated to quantify the diagnostic performance of each potential biomarker.</p><p>PFS was defined as the time from anti-BRAF/EGFR therapy initiation to disease progression or death, whichever occurred first. OS was defined as the time from anti-BRAF/EGFR therapy initiation to death from any cause. PFS and OS were estimated using the Kaplan–Meier method and compared by the log-rank test. Cox proportional-hazard models were used to obtain HRs with 95% CIs. Formal statistical testing was only used in the validation cohort. No data imputation was performed. All tests were two sided with a value of <i>P</i> &lt; 0.05 considered statistically significant without adjustment for multiple comparisons. All statistical analyses were performed using R statistical software.</p><h3 class="c-article__sub-heading" id="Sec25">Reporting summary</h3><p>Further information on research design is available in the <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01976-z#MOESM1">Nature Research Reporting Summary</a> linked to this article.</p></div></div></section>
                    
                </div>
            

            <div class="u-mt-32">
                <section data-title="Data availability"><div class="c-article-section" id="data-availability-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="data-availability">Data availability</h2><div class="c-article-section__content" id="data-availability-content">
              
              <p>Reference genome GRCh38 was used for alignment. The FASTQ files corresponding to the WES data from clinical samples analyzed in the paper have been deposited in the European Genome-phenome Archive (EGA, <a href="https://ega-archive.org">https://ega-archive.org</a>) under study ID <a href="https://ega-archive.org/studies/EGAS00001006247">EGAS00001006247</a> and dataset ID <a href="https://ega-archive.org/datasets/EGAD00001008755">EGAD00001008755</a> with appropriate measures for controlled access (DUO: 0000020, DUO: 0000021). Further information about EGA can be found on <a href="https://ega-archive.org">https://ega-archive.org</a>, “The European Genome-phenome Archive in 2021” (<a href="https://academic.oup.com/nar/advance-article/doi/10.1093/nar/gkab1059/6430505">https://academic.oup.com/nar/advance-article/doi/10.1093/nar/gkab1059/6430505</a>). Clinical and genetic data for the patients are available in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-01976-z#MOESM1">1</a>. <a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-022-01976-z#Sec29">Source data</a> are provided with this paper.</p>
            </div></div></section><section data-title="Code availability"><div class="c-article-section" id="code-availability-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="code-availability">Code availability</h2><div class="c-article-section__content" id="code-availability-content">
              
              <p>The code for the pipeline that was used to process all samples can be found at <a href="https://github.com/nf-core/sarek">https://github.com/nf-core/sarek</a>. Sarek is a Nextflow-based pipeline that integrates all the processing, mapping, variant calling and quality control steps<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 25" title="Martincorena, I. et al. Universal patterns of selection in cancer and somatic tissues. Cell 171, 1029–1041 (2017)." href="/articles/s41591-022-01976-z#ref-CR25" id="ref-link-section-d68499825e2795">25</a></sup>. The code used for postprocessing, filtering, validation and analysis of the mutational data is available at <a href="https://github.com/jfnavarro/scitron">https://github.com/jfnavarro/scitron</a>.</p>
            </div></div></section><div id="MagazineFulltextArticleBodySuffix"><section aria-labelledby="Bib1" data-title="References"><div class="c-article-section" id="Bib1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Bib1">References</h2><div class="c-article-section__content" id="Bib1-content"><div data-container-section="references"><ol class="c-article-references" data-track-component="outbound reference" data-track-context="references section"><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="1."><p class="c-article-references__text" id="ref-CR1">Di Nicolantonio, F. et al. Precision oncology in metastatic colorectal cancer—from biology to medicine. <i>Nat. Rev. Clin. Oncol.</i> <b>18</b>, 506–525 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41571-021-00495-z" data-track-item_id="10.1038/s41571-021-00495-z" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41571-021-00495-z" aria-label="Article reference 1" data-doi="10.1038/s41571-021-00495-z">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 1" href="http://scholar.google.com/scholar_lookup?&amp;title=Precision%20oncology%20in%20metastatic%20colorectal%20cancer%E2%80%94from%20biology%20to%20medicine&amp;journal=Nat.%20Rev.%20Clin.%20Oncol.&amp;doi=10.1038%2Fs41571-021-00495-z&amp;volume=18&amp;pages=506-525&amp;publication_year=2021&amp;author=Nicolantonio%2CF">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="2."><p class="c-article-references__text" id="ref-CR2">Morris, V. et al. Progression-free survival remains poor over sequential lines of systemic therapy in patients with <i>BRAF</i>-mutated colorectal cancer. <i>Clin. Colorectal Cancer</i> <b>13</b>, 164–171 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.clcc.2014.06.001" data-track-item_id="10.1016/j.clcc.2014.06.001" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.clcc.2014.06.001" aria-label="Article reference 2" data-doi="10.1016/j.clcc.2014.06.001">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 2" href="http://scholar.google.com/scholar_lookup?&amp;title=Progression-free%20survival%20remains%20poor%20over%20sequential%20lines%20of%20systemic%20therapy%20in%20patients%20with%20BRAF-mutated%20colorectal%20cancer&amp;journal=Clin.%20Colorectal%20Cancer&amp;doi=10.1016%2Fj.clcc.2014.06.001&amp;volume=13&amp;pages=164-171&amp;publication_year=2014&amp;author=Morris%2CV">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="3."><p class="c-article-references__text" id="ref-CR3">Cremolini, C. et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. <i>Lancet Oncol.</i> <b>16</b>, 1306–1315 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/S1470-2045(15)00122-9" data-track-item_id="10.1016/S1470-2045(15)00122-9" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2FS1470-2045%2815%2900122-9" aria-label="Article reference 3" data-doi="10.1016/S1470-2045(15)00122-9">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXhsVOntL3F" aria-label="CAS reference 3">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 3" href="http://scholar.google.com/scholar_lookup?&amp;title=FOLFOXIRI%20plus%20bevacizumab%20versus%20FOLFIRI%20plus%20bevacizumab%20as%20first-line%20treatment%20of%20patients%20with%20metastatic%20colorectal%20cancer%3A%20updated%20overall%20survival%20and%20molecular%20subgroup%20analyses%20of%20the%20open-label%2C%20phase%203%20TRIBE%20study&amp;journal=Lancet%20Oncol.&amp;doi=10.1016%2FS1470-2045%2815%2900122-9&amp;volume=16&amp;pages=1306-1315&amp;publication_year=2015&amp;author=Cremolini%2CC">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="4."><p class="c-article-references__text" id="ref-CR4">Yaeger, R. et al. Clinical sequencing defines the genomic landscape of metastatic colorectal cancer. <i>Cancer Cell</i> <b>33</b>, 125–136 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.ccell.2017.12.004" data-track-item_id="10.1016/j.ccell.2017.12.004" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.ccell.2017.12.004" aria-label="Article reference 4" data-doi="10.1016/j.ccell.2017.12.004">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXntVejsg%3D%3D" aria-label="CAS reference 4">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 4" href="http://scholar.google.com/scholar_lookup?&amp;title=Clinical%20sequencing%20defines%20the%20genomic%20landscape%20of%20metastatic%20colorectal%20cancer&amp;journal=Cancer%20Cell&amp;doi=10.1016%2Fj.ccell.2017.12.004&amp;volume=33&amp;pages=125-136&amp;publication_year=2018&amp;author=Yaeger%2CR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="5."><p class="c-article-references__text" id="ref-CR5">Hoadley, K. A. et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. <i>Cell</i> <b>173</b>, 291–304 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.cell.2018.03.022" data-track-item_id="10.1016/j.cell.2018.03.022" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.cell.2018.03.022" aria-label="Article reference 5" data-doi="10.1016/j.cell.2018.03.022">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXntFahs7k%3D" aria-label="CAS reference 5">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 5" href="http://scholar.google.com/scholar_lookup?&amp;title=Cell-of-origin%20patterns%20dominate%20the%20molecular%20classification%20of%2010%2C000%20tumors%20from%2033%20types%20of%20cancer&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2018.03.022&amp;volume=173&amp;pages=291-304&amp;publication_year=2018&amp;author=Hoadley%2CKA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="6."><p class="c-article-references__text" id="ref-CR6">Koo, B. K. et al. Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. <i>Nature</i> <b>488</b>, 665–669 (2012).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nature11308" data-track-item_id="10.1038/nature11308" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnature11308" aria-label="Article reference 6" data-doi="10.1038/nature11308">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC38XhtF2rurjE" aria-label="CAS reference 6">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 6" href="http://scholar.google.com/scholar_lookup?&amp;title=Tumour%20suppressor%20RNF43%20is%20a%20stem-cell%20E3%20ligase%20that%20induces%20endocytosis%20of%20Wnt%20receptors&amp;journal=Nature&amp;doi=10.1038%2Fnature11308&amp;volume=488&amp;pages=665-669&amp;publication_year=2012&amp;author=Koo%2CBK">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="7."><p class="c-article-references__text" id="ref-CR7">Nusse, R. &amp; Clevers, H. Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. <i>Cell</i> <b>169</b>, 985–999 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.cell.2017.05.016" data-track-item_id="10.1016/j.cell.2017.05.016" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.cell.2017.05.016" aria-label="Article reference 7" data-doi="10.1016/j.cell.2017.05.016">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXpt1agsro%3D" aria-label="CAS reference 7">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 7" href="http://scholar.google.com/scholar_lookup?&amp;title=Wnt%2F%CE%B2-catenin%20signaling%2C%20disease%2C%20and%20emerging%20therapeutic%20modalities&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2017.05.016&amp;volume=169&amp;pages=985-999&amp;publication_year=2017&amp;author=Nusse%2CR&amp;author=Clevers%2CH">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="8."><p class="c-article-references__text" id="ref-CR8">Hyman, D. M. et al. Vemurafenib in multiple nonmelanoma cancers with <i>BRAF</i><sup>V600</sup> mutations. <i>N. Engl. J. Med.</i> <b>373</b>, 726–736 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1502309" data-track-item_id="10.1056/NEJMoa1502309" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1502309" aria-label="Article reference 8" data-doi="10.1056/NEJMoa1502309">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28XkvFWrtg%3D%3D" aria-label="CAS reference 8">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 8" href="http://scholar.google.com/scholar_lookup?&amp;title=Vemurafenib%20in%20multiple%20nonmelanoma%20cancers%20with%20BRAFV600%20mutations&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1502309&amp;volume=373&amp;pages=726-736&amp;publication_year=2015&amp;author=Hyman%2CDM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="9."><p class="c-article-references__text" id="ref-CR9">Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. <i>N. Engl. J. Med.</i> <b>363</b>, 809–819 (2010).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1002011" data-track-item_id="10.1056/NEJMoa1002011" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1002011" aria-label="Article reference 9" data-doi="10.1056/NEJMoa1002011">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3cXhtVyksb3M" aria-label="CAS reference 9">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 9" href="http://scholar.google.com/scholar_lookup?&amp;title=Inhibition%20of%20mutated%2C%20activated%20BRAF%20in%20metastatic%20melanoma&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1002011&amp;volume=363&amp;pages=809-819&amp;publication_year=2010&amp;author=Flaherty%2CKT">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="10."><p class="c-article-references__text" id="ref-CR10">Sosman, J. A. et al. Survival in <i>BRAF</i><sup>V600</sup>-mutant advanced melanoma treated with vemurafenib. <i>N. Engl. J. Med.</i> <b>366</b>, 707–714 (2012).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1112302" data-track-item_id="10.1056/NEJMoa1112302" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1112302" aria-label="Article reference 10" data-doi="10.1056/NEJMoa1112302">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC38XjtFOqtr0%3D" aria-label="CAS reference 10">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 10" href="http://scholar.google.com/scholar_lookup?&amp;title=Survival%20in%20BRAFV600-mutant%20advanced%20melanoma%20treated%20with%20vemurafenib&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1112302&amp;volume=366&amp;pages=707-714&amp;publication_year=2012&amp;author=Sosman%2CJA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="11."><p class="c-article-references__text" id="ref-CR11">Kopetz, S. et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. <i>J. Clin. Oncol.</i> <b>28</b>, 3534 (2010).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1200/jco.2010.28.15_suppl.3534" data-track-item_id="10.1200/jco.2010.28.15_suppl.3534" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1200%2Fjco.2010.28.15_suppl.3534" aria-label="Article reference 11" data-doi="10.1200/jco.2010.28.15_suppl.3534">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 11" href="http://scholar.google.com/scholar_lookup?&amp;title=PLX4032%20in%20metastatic%20colorectal%20cancer%20patients%20with%20mutant%20BRAF%20tumors&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2Fjco.2010.28.15_suppl.3534&amp;volume=28&amp;publication_year=2010&amp;author=Kopetz%2CS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="12."><p class="c-article-references__text" id="ref-CR12">Kopetz, S. et al. Phase II pilot study of vemurafenib in patients with metastatic <i>BRAF</i>-mutated colorectal cancer. <i>J. Clin. Oncol.</i> <b>33</b>, 4032–4038 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1200/JCO.2015.63.2497" data-track-item_id="10.1200/JCO.2015.63.2497" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2015.63.2497" aria-label="Article reference 12" data-doi="10.1200/JCO.2015.63.2497">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28XmvV2gtr8%3D" aria-label="CAS reference 12">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 12" href="http://scholar.google.com/scholar_lookup?&amp;title=Phase%20II%20pilot%20study%20of%20vemurafenib%20in%20patients%20with%20metastatic%20BRAF-mutated%20colorectal%20cancer&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2015.63.2497&amp;volume=33&amp;pages=4032-4038&amp;publication_year=2015&amp;author=Kopetz%2CS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="13."><p class="c-article-references__text" id="ref-CR13">Prahallad, A. et al. Unresponsiveness of colon cancer to BRAF<sup>V600E</sup> inhibition through feedback activation of EGFR. <i>Nature</i> <b>483</b>, 100–103 (2012).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nature10868" data-track-item_id="10.1038/nature10868" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnature10868" aria-label="Article reference 13" data-doi="10.1038/nature10868">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC38XjtFOktb4%3D" aria-label="CAS reference 13">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 13" href="http://scholar.google.com/scholar_lookup?&amp;title=Unresponsiveness%20of%20colon%20cancer%20to%20BRAFV600E%20inhibition%20through%20feedback%20activation%20of%20EGFR&amp;journal=Nature&amp;doi=10.1038%2Fnature10868&amp;volume=483&amp;pages=100-103&amp;publication_year=2012&amp;author=Prahallad%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="14."><p class="c-article-references__text" id="ref-CR14">Corcoran, R. B. et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of <i>BRAF</i> mutant colorectal cancers to RAF inhibition with vemurafenib. <i>Cancer Discov.</i> <b>2</b>, 227–235 (2012).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/2159-8290.CD-11-0341" data-track-item_id="10.1158/2159-8290.CD-11-0341" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F2159-8290.CD-11-0341" aria-label="Article reference 14" data-doi="10.1158/2159-8290.CD-11-0341">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC38XktVGntbs%3D" aria-label="CAS reference 14">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 14" href="http://scholar.google.com/scholar_lookup?&amp;title=EGFR-mediated%20re-activation%20of%20MAPK%20signaling%20contributes%20to%20insensitivity%20of%20BRAF%20mutant%20colorectal%20cancers%20to%20RAF%20inhibition%20with%20vemurafenib&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-11-0341&amp;volume=2&amp;pages=227-235&amp;publication_year=2012&amp;author=Corcoran%2CRB">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="15."><p class="c-article-references__text" id="ref-CR15">van Geel, R. et al. A phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic <i>BRAF</i>-mutant colorectal cancer. <i>Cancer Discov.</i> <b>7</b>, 610–619 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/2159-8290.CD-16-0795" data-track-item_id="10.1158/2159-8290.CD-16-0795" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F2159-8290.CD-16-0795" aria-label="Article reference 15" data-doi="10.1158/2159-8290.CD-16-0795">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 15" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20phase%20Ib%20dose-escalation%20study%20of%20encorafenib%20and%20cetuximab%20with%20or%20without%20alpelisib%20in%20metastatic%20BRAF-mutant%20colorectal%20cancer&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-16-0795&amp;volume=7&amp;pages=610-619&amp;publication_year=2017&amp;author=Geel%2CR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="16."><p class="c-article-references__text" id="ref-CR16">Kopetz, S. et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in <i>BRAF</i>-mutant metastatic colorectal cancer (SWOG S1406). <i>J. Clin. Oncol.</i> <b>39</b>, 285–294 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1200/JCO.20.01994" data-track-item_id="10.1200/JCO.20.01994" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.20.01994" aria-label="Article reference 16" data-doi="10.1200/JCO.20.01994">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XhslKmtbc%3D" aria-label="CAS reference 16">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 16" href="http://scholar.google.com/scholar_lookup?&amp;title=Randomized%20trial%20of%20irinotecan%20and%20cetuximab%20with%20or%20without%20vemurafenib%20in%20BRAF-mutant%20metastatic%20colorectal%20cancer%20%28SWOG%20S1406%29&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.20.01994&amp;volume=39&amp;pages=285-294&amp;publication_year=2021&amp;author=Kopetz%2CS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="17."><p class="c-article-references__text" id="ref-CR17">Ahronian, L. G. et al. Clinical acquired resistance to RAF inhibitor combinations in <i>BRAF</i>-mutant colorectal cancer through MAPK pathway alterations. <i>Cancer Discov.</i> <b>5</b>, 358–367 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/2159-8290.CD-14-1518" data-track-item_id="10.1158/2159-8290.CD-14-1518" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F2159-8290.CD-14-1518" aria-label="Article reference 17" data-doi="10.1158/2159-8290.CD-14-1518">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXmsVSrsbc%3D" aria-label="CAS reference 17">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 17" href="http://scholar.google.com/scholar_lookup?&amp;title=Clinical%20acquired%20resistance%20to%20RAF%20inhibitor%20combinations%20in%20BRAF-mutant%20colorectal%20cancer%20through%20MAPK%20pathway%20alterations&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-14-1518&amp;volume=5&amp;pages=358-367&amp;publication_year=2015&amp;author=Ahronian%2CLG">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="18."><p class="c-article-references__text" id="ref-CR18">Kopetz, S. et al. Encorafenib, binimetinib, and cetuximab in <i>BRAF</i><sup>V600E</sup>-mutated colorectal cancer. <i>N. Engl. J. Med.</i> <b>381</b>, 1632–1643 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1908075" data-track-item_id="10.1056/NEJMoa1908075" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1908075" aria-label="Article reference 18" data-doi="10.1056/NEJMoa1908075">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXitFWkt73E" aria-label="CAS reference 18">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 18" href="http://scholar.google.com/scholar_lookup?&amp;title=Encorafenib%2C%20binimetinib%2C%20and%20cetuximab%20in%20BRAFV600E-mutated%20colorectal%20cancer&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1908075&amp;volume=381&amp;pages=1632-1643&amp;publication_year=2019&amp;author=Kopetz%2CS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="19."><p class="c-article-references__text" id="ref-CR19">Van Cutsem, E. et al. Binimetinib, encorafenib, and cetuximab triplet therapy for patients with <i>BRAF</i><sup>V600E</sup>-mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON colorectal cancer study. <i>J. Clin. Oncol.</i> <b>37</b>, 1460–1469 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1200/JCO.18.02459" data-track-item_id="10.1200/JCO.18.02459" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.18.02459" aria-label="Article reference 19" data-doi="10.1200/JCO.18.02459">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 19" href="http://scholar.google.com/scholar_lookup?&amp;title=Binimetinib%2C%20encorafenib%2C%20and%20cetuximab%20triplet%20therapy%20for%20patients%20with%20BRAFV600E-mutant%20metastatic%20colorectal%20cancer%3A%20safety%20lead-in%20results%20from%20the%20phase%20III%20BEACON%20colorectal%20cancer%20study&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.18.02459&amp;volume=37&amp;pages=1460-1469&amp;publication_year=2019&amp;author=Cutsem%2CE">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="20."><p class="c-article-references__text" id="ref-CR20">Tabernero, J. et al. Encorafenib plus cetuximab as a new standard of care for previously treated <i>BRAF</i><sup>V600E</sup>-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. <i>J. Clin. Oncol.</i> <b>39</b>, 273–284 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1200/JCO.20.02088" data-track-item_id="10.1200/JCO.20.02088" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.20.02088" aria-label="Article reference 20" data-doi="10.1200/JCO.20.02088">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XhslKmtbY%3D" aria-label="CAS reference 20">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 20" href="http://scholar.google.com/scholar_lookup?&amp;title=Encorafenib%20plus%20cetuximab%20as%20a%20new%20standard%20of%20care%20for%20previously%20treated%20BRAFV600E-mutant%20metastatic%20colorectal%20cancer%3A%20updated%20survival%20results%20and%20subgroup%20analyses%20from%20the%20BEACON%20study&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.20.02088&amp;volume=39&amp;pages=273-284&amp;publication_year=2021&amp;author=Tabernero%2CJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="21."><p class="c-article-references__text" id="ref-CR21">Kopetz, S. et al. Molecular correlates of clinical benefit in previously treated patients (pts) with <i>BRAF</i><sup>V600E</sup>-mutant metastatic colorectal cancer (mCRC) from the BEACON study. <i>J. Clin. Oncol.</i> <b>39</b>, 3513 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1200/JCO.2021.39.15_suppl.3513" data-track-item_id="10.1200/JCO.2021.39.15_suppl.3513" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2021.39.15_suppl.3513" aria-label="Article reference 21" data-doi="10.1200/JCO.2021.39.15_suppl.3513">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 21" href="http://scholar.google.com/scholar_lookup?&amp;title=Molecular%20correlates%20of%20clinical%20benefit%20in%20previously%20treated%20patients%20%28pts%29%20with%20BRAFV600E-mutant%20metastatic%20colorectal%20cancer%20%28mCRC%29%20from%20the%20BEACON%20study&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2021.39.15_suppl.3513&amp;volume=39&amp;publication_year=2021&amp;author=Kopetz%2CS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="22."><p class="c-article-references__text" id="ref-CR22">Schwartz, L. H. et al. RECIST 1.1—standardisation and disease-specific adaptations: perspectives from the RECIST Working Group. <i>Eur. J. Cancer</i> <b>62</b>, 138–145 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.ejca.2016.03.082" data-track-item_id="10.1016/j.ejca.2016.03.082" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.ejca.2016.03.082" aria-label="Article reference 22" data-doi="10.1016/j.ejca.2016.03.082">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 22" href="http://scholar.google.com/scholar_lookup?&amp;title=RECIST%201.1%E2%80%94standardisation%20and%20disease-specific%20adaptations%3A%20perspectives%20from%20the%20RECIST%20Working%20Group&amp;journal=Eur.%20J.%20Cancer&amp;doi=10.1016%2Fj.ejca.2016.03.082&amp;volume=62&amp;pages=138-145&amp;publication_year=2016&amp;author=Schwartz%2CLH">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="23."><p class="c-article-references__text" id="ref-CR23">Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. <i>Cancer Discov.</i> <b>2</b>, 401–404 (2012).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/2159-8290.CD-12-0095" data-track-item_id="10.1158/2159-8290.CD-12-0095" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F2159-8290.CD-12-0095" aria-label="Article reference 23" data-doi="10.1158/2159-8290.CD-12-0095">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 23" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20cBio%20cancer%20genomics%20portal%3A%20an%20open%20platform%20for%20exploring%20multidimensional%20cancer%20genomics%20data&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-12-0095&amp;volume=2&amp;pages=401-404&amp;publication_year=2012&amp;author=Cerami%2CE">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="24."><p class="c-article-references__text" id="ref-CR24">Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. <i>Sci. Signal.</i> <b>6</b>, pl1 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1126/scisignal.2004088" data-track-item_id="10.1126/scisignal.2004088" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1126%2Fscisignal.2004088" aria-label="Article reference 24" data-doi="10.1126/scisignal.2004088">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 24" href="http://scholar.google.com/scholar_lookup?&amp;title=Integrative%20analysis%20of%20complex%20cancer%20genomics%20and%20clinical%20profiles%20using%20the%20cBioPortal&amp;journal=Sci.%20Signal.&amp;doi=10.1126%2Fscisignal.2004088&amp;volume=6&amp;publication_year=2013&amp;author=Gao%2CJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="25."><p class="c-article-references__text" id="ref-CR25">Martincorena, I. et al. Universal patterns of selection in cancer and somatic tissues. <i>Cell</i> <b>171</b>, 1029–1041 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.cell.2017.09.042" data-track-item_id="10.1016/j.cell.2017.09.042" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.cell.2017.09.042" aria-label="Article reference 25" data-doi="10.1016/j.cell.2017.09.042">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXhs12lsLzO" aria-label="CAS reference 25">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 25" href="http://scholar.google.com/scholar_lookup?&amp;title=Universal%20patterns%20of%20selection%20in%20cancer%20and%20somatic%20tissues&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2017.09.042&amp;volume=171&amp;pages=1029-1041&amp;publication_year=2017&amp;author=Martincorena%2CI">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="26."><p class="c-article-references__text" id="ref-CR26">Tu, J. et al. The most common RNF43 mutant G659Vfs*41 is fully functional in inhibiting Wnt signaling and unlikely to play a role in tumorigenesis. <i>Sci. Rep.</i> <b>9</b>, 18557 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41598-019-54931-3" data-track-item_id="10.1038/s41598-019-54931-3" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41598-019-54931-3" aria-label="Article reference 26" data-doi="10.1038/s41598-019-54931-3">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXitl2htbzO" aria-label="CAS reference 26">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 26" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20most%20common%20RNF43%20mutant%20G659Vfs%2A41%20is%20fully%20functional%20in%20inhibiting%20Wnt%20signaling%20and%20unlikely%20to%20play%20a%20role%20in%20tumorigenesis&amp;journal=Sci.%20Rep.&amp;doi=10.1038%2Fs41598-019-54931-3&amp;volume=9&amp;publication_year=2019&amp;author=Tu%2CJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="27."><p class="c-article-references__text" id="ref-CR27">Yu, J. et al. The functional landscape of patient-derived <i>RNF43</i> mutations predicts sensitivity to Wnt inhibition. <i>Cancer Res.</i> <b>80</b>, 5619–5632 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/0008-5472.CAN-20-0957" data-track-item_id="10.1158/0008-5472.CAN-20-0957" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F0008-5472.CAN-20-0957" aria-label="Article reference 27" data-doi="10.1158/0008-5472.CAN-20-0957">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXlvFemtLo%3D" aria-label="CAS reference 27">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 27" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20functional%20landscape%20of%20patient-derived%20RNF43%20mutations%20predicts%20sensitivity%20to%20Wnt%20inhibition&amp;journal=Cancer%20Res.&amp;doi=10.1158%2F0008-5472.CAN-20-0957&amp;volume=80&amp;pages=5619-5632&amp;publication_year=2020&amp;author=Yu%2CJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="28."><p class="c-article-references__text" id="ref-CR28">Li, S. et al. Commonly observed <i>RNF43</i> mutations retain functionality in attenuating Wnt/β-catenin signaling and unlikely confer Wnt-dependency onto colorectal cancers. <i>Oncogene</i> <b>39</b>, 3458–3472 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41388-020-1232-5" data-track-item_id="10.1038/s41388-020-1232-5" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41388-020-1232-5" aria-label="Article reference 28" data-doi="10.1038/s41388-020-1232-5">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXjvFKiur4%3D" aria-label="CAS reference 28">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 28" href="http://scholar.google.com/scholar_lookup?&amp;title=Commonly%20observed%20RNF43%20mutations%20retain%20functionality%20in%20attenuating%20Wnt%2F%CE%B2-catenin%20signaling%20and%20unlikely%20confer%20Wnt-dependency%20onto%20colorectal%20cancers&amp;journal=Oncogene&amp;doi=10.1038%2Fs41388-020-1232-5&amp;volume=39&amp;pages=3458-3472&amp;publication_year=2020&amp;author=Li%2CS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="29."><p class="c-article-references__text" id="ref-CR29">Van Cutsem, E., Cervantes, A., Nordlinger, B. &amp; Arnold, D. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann. Oncol.</i> <b>25</b>, iii1–iii9 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/annonc/mdu260" data-track-item_id="10.1093/annonc/mdu260" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fannonc%2Fmdu260" aria-label="Article reference 29" data-doi="10.1093/annonc/mdu260">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 29" href="http://scholar.google.com/scholar_lookup?&amp;title=Metastatic%20colorectal%20cancer%3A%20ESMO%20Clinical%20Practice%20Guidelines%20for%20diagnosis%2C%20treatment%20and%20follow-up&amp;journal=Ann.%20Oncol.&amp;doi=10.1093%2Fannonc%2Fmdu260&amp;volume=25&amp;pages=iii1-iii9&amp;publication_year=2014&amp;author=Cutsem%2CE&amp;author=Cervantes%2CA&amp;author=Nordlinger%2CB&amp;author=Arnold%2CD">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="30."><p class="c-article-references__text" id="ref-CR30">Van Cutsem, E. et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. <i>J. Clin. Oncol.</i> <b>30</b>, 3499–3506 (2012).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1200/JCO.2012.42.8201" data-track-item_id="10.1200/JCO.2012.42.8201" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2012.42.8201" aria-label="Article reference 30" data-doi="10.1200/JCO.2012.42.8201">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 30" href="http://scholar.google.com/scholar_lookup?&amp;title=Addition%20of%20aflibercept%20to%20fluorouracil%2C%20leucovorin%2C%20and%20irinotecan%20improves%20survival%20in%20a%20phase%20III%20randomized%20trial%20in%20patients%20with%20metastatic%20colorectal%20cancer%20previously%20treated%20with%20an%20oxaliplatin-based%20regimen&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2012.42.8201&amp;volume=30&amp;pages=3499-3506&amp;publication_year=2012&amp;author=Cutsem%2CE">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="31."><p class="c-article-references__text" id="ref-CR31">Tabernero, J. et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. <i>Lancet Oncol.</i> <b>16</b>, 499–508 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/S1470-2045(15)70127-0" data-track-item_id="10.1016/S1470-2045(15)70127-0" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2FS1470-2045%2815%2970127-0" aria-label="Article reference 31" data-doi="10.1016/S1470-2045(15)70127-0">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXmsFSgu7w%3D" aria-label="CAS reference 31">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 31" href="http://scholar.google.com/scholar_lookup?&amp;title=Ramucirumab%20versus%20placebo%20in%20combination%20with%20second-line%20FOLFIRI%20in%20patients%20with%20metastatic%20colorectal%20carcinoma%20that%20progressed%20during%20or%20after%20first-line%20therapy%20with%20bevacizumab%2C%20oxaliplatin%2C%20and%20a%20fluoropyrimidine%20%28RAISE%29%3A%20a%20randomised%2C%20double-blind%2C%20multicentre%2C%20phase%203%20study&amp;journal=Lancet%20Oncol.&amp;doi=10.1016%2FS1470-2045%2815%2970127-0&amp;volume=16&amp;pages=499-508&amp;publication_year=2015&amp;author=Tabernero%2CJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="32."><p class="c-article-references__text" id="ref-CR32">Middleton, G. et al. <i>BRAF</i>-mutant transcriptional subtypes predict outcome of combined BRAF, MEK, and EGFR blockade with dabrafenib, trametinib, and panitumumab in patients with colorectal cancer. <i>Clin. Cancer Res.</i> <b>26</b>, 2466–2476 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-19-3579" data-track-item_id="10.1158/1078-0432.CCR-19-3579" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-19-3579" aria-label="Article reference 32" data-doi="10.1158/1078-0432.CCR-19-3579">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXitVOgtbfN" aria-label="CAS reference 32">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 32" href="http://scholar.google.com/scholar_lookup?&amp;title=BRAF-mutant%20transcriptional%20subtypes%20predict%20outcome%20of%20combined%20BRAF%2C%20MEK%2C%20and%20EGFR%20blockade%20with%20dabrafenib%2C%20trametinib%2C%20and%20panitumumab%20in%20patients%20with%20colorectal%20cancer&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-19-3579&amp;volume=26&amp;pages=2466-2476&amp;publication_year=2020&amp;author=Middleton%2CG">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="33."><p class="c-article-references__text" id="ref-CR33">Kabiri, Z. et al. Wnt signaling suppresses MAPK-driven proliferation of intestinal stem cells. <i>J. Clin. Invest.</i> <b>128</b>, 3806–3812 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1172/JCI99325" data-track-item_id="10.1172/JCI99325" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1172%2FJCI99325" aria-label="Article reference 33" data-doi="10.1172/JCI99325">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 33" href="http://scholar.google.com/scholar_lookup?&amp;title=Wnt%20signaling%20suppresses%20MAPK-driven%20proliferation%20of%20intestinal%20stem%20cells&amp;journal=J.%20Clin.%20Invest.&amp;doi=10.1172%2FJCI99325&amp;volume=128&amp;pages=3806-3812&amp;publication_year=2018&amp;author=Kabiri%2CZ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="34."><p class="c-article-references__text" id="ref-CR34">Tsukiyama, T. et al. A phospho-switch controls RNF43-mediated degradation of Wnt receptors to suppress tumorigenesis. <i>Nat. Commun.</i> <b>11</b>, 4586 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41467-020-18257-3" data-track-item_id="10.1038/s41467-020-18257-3" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41467-020-18257-3" aria-label="Article reference 34" data-doi="10.1038/s41467-020-18257-3">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 34" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20phospho-switch%20controls%20RNF43-mediated%20degradation%20of%20Wnt%20receptors%20to%20suppress%20tumorigenesis&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fs41467-020-18257-3&amp;volume=11&amp;publication_year=2020&amp;author=Tsukiyama%2CT">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="35."><p class="c-article-references__text" id="ref-CR35">Radaszkiewicz, T. et al. RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy. <i>eLife</i> <b>10</b>, e65759 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.7554/eLife.65759" data-track-item_id="10.7554/eLife.65759" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.7554%2FeLife.65759" aria-label="Article reference 35" data-doi="10.7554/eLife.65759">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XotVSlt7w%3D" aria-label="CAS reference 35">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 35" href="http://scholar.google.com/scholar_lookup?&amp;title=RNF43%20inhibits%20WNT5A-driven%20signaling%20and%20suppresses%20melanoma%20invasion%20and%20resistance%20to%20the%20targeted%20therapy&amp;journal=eLife&amp;doi=10.7554%2FeLife.65759&amp;volume=10&amp;publication_year=2021&amp;author=Radaszkiewicz%2CT">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="36."><p class="c-article-references__text" id="ref-CR36">Garcia-Barcena, C., Osinalde, N., Ramirez, J. &amp; Mayor, U. How to inactivate human ubiquitin E3 ligases by mutation. <i>Front. Cell Dev. Biol.</i> <b>8</b>, 39 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.3389/fcell.2020.00039" data-track-item_id="10.3389/fcell.2020.00039" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.3389%2Ffcell.2020.00039" aria-label="Article reference 36" data-doi="10.3389/fcell.2020.00039">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 36" href="http://scholar.google.com/scholar_lookup?&amp;title=How%20to%20inactivate%20human%20ubiquitin%20E3%20ligases%20by%20mutation&amp;journal=Front.%20Cell%20Dev.%20Biol.&amp;doi=10.3389%2Ffcell.2020.00039&amp;volume=8&amp;publication_year=2020&amp;author=Garcia-Barcena%2CC&amp;author=Osinalde%2CN&amp;author=Ramirez%2CJ&amp;author=Mayor%2CU">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="37."><p class="c-article-references__text" id="ref-CR37">Toledo, R. A. et al. Exome sequencing of plasma DNA portrays the mutation landscape of colorectal cancer and discovers mutated VEGFR2 receptors as modulators of antiangiogenic therapies. <i>Clin. Cancer Res.</i> <b>24</b>, 3550–3559 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-18-0103" data-track-item_id="10.1158/1078-0432.CCR-18-0103" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-18-0103" aria-label="Article reference 37" data-doi="10.1158/1078-0432.CCR-18-0103">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXhsVWrtr3L" aria-label="CAS reference 37">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 37" href="http://scholar.google.com/scholar_lookup?&amp;title=Exome%20sequencing%20of%20plasma%20DNA%20portrays%20the%20mutation%20landscape%20of%20colorectal%20cancer%20and%20discovers%20mutated%20VEGFR2%20receptors%20as%20modulators%20of%20antiangiogenic%20therapies&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-18-0103&amp;volume=24&amp;pages=3550-3559&amp;publication_year=2018&amp;author=Toledo%2CRA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="38."><p class="c-article-references__text" id="ref-CR38">Hastings, R. K. et al. Longitudinal whole-exome sequencing of cell-free DNA for tracking the co-evolutionary tumor and immune evasion dynamics: longitudinal data from a single patient. <i>Ann. Oncol.</i> <b>32</b>, 681–684 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.annonc.2021.02.007" data-track-item_id="10.1016/j.annonc.2021.02.007" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.annonc.2021.02.007" aria-label="Article reference 38" data-doi="10.1016/j.annonc.2021.02.007">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XhvVKqs7s%3D" aria-label="CAS reference 38">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 38" href="http://scholar.google.com/scholar_lookup?&amp;title=Longitudinal%20whole-exome%20sequencing%20of%20cell-free%20DNA%20for%20tracking%20the%20co-evolutionary%20tumor%20and%20immune%20evasion%20dynamics%3A%20longitudinal%20data%20from%20a%20single%20patient&amp;journal=Ann.%20Oncol.&amp;doi=10.1016%2Fj.annonc.2021.02.007&amp;volume=32&amp;pages=681-684&amp;publication_year=2021&amp;author=Hastings%2CRK">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="39."><p class="c-article-references__text" id="ref-CR39">Randon, G. et al. Tumour mutational burden predicts resistance to EGFR/BRAF blockade in <i>BRAF</i>-mutated microsatellite stable metastatic colorectal cancer. <i>Eur. J. Cancer</i> <b>161</b>, 90–98 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.ejca.2021.11.018" data-track-item_id="10.1016/j.ejca.2021.11.018" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.ejca.2021.11.018" aria-label="Article reference 39" data-doi="10.1016/j.ejca.2021.11.018">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XhtVWgtr3F" aria-label="CAS reference 39">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 39" href="http://scholar.google.com/scholar_lookup?&amp;title=Tumour%20mutational%20burden%20predicts%20resistance%20to%20EGFR%2FBRAF%20blockade%20in%20BRAF-mutated%20microsatellite%20stable%20metastatic%20colorectal%20cancer&amp;journal=Eur.%20J.%20Cancer&amp;doi=10.1016%2Fj.ejca.2021.11.018&amp;volume=161&amp;pages=90-98&amp;publication_year=2022&amp;author=Randon%2CG">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="40."><p class="c-article-references__text" id="ref-CR40">Garcia, M. et al. Sarek: a portable workflow for whole-genome sequencing analysis of germline and somatic variants. <i>F1000Res</i> <b>9</b>, 63 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.12688/f1000research.16665.2" data-track-item_id="10.12688/f1000research.16665.2" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.12688%2Ff1000research.16665.2" aria-label="Article reference 40" data-doi="10.12688/f1000research.16665.2">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 40" href="http://scholar.google.com/scholar_lookup?&amp;title=Sarek%3A%20a%20portable%20workflow%20for%20whole-genome%20sequencing%20analysis%20of%20germline%20and%20somatic%20variants&amp;journal=F1000Res&amp;doi=10.12688%2Ff1000research.16665.2&amp;volume=9&amp;publication_year=2020&amp;author=Garcia%2CM">
                    Google Scholar</a>&nbsp;
                </p></li></ol><p class="c-article-references__download u-hide-print"><a data-track="click" data-track-action="download citation references" data-track-label="link" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1038/s41591-022-01976-z?format=refman&amp;flavour=references">Download references<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-download-medium"></use></svg></a></p></div></div></div></section></div><section data-title="Acknowledgements"><div class="c-article-section" id="Ack1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Ack1">Acknowledgements</h2><div class="c-article-section__content" id="Ack1-content"><p>VHIO would like to acknowledge the Cellex Foundation for providing research facilities and equipment, the FERO Foundation for their funding support, the Consorcio Centro de Investigación Biomédica en Red de Cáncer (CIBERONC, CB16/12/00259) from the Institute of Health Carlos III (ISCIII), Ministry of Science and Innovation, and the Department of Health (Generalitat de Catalunya, SLT008/18/00198 and SLT008/18/00205) for their support on this research. Authors acknowledge financial support from the State Agency for Research (Agencia Estatal de Investigación) (CEX2020-001024-S / AEI / 10.13039 /501100011033). This research is funded by the SCITRON program; Novartis funded the genomics characterization by WES of samples from 28 patients from the discovery cohort and had no influence on data analysis/interpretation or writing of the paper (3003145512 to R.A.T.). S.Li. is financially supported by a Chinese Scholarship Council PhD fellowship (201909370083 to S. Li). R.P.-L. is supported by a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigación en Salud (PI18/01395 and PI21/01019 to R.P.-L.) and the Prostate Cancer Foundation (Young Investigator Award). This work was supported by the Miguel Servet-I Research Award from ISCIII of the Ministry of Economy (CP17/00199 to R.A.T.), the Olga Torres Foundation Award to emerging researchers (2601 to R.A.T.), the ISCIII-FEDER (PI17/00947 and PI20/00968 to E.E.), and the Fundación AECC (CLSEN19001ELEZ to E.E.) and Ministry of Science and Innovation (Europa Redes y Gestores, ECT2020-000827 to E.E.).</p></div></div></section><section aria-labelledby="author-information" data-title="Author information"><div class="c-article-section" id="author-information-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="author-information">Author information</h2><div class="c-article-section__content" id="author-information-content"><span class="c-article-author-information__subtitle u-visually-hidden" id="author-notes">Author notes</span><ol class="c-article-author-information__list"><li class="c-article-author-information__item" id="nAff13"><p class="c-article-author-information__authors-list">Diana Graus</p><p class="js-present-address">Present address: Ridgeline Discovery, Basel, Switzerland</p></li></ol><h3 class="c-article__sub-heading" id="affiliations">Authors and Affiliations</h3><ol class="c-article-author-affiliation__list"><li id="Aff1"><p class="c-article-author-affiliation__address">Medical Oncology Department, Vall d’Hebron University Hospital, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain</p><p class="c-article-author-affiliation__authors-list">Elena Elez,&nbsp;Javier Ros&nbsp;&amp;&nbsp;Josep Tabernero</p></li><li id="Aff2"><p class="c-article-author-affiliation__address">Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain</p><p class="c-article-author-affiliation__authors-list">Elena Elez,&nbsp;Javier Ros,&nbsp;Jose Fernández,&nbsp;Guillermo Villacampa,&nbsp;Ana Belén Moreno-Cárdenas,&nbsp;Carlota Arenillas,&nbsp;Kinga Bernatowicz,&nbsp;Raquel Comas,&nbsp;Roberta Fasani,&nbsp;Ariadna Garcia,&nbsp;Javier Gonzalo-Ruiz,&nbsp;Alejandro Piris-Gimenez,&nbsp;Paolo Nuciforo,&nbsp;Ana Vivancos,&nbsp;Raquel Perez-Lopez,&nbsp;Rodrigo Dienstmann,&nbsp;Josep Tabernero&nbsp;&amp;&nbsp;Rodrigo A. Toledo</p></li><li id="Aff3"><p class="c-article-author-affiliation__address">Oncologia Medica, Dipartimento di Medicina di Precisione, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy</p><p class="c-article-author-affiliation__authors-list">Javier Ros</p></li><li id="Aff4"><p class="c-article-author-affiliation__address">Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Institute of Health Carlos III (ISCIII), Madrid, Spain</p><p class="c-article-author-affiliation__authors-list">Carlota Arenillas,&nbsp;Josep Tabernero&nbsp;&amp;&nbsp;Rodrigo A. Toledo</p></li><li id="Aff5"><p class="c-article-author-affiliation__address">Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, the Netherlands</p><p class="c-article-author-affiliation__authors-list">Shanshan Li&nbsp;&amp;&nbsp;Ron Smits</p></li><li id="Aff6"><p class="c-article-author-affiliation__address">Novartis Institutes for BioMedical Research, Cambridge, MA, USA</p><p class="c-article-author-affiliation__authors-list">David Philip Kodack</p></li><li id="Aff7"><p class="c-article-author-affiliation__address">Oncology Department, Novartis Institutes for Biomedical Research, Novartis, Basel, Switzerland</p><p class="c-article-author-affiliation__authors-list">Grainne Kerr&nbsp;&amp;&nbsp;Diana Graus</p></li><li id="Aff8"><p class="c-article-author-affiliation__address">Department of Oncology, Veneto Institute of Oncology IRCCS, Padova, Italy</p><p class="c-article-author-affiliation__authors-list">Rossana Intini,&nbsp;Aldo Montagna&nbsp;&amp;&nbsp;Sara Lonardi</p></li><li id="Aff9"><p class="c-article-author-affiliation__address">Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Department of Trans-lational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy</p><p class="c-article-author-affiliation__authors-list">Marco Maria Germani&nbsp;&amp;&nbsp;Chiara Cremolini</p></li><li id="Aff10"><p class="c-article-author-affiliation__address">Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy</p><p class="c-article-author-affiliation__authors-list">Giovanni Randon&nbsp;&amp;&nbsp;Filippo Pietrantonio</p></li><li id="Aff11"><p class="c-article-author-affiliation__address">Radiology Department, Vall d’Hebron University Hospital, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain</p><p class="c-article-author-affiliation__authors-list">Raquel Perez-Lopez</p></li><li id="Aff12"><p class="c-article-author-affiliation__address">UVic-UCC, IOB-Quirón, Barcelona, Spain</p><p class="c-article-author-affiliation__authors-list">Josep Tabernero</p></li></ol><div class="u-js-hide u-hide-print" data-test="author-info"><span class="c-article__sub-heading">Authors</span><ol class="c-article-authors-search u-list-reset"><li id="auth-Elena-Elez-Aff1-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Elena Elez</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Elena%20Elez" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Elena%20Elez" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Elena%20Elez%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Javier-Ros-Aff1-Aff2-Aff3"><span class="c-article-authors-search__title u-h3 js-search-name">Javier Ros</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Javier%20Ros" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Javier%20Ros" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Javier%20Ros%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Jose-Fern_ndez-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Jose Fernández</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Jose%20Fern%C3%A1ndez" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Jose%20Fern%C3%A1ndez" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Jose%20Fern%C3%A1ndez%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Guillermo-Villacampa-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Guillermo Villacampa</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Guillermo%20Villacampa" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Guillermo%20Villacampa" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Guillermo%20Villacampa%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Ana_Bel_n-Moreno_C_rdenas-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Ana Belén Moreno-Cárdenas</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Ana%20Bel%C3%A9n%20Moreno-C%C3%A1rdenas" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Ana%20Bel%C3%A9n%20Moreno-C%C3%A1rdenas" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Ana%20Bel%C3%A9n%20Moreno-C%C3%A1rdenas%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Carlota-Arenillas-Aff2-Aff4"><span class="c-article-authors-search__title u-h3 js-search-name">Carlota Arenillas</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Carlota%20Arenillas" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Carlota%20Arenillas" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Carlota%20Arenillas%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Kinga-Bernatowicz-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Kinga Bernatowicz</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Kinga%20Bernatowicz" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Kinga%20Bernatowicz" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Kinga%20Bernatowicz%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Raquel-Comas-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Raquel Comas</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Raquel%20Comas" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Raquel%20Comas" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Raquel%20Comas%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Shanshan-Li-Aff5"><span class="c-article-authors-search__title u-h3 js-search-name">Shanshan Li</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Shanshan%20Li" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Shanshan%20Li" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Shanshan%20Li%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-David_Philip-Kodack-Aff6"><span class="c-article-authors-search__title u-h3 js-search-name">David Philip Kodack</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=David%20Philip%20Kodack" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=David%20Philip%20Kodack" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22David%20Philip%20Kodack%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Roberta-Fasani-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Roberta Fasani</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Roberta%20Fasani" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Roberta%20Fasani" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Roberta%20Fasani%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Ariadna-Garcia-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Ariadna Garcia</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Ariadna%20Garcia" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Ariadna%20Garcia" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Ariadna%20Garcia%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Javier-Gonzalo_Ruiz-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Javier Gonzalo-Ruiz</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Javier%20Gonzalo-Ruiz" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Javier%20Gonzalo-Ruiz" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Javier%20Gonzalo-Ruiz%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Alejandro-Piris_Gimenez-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Alejandro Piris-Gimenez</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Alejandro%20Piris-Gimenez" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Alejandro%20Piris-Gimenez" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Alejandro%20Piris-Gimenez%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Paolo-Nuciforo-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Paolo Nuciforo</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Paolo%20Nuciforo" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Paolo%20Nuciforo" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Paolo%20Nuciforo%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Grainne-Kerr-Aff7"><span class="c-article-authors-search__title u-h3 js-search-name">Grainne Kerr</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Grainne%20Kerr" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Grainne%20Kerr" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Grainne%20Kerr%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Rossana-Intini-Aff8"><span class="c-article-authors-search__title u-h3 js-search-name">Rossana Intini</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Rossana%20Intini" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Rossana%20Intini" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Rossana%20Intini%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Aldo-Montagna-Aff8"><span class="c-article-authors-search__title u-h3 js-search-name">Aldo Montagna</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Aldo%20Montagna" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Aldo%20Montagna" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Aldo%20Montagna%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Marco_Maria-Germani-Aff9"><span class="c-article-authors-search__title u-h3 js-search-name">Marco Maria Germani</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Marco%20Maria%20Germani" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Marco%20Maria%20Germani" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Marco%20Maria%20Germani%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Giovanni-Randon-Aff10"><span class="c-article-authors-search__title u-h3 js-search-name">Giovanni Randon</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Giovanni%20Randon" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Giovanni%20Randon" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Giovanni%20Randon%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Ana-Vivancos-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Ana Vivancos</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Ana%20Vivancos" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Ana%20Vivancos" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Ana%20Vivancos%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Ron-Smits-Aff5"><span class="c-article-authors-search__title u-h3 js-search-name">Ron Smits</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Ron%20Smits" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Ron%20Smits" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Ron%20Smits%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Diana-Graus-Aff7-Aff13"><span class="c-article-authors-search__title u-h3 js-search-name">Diana Graus</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Diana%20Graus" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Diana%20Graus" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Diana%20Graus%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Raquel-Perez_Lopez-Aff2-Aff11"><span class="c-article-authors-search__title u-h3 js-search-name">Raquel Perez-Lopez</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Raquel%20Perez-Lopez" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Raquel%20Perez-Lopez" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Raquel%20Perez-Lopez%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Chiara-Cremolini-Aff9"><span class="c-article-authors-search__title u-h3 js-search-name">Chiara Cremolini</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Chiara%20Cremolini" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Chiara%20Cremolini" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Chiara%20Cremolini%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Sara-Lonardi-Aff8"><span class="c-article-authors-search__title u-h3 js-search-name">Sara Lonardi</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Sara%20Lonardi" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Sara%20Lonardi" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Sara%20Lonardi%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Filippo-Pietrantonio-Aff10"><span class="c-article-authors-search__title u-h3 js-search-name">Filippo Pietrantonio</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Filippo%20Pietrantonio" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Filippo%20Pietrantonio" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Filippo%20Pietrantonio%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Rodrigo-Dienstmann-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Rodrigo Dienstmann</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Rodrigo%20Dienstmann" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Rodrigo%20Dienstmann" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Rodrigo%20Dienstmann%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Josep-Tabernero-Aff1-Aff2-Aff4-Aff12"><span class="c-article-authors-search__title u-h3 js-search-name">Josep Tabernero</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Josep%20Tabernero" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Josep%20Tabernero" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Josep%20Tabernero%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Rodrigo_A_-Toledo-Aff2-Aff4"><span class="c-article-authors-search__title u-h3 js-search-name">Rodrigo A. Toledo</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Rodrigo%20A.%20Toledo" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Rodrigo%20A.%20Toledo" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Rodrigo%20A.%20Toledo%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li></ol></div><h3 class="c-article__sub-heading" id="contributions">Contributions</h3><p>E.E., J.T. and R.A.T. conceived and designed the study. E.E., J.R., A.B.M.-C., C.A., A.G., P.N., R.I., A.M., M.M.G., G.R., C.C., S. Lonardi, F.P. and R.A.T. were involved in sample collection and data acquisition. E.E., J.R., J.F., A.B.M.-C., C.A., S. Li, R.F., A.V., R.S., C.C., S. Lonardi, F.P., R.D., J.T. and R.A.T. performed experiments, analysis and data interpretation. J.G.-R., A.P., D.P.K. and D.G. were involved in the project and study management. G.V., R.C. and R.D. performed the data and statistical analyses. K.B. and R.P.-L. performed the imaging and radiological analyses. A.B.M.-C. and A.V. performed genomic analyses. J.F. performed the bioinformatics analyses of the WES data and other computational analyses. G.K. performed computational analysis. C.A. and R.A.T. created Figs. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig1">1</a> and <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig6">6e</a> and Extended Data Figs. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig7">1a</a>, <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig8">2b</a> and <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-01976-z#Fig9">3a</a> with <a href="https://biorender.com/">BioRender.com</a>. R.A.T. wrote the manuscript, and E.E., J.R., R.S., A.B.M.-C., C.A., C.C., S. Lonardi, F.P., R.D. and J.T. participated in the review and editing. All authors approved the manuscript.</p><h3 class="c-article__sub-heading" id="corresponding-author">Corresponding authors</h3><p id="corresponding-author-list">Correspondence to
                <a id="corresp-c1" href="mailto:meelez@vhio.net">Elena Elez</a> or <a id="corresp-c2" href="mailto:rtoledo@vhio.net">Rodrigo A. Toledo</a>.</p></div></div></section><section data-title="Ethics declarations"><div class="c-article-section" id="ethics-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="ethics">Ethics declarations</h2><div class="c-article-section__content" id="ethics-content">
              
                <h3 class="c-article__sub-heading" id="FPar4">Competing interests</h3>
                <p>C.C. reports receiving honoraria and speaker’s bureau compensation from Servier, Bayer, Merck, Amgen, Pierre Fabre, MSD, Roche and Nordic Pharma and research grants from Merck, Servier and Amgen. D.G. was an employee of Novartis and was a shareholder while this work was being conducted. D.P.K. is an employee of Novartis. E.E. reports receiving honoraria for an advisory role, travel grants and research grants (past 5 years) from Hoffmann-La Roche, Bristol-Myers Squibb, Servier, Amgen, Merck Serono, Array Biopharma, Sanofi and Bayer. Her institution received honoraria due to her investigator contribution in clinical trials from Array Biopharma, MSD, Abbvie, Amgen, GlaxoSmithKline, AstraZeneca, Merck Sharp &amp; Dohme, Bristol-Myers Squibb, Novartis, Boehringer Ingelheim, Hoffmann-La Roche, Medimmune, Pierre-Fabre and Sanofi Aventis. F.P. received honoraria from Amgen, Merck Serono, Lilly, Sanofi, Bayer, Servier, MSD, AstraZeneca and Organon and research grants from AstraZeneca and BMS. G.K. is an employee of Novartis. G.V.﻿ has received a speaker’s fee from MSD and Pierre Fabrer and has held an advisory role with AstraZeneca. J.R. declares receiving honoraria from Sanofi and travel and accommodation expenses from Amgen, Merck and Sanofi. J.T. reports having a personal financial interest in the form of a scientific consultancy role for Array Biopharma, AstraZeneca, Avvinity, Bayer, Boehringer Ingelheim, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche, Genentech, HalioDX, Hutchison MediPharma International, Ikena Oncology, Inspirna, IQVIA, Lilly, Menarini, Merck Serono, Merus, MSD, Mirati, Neophore, Novartis, Ona Therapeutics, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Seattle Genetics, Scandion Oncology, Servier, Sotio Biotech, Taiho, Tessa Therapeutics and TheraMyc, as well as educational collaboration with Imedex, Medscape Education, MJH Life Sciences, PeerView Institute for Medical Education and Physicians Education Resource (PER). P.N. reports receiving honoraria or consultation fees from Novartis, Bayer and MSD Oncology and had travel and accommodation paid for or reimbursed by Novartis. R.A.T. reports receiving a research grant related to this study from Novartis and research grants unrelated to this study from AstraZeneca and Beigene. R.D. declares an advisory role for Roche and Boehringer Ingelheim and received a speaker’s fee from Roche, Boehringer Ingelheim, Ipsen, Amgen, Servier, Sanofi, Libbs and Merck Sharp &amp; Dohme and research grants from Merck and Pierre Fabre. R.P.-L. has acted in a consulting or advisory role for Roche, and she has participated in speaker bureaus sponsored by Roche and Pfizer. She is also the principal investigator in research grants to VHIO funded by AstraZeneca and Roche. S. Lonardi declares no conflict of interest inside the scope of the present work but declares interests in other projects from a consulting or advisory role (Amgen, Merck Serono, Lilly, AstraZeneca, Incyte, Daiichi-Sankyo, Bristol-Myers Squibb, Servier and MSD); speaker’s bureau compensation from Roche, Lilly, Bristol-Myers Squibb, Servier, Merck Serono, Pierre-Fabre, GSK and Amgen; and research funding from Amgen, Merck Serono, Bayer, Roche, Lilly, AstraZeneca and Bristol-Myers Squibb. The other authors declare no conflicts of interest.</p>
              
            </div></div></section><section data-title="Peer review"><div class="c-article-section" id="peer-review-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="peer-review">Peer review</h2><div class="c-article-section__content" id="peer-review-content">
              
              
                <h3 class="c-article__sub-heading" id="FPar3">Peer review information</h3>
                <p><i>Nature Medicine</i> thanks Jan Paul Medema, Fortunato Ciardiello and Dominik Modest for their contribution to the peer review of this work. Primary Handling Editor: Joao Monteiro, in collaboration with the <i>Nature Medicine</i> team.</p>
              
            </div></div></section><section data-title="Additional information"><div class="c-article-section" id="additional-information-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="additional-information">Additional information</h2><div class="c-article-section__content" id="additional-information-content"><p><b>Publisher’s note</b> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div></div></section><section data-title="Extended data"><div class="c-article-section" id="Sec27-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec27">Extended data</h2><div class="c-article-section__content" id="Sec27-content"><div data-test="supplementary-info"><div id="figshareContainer" class="c-article-figshare-container" data-test="figshare-container"></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig7"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 1 patients’ characteristics." href="/articles/s41591-022-01976-z/figures/7" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig7_ESM.jpg">Extended Data Fig. 1 Patients’ characteristics.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>A)</b> Patient and therapy flowchart. Specific clinical and genetic characteristics of mCRC<sup>BRAF-V600E</sup> compared to mCRC<sup>BRAF-wild-type</sup> tumors. Schematic description of the anti-BRAF/EGFR combinatorial therapies (doublet vs triplet) for patients with mCRC<sup>BRAF-V600E</sup>. <b>B)</b> Clinical characteristics of patients in the discovery (n = 46) and validation (n = 52) cohorts. Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance Status; ICIs, immune checkpoint inhibitors; MSI-high, microsatellite instability high; MSS, microsatellite stable.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig8"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 2 bioinformatics pipeline for g" href="/articles/s41591-022-01976-z/figures/8" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig8_ESM.jpg">Extended Data Fig. 2 Bioinformatics pipeline for genomic data analysis.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>A)</b> Description of the Sarek bioinformatics pipeline, a Nextflow-based pipeline that integrates all the processing, mapping, variant calling, and QC steps<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 40" title="Garcia, M. et al. Sarek: a portable workflow for whole-genome sequencing analysis of germline and somatic variants. F1000Res 9, 63 (2020)." href="/articles/s41591-022-01976-z#ref-CR40" id="ref-link-section-d68499825e2873">40</a></sup>, used for the WES analysis. <b>B)</b> WES based on responders vs non-responders from the discovery cohort (n = 28) followed by dNdScv<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 25" title="Martincorena, I. et al. Universal patterns of selection in cancer and somatic tissues. Cell 171, 1029–1041 (2017)." href="/articles/s41591-022-01976-z#ref-CR25" id="ref-link-section-d68499825e2880">25</a></sup> maximum-likelihood unbiased mutation enrichment analysis was used as the genomic biomarker discovery strategy on 55 biological samples from mCRC<sup>BRAF-V600E</sup> patients collected at baseline to anti-BRAF/EGFR ± MEKi therapies. The FastQ files have been deposited in the European Genome-phenome Archive (EGA, <a href="https://ega-archive.org">https://ega-archive.org</a>) biorepository. The code of the bioinformatics pipelines can be found at <a href="https://github.com/nf-core/sarek">https://github.com/nf-core/sarek</a> and at <a href="https://github.com/jfnavarro/scitron">https://github.com/jfnavarro/scitron</a>. Abbreviations: cfDNA, cell-free DNA; CNA, copy number alteration; QC, quality control; PDX, patient-derived xenograft.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig9"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 3 the utility of liquid biopsy " href="/articles/s41591-022-01976-z/figures/9" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig9_ESM.jpg">Extended Data Fig. 3 The utility of liquid biopsy to assess <i>BRAF</i> and <i>RNF43</i> mutational status in patiets with mCRC<sup>BRAF-V600E</sup> treated with anti-BRAF/EGFR combinatorial therapies.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>A)</b> WES was performed in 55 baseline biological samples from 19 gDNA, 22 tDNA, 9 cfDNA, and 5 pdxDNA from 28 patients with mCRC<sup>BRAF-V600E</sup> from the discovery cohort treated with anti-BRAF/EGFR combinatorial therapies. The presence of the <i>BRAF</i><sup>V600E</sup> and <i>RNF43</i> mutations was interrogated in tumor-derived and plasma-derived samples. <b>B)</b> Mutation allele frequencies (MAF) of the <i>BRAF</i> and <i>RNF43</i> specific mutations are shown to gDNA, tDNA, and pdxDNA from patients with multiple samples which are available. <b>C)</b> <i>BRAF</i><sup>V600E</sup> and <i>RNF43</i> mutations were detected not only in tDNA and/or pdxDNA but also in available cfDNA samples, suggesting the utility of liquid biopsy for the assessment of these biomarkers. Abbreviations: gDNA, germline DNA; tDNA, tumor DNA; cfDNA, cell-free DNA; MSI, microsatellite instability high; MSS, microsatellite stable; pdxDNA, patient-derived xenograft DNA.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig10"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 4 overall response rate (orr) (" href="/articles/s41591-022-01976-z/figures/10" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig10_ESM.jpg">Extended Data Fig. 4 Overall response rate (ORR) (%) of the discovery (n = 45, A–C) and validation (n = 50, D–F) cohorts and diagnostic performance analyses (G) defined by MSS/MSI and <i>RNF43</i> mutation statuses.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>A)</b> Patients with <i>RNF43</i><sup>mutated</sup> tumors exhibited an increased ORR (63%) compared to patients with <i>RNF43</i><sup>wild-type</sup> (31%). <b>B)</b> There were no significant differences between ORRs according to MSI/MSS status (50% and 43%, respectively). <b>C)</b> Interestingly, patients with mCRC<sup>BRAF-V600E</sup> with MSS-<i>RNF43</i><sup>mutated</sup> tumors demonstrated increased ORR (73%) compared to the other groups, as MSI-<i>RNF43</i><sup>mutated</sup> and MSS-<i>RNF43</i><sup>wild-type</sup> (50% and 31%, respectively) (<i>P</i> = 0.03). Chi-square test was used for the statistical analysis. <b>D–F)</b> ORR of the validation cohort including 50 patients with mCRC<sup>BRAF-V600E</sup> tumors treated with anti-BRAF/EGFR combinatorial therapies in 2nd or 3rd line. <b>D)</b> <i>RNF43</i><sup>mutated</sup> group exhibited an increased ORR (36%) compared to <i>RNF43</i><sup>wild-type</sup> group (21%). <b>E)</b> There were no significant differences between MSI/MSS status (31% and 17%, respectively). <b>F)</b> Interestingly, MSS-<i>RNF43</i><sup>mutated</sup> group showed increased ORR (54%) compared to the other groups, MSI-<i>RNF43</i><sup>mutated</sup> and MSS-<i>RNF43</i><sup>wild-type</sup> (18% and 21%), respectively (<i>P</i> = 0.02). Chi-square test was used for the statistical analysis﻿ (*<i>P</i> &lt; 0.05). <b>G)</b> Table showing results of the accuracy, sensitivity, specificity, and positive (PPV) and negative predictive value (NPV) calculated to quantify the diagnostic performance of statuses of each potential biomarker (MSS/MSI and <i>RNF43</i> separated, and MSS/MSI-<i>RNF43</i> combined, in the discovery and validation cohorts). Abbreviations: MSI, microsatellite instability high; MSS, microsatellite stable.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig11"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 5 waterfall plots depicting dif" href="/articles/s41591-022-01976-z/figures/11" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig11_ESM.jpg">Extended Data Fig. 5 Waterfall plots depicting different molecular subtypes.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>A)</b> Integrated waterfall plot showing best change in the total diameter of target lesions from baseline in 86 patients with mCRC<sup>BRAF-V600E</sup> tumors treated with anti-BRAF/EGFR combinatory therapies (discovery cohort, n = 44, plus validation cohort, n = 42). As a common in real-world clinical practice for aggressive tumors like mCRC<sup>BRAF-V600E</sup>, images from a proportion of patients (n = 12) were not available, mostly due to rapid clinical deterioration. <b>B–D)</b> Waterfall plots including patients with the different molecular subtypes: <b>B)</b> MSI-<i>RNF43</i><sup>mutated</sup> tumors are shown in gray, <b>C)</b> MSS-<i>RNF43</i><sup>wild-type</sup> tumors are shown in yellow, and <b>D)</b> MSS-<i>RNF43</i><sup>mutated</sup> tumors are shown in blue. <b>E)</b> The post-contrast CT scan at baseline shows multiple liver metastases (yellow arrows) in a patient with mCRC<sup>BRAF-V600E</sup> with a MSS-<i>RNF43</i><sup>mutated</sup> tumor. <b>F)</b> The post-contrast CT scan after 3 months of treatment shows marked reduction in size of the liver metastases (yellow arrows); some of the lesions are no longer seen in the follow-up CT-scan (yellow circles). Abbreviations: MSI, microsatellite instability high; MSS, microsatellite stable.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig12"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 6 kaplan-meier curves of pfs an" href="/articles/s41591-022-01976-z/figures/12" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig12_ESM.jpg">Extended Data Fig. 6 Kaplan-Meier curves of PFS and OS from patients with mCRC<sup>BRAF-V600E</sup> tumors (discovery cohort, n = 45) treated with anti-BRAF/EGFR combinatory therapies with regard to <i>RNF43</i> mutations (left) and <i>RNF43</i> mutations combined with MSS/MSI status (right).</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>A)</b> PFS of patients with <i>RNF43</i><sup>mutated</sup> (n = 19) and <i>RNF43</i><sup>wildtype</sup> (n = 26) tumors and <b>B)</b> combined <i>RNF43</i> and MSS/MSI statuses (MSS-<i>RNF43</i><sup>wild-type</sup> [n = 26], MSS-<i>RNF43</i><sup>mutated</sup> [n = 11], MSI-<i>RNF43</i><sup>mutated</sup> [n = 8]). <b>C)</b> Event-free survival of patients with <i>RNF43</i><sup>mutated</sup> (n = 19) and <i>RNF43</i><sup>wild-type</sup> (n = 26) tumors and <b>D)</b> combined <i>RNF43</i> and MSS/MSI statuses (MSS-<i>RNF43</i><sup>wild-type</sup> [n = 26], MSS-<i>RNF43</i><sup>mutated</sup> [n = 11], MSI-<i>RNF43</i><sup>mutated</sup> [n = 8]). Cox models were used to obtain hazard ratios with 95% CIs, and the two-sided log-rank test was used for statistical comparisons without adjustment for multiplicity. Colors indicate molecular subtypes: RNF43<sup>wild-type</sup> tumors with or without MSS (yellow), RNF43<sup>mutated</sup> tumors with or without MSS (blue) and MSI-RNF43<sup>mutated</sup> tumors (gray). Significant values are shown in bold. Abbreviations: CI, confidence interval; HR, hazard ratio.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig13"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 7 clinical characteristics and " href="/articles/s41591-022-01976-z/figures/13" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig13_ESM.jpg">Extended Data Fig. 7 Clinical characteristics and mutational profile of patients with mCRC<sup>BRAF-V600E</sup> treated with no anti-BRAF/EGFR combinatorial therapies.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>A)</b> Clinical and therapeutic characteristics of patients from the control cohort, patients receiving standard chemotherapy ± antiangiogenic agents (total N = 68). These patients received in total 135 chemotherapy regimens with/without anti-angiogenic drugs during first, second, or third lines. A total of 67 treatment lines (second and third line) in MSS patients were analyzed. <b>B</b>–<b>E)</b> Comparison of <i>RNF43</i> mutation frequencies and protein location between discovery/validation (<b>B,D</b>) and control <b>(C,E)</b> cohorts. <i>RNF43</i> mutation frequencies of the mCRC<sup>BRAF-V600E</sup> MSS subgroup from discovery/validation (29%, 22/76) and control (22%, 15/68) cohorts were similar (<b>B</b>, <b>C</b>), respectively. Also, the MSS discovery/validation and control cohorts showed a similar <i>RNF43</i> mutational profile regarding localization and predictive functional status (<b>D, E</b>). Abbreviations: MSS, microsatellite stable.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig14"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 8 analysis of the prognostic/pr" href="/articles/s41591-022-01976-z/figures/14" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig14_ESM.jpg">Extended Data Fig. 8 Analysis of the prognostic/predictive value of <i>RNF43</i> mutations in the control cohort of patients with mCRC<sup>BRAF-V600E</sup> with MSS tumors treated with standard-of-care regimens only, with no exposure to anti-BRAF therapies.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>A, B)</b> Kaplan-Meier curves of PFS and OS from the control cohort treated in second or third line (n = 67) <b>C, D)</b> and in first line (n = 68) with standard-of-care regimens only, with no exposure to anti-BRAF therapies. Colors refer to molecular subtypes:﻿ <i>RNF43</i><sup>wild-type</sup> (yellow), ﻿<i>RNF43</i><sup>mutated</sup> tumors (blue)<sup>wild-type</sup>. Cox models were used to obtain hazard ratios with 95% CI, and the two-sided log-rank test was used for statistical comparisons without adjustment for multiplicity. Abbreviations: CI, confidence interval; HR, hazard ratio.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig15"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 9 mutation frequencies of rnf43" href="/articles/s41591-022-01976-z/figures/15" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig15_ESM.jpg">Extended Data Fig. 9 Mutation frequencies of <i>RNF43</i> and <i>APC</i> genes in MSS status and immunohistochemical analysis against human β-catenin of mCRC<sup>BRAF-V600E</sup> tumor samples.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>A, B)</b> Mutation frequencies of <i>RNF43</i> and <i>APC</i> genes, and response status from patients with mCRC<sup>BRAF-V600E</sup> with MSS tumors from the discovery (<b>A</b>) and validation (<b>B</b>) cohorts. Chi-square test was used for the statistical analysis. Abbreviations: CR, complete response; MSS, microsatellite stable; PD, progressive disease; PR, partial response; SD, stable disease. <b>C–D)</b> Immunohistochemical analysis against human β-catenin was performed in MSS-<i>RNF43</i><sup>wild-type</sup>, MSS-<i>RNF43</i><sup>mutated</sup>, and MSI-<i>RNF43</i><sup>mutated</sup> mCRC<sup>BRAF-V600E</sup> tumor samples (n = 33) to search for potential differential pattern in total expression or cellular localization of β-catenin protein. No correlation was found between β-catenin protein expression levels (0, no staining; 1, weak; 2, moderate; and 3, strong) and cellular localization (cytoplasm, membrane, nucleus) with response to anti-BRAF/EGFR ± combinatorial therapies. Representative immunohistochemistry for β-catenin with strong membrane positivity, weak-moderate cytoplasmic positivity, and few weak nucleus positivity (magnification 40x) (<b>C</b>) and strong-moderate nuclear and cytoplasmic positivity <b>(D)</b> (magnification 40x).</p></div></div></div></div></div></section><section data-title="Supplementary information"><div class="c-article-section" id="Sec28-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec28">Supplementary information</h2><div class="c-article-section__content" id="Sec28-content"><div data-test="supplementary-info"><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM1"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="reporting summary" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_MOESM1_ESM.pdf" data-supp-info-image="">Reporting Summary</a></h3></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM2"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="supplementary tables" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_MOESM2_ESM.xlsx" data-supp-info-image="">Supplementary Tables</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Supplementary Table 1: Clinical and genetic dataset of mCRC<sup>BRAF-V600E</sup> from the discovery and validation cohorts. Supplementary Table 2: Comparison of mutation frequencies of cancer-related genes from the discovery cohort and patients with mCRC<sup>BRAF-V600E</sup> from the TCGA PanCancer Atlas.</p></div></div></div></div></div></section><section data-title="Source data"><div class="c-article-section" id="Sec29-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec29">Source data</h2><div class="c-article-section__content" id="Sec29-content"><div data-test="supplementary-info"><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM3"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="source data fig. 6" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_MOESM3_ESM.pdf" data-supp-info-image="">Source Data Fig. 6</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Original unprocessed western blot from Fig. 6c.</p></div></div></div></div></div></section><section data-title="Rights and permissions"><div class="c-article-section" id="rightslink-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="rightslink">Rights and permissions</h2><div class="c-article-section__content" id="rightslink-content">
                <p><b>Open Access</b>  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <a href="http://creativecommons.org/licenses/by/4.0/" rel="license">http://creativecommons.org/licenses/by/4.0/</a>.</p>
              <p class="c-article-rights"><a data-track="click" data-track-action="view rights and permissions" data-track-label="link" href="https://s100.copyright.com/AppDispatchServlet?title=RNF43%20mutations%20predict%20response%20to%20anti-BRAF%2FEGFR%20combinatory%20therapies%20in%20BRAFV600E%20metastatic%20colorectal%20cancer&amp;author=Elena%20Elez%20et%20al&amp;contentID=10.1038%2Fs41591-022-01976-z&amp;copyright=The%20Author%28s%29&amp;publication=1078-8956&amp;publicationDate=2022-09-12&amp;publisherName=SpringerNature&amp;orderBeanReset=true&amp;oa=CC%20BY">Reprints and permissions</a></p></div></div></section><section aria-labelledby="article-info" data-title="About this article"><div class="c-article-section" id="article-info-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="article-info">About this article</h2><div class="c-article-section__content" id="article-info-content"><div class="c-bibliographic-information"><div class="u-hide-print c-bibliographic-information__column c-bibliographic-information__column--border"><a data-crossmark="10.1038/s41591-022-01976-z" target="_blank" rel="noopener" href="https://crossmark.crossref.org/dialog/?doi=10.1038/s41591-022-01976-z" data-track="click" data-track-action="Click Crossmark" data-track-label="link" data-test="crossmark"><img loading="lazy" width="57" height="81" alt="Check for updates. Verify currency and authenticity via CrossMark" src="data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>"></a></div><div class="c-bibliographic-information__column"><h3 class="c-article__sub-heading" id="citeas">Cite this article</h3><p class="c-bibliographic-information__citation">Elez, E., Ros, J., Fernández, J. <i>et al.</i> <i>RNF43</i> mutations predict response to anti-BRAF/EGFR combinatory therapies in <i>BRAF</i><sup>V600E</sup> metastatic colorectal cancer.
                    <i>Nat Med</i> <b>28</b>, 2162–2170 (2022). https://doi.org/10.1038/s41591-022-01976-z</p><p class="c-bibliographic-information__download-citation u-hide-print"><a data-test="citation-link" data-track="click" data-track-action="download article citation" data-track-label="link" data-track-external="" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1038/s41591-022-01976-z?format=refman&amp;flavour=citation">Download citation<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-download-medium"></use></svg></a></p><ul class="c-bibliographic-information__list" data-test="publication-history"><li class="c-bibliographic-information__list-item"><p>Received<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2022-03-08">08 March 2022</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Accepted<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2022-07-26">26 July 2022</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Published<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2022-09-12">12 September 2022</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Issue Date<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2022-10">October 2022</time></span></p></li><li class="c-bibliographic-information__list-item c-bibliographic-information__list-item--full-width"><p><abbr title="Digital Object Identifier">DOI</abbr><span class="u-hide">: </span><span class="c-bibliographic-information__value">https://doi.org/10.1038/s41591-022-01976-z</span></p></li></ul><div data-component="share-box"><div class="c-article-share-box u-display-block"><h3 class="c-article__sub-heading">Share this article</h3><p class="c-article-share-box__description">Anyone you share the following link with will be able to read this content:</p><button class="js-get-share-url c-article-share-box__button" type="button" id="get-share-url" data-track="click" data-track-label="button" data-track-external="" data-track-action="get shareable link">Get shareable link</button><div class="js-no-share-url-container u-display-none" hidden=""><p class="js-c-article-share-box__no-sharelink-info c-article-share-box__no-sharelink-info">Sorry, a shareable link is not currently available for this article.</p></div><div class="js-share-url-container u-display-none" hidden=""><p class="js-share-url c-article-share-box__only-read-input" id="share-url" data-track="click" data-track-label="button" data-track-action="select share url"></p><button class="js-copy-share-url c-article-share-box__button--link-like" type="button" id="copy-share-url" data-track="click" data-track-label="button" data-track-action="copy share url" data-track-external="">Copy to clipboard</button></div><p class="js-c-article-share-box__additional-info c-article-share-box__additional-info">
                            Provided by the Springer Nature SharedIt content-sharing initiative
                        </p></div></div><div data-component="article-info-list">
        <h3 class="c-article__sub-heading">Subjects</h3>
        <ul class="c-article-subject-list">
            <li class="c-article-subject-list__subject"><a href="/subjects/colorectal-cancer" data-track="click" data-track-action="view subject" data-track-label="link">Colorectal cancer</a></li><li class="c-article-subject-list__subject"><a href="/subjects/predictive-markers" data-track="click" data-track-action="view subject" data-track-label="link">Predictive markers</a></li><li class="c-article-subject-list__subject"><a href="/subjects/tumour-biomarkers" data-track="click" data-track-action="view subject" data-track-label="link">Tumour biomarkers</a></li>
        </ul>
    </div></div></div></div></div></section>
            </div>

            
        <section>
            <div class="c-article-section js-article-section" id="further-reading-section" data-test="further-reading-section">
                <h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="further-reading">This article is cited by</h2>
                <div class="c-article-section__content js-collapsible-section" id="further-reading-content">
                    <ul class="c-article-further-reading__list" id="further-reading-list">
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Lack of dominant-negative activity for tumor-related ZNRF3 missense mutations at endogenous levels" href="https://doi.org/10.1038/s41388-024-03253-4">
                                        Lack of dominant-negative activity for tumor-related ZNRF3 missense mutations at endogenous levels
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Shanshan Li</li><li>Jiahui Niu</li><li>Ron Smits</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Oncogene</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm" href="https://doi.org/10.1038/s41571-024-00965-0">
                                        Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Paolo Ciracì</li><li>Vittorio Studiale</li><li>Chiara Cremolini</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Nature Reviews Clinical Oncology</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Co-occurring mutations identify prognostic subgroups of microsatellite stable colorectal cancer" href="https://doi.org/10.1186/s12943-024-02173-x">
                                        Co-occurring mutations identify prognostic subgroups of microsatellite stable colorectal cancer
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Luís Nunes</li><li>Jakob Mørkved Stenersen</li><li>Anita Sveen</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Molecular Cancer</i> (2024)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Evolutionary dependency of cancer mutations in gene pairs inferred by nonsynonymous-synonymous mutation ratios" href="https://doi.org/10.1186/s13073-024-01376-7">
                                        Evolutionary dependency of cancer mutations in gene pairs inferred by nonsynonymous-synonymous mutation ratios
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Dong-Jin Han</li><li>Sunmin Kim</li><li>Tae-Min Kim</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Genome Medicine</i> (2024)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial" href="https://doi.org/10.1038/s41591-024-03235-9">
                                        Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Scott Kopetz</li><li>Danielle A. Murphy</li><li>Josep Tabernero</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Nature Medicine</i> (2024)</p>
                            </li>
                        
                    </ul>
                </div>
            </div>
        </section>
    

        </div>
</article>
</main>

<aside class="c-article-extras u-hide-print" aria-label="Article navigation" data-component-reading-companion="" data-container-type="reading-companion" data-track-component="reading companion">
    <div class="js-context-bar-sticky-point-desktop" data-track-context="reading companion">
        

        
            
                
                    
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-022-01976-z.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                
            
        
    </div>

    
        
    

    
    
        <div class="c-article-associated-content__container">
            <section>
                <h2 class="c-article-associated-content__title u-mb-24">Associated content</h2>
                
                    
                    
                        <div class="u-full-height u-mb-24">
                            
    <article class="u-full-height c-card c-card--flush">
        <div class="c-card__layout u-full-height">
            <div class="c-card__body">
                <h3 class="c-card__title">
                    <a href="https://www.nature.com/articles/s41591-022-01988-9" class="c-card__link u-link-inherit" data-track="click" data-track-action="view article" data-track-category="associated content" data-track-label="news_and_views">A biomarker of response to therapy in metastatic BRAF<sup>V600E</sup> colorectal cancers</a>
                </h3>
                
                
    <div class="c-card__section c-meta">
        
            <span class="c-meta__item">Nature Medicine</span>
        
        <span class="c-meta__item" data-test="article.type"><span class="c-meta__type">Research Briefing</span></span>
        
        
            <time class="c-meta__item" datetime="2022-09-14">14 Sept 2022</time>
        
    </div>

            </div>
        </div>
    </article>


                        </div>
                    
                
            </section>
        </div>
        <script>
            window.dataLayer = window.dataLayer || [];
            window.dataLayer[0] = window.dataLayer[0] || {};
            window.dataLayer[0].content = window.dataLayer[0].content || {};
            window.dataLayer[0].content.associatedContentTypes = "news_and_views";
            
        </script>
    

    

    <div class="c-reading-companion">
        <div class="c-reading-companion__sticky" data-component="reading-companion-sticky" data-test="reading-companion-sticky" style="top: 40px;">
            <ul class="c-reading-companion__tabs" role="tablist"><li role="presentation"><button data-tab-target="sections" role="tab" id="tab-sections" aria-controls="tabpanel-sections" aria-selected="true" class="c-reading-companion__tab c-reading-companion__tab--active" data-track="click" data-track-action="sections tab" data-track-label="tab">Sections</button></li><li role="presentation"><button data-tab-target="figures" role="tab" id="tab-figures" aria-controls="tabpanel-figures" aria-selected="false" tabindex="-1" class="c-reading-companion__tab" data-track="click" data-track-action="figures tab" data-track-label="tab">Figures</button></li><li role="presentation"><button data-tab-target="references" role="tab" id="tab-references" aria-controls="tabpanel-references" aria-selected="false" tabindex="-1" class="c-reading-companion__tab" data-track="click" data-track-action="references tab" data-track-label="tab">References</button></li></ul><div class="c-reading-companion__panel c-reading-companion__sections c-reading-companion__panel--active" id="tabpanel-sections" aria-labelledby="tab-sections" role="tabpanel"><div class="c-reading-companion__scroll-pane" style="max-height: none;"><ul class="c-reading-companion__sections-list"><li id="rc-sec-Abs1" class="c-reading-companion__section-item"><a href="#Abs1" data-track="click" data-track-action="section anchor" data-track-label="link:Abstract">Abstract</a></li><li id="rc-sec-Sec1" class="c-reading-companion__section-item"><a href="#Sec1" data-track="click" data-track-action="section anchor" data-track-label="link:Main">Main</a></li><li id="rc-sec-Sec2" class="c-reading-companion__section-item"><a href="#Sec2" data-track="click" data-track-action="section anchor" data-track-label="link:Results">Results</a></li><li id="rc-sec-Sec8" class="c-reading-companion__section-item"><a href="#Sec8" data-track="click" data-track-action="section anchor" data-track-label="link:Discussion">Discussion</a></li><li id="rc-sec-Sec9" class="c-reading-companion__section-item"><a href="#Sec9" data-track="click" data-track-action="section anchor" data-track-label="link:Methods">Methods</a></li><li id="rc-sec-data-availability" class="c-reading-companion__section-item"><a href="#data-availability" data-track="click" data-track-action="section anchor" data-track-label="link:Data availability">Data availability</a></li><li id="rc-sec-code-availability" class="c-reading-companion__section-item"><a href="#code-availability" data-track="click" data-track-action="section anchor" data-track-label="link:Code availability">Code availability</a></li><li id="rc-sec-Bib1" class="c-reading-companion__section-item"><a href="#Bib1" data-track="click" data-track-action="section anchor" data-track-label="link:References">References</a></li><li id="rc-sec-Ack1" class="c-reading-companion__section-item"><a href="#Ack1" data-track="click" data-track-action="section anchor" data-track-label="link:Acknowledgements">Acknowledgements</a></li><li id="rc-sec-author-information" class="c-reading-companion__section-item"><a href="#author-information" data-track="click" data-track-action="section anchor" data-track-label="link:Author information">Author information</a></li><li id="rc-sec-ethics" class="c-reading-companion__section-item"><a href="#ethics" data-track="click" data-track-action="section anchor" data-track-label="link:Ethics declarations">Ethics declarations</a></li><li id="rc-sec-peer-review" class="c-reading-companion__section-item"><a href="#peer-review" data-track="click" data-track-action="section anchor" data-track-label="link:Peer review">Peer review</a></li><li id="rc-sec-additional-information" class="c-reading-companion__section-item"><a href="#additional-information" data-track="click" data-track-action="section anchor" data-track-label="link:Additional information">Additional information</a></li><li id="rc-sec-Sec27" class="c-reading-companion__section-item"><a href="#Sec27" data-track="click" data-track-action="section anchor" data-track-label="link:Extended data">Extended data</a></li><li id="rc-sec-Sec28" class="c-reading-companion__section-item"><a href="#Sec28" data-track="click" data-track-action="section anchor" data-track-label="link:Supplementary information">Supplementary information</a></li><li id="rc-sec-Sec29" class="c-reading-companion__section-item"><a href="#Sec29" data-track="click" data-track-action="section anchor" data-track-label="link:Source data">Source data</a></li><li id="rc-sec-rightslink" class="c-reading-companion__section-item"><a href="#rightslink" data-track="click" data-track-action="section anchor" data-track-label="link:Rights and permissions">Rights and permissions</a></li><li id="rc-sec-article-info" class="c-reading-companion__section-item"><a href="#article-info" data-track="click" data-track-action="section anchor" data-track-label="link:About this article">About this article</a></li><li id="rc-sec-further-reading" class="c-reading-companion__section-item"><a href="#further-reading" data-track="click" data-track-action="section anchor" data-track-label="link:This article is cited by">This article is cited by</a></li></ul></div>
                <div class="u-lazy-ad-wrapper u-mt-16 u-show" data-component-mpu="" style="display: none !important;">
                    <div class="c-ad c-ad--300x250">
                        <div class="c-ad__inner">
                            <p class="c-ad__label">Advertisement</p>
                            
    <div id="div-gpt-ad-right-2" class="div-gpt-ad advert medium-rectangle js-ad text-center hide-print grade-c-hide" data-ad-type="right" data-test="right-ad" data-pa11y-ignore="" data-gpt="" data-gpt-unitpath="/285/medicine.nature.com/article" data-gpt-sizes="300x250" data-gpt-targeting="type=article;pos=right;artid=s41591-022-01976-z;doi=10.1038/s41591-022-01976-z;subjmeta=1504,1857,1885,2423,308,53,631,67,692;kwrd=Colorectal+cancer,Predictive+markers,Tumour+biomarkers">
        <noscript>
            <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/285/medicine.nature.com/article&amp;sz=300x250&amp;c=-891498472&amp;t=pos%3Dright%26type%3Darticle%26artid%3Ds41591-022-01976-z%26doi%3D10.1038/s41591-022-01976-z%26subjmeta%3D1504,1857,1885,2423,308,53,631,67,692%26kwrd%3DColorectal+cancer,Predictive+markers,Tumour+biomarkers">
                <img data-test="gpt-advert-fallback-img"
                     src="//pubads.g.doubleclick.net/gampad/ad?iu=/285/medicine.nature.com/article&amp;sz=300x250&amp;c=-891498472&amp;t=pos%3Dright%26type%3Darticle%26artid%3Ds41591-022-01976-z%26doi%3D10.1038/s41591-022-01976-z%26subjmeta%3D1504,1857,1885,2423,308,53,631,67,692%26kwrd%3DColorectal+cancer,Predictive+markers,Tumour+biomarkers"
                     alt="Advertisement"
                     width="300"
                     height="250"></a>
        </noscript>
    </div>

                        </div>
                    </div>
                </div>
            </div>
            <div class="c-reading-companion__panel c-reading-companion__figures c-reading-companion__panel--full-width" id="tabpanel-figures" aria-labelledby="tab-figures" role="tabpanel"><div class="c-reading-companion__scroll-pane"><ul class="c-reading-companion__figures-list"><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig1">Fig. 1: Study design.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig1_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig1_HTML.png" alt="figure 1" aria-describedby="rc-Fig1"></picture><p class="c-reading-companion__figure-links"><a href="#Fig1" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01976-z/figures/1" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig2">Fig. 2: Clinical responses to BRAF/EGFR inhibition according to MSS/MSI and <i>RNF43</i> status.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig2_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig2_HTML.png" alt="figure 2" aria-describedby="rc-Fig2"></picture><p class="c-reading-companion__figure-links"><a href="#Fig2" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01976-z/figures/2" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig3">Fig. 3: Survival analysis of patients undergoing BRAF/EGFR inhibition according to MSS/MSI and <i>RNF43</i> status.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig3_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig3_HTML.png" alt="figure 3" aria-describedby="rc-Fig3"></picture><p class="c-reading-companion__figure-links"><a href="#Fig3" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01976-z/figures/3" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig4">Fig. 4: Univariate and multivariate Cox regression models.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig4_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig4_HTML.png" alt="figure 4" aria-describedby="rc-Fig4"></picture><p class="c-reading-companion__figure-links"><a href="#Fig4" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01976-z/figures/4" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig5">Fig. 5: Predictive value of MSS/MSI-<i>RNF43</i> status.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig5_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig5_HTML.png" alt="figure 5" aria-describedby="rc-Fig5"></picture><p class="c-reading-companion__figure-links"><a href="#Fig5" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01976-z/figures/5" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig6">Fig. 6: Functional analysis of <i>RNF43</i> mutations.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig6_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig6_HTML.png" alt="figure 6" aria-describedby="rc-Fig6"></picture><p class="c-reading-companion__figure-links"><a href="#Fig6" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01976-z/figures/6" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig7">Extended Data Fig. 1 Patients’ characteristics.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig7_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig7_ESM.jpg" alt="extended data figure 7" aria-describedby="rc-Fig7"></picture><p class="c-reading-companion__figure-links"><a href="#Fig7" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01976-z/figures/7" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig8">Extended Data Fig. 2 Bioinformatics pipeline for genomic data analysis.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig8_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig8_ESM.jpg" alt="extended data figure 8" aria-describedby="rc-Fig8"></picture><p class="c-reading-companion__figure-links"><a href="#Fig8" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01976-z/figures/8" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig9">Extended Data Fig. 3 The utility of liquid biopsy to assess <i>BRAF</i> and <i>RNF43</i> mutational status in patiets with mCRC<sup>BRAF-V600E</sup> treated with anti-BRAF/EGFR combinatorial therapies.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig9_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig9_ESM.jpg" alt="extended data figure 9" aria-describedby="rc-Fig9"></picture><p class="c-reading-companion__figure-links"><a href="#Fig9" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01976-z/figures/9" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig10">Extended Data Fig. 4 Overall response rate (ORR) (%) of the discovery (n = 45, A–C) and validation (n = 50, D–F) cohorts and diagnostic performance analyses (G) defined by MSS/MSI and <i>RNF43</i> mutation statuses.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig10_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig10_ESM.jpg" alt="extended data figure 10" aria-describedby="rc-Fig10"></picture><p class="c-reading-companion__figure-links"><a href="#Fig10" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01976-z/figures/10" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig11">Extended Data Fig. 5 Waterfall plots depicting different molecular subtypes.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig11_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig11_ESM.jpg" alt="extended data figure 11" aria-describedby="rc-Fig11"></picture><p class="c-reading-companion__figure-links"><a href="#Fig11" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01976-z/figures/11" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig12">Extended Data Fig. 6 Kaplan-Meier curves of PFS and OS from patients with mCRC<sup>BRAF-V600E</sup> tumors (discovery cohort, n = 45) treated with anti-BRAF/EGFR combinatory therapies with regard to <i>RNF43</i> mutations (left) and <i>RNF43</i> mutations combined with MSS/MSI status (right).</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig12_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig12_ESM.jpg" alt="extended data figure 12" aria-describedby="rc-Fig12"></picture><p class="c-reading-companion__figure-links"><a href="#Fig12" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01976-z/figures/12" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig13">Extended Data Fig. 7 Clinical characteristics and mutational profile of patients with mCRC<sup>BRAF-V600E</sup> treated with no anti-BRAF/EGFR combinatorial therapies.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig13_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig13_ESM.jpg" alt="extended data figure 13" aria-describedby="rc-Fig13"></picture><p class="c-reading-companion__figure-links"><a href="#Fig13" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01976-z/figures/13" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig14">Extended Data Fig. 8 Analysis of the prognostic/predictive value of <i>RNF43</i> mutations in the control cohort of patients with mCRC<sup>BRAF-V600E</sup> with MSS tumors treated with standard-of-care regimens only, with no exposure to anti-BRAF therapies.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig14_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig14_ESM.jpg" alt="extended data figure 14" aria-describedby="rc-Fig14"></picture><p class="c-reading-companion__figure-links"><a href="#Fig14" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01976-z/figures/14" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig15">Extended Data Fig. 9 Mutation frequencies of <i>RNF43</i> and <i>APC</i> genes in MSS status and immunohistochemical analysis against human β-catenin of mCRC<sup>BRAF-V600E</sup> tumor samples.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig15_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-01976-z/MediaObjects/41591_2022_1976_Fig15_ESM.jpg" alt="extended data figure 15" aria-describedby="rc-Fig15"></picture><p class="c-reading-companion__figure-links"><a href="#Fig15" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-01976-z/figures/15" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li></ul></div></div>
            <div class="c-reading-companion__panel c-reading-companion__references c-reading-companion__panel--full-width" id="tabpanel-references" aria-labelledby="tab-references" role="tabpanel"><div class="c-reading-companion__scroll-pane"><ol class="c-reading-companion__references-list c-reading-companion__references-list--numeric" data-track-context="article references sidebar"><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR1">Di Nicolantonio, F. et al. Precision oncology in metastatic colorectal cancer—from biology to medicine. <i>Nat. Rev. Clin. Oncol.</i> <b>18</b>, 506–525 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41571-021-00495-z" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41571-021-00495-z" data-track-item_id="10.1038/s41571-021-00495-z">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Precision%20oncology%20in%20metastatic%20colorectal%20cancer%E2%80%94from%20biology%20to%20medicine&amp;journal=Nat.%20Rev.%20Clin.%20Oncol.&amp;doi=10.1038%2Fs41571-021-00495-z&amp;volume=18&amp;pages=506-525&amp;publication_year=2021&amp;author=Nicolantonio%2CF" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR2">Morris, V. et al. Progression-free survival remains poor over sequential lines of systemic therapy in patients with <i>BRAF</i>-mutated colorectal cancer. <i>Clin. Colorectal Cancer</i> <b>13</b>, 164–171 (2014).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.clcc.2014.06.001" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.clcc.2014.06.001" data-track-item_id="10.1016/j.clcc.2014.06.001">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Progression-free%20survival%20remains%20poor%20over%20sequential%20lines%20of%20systemic%20therapy%20in%20patients%20with%20BRAF-mutated%20colorectal%20cancer&amp;journal=Clin.%20Colorectal%20Cancer&amp;doi=10.1016%2Fj.clcc.2014.06.001&amp;volume=13&amp;pages=164-171&amp;publication_year=2014&amp;author=Morris%2CV" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR3">Cremolini, C. et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. <i>Lancet Oncol.</i> <b>16</b>, 1306–1315 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2FS1470-2045%2815%2900122-9" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/S1470-2045(15)00122-9" data-track-item_id="10.1016/S1470-2045(15)00122-9">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXhsVOntL3F" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=FOLFOXIRI%20plus%20bevacizumab%20versus%20FOLFIRI%20plus%20bevacizumab%20as%20first-line%20treatment%20of%20patients%20with%20metastatic%20colorectal%20cancer%3A%20updated%20overall%20survival%20and%20molecular%20subgroup%20analyses%20of%20the%20open-label%2C%20phase%203%20TRIBE%20study&amp;journal=Lancet%20Oncol.&amp;doi=10.1016%2FS1470-2045%2815%2900122-9&amp;volume=16&amp;pages=1306-1315&amp;publication_year=2015&amp;author=Cremolini%2CC" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR4">Yaeger, R. et al. Clinical sequencing defines the genomic landscape of metastatic colorectal cancer. <i>Cancer Cell</i> <b>33</b>, 125–136 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.ccell.2017.12.004" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.ccell.2017.12.004" data-track-item_id="10.1016/j.ccell.2017.12.004">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXntVejsg%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Clinical%20sequencing%20defines%20the%20genomic%20landscape%20of%20metastatic%20colorectal%20cancer&amp;journal=Cancer%20Cell&amp;doi=10.1016%2Fj.ccell.2017.12.004&amp;volume=33&amp;pages=125-136&amp;publication_year=2018&amp;author=Yaeger%2CR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR5">Hoadley, K. A. et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. <i>Cell</i> <b>173</b>, 291–304 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.cell.2018.03.022" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.cell.2018.03.022" data-track-item_id="10.1016/j.cell.2018.03.022">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXntFahs7k%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Cell-of-origin%20patterns%20dominate%20the%20molecular%20classification%20of%2010%2C000%20tumors%20from%2033%20types%20of%20cancer&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2018.03.022&amp;volume=173&amp;pages=291-304&amp;publication_year=2018&amp;author=Hoadley%2CKA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR6">Koo, B. K. et al. Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. <i>Nature</i> <b>488</b>, 665–669 (2012).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fnature11308" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/nature11308" data-track-item_id="10.1038/nature11308">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XhtF2rurjE" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Tumour%20suppressor%20RNF43%20is%20a%20stem-cell%20E3%20ligase%20that%20induces%20endocytosis%20of%20Wnt%20receptors&amp;journal=Nature&amp;doi=10.1038%2Fnature11308&amp;volume=488&amp;pages=665-669&amp;publication_year=2012&amp;author=Koo%2CBK" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR7">Nusse, R. &amp; Clevers, H. Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. <i>Cell</i> <b>169</b>, 985–999 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.cell.2017.05.016" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.cell.2017.05.016" data-track-item_id="10.1016/j.cell.2017.05.016">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXpt1agsro%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Wnt%2F%CE%B2-catenin%20signaling%2C%20disease%2C%20and%20emerging%20therapeutic%20modalities&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2017.05.016&amp;volume=169&amp;pages=985-999&amp;publication_year=2017&amp;author=Nusse%2CR&amp;author=Clevers%2CH" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR8">Hyman, D. M. et al. Vemurafenib in multiple nonmelanoma cancers with <i>BRAF</i><sup>V600</sup> mutations. <i>N. Engl. J. Med.</i> <b>373</b>, 726–736 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa1502309" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa1502309" data-track-item_id="10.1056/NEJMoa1502309">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XkvFWrtg%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Vemurafenib%20in%20multiple%20nonmelanoma%20cancers%20with%20BRAFV600%20mutations&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1502309&amp;volume=373&amp;pages=726-736&amp;publication_year=2015&amp;author=Hyman%2CDM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR9">Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. <i>N. Engl. J. Med.</i> <b>363</b>, 809–819 (2010).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa1002011" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa1002011" data-track-item_id="10.1056/NEJMoa1002011">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3cXhtVyksb3M" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Inhibition%20of%20mutated%2C%20activated%20BRAF%20in%20metastatic%20melanoma&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1002011&amp;volume=363&amp;pages=809-819&amp;publication_year=2010&amp;author=Flaherty%2CKT" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR10">Sosman, J. A. et al. Survival in <i>BRAF</i><sup>V600</sup>-mutant advanced melanoma treated with vemurafenib. <i>N. Engl. J. Med.</i> <b>366</b>, 707–714 (2012).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa1112302" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa1112302" data-track-item_id="10.1056/NEJMoa1112302">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XjtFOqtr0%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Survival%20in%20BRAFV600-mutant%20advanced%20melanoma%20treated%20with%20vemurafenib&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1112302&amp;volume=366&amp;pages=707-714&amp;publication_year=2012&amp;author=Sosman%2CJA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR11">Kopetz, S. et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. <i>J. Clin. Oncol.</i> <b>28</b>, 3534 (2010).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1200%2Fjco.2010.28.15_suppl.3534" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1200/jco.2010.28.15_suppl.3534" data-track-item_id="10.1200/jco.2010.28.15_suppl.3534">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=PLX4032%20in%20metastatic%20colorectal%20cancer%20patients%20with%20mutant%20BRAF%20tumors&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2Fjco.2010.28.15_suppl.3534&amp;volume=28&amp;publication_year=2010&amp;author=Kopetz%2CS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR12">Kopetz, S. et al. Phase II pilot study of vemurafenib in patients with metastatic <i>BRAF</i>-mutated colorectal cancer. <i>J. Clin. Oncol.</i> <b>33</b>, 4032–4038 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1200%2FJCO.2015.63.2497" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1200/JCO.2015.63.2497" data-track-item_id="10.1200/JCO.2015.63.2497">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XmvV2gtr8%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Phase%20II%20pilot%20study%20of%20vemurafenib%20in%20patients%20with%20metastatic%20BRAF-mutated%20colorectal%20cancer&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2015.63.2497&amp;volume=33&amp;pages=4032-4038&amp;publication_year=2015&amp;author=Kopetz%2CS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR13">Prahallad, A. et al. Unresponsiveness of colon cancer to BRAF<sup>V600E</sup> inhibition through feedback activation of EGFR. <i>Nature</i> <b>483</b>, 100–103 (2012).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fnature10868" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/nature10868" data-track-item_id="10.1038/nature10868">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XjtFOktb4%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Unresponsiveness%20of%20colon%20cancer%20to%20BRAFV600E%20inhibition%20through%20feedback%20activation%20of%20EGFR&amp;journal=Nature&amp;doi=10.1038%2Fnature10868&amp;volume=483&amp;pages=100-103&amp;publication_year=2012&amp;author=Prahallad%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR14">Corcoran, R. B. et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of <i>BRAF</i> mutant colorectal cancers to RAF inhibition with vemurafenib. <i>Cancer Discov.</i> <b>2</b>, 227–235 (2012).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F2159-8290.CD-11-0341" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/2159-8290.CD-11-0341" data-track-item_id="10.1158/2159-8290.CD-11-0341">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XktVGntbs%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=EGFR-mediated%20re-activation%20of%20MAPK%20signaling%20contributes%20to%20insensitivity%20of%20BRAF%20mutant%20colorectal%20cancers%20to%20RAF%20inhibition%20with%20vemurafenib&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-11-0341&amp;volume=2&amp;pages=227-235&amp;publication_year=2012&amp;author=Corcoran%2CRB" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR15">van Geel, R. et al. A phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic <i>BRAF</i>-mutant colorectal cancer. <i>Cancer Discov.</i> <b>7</b>, 610–619 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F2159-8290.CD-16-0795" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/2159-8290.CD-16-0795" data-track-item_id="10.1158/2159-8290.CD-16-0795">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=A%20phase%20Ib%20dose-escalation%20study%20of%20encorafenib%20and%20cetuximab%20with%20or%20without%20alpelisib%20in%20metastatic%20BRAF-mutant%20colorectal%20cancer&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-16-0795&amp;volume=7&amp;pages=610-619&amp;publication_year=2017&amp;author=Geel%2CR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR16">Kopetz, S. et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in <i>BRAF</i>-mutant metastatic colorectal cancer (SWOG S1406). <i>J. Clin. Oncol.</i> <b>39</b>, 285–294 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1200%2FJCO.20.01994" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1200/JCO.20.01994" data-track-item_id="10.1200/JCO.20.01994">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XhslKmtbc%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Randomized%20trial%20of%20irinotecan%20and%20cetuximab%20with%20or%20without%20vemurafenib%20in%20BRAF-mutant%20metastatic%20colorectal%20cancer%20%28SWOG%20S1406%29&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.20.01994&amp;volume=39&amp;pages=285-294&amp;publication_year=2021&amp;author=Kopetz%2CS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR17">Ahronian, L. G. et al. Clinical acquired resistance to RAF inhibitor combinations in <i>BRAF</i>-mutant colorectal cancer through MAPK pathway alterations. <i>Cancer Discov.</i> <b>5</b>, 358–367 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F2159-8290.CD-14-1518" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/2159-8290.CD-14-1518" data-track-item_id="10.1158/2159-8290.CD-14-1518">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXmsVSrsbc%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Clinical%20acquired%20resistance%20to%20RAF%20inhibitor%20combinations%20in%20BRAF-mutant%20colorectal%20cancer%20through%20MAPK%20pathway%20alterations&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-14-1518&amp;volume=5&amp;pages=358-367&amp;publication_year=2015&amp;author=Ahronian%2CLG" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR18">Kopetz, S. et al. Encorafenib, binimetinib, and cetuximab in <i>BRAF</i><sup>V600E</sup>-mutated colorectal cancer. <i>N. Engl. J. Med.</i> <b>381</b>, 1632–1643 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa1908075" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa1908075" data-track-item_id="10.1056/NEJMoa1908075">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXitFWkt73E" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Encorafenib%2C%20binimetinib%2C%20and%20cetuximab%20in%20BRAFV600E-mutated%20colorectal%20cancer&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1908075&amp;volume=381&amp;pages=1632-1643&amp;publication_year=2019&amp;author=Kopetz%2CS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR19">Van Cutsem, E. et al. Binimetinib, encorafenib, and cetuximab triplet therapy for patients with <i>BRAF</i><sup>V600E</sup>-mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON colorectal cancer study. <i>J. Clin. Oncol.</i> <b>37</b>, 1460–1469 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1200%2FJCO.18.02459" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1200/JCO.18.02459" data-track-item_id="10.1200/JCO.18.02459">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Binimetinib%2C%20encorafenib%2C%20and%20cetuximab%20triplet%20therapy%20for%20patients%20with%20BRAFV600E-mutant%20metastatic%20colorectal%20cancer%3A%20safety%20lead-in%20results%20from%20the%20phase%20III%20BEACON%20colorectal%20cancer%20study&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.18.02459&amp;volume=37&amp;pages=1460-1469&amp;publication_year=2019&amp;author=Cutsem%2CE" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR20">Tabernero, J. et al. Encorafenib plus cetuximab as a new standard of care for previously treated <i>BRAF</i><sup>V600E</sup>-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. <i>J. Clin. Oncol.</i> <b>39</b>, 273–284 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1200%2FJCO.20.02088" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1200/JCO.20.02088" data-track-item_id="10.1200/JCO.20.02088">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XhslKmtbY%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Encorafenib%20plus%20cetuximab%20as%20a%20new%20standard%20of%20care%20for%20previously%20treated%20BRAFV600E-mutant%20metastatic%20colorectal%20cancer%3A%20updated%20survival%20results%20and%20subgroup%20analyses%20from%20the%20BEACON%20study&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.20.02088&amp;volume=39&amp;pages=273-284&amp;publication_year=2021&amp;author=Tabernero%2CJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR21">Kopetz, S. et al. Molecular correlates of clinical benefit in previously treated patients (pts) with <i>BRAF</i><sup>V600E</sup>-mutant metastatic colorectal cancer (mCRC) from the BEACON study. <i>J. Clin. Oncol.</i> <b>39</b>, 3513 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1200%2FJCO.2021.39.15_suppl.3513" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1200/JCO.2021.39.15_suppl.3513" data-track-item_id="10.1200/JCO.2021.39.15_suppl.3513">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Molecular%20correlates%20of%20clinical%20benefit%20in%20previously%20treated%20patients%20%28pts%29%20with%20BRAFV600E-mutant%20metastatic%20colorectal%20cancer%20%28mCRC%29%20from%20the%20BEACON%20study&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2021.39.15_suppl.3513&amp;volume=39&amp;publication_year=2021&amp;author=Kopetz%2CS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR22">Schwartz, L. H. et al. RECIST 1.1—standardisation and disease-specific adaptations: perspectives from the RECIST Working Group. <i>Eur. J. Cancer</i> <b>62</b>, 138–145 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.ejca.2016.03.082" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.ejca.2016.03.082" data-track-item_id="10.1016/j.ejca.2016.03.082">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=RECIST%201.1%E2%80%94standardisation%20and%20disease-specific%20adaptations%3A%20perspectives%20from%20the%20RECIST%20Working%20Group&amp;journal=Eur.%20J.%20Cancer&amp;doi=10.1016%2Fj.ejca.2016.03.082&amp;volume=62&amp;pages=138-145&amp;publication_year=2016&amp;author=Schwartz%2CLH" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR23">Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. <i>Cancer Discov.</i> <b>2</b>, 401–404 (2012).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F2159-8290.CD-12-0095" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/2159-8290.CD-12-0095" data-track-item_id="10.1158/2159-8290.CD-12-0095">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20cBio%20cancer%20genomics%20portal%3A%20an%20open%20platform%20for%20exploring%20multidimensional%20cancer%20genomics%20data&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-12-0095&amp;volume=2&amp;pages=401-404&amp;publication_year=2012&amp;author=Cerami%2CE" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR24">Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. <i>Sci. Signal.</i> <b>6</b>, pl1 (2013).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1126%2Fscisignal.2004088" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1126/scisignal.2004088" data-track-item_id="10.1126/scisignal.2004088">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Integrative%20analysis%20of%20complex%20cancer%20genomics%20and%20clinical%20profiles%20using%20the%20cBioPortal&amp;journal=Sci.%20Signal.&amp;doi=10.1126%2Fscisignal.2004088&amp;volume=6&amp;publication_year=2013&amp;author=Gao%2CJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR25">Martincorena, I. et al. Universal patterns of selection in cancer and somatic tissues. <i>Cell</i> <b>171</b>, 1029–1041 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.cell.2017.09.042" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.cell.2017.09.042" data-track-item_id="10.1016/j.cell.2017.09.042">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhs12lsLzO" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Universal%20patterns%20of%20selection%20in%20cancer%20and%20somatic%20tissues&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2017.09.042&amp;volume=171&amp;pages=1029-1041&amp;publication_year=2017&amp;author=Martincorena%2CI" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR26">Tu, J. et al. The most common RNF43 mutant G659Vfs*41 is fully functional in inhibiting Wnt signaling and unlikely to play a role in tumorigenesis. <i>Sci. Rep.</i> <b>9</b>, 18557 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41598-019-54931-3" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41598-019-54931-3" data-track-item_id="10.1038/s41598-019-54931-3">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXitl2htbzO" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20most%20common%20RNF43%20mutant%20G659Vfs%2A41%20is%20fully%20functional%20in%20inhibiting%20Wnt%20signaling%20and%20unlikely%20to%20play%20a%20role%20in%20tumorigenesis&amp;journal=Sci.%20Rep.&amp;doi=10.1038%2Fs41598-019-54931-3&amp;volume=9&amp;publication_year=2019&amp;author=Tu%2CJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR27">Yu, J. et al. The functional landscape of patient-derived <i>RNF43</i> mutations predicts sensitivity to Wnt inhibition. <i>Cancer Res.</i> <b>80</b>, 5619–5632 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F0008-5472.CAN-20-0957" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/0008-5472.CAN-20-0957" data-track-item_id="10.1158/0008-5472.CAN-20-0957">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXlvFemtLo%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20functional%20landscape%20of%20patient-derived%20RNF43%20mutations%20predicts%20sensitivity%20to%20Wnt%20inhibition&amp;journal=Cancer%20Res.&amp;doi=10.1158%2F0008-5472.CAN-20-0957&amp;volume=80&amp;pages=5619-5632&amp;publication_year=2020&amp;author=Yu%2CJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR28">Li, S. et al. Commonly observed <i>RNF43</i> mutations retain functionality in attenuating Wnt/β-catenin signaling and unlikely confer Wnt-dependency onto colorectal cancers. <i>Oncogene</i> <b>39</b>, 3458–3472 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41388-020-1232-5" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41388-020-1232-5" data-track-item_id="10.1038/s41388-020-1232-5">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXjvFKiur4%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Commonly%20observed%20RNF43%20mutations%20retain%20functionality%20in%20attenuating%20Wnt%2F%CE%B2-catenin%20signaling%20and%20unlikely%20confer%20Wnt-dependency%20onto%20colorectal%20cancers&amp;journal=Oncogene&amp;doi=10.1038%2Fs41388-020-1232-5&amp;volume=39&amp;pages=3458-3472&amp;publication_year=2020&amp;author=Li%2CS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR29">Van Cutsem, E., Cervantes, A., Nordlinger, B. &amp; Arnold, D. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann. Oncol.</i> <b>25</b>, iii1–iii9 (2014).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1093%2Fannonc%2Fmdu260" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1093/annonc/mdu260" data-track-item_id="10.1093/annonc/mdu260">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Metastatic%20colorectal%20cancer%3A%20ESMO%20Clinical%20Practice%20Guidelines%20for%20diagnosis%2C%20treatment%20and%20follow-up&amp;journal=Ann.%20Oncol.&amp;doi=10.1093%2Fannonc%2Fmdu260&amp;volume=25&amp;pages=iii1-iii9&amp;publication_year=2014&amp;author=Cutsem%2CE&amp;author=Cervantes%2CA&amp;author=Nordlinger%2CB&amp;author=Arnold%2CD" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR30">Van Cutsem, E. et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. <i>J. Clin. Oncol.</i> <b>30</b>, 3499–3506 (2012).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1200%2FJCO.2012.42.8201" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1200/JCO.2012.42.8201" data-track-item_id="10.1200/JCO.2012.42.8201">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Addition%20of%20aflibercept%20to%20fluorouracil%2C%20leucovorin%2C%20and%20irinotecan%20improves%20survival%20in%20a%20phase%20III%20randomized%20trial%20in%20patients%20with%20metastatic%20colorectal%20cancer%20previously%20treated%20with%20an%20oxaliplatin-based%20regimen&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2012.42.8201&amp;volume=30&amp;pages=3499-3506&amp;publication_year=2012&amp;author=Cutsem%2CE" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR31">Tabernero, J. et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. <i>Lancet Oncol.</i> <b>16</b>, 499–508 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2FS1470-2045%2815%2970127-0" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/S1470-2045(15)70127-0" data-track-item_id="10.1016/S1470-2045(15)70127-0">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXmsFSgu7w%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Ramucirumab%20versus%20placebo%20in%20combination%20with%20second-line%20FOLFIRI%20in%20patients%20with%20metastatic%20colorectal%20carcinoma%20that%20progressed%20during%20or%20after%20first-line%20therapy%20with%20bevacizumab%2C%20oxaliplatin%2C%20and%20a%20fluoropyrimidine%20%28RAISE%29%3A%20a%20randomised%2C%20double-blind%2C%20multicentre%2C%20phase%203%20study&amp;journal=Lancet%20Oncol.&amp;doi=10.1016%2FS1470-2045%2815%2970127-0&amp;volume=16&amp;pages=499-508&amp;publication_year=2015&amp;author=Tabernero%2CJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR32">Middleton, G. et al. <i>BRAF</i>-mutant transcriptional subtypes predict outcome of combined BRAF, MEK, and EGFR blockade with dabrafenib, trametinib, and panitumumab in patients with colorectal cancer. <i>Clin. Cancer Res.</i> <b>26</b>, 2466–2476 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F1078-0432.CCR-19-3579" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/1078-0432.CCR-19-3579" data-track-item_id="10.1158/1078-0432.CCR-19-3579">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXitVOgtbfN" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=BRAF-mutant%20transcriptional%20subtypes%20predict%20outcome%20of%20combined%20BRAF%2C%20MEK%2C%20and%20EGFR%20blockade%20with%20dabrafenib%2C%20trametinib%2C%20and%20panitumumab%20in%20patients%20with%20colorectal%20cancer&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-19-3579&amp;volume=26&amp;pages=2466-2476&amp;publication_year=2020&amp;author=Middleton%2CG" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR33">Kabiri, Z. et al. Wnt signaling suppresses MAPK-driven proliferation of intestinal stem cells. <i>J. Clin. Invest.</i> <b>128</b>, 3806–3812 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1172%2FJCI99325" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1172/JCI99325" data-track-item_id="10.1172/JCI99325">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Wnt%20signaling%20suppresses%20MAPK-driven%20proliferation%20of%20intestinal%20stem%20cells&amp;journal=J.%20Clin.%20Invest.&amp;doi=10.1172%2FJCI99325&amp;volume=128&amp;pages=3806-3812&amp;publication_year=2018&amp;author=Kabiri%2CZ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR34">Tsukiyama, T. et al. A phospho-switch controls RNF43-mediated degradation of Wnt receptors to suppress tumorigenesis. <i>Nat. Commun.</i> <b>11</b>, 4586 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41467-020-18257-3" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41467-020-18257-3" data-track-item_id="10.1038/s41467-020-18257-3">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=A%20phospho-switch%20controls%20RNF43-mediated%20degradation%20of%20Wnt%20receptors%20to%20suppress%20tumorigenesis&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fs41467-020-18257-3&amp;volume=11&amp;publication_year=2020&amp;author=Tsukiyama%2CT" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR35">Radaszkiewicz, T. et al. RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy. <i>eLife</i> <b>10</b>, e65759 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.7554%2FeLife.65759" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.7554/eLife.65759" data-track-item_id="10.7554/eLife.65759">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XotVSlt7w%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=RNF43%20inhibits%20WNT5A-driven%20signaling%20and%20suppresses%20melanoma%20invasion%20and%20resistance%20to%20the%20targeted%20therapy&amp;journal=eLife&amp;doi=10.7554%2FeLife.65759&amp;volume=10&amp;publication_year=2021&amp;author=Radaszkiewicz%2CT" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR36">Garcia-Barcena, C., Osinalde, N., Ramirez, J. &amp; Mayor, U. How to inactivate human ubiquitin E3 ligases by mutation. <i>Front. Cell Dev. Biol.</i> <b>8</b>, 39 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.3389%2Ffcell.2020.00039" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.3389/fcell.2020.00039" data-track-item_id="10.3389/fcell.2020.00039">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=How%20to%20inactivate%20human%20ubiquitin%20E3%20ligases%20by%20mutation&amp;journal=Front.%20Cell%20Dev.%20Biol.&amp;doi=10.3389%2Ffcell.2020.00039&amp;volume=8&amp;publication_year=2020&amp;author=Garcia-Barcena%2CC&amp;author=Osinalde%2CN&amp;author=Ramirez%2CJ&amp;author=Mayor%2CU" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR37">Toledo, R. A. et al. Exome sequencing of plasma DNA portrays the mutation landscape of colorectal cancer and discovers mutated VEGFR2 receptors as modulators of antiangiogenic therapies. <i>Clin. Cancer Res.</i> <b>24</b>, 3550–3559 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F1078-0432.CCR-18-0103" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/1078-0432.CCR-18-0103" data-track-item_id="10.1158/1078-0432.CCR-18-0103">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXhsVWrtr3L" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Exome%20sequencing%20of%20plasma%20DNA%20portrays%20the%20mutation%20landscape%20of%20colorectal%20cancer%20and%20discovers%20mutated%20VEGFR2%20receptors%20as%20modulators%20of%20antiangiogenic%20therapies&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-18-0103&amp;volume=24&amp;pages=3550-3559&amp;publication_year=2018&amp;author=Toledo%2CRA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR38">Hastings, R. K. et al. Longitudinal whole-exome sequencing of cell-free DNA for tracking the co-evolutionary tumor and immune evasion dynamics: longitudinal data from a single patient. <i>Ann. Oncol.</i> <b>32</b>, 681–684 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.annonc.2021.02.007" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.annonc.2021.02.007" data-track-item_id="10.1016/j.annonc.2021.02.007">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XhvVKqs7s%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Longitudinal%20whole-exome%20sequencing%20of%20cell-free%20DNA%20for%20tracking%20the%20co-evolutionary%20tumor%20and%20immune%20evasion%20dynamics%3A%20longitudinal%20data%20from%20a%20single%20patient&amp;journal=Ann.%20Oncol.&amp;doi=10.1016%2Fj.annonc.2021.02.007&amp;volume=32&amp;pages=681-684&amp;publication_year=2021&amp;author=Hastings%2CRK" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR39">Randon, G. et al. Tumour mutational burden predicts resistance to EGFR/BRAF blockade in <i>BRAF</i>-mutated microsatellite stable metastatic colorectal cancer. <i>Eur. J. Cancer</i> <b>161</b>, 90–98 (2022).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.ejca.2021.11.018" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.ejca.2021.11.018" data-track-item_id="10.1016/j.ejca.2021.11.018">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XhtVWgtr3F" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Tumour%20mutational%20burden%20predicts%20resistance%20to%20EGFR%2FBRAF%20blockade%20in%20BRAF-mutated%20microsatellite%20stable%20metastatic%20colorectal%20cancer&amp;journal=Eur.%20J.%20Cancer&amp;doi=10.1016%2Fj.ejca.2021.11.018&amp;volume=161&amp;pages=90-98&amp;publication_year=2022&amp;author=Randon%2CG" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR40">Garcia, M. et al. Sarek: a portable workflow for whole-genome sequencing analysis of germline and somatic variants. <i>F1000Res</i> <b>9</b>, 63 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.12688%2Ff1000research.16665.2" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.12688/f1000research.16665.2" data-track-item_id="10.12688/f1000research.16665.2">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Sarek%3A%20a%20portable%20workflow%20for%20whole-genome%20sequencing%20analysis%20of%20germline%20and%20somatic%20variants&amp;journal=F1000Res&amp;doi=10.12688%2Ff1000research.16665.2&amp;volume=9&amp;publication_year=2020&amp;author=Garcia%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li></ol></div></div>
        </div>
    </div>
</aside>
</div>


    
        
    
    
        
            
        

        
            
        
    
    <script>
        window.dataLayer = window.dataLayer || [];
        window.dataLayer.push({
            page: {
                content: {
                    fundingWidget: "true",
                        }
                    }
                });
    </script>




<footer class="composite-layer" itemscope="" itemtype="http://schema.org/Periodical">
        <meta itemprop="publisher" content="Springer Nature">
        

        <div class="u-mt-16 u-mb-16">
    <div class="u-container">
        <div class="u-display-flex u-flex-wrap u-justify-content-space-between">
            

            <div class="c-meta u-ma-0 u-flex-shrink">
                <p class="c-meta__item c-meta__type u-mt-0">
                    <span itemprop="name">
                        Nature Medicine
                    </span>
                    (<i itemprop="alternateName">Nat Med</i>)
                </p>
                
    
        <p class="c-meta__item u-mt-0">
            <abbr title="International Standard Serial Number">ISSN</abbr> <span itemprop="issn">1546-170X</span> (online)
        </p>
    

                
    
        <p class="c-meta__item u-mt-0">
            <abbr title="International Standard Serial Number">ISSN</abbr> <span itemprop="issn">1078-8956</span> (print)
        </p>
    

            </div>
        </div>
    </div>
</div>

    <div class="c-footer">
        <div class="u-hide-print" data-track-component="footer">
    <h2 class="u-visually-hidden">nature.com sitemap</h2>
    <div class="c-footer__container">
        <div class="c-footer__grid c-footer__group--separator">
            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">About Nature Portfolio</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/npg_/company_info/index.html" data-track="click" data-track-action="about us" data-track-label="link">About us</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/npg_/press_room/press_releases.html" data-track="click" data-track-action="press releases" data-track-label="link">Press releases</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://press.nature.com/" data-track="click" data-track-action="press office" data-track-label="link">Press office</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://support.nature.com/support/home" data-track="click" data-track-action="contact us" data-track-label="link">Contact us</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Discover content</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/siteindex" data-track="click" data-track-action="journals a-z" data-track-label="link">Journals A-Z</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/subjects" data-track="click" data-track-action="article by subject" data-track-label="link">Articles by subject</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.protocols.io/" data-track="click" data-track-action="protocols.io" data-track-label="link">protocols.io</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.natureindex.com/" data-track="click" data-track-action="nature index" data-track-label="link">Nature Index</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Publishing policies</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/authors/editorial_policies" data-track="click" data-track-action="Nature portfolio policies" data-track-label="link">Nature portfolio policies</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nature-research/open-access" data-track="click" data-track-action="open access" data-track-label="link">Open access</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Author &amp; Researcher services</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/reprints" data-track="click" data-track-action="reprints and permissions" data-track-label="link">Reprints &amp; permissions</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/authors/research-data" data-track="click" data-track-action="data research service" data-track-label="link">Research data</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://authorservices.springernature.com/language-editing/" data-track="click" data-track-action="language editing" data-track-label="link">Language editing</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://authorservices.springernature.com/scientific-editing/" data-track="click" data-track-action="scientific editing" data-track-label="link">Scientific editing</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://masterclasses.nature.com/" data-track="click" data-track-action="nature masterclasses" data-track-label="link">Nature Masterclasses</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://solutions.springernature.com/" data-track="click" data-track-action="research solutions" data-track-label="link">Research Solutions</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Libraries &amp; institutions</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/tools-services" data-track="click" data-track-action="librarian service and tools" data-track-label="link">Librarian service &amp; tools</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/manage-your-account/librarianportal" data-track="click" data-track-action="librarian portal" data-track-label="link">Librarian portal</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/openresearch/about-open-access/information-for-institutions" data-track="click" data-track-action="open research" data-track-label="link">Open research</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/recommend-to-your-library" data-track="click" data-track-action="Recommend to library" data-track-label="link">Recommend to library</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Advertising &amp; partnerships</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/product/digital-advertising/" data-track="click" data-track-action="advertising" data-track-label="link">Advertising</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/" data-track="click" data-track-action="partnerships and services" data-track-label="link">Partnerships &amp; Services</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/media-kits/" data-track="click" data-track-action="media kits" data-track-label="link">Media kits</a>
                    </li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/product/branded-content-native-advertising/" data-track-action="branded content" data-track-label="link">Branded
                        content</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Professional development</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/naturecareers/" data-track="click" data-track-action="nature careers" data-track-label="link">Nature Careers</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://conferences.nature.com" data-track="click" data-track-action="nature conferences" data-track-label="link">Nature<span class="u-visually-hidden"> </span>
                        Conferences</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Regional websites</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/natafrica" data-track="click" data-track-action="nature africa" data-track-label="link">Nature Africa</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="http://www.naturechina.com" data-track="click" data-track-action="nature china" data-track-label="link">Nature China</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nindia" data-track="click" data-track-action="nature india" data-track-label="link">Nature India</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/natitaly" data-track="click" data-track-action="nature Italy" data-track-label="link">Nature Italy</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.natureasia.com/ja-jp" data-track="click" data-track-action="nature japan" data-track-label="link">Nature Japan</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nmiddleeast" data-track="click" data-track-action="nature middle east" data-track-label="link">Nature Middle East</a></li>
                </ul>
            </div>

        </div>
    </div>
    <div class="c-footer__container">
        <ul class="c-footer__links">
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/privacy" data-track="click" data-track-action="privacy policy" data-track-label="link">Privacy
                Policy</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/cookies" data-track="click" data-track-action="use of cookies" data-track-label="link">Use
                of cookies</a></li>
            <li class="c-footer__item">
                <button class="optanon-toggle-display c-footer__link" onclick="javascript:;" data-cc-action="preferences" data-track="click" data-track-action="manage cookies" data-track-label="link">Your privacy choices/Manage cookies
                </button>
            </li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/legal-notice" data-track="click" data-track-action="legal notice" data-track-label="link">Legal
                notice</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/accessibility-statement" data-track="click" data-track-action="accessibility statement" data-track-label="link">Accessibility
                statement</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/terms-and-conditions" data-track="click" data-track-action="terms and conditions" data-track-label="link">Terms &amp; Conditions</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/ccpa" data-track="click" data-track-action="california privacy statement" data-track-label="link">Your US state privacy rights</a></li>
            
        </ul>
    </div>
</div>


        <div class="c-footer__container">
    <a href="https://www.springernature.com/" class="c-footer__link">
        <img src="/static/images/logos/sn-logo-white-ea63208b81.svg" alt="Springer Nature" loading="lazy" width="200" height="20">
    </a>
    <p class="c-footer__legal" data-test="copyright">© 2025 Springer Nature Limited</p>
</div>

    </div>
    <div class="u-visually-hidden" aria-hidden="true">
    
    <!--?xml version="1.0" encoding="UTF-8"?--><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><defs><path id="a" d="M0 .74h56.72v55.24H0z"></path></defs><symbol id="icon-access" viewBox="0 0 18 18"><path d="m14 8c.5522847 0 1 .44771525 1 1v7h2.5c.2761424 0 .5.2238576.5.5v1.5h-18v-1.5c0-.2761424.22385763-.5.5-.5h2.5v-7c0-.55228475.44771525-1 1-1s1 .44771525 1 1v6.9996556h8v-6.9996556c0-.55228475.4477153-1 1-1zm-8 0 2 1v5l-2 1zm6 0v7l-2-1v-5zm-2.42653766-7.59857636 7.03554716 4.92488299c.4162533.29137735.5174853.86502537.226108 1.28127873-.1721584.24594054-.4534847.39241464-.7536934.39241464h-14.16284822c-.50810197 0-.92-.41189803-.92-.92 0-.30020869.1464741-.58153499.39241464-.75369337l7.03554714-4.92488299c.34432015-.2410241.80260453-.2410241 1.14692468 0zm-.57346234 2.03988748-3.65526982 2.55868888h7.31053962z" fill-rule="evenodd"></path></symbol><symbol id="icon-account" viewBox="0 0 18 18"><path d="m10.2379028 16.9048051c1.3083556-.2032362 2.5118471-.7235183 3.5294683-1.4798399-.8731327-2.5141501-2.0638925-3.935978-3.7673711-4.3188248v-1.27684611c1.1651924-.41183641 2-1.52307546 2-2.82929429 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.30621883.83480763 2.41745788 2 2.82929429v1.27684611c-1.70347856.3828468-2.89423845 1.8046747-3.76737114 4.3188248 1.01762123.7563216 2.22111275 1.2766037 3.52946833 1.4798399.40563808.0629726.81921174.0951949 1.23790281.0951949s.83226473-.0322223 1.2379028-.0951949zm4.3421782-2.1721994c1.4927655-1.4532925 2.419919-3.484675 2.419919-5.7326057 0-4.418278-3.581722-8-8-8s-8 3.581722-8 8c0 2.2479307.92715352 4.2793132 2.41991895 5.7326057.75688473-2.0164459 1.83949951-3.6071894 3.48926591-4.3218837-1.14534283-.70360829-1.90918486-1.96796271-1.90918486-3.410722 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.44275929-.763842 2.70711371-1.9091849 3.410722 1.6497664.7146943 2.7323812 2.3054378 3.4892659 4.3218837zm-5.580081 3.2673943c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-alert" viewBox="0 0 18 18"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-broad" viewBox="0 0 16 16"><path d="m6.10307866 2.97190702v7.69043288l2.44965196-2.44676915c.38776071-.38730439 1.0088052-.39493524 1.38498697-.01919617.38609051.38563612.38643641 1.01053024-.00013864 1.39665039l-4.12239817 4.11754683c-.38616704.3857126-1.01187344.3861062-1.39846576-.0000311l-4.12258206-4.11773056c-.38618426-.38572979-.39254614-1.00476697-.01636437-1.38050605.38609047-.38563611 1.01018509-.38751562 1.4012233.00306241l2.44985644 2.4469734v-8.67638639c0-.54139983.43698413-.98042709.98493125-.98159081l7.89910522-.0043627c.5451687 0 .9871152.44142642.9871152.98595351s-.4419465.98595351-.9871152.98595351z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 14 15)"></path></symbol><symbol id="icon-arrow-down" viewBox="0 0 16 16"><path d="m3.28337502 11.5302405 4.03074001 4.176208c.37758093.3912076.98937525.3916069 1.367372-.0000316l4.03091977-4.1763942c.3775978-.3912252.3838182-1.0190815.0160006-1.4001736-.3775061-.39113013-.9877245-.39303641-1.3700683.003106l-2.39538585 2.4818345v-11.6147896l-.00649339-.11662112c-.055753-.49733869-.46370161-.88337888-.95867408-.88337888-.49497246 0-.90292107.38604019-.95867408.88337888l-.00649338.11662112v11.6147896l-2.39518594-2.4816273c-.37913917-.39282218-.98637524-.40056175-1.35419292-.0194697-.37750607.3911302-.37784433 1.0249269.00013556 1.4165479z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-left" viewBox="0 0 16 16"><path d="m4.46975946 3.28337502-4.17620792 4.03074001c-.39120768.37758093-.39160691.98937525.0000316 1.367372l4.1763942 4.03091977c.39122514.3775978 1.01908149.3838182 1.40017357.0160006.39113012-.3775061.3930364-.9877245-.00310603-1.3700683l-2.48183446-2.39538585h11.61478958l.1166211-.00649339c.4973387-.055753.8833789-.46370161.8833789-.95867408 0-.49497246-.3860402-.90292107-.8833789-.95867408l-.1166211-.00649338h-11.61478958l2.4816273-2.39518594c.39282216-.37913917.40056173-.98637524.01946965-1.35419292-.39113012-.37750607-1.02492687-.37784433-1.41654791.00013556z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-right" viewBox="0 0 16 16"><path d="m11.5302405 12.716625 4.176208-4.03074003c.3912076-.37758093.3916069-.98937525-.0000316-1.367372l-4.1763942-4.03091981c-.3912252-.37759778-1.0190815-.38381821-1.4001736-.01600053-.39113013.37750607-.39303641.98772445.003106 1.37006824l2.4818345 2.39538588h-11.6147896l-.11662112.00649339c-.49733869.055753-.88337888.46370161-.88337888.95867408 0 .49497246.38604019.90292107.88337888.95867408l.11662112.00649338h11.6147896l-2.4816273 2.39518592c-.39282218.3791392-.40056175.9863753-.0194697 1.3541929.3911302.3775061 1.0249269.3778444 1.4165479-.0001355z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-sub" viewBox="0 0 16 16"><path d="m7.89692134 4.97190702v7.69043288l-2.44965196-2.4467692c-.38776071-.38730434-1.0088052-.39493519-1.38498697-.0191961-.38609047.3856361-.38643643 1.0105302.00013864 1.3966504l4.12239817 4.1175468c.38616704.3857126 1.01187344.3861062 1.39846576-.0000311l4.12258202-4.1177306c.3861843-.3857298.3925462-1.0047669.0163644-1.380506-.3860905-.38563612-1.0101851-.38751563-1.4012233.0030624l-2.44985643 2.4469734v-8.67638639c0-.54139983-.43698413-.98042709-.98493125-.98159081l-7.89910525-.0043627c-.54516866 0-.98711517.44142642-.98711517.98595351s.44194651.98595351.98711517.98595351z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-up" viewBox="0 0 16 16"><path d="m12.716625 4.46975946-4.03074003-4.17620792c-.37758093-.39120768-.98937525-.39160691-1.367372.0000316l-4.03091981 4.1763942c-.37759778.39122514-.38381821 1.01908149-.01600053 1.40017357.37750607.39113012.98772445.3930364 1.37006824-.00310603l2.39538588-2.48183446v11.61478958l.00649339.1166211c.055753.4973387.46370161.8833789.95867408.8833789.49497246 0 .90292107-.3860402.95867408-.8833789l.00649338-.1166211v-11.61478958l2.39518592 2.4816273c.3791392.39282216.9863753.40056173 1.3541929.01946965.3775061-.39113012.3778444-1.02492687-.0001355-1.41654791z" fill-rule="evenodd"></path></symbol><symbol id="icon-article" viewBox="0 0 18 18"><path d="m13 15v-12.9906311c0-.0073595-.0019884-.0093689.0014977-.0093689l-11.00158888.00087166v13.00506804c0 .5482678.44615281.9940603.99415146.9940603h10.27350412c-.1701701-.2941734-.2675644-.6357129-.2675644-1zm-12 .0059397v-13.00506804c0-.5562408.44704472-1.00087166.99850233-1.00087166h11.00299537c.5510129 0 .9985023.45190985.9985023 1.0093689v2.9906311h3v9.9914698c0 1.1065798-.8927712 2.0085302-1.9940603 2.0085302h-12.01187942c-1.09954652 0-1.99406028-.8927712-1.99406028-1.9940603zm13-9.0059397v9c0 .5522847.4477153 1 1 1s1-.4477153 1-1v-9zm-10-2h7v4h-7zm1 1v2h5v-2zm-1 4h7v1h-7zm0 2h7v1h-7zm0 2h7v1h-7z" fill-rule="evenodd"></path></symbol><symbol id="icon-audio" viewBox="0 0 18 18"><path d="m13.0957477 13.5588459c-.195279.1937043-.5119137.193729-.7072234.0000551-.1953098-.193674-.1953346-.5077061-.0000556-.7014104 1.0251004-1.0168342 1.6108711-2.3905226 1.6108711-3.85745208 0-1.46604976-.5850634-2.83898246-1.6090736-3.85566829-.1951894-.19379323-.1950192-.50782531.0003802-.70141028.1953993-.19358497.512034-.19341614.7072234.00037709 1.2094886 1.20083761 1.901635 2.8250555 1.901635 4.55670148 0 1.73268608-.6929822 3.35779608-1.9037571 4.55880738zm2.1233994 2.1025159c-.195234.193749-.5118687.1938462-.7072235.0002171-.1953548-.1936292-.1954528-.5076613-.0002189-.7014104 1.5832215-1.5711805 2.4881302-3.6939808 2.4881302-5.96012998 0-2.26581266-.9046382-4.3883241-2.487443-5.95944795-.1952117-.19377107-.1950777-.50780316.0002993-.70141031s.5120117-.19347426.7072234.00029682c1.7683321 1.75528196 2.7800854 4.12911258 2.7800854 6.66056144 0 2.53182498-1.0120556 4.90597838-2.7808529 6.66132328zm-14.21898205-3.6854911c-.5523759 0-1.00016505-.4441085-1.00016505-.991944v-3.96777631c0-.54783558.44778915-.99194407 1.00016505-.99194407h2.0003301l5.41965617-3.8393633c.44948677-.31842296 1.07413994-.21516983 1.39520191.23062232.12116339.16823446.18629727.36981184.18629727.57655577v12.01603479c0 .5478356-.44778914.9919441-1.00016505.9919441-.20845738 0-.41170538-.0645985-.58133413-.184766l-5.41965617-3.8393633zm0-.991944h2.32084805l5.68047235 4.0241292v-12.01603479l-5.68047235 4.02412928h-2.32084805z" fill-rule="evenodd"></path></symbol><symbol id="icon-block" viewBox="0 0 24 24"><path d="m0 0h24v24h-24z" fill-rule="evenodd"></path></symbol><symbol id="icon-book" viewBox="0 0 18 18"><path d="m4 13v-11h1v11h11v-11h-13c-.55228475 0-1 .44771525-1 1v10.2675644c.29417337-.1701701.63571286-.2675644 1-.2675644zm12 1h-13c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1h13zm0 3h-13c-1.1045695 0-2-.8954305-2-2v-12c0-1.1045695.8954305-2 2-2h13c.5522847 0 1 .44771525 1 1v14c0 .5522847-.4477153 1-1 1zm-8.5-13h6c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1 2h4c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-4c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-broad" viewBox="0 0 24 24"><path d="m9.18274226 7.81v7.7999954l2.48162734-2.4816273c.3928221-.3928221 1.0219731-.4005617 1.4030652-.0194696.3911301.3911301.3914806 1.0249268-.0001404 1.4165479l-4.17620796 4.1762079c-.39120769.3912077-1.02508144.3916069-1.41671995-.0000316l-4.1763942-4.1763942c-.39122514-.3912251-.39767006-1.0190815-.01657798-1.4001736.39113012-.3911301 1.02337106-.3930364 1.41951349.0031061l2.48183446 2.4818344v-8.7999954c0-.54911294.4426881-.99439484.99778758-.99557515l8.00221246-.00442485c.5522847 0 1 .44771525 1 1s-.4477153 1-1 1z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 20.182742 24.805206)"></path></symbol><symbol id="icon-calendar" viewBox="0 0 18 18"><path d="m12.5 0c.2761424 0 .5.21505737.5.49047852v.50952148h2c1.1072288 0 2 .89451376 2 2v12c0 1.1072288-.8945138 2-2 2h-12c-1.1072288 0-2-.8945138-2-2v-12c0-1.1072288.89451376-2 2-2h1v1h-1c-.55393837 0-1 .44579254-1 1v3h14v-3c0-.55393837-.4457925-1-1-1h-2v1.50952148c0 .27088381-.2319336.49047852-.5.49047852-.2761424 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.2319336-.49047852.5-.49047852zm3.5 7h-14v8c0 .5539384.44579254 1 1 1h12c.5539384 0 1-.4457925 1-1zm-11 6v1h-1v-1zm3 0v1h-1v-1zm3 0v1h-1v-1zm-6-2v1h-1v-1zm3 0v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-3-2v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-5.5-9c.27614237 0 .5.21505737.5.49047852v.50952148h5v1h-5v1.50952148c0 .27088381-.23193359.49047852-.5.49047852-.27614237 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.23193359-.49047852.5-.49047852z" fill-rule="evenodd"></path></symbol><symbol id="icon-cart" viewBox="0 0 18 18"><path d="m5 14c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm10 0c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm-10 1c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1 1-.4477153 1-1-.44771525-1-1-1zm10 0c-.5522847 0-1 .4477153-1 1s.4477153 1 1 1 1-.4477153 1-1-.4477153-1-1-1zm-12.82032249-15c.47691417 0 .88746157.33678127.98070211.80449199l.23823144 1.19501025 13.36277974.00045554c.5522847.00001882.9999659.44774934.9999659 1.00004222 0 .07084994-.0075361.14150708-.022474.2107727l-1.2908094 5.98534344c-.1007861.46742419-.5432548.80388386-1.0571651.80388386h-10.24805106c-.59173366 0-1.07142857.4477153-1.07142857 1 0 .5128358.41361449.9355072.94647737.9932723l.1249512.0067277h10.35933776c.2749512 0 .4979349.2228539.4979349.4978051 0 .2749417-.2227336.4978951-.4976753.4980063l-10.35959736.0041886c-1.18346732 0-2.14285714-.8954305-2.14285714-2 0-.6625717.34520317-1.24989198.87690425-1.61383592l-1.63768102-8.19004794c-.01312273-.06561364-.01950005-.131011-.0196107-.19547395l-1.71961253-.00064219c-.27614237 0-.5-.22385762-.5-.5 0-.27614237.22385763-.5.5-.5zm14.53193359 2.99950224h-13.11300004l1.20580469 6.02530174c.11024034-.0163252.22327998-.02480398.33844139-.02480398h10.27064786z"></path></symbol><symbol id="icon-chevron-less" viewBox="0 0 10 10"><path d="m5.58578644 4-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 -1 -1 0 9 9)"></path></symbol><symbol id="icon-chevron-more" viewBox="0 0 10 10"><path d="m5.58578644 6-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4.00000002c-.39052429.3905243-1.02368927.3905243-1.41421356 0s-.39052429-1.02368929 0-1.41421358z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 1)"></path></symbol><symbol id="icon-chevron-right" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-circle-fill" viewBox="0 0 16 16"><path d="m8 14c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"></path></symbol><symbol id="icon-circle" viewBox="0 0 16 16"><path d="m8 12c2.209139 0 4-1.790861 4-4s-1.790861-4-4-4-4 1.790861-4 4 1.790861 4 4 4zm0 2c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"></path></symbol><symbol id="icon-citation" viewBox="0 0 18 18"><path d="m8.63593473 5.99995183c2.20913897 0 3.99999997 1.79084375 3.99999997 3.99996146 0 1.40730761-.7267788 2.64486871-1.8254829 3.35783281 1.6240224.6764218 2.8754442 2.0093871 3.4610603 3.6412466l-1.0763845.000006c-.5310008-1.2078237-1.5108121-2.1940153-2.7691712-2.7181346l-.79002167-.329052v-1.023992l.63016577-.4089232c.8482885-.5504661 1.3698342-1.4895187 1.3698342-2.51898361 0-1.65683828-1.3431457-2.99996146-2.99999997-2.99996146-1.65685425 0-3 1.34312318-3 2.99996146 0 1.02946491.52154569 1.96851751 1.36983419 2.51898361l.63016581.4089232v1.023992l-.79002171.329052c-1.25835905.5241193-2.23817037 1.5103109-2.76917113 2.7181346l-1.07638453-.000006c.58561612-1.6318595 1.8370379-2.9648248 3.46106024-3.6412466-1.09870405-.7129641-1.82548287-1.9505252-1.82548287-3.35783281 0-2.20911771 1.790861-3.99996146 4-3.99996146zm7.36897597-4.99995183c1.1018574 0 1.9950893.89353404 1.9950893 2.00274083v5.994422c0 1.10608317-.8926228 2.00274087-1.9950893 2.00274087l-3.0049107-.0009037v-1l3.0049107.00091329c.5490631 0 .9950893-.44783123.9950893-1.00275046v-5.994422c0-.55646537-.4450595-1.00275046-.9950893-1.00275046h-14.00982141c-.54906309 0-.99508929.44783123-.99508929 1.00275046v5.9971821c0 .66666024.33333333.99999036 1 .99999036l2-.00091329v1l-2 .0009037c-1 0-2-.99999041-2-1.99998077v-5.9971821c0-1.10608322.8926228-2.00274083 1.99508929-2.00274083zm-8.5049107 2.9999711c.27614237 0 .5.22385547.5.5 0 .2761349-.22385763.5-.5.5h-4c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm3 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-1c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm4 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238651-.5-.5 0-.27614453.2238576-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-close" viewBox="0 0 16 16"><path d="m2.29679575 12.2772478c-.39658757.3965876-.39438847 1.0328109-.00062148 1.4265779.39651227.3965123 1.03246768.3934888 1.42657791-.0006214l4.27724782-4.27724787 4.2772478 4.27724787c.3965876.3965875 1.0328109.3943884 1.4265779.0006214.3965123-.3965122.3934888-1.0324677-.0006214-1.4265779l-4.27724787-4.2772478 4.27724787-4.27724782c.3965875-.39658757.3943884-1.03281091.0006214-1.42657791-.3965122-.39651226-1.0324677-.39348875-1.4265779.00062148l-4.2772478 4.27724782-4.27724782-4.27724782c-.39658757-.39658757-1.03281091-.39438847-1.42657791-.00062148-.39651226.39651227-.39348875 1.03246768.00062148 1.42657791l4.27724782 4.27724782z" fill-rule="evenodd"></path></symbol><symbol id="icon-collections" viewBox="0 0 18 18"><path d="m15 4c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2h1c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-1v-1zm-4-3c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2v-9c0-1.1045695.8954305-2 2-2zm0 1h-8c-.51283584 0-.93550716.38604019-.99327227.88337887l-.00672773.11662113v9c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227zm-1.5 7c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-compare" viewBox="0 0 18 18"><path d="m12 3c3.3137085 0 6 2.6862915 6 6s-2.6862915 6-6 6c-1.0928452 0-2.11744941-.2921742-2.99996061-.8026704-.88181407.5102749-1.90678042.8026704-3.00003939.8026704-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6c1.09325897 0 2.11822532.29239547 3.00096303.80325037.88158756-.51107621 1.90619177-.80325037 2.99903697-.80325037zm-6 1c-2.76142375 0-5 2.23857625-5 5 0 2.7614237 2.23857625 5 5 5 .74397391 0 1.44999672-.162488 2.08451611-.4539116-1.27652344-1.1000812-2.08451611-2.7287264-2.08451611-4.5460884s.80799267-3.44600721 2.08434391-4.5463015c-.63434719-.29121054-1.34037-.4536985-2.08434391-.4536985zm6 0c-.7439739 0-1.4499967.16248796-2.08451611.45391156 1.27652341 1.10008123 2.08451611 2.72872644 2.08451611 4.54608844s-.8079927 3.4460072-2.08434391 4.5463015c.63434721.2912105 1.34037001.4536985 2.08434391.4536985 2.7614237 0 5-2.2385763 5-5 0-2.76142375-2.2385763-5-5-5zm-1.4162763 7.0005324h-3.16744736c.15614659.3572676.35283837.6927622.58425872 1.0006671h1.99892988c.23142036-.3079049.42811216-.6433995.58425876-1.0006671zm.4162763-2.0005324h-4c0 .34288501.0345146.67770871.10025909 1.0011864h3.79948181c.0657445-.32347769.1002591-.65830139.1002591-1.0011864zm-.4158423-1.99953894h-3.16831543c-.13859957.31730812-.24521946.651783-.31578599.99935097h3.79988742c-.0705665-.34756797-.1771864-.68204285-.315786-.99935097zm-1.58295822-1.999926-.08316107.06199199c-.34550042.27081213-.65446126.58611297-.91825862.93727862h2.00044041c-.28418626-.37830727-.6207872-.71499149-.99902072-.99927061z" fill-rule="evenodd"></path></symbol><symbol id="icon-download-file" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.5046024 4c.27614237 0 .5.21637201.5.49209595v6.14827645l1.7462789-1.77990922c.1933927-.1971171.5125222-.19455839.7001689-.0069117.1932998.19329992.1910058.50899492-.0027774.70277812l-2.59089271 2.5908927c-.19483374.1948337-.51177825.1937771-.70556873-.0000133l-2.59099079-2.5909908c-.19484111-.1948411-.19043735-.5151448-.00279066-.70279146.19329987-.19329987.50465175-.19237083.70018565.00692852l1.74638684 1.78001764v-6.14827695c0-.27177709.23193359-.49209595.5-.49209595z" fill-rule="evenodd"></path></symbol><symbol id="icon-download" viewBox="0 0 16 16"><path d="m12.9975267 12.999368c.5467123 0 1.0024733.4478567 1.0024733 1.000316 0 .5563109-.4488226 1.000316-1.0024733 1.000316h-9.99505341c-.54671233 0-1.00247329-.4478567-1.00247329-1.000316 0-.5563109.44882258-1.000316 1.00247329-1.000316zm-4.9975267-11.999368c.55228475 0 1 .44497754 1 .99589209v6.80214418l2.4816273-2.48241149c.3928222-.39294628 1.0219732-.4006883 1.4030652-.01947579.3911302.39125371.3914806 1.02525073-.0001404 1.41699553l-4.17620792 4.17752758c-.39120769.3913313-1.02508144.3917306-1.41671995-.0000316l-4.17639421-4.17771394c-.39122513-.39134876-.39767006-1.01940351-.01657797-1.40061601.39113012-.39125372 1.02337105-.3931606 1.41951349.00310701l2.48183446 2.48261871v-6.80214418c0-.55001601.44386482-.99589209 1-.99589209z" fill-rule="evenodd"></path></symbol><symbol id="icon-editors" viewBox="0 0 18 18"><path d="m8.72592184 2.54588137c-.48811714-.34391207-1.08343326-.54588137-1.72592184-.54588137-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400182l-.79002171.32905522c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274v.9009805h-1v-.9009805c0-2.5479714 1.54557359-4.79153984 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4 1.09079823 0 2.07961816.43662103 2.80122451 1.1446278-.37707584.09278571-.7373238.22835063-1.07530267.40125357zm-2.72592184 14.45411863h-1v-.9009805c0-2.5479714 1.54557359-4.7915398 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.40732121-.7267788 2.64489414-1.8254829 3.3578652 2.2799093.9496145 3.8254829 3.1931829 3.8254829 5.7411543v.9009805h-1v-.9009805c0-2.1155483-1.2760206-4.0125067-3.2099783-4.8180274l-.7900217-.3290552v-1.02400184l.6301658-.40892721c.8482885-.55047139 1.3698342-1.489533 1.3698342-2.51900785 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400184l-.79002171.3290552c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274z" fill-rule="evenodd"></path></symbol><symbol id="icon-email" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-.0049107 2.55749512v1.44250488l-7 4-7-4v-1.44250488l7 4z" fill-rule="evenodd"></path></symbol><symbol id="icon-error" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm2.8630343 4.71100931-2.8630343 2.86303426-2.86303426-2.86303426c-.39658757-.39658757-1.03281091-.39438847-1.4265779-.00062147-.39651227.39651226-.39348876 1.03246767.00062147 1.4265779l2.86303426 2.86303426-2.86303426 2.8630343c-.39658757.3965875-.39438847 1.0328109-.00062147 1.4265779.39651226.3965122 1.03246767.3934887 1.4265779-.0006215l2.86303426-2.8630343 2.8630343 2.8630343c.3965875.3965876 1.0328109.3943885 1.4265779.0006215.3965122-.3965123.3934887-1.0324677-.0006215-1.4265779l-2.8630343-2.8630343 2.8630343-2.86303426c.3965876-.39658757.3943885-1.03281091.0006215-1.4265779-.3965123-.39651227-1.0324677-.39348876-1.4265779.00062147z" fill-rule="evenodd"></path></symbol><symbol id="icon-ethics" viewBox="0 0 18 18"><path d="m6.76384967 1.41421356.83301651-.8330165c.77492941-.77492941 2.03133823-.77492941 2.80626762 0l.8330165.8330165c.3750728.37507276.8837806.58578644 1.4142136.58578644h1.3496361c1.1045695 0 2 .8954305 2 2v1.34963611c0 .53043298.2107137 1.03914081.5857864 1.41421356l.8330165.83301651c.7749295.77492941.7749295 2.03133823 0 2.80626762l-.8330165.8330165c-.3750727.3750728-.5857864.8837806-.5857864 1.4142136v1.3496361c0 1.1045695-.8954305 2-2 2h-1.3496361c-.530433 0-1.0391408.2107137-1.4142136.5857864l-.8330165.8330165c-.77492939.7749295-2.03133821.7749295-2.80626762 0l-.83301651-.8330165c-.37507275-.3750727-.88378058-.5857864-1.41421356-.5857864h-1.34963611c-1.1045695 0-2-.8954305-2-2v-1.3496361c0-.530433-.21071368-1.0391408-.58578644-1.4142136l-.8330165-.8330165c-.77492941-.77492939-.77492941-2.03133821 0-2.80626762l.8330165-.83301651c.37507276-.37507275.58578644-.88378058.58578644-1.41421356v-1.34963611c0-1.1045695.8954305-2 2-2h1.34963611c.53043298 0 1.03914081-.21071368 1.41421356-.58578644zm-1.41421356 1.58578644h-1.34963611c-.55228475 0-1 .44771525-1 1v1.34963611c0 .79564947-.31607052 1.55871121-.87867966 2.12132034l-.8330165.83301651c-.38440512.38440512-.38440512 1.00764896 0 1.39205408l.8330165.83301646c.56260914.5626092.87867966 1.3256709.87867966 2.1213204v1.3496361c0 .5522847.44771525 1 1 1h1.34963611c.79564947 0 1.55871121.3160705 2.12132034.8786797l.83301651.8330165c.38440512.3844051 1.00764896.3844051 1.39205408 0l.83301646-.8330165c.5626092-.5626092 1.3256709-.8786797 2.1213204-.8786797h1.3496361c.5522847 0 1-.4477153 1-1v-1.3496361c0-.7956495.3160705-1.5587112.8786797-2.1213204l.8330165-.83301646c.3844051-.38440512.3844051-1.00764896 0-1.39205408l-.8330165-.83301651c-.5626092-.56260913-.8786797-1.32567087-.8786797-2.12132034v-1.34963611c0-.55228475-.4477153-1-1-1h-1.3496361c-.7956495 0-1.5587112-.31607052-2.1213204-.87867966l-.83301646-.8330165c-.38440512-.38440512-1.00764896-.38440512-1.39205408 0l-.83301651.8330165c-.56260913.56260914-1.32567087.87867966-2.12132034.87867966zm3.58698944 11.4960218c-.02081224.002155-.04199226.0030286-.06345763.002542-.98766446-.0223875-1.93408568-.3063547-2.75885125-.8155622-.23496767-.1450683-.30784554-.4531483-.16277726-.688116.14506827-.2349677.45314827-.3078455.68811595-.1627773.67447084.4164161 1.44758575.6483839 2.25617384.6667123.01759529.0003988.03495764.0017019.05204365.0038639.01713363-.0017748.03452416-.0026845.05212715-.0026845 2.4852814 0 4.5-2.0147186 4.5-4.5 0-1.04888973-.3593547-2.04134635-1.0074477-2.83787157-.1742817-.21419731-.1419238-.5291218.0722736-.70340353.2141973-.17428173.5291218-.14192375.7034035.07227357.7919032.97327203 1.2317706 2.18808682 1.2317706 3.46900153 0 3.0375661-2.4624339 5.5-5.5 5.5-.02146768 0-.04261937-.0013529-.06337445-.0039782zm1.57975095-10.78419583c.2654788.07599731.419084.35281842.3430867.61829728-.0759973.26547885-.3528185.419084-.6182973.3430867-.37560116-.10752146-.76586237-.16587951-1.15568824-.17249193-2.5587807-.00064534-4.58547766 2.00216524-4.58547766 4.49928198 0 .62691557.12797645 1.23496.37274865 1.7964426.11035133.2531347-.0053975.5477984-.25853224.6581497-.25313473.1103514-.54779841-.0053975-.65814974-.2585322-.29947131-.6869568-.45606667-1.43097603-.45606667-2.1960601 0-3.05211432 2.47714695-5.50006595 5.59399617-5.49921198.48576182.00815502.96289603.0795037 1.42238033.21103795zm-1.9766658 6.41091303 2.69835-2.94655317c.1788432-.21040373.4943901-.23598862.7047939-.05714545.2104037.17884318.2359886.49439014.0571454.70479387l-3.01637681 3.34277395c-.18039088.1999106-.48669547.2210637-.69285412.0478478l-1.93095347-1.62240047c-.21213845-.17678204-.24080048-.49206439-.06401844-.70420284.17678204-.21213844.49206439-.24080048.70420284-.06401844z" fill-rule="evenodd"></path></symbol><symbol id="icon-expand"><path d="M7.498 11.918a.997.997 0 0 0-.003-1.411.995.995 0 0 0-1.412-.003l-4.102 4.102v-3.51A1 1 0 0 0 .98 10.09.992.992 0 0 0 0 11.092V17c0 .554.448 1.002 1.002 1.002h5.907c.554 0 1.002-.45 1.002-1.003 0-.539-.45-.978-1.006-.978h-3.51zm3.005-5.835a.997.997 0 0 0 .003 1.412.995.995 0 0 0 1.411.003l4.103-4.103v3.51a1 1 0 0 0 1.001 1.006A.992.992 0 0 0 18 6.91V1.002A1 1 0 0 0 17 0h-5.907a1.003 1.003 0 0 0-1.002 1.003c0 .539.45.978 1.006.978h3.51z" fill-rule="evenodd"></path></symbol><symbol id="icon-explore" viewBox="0 0 18 18"><path d="m9 17c4.418278 0 8-3.581722 8-8s-3.581722-8-8-8-8 3.581722-8 8 3.581722 8 8 8zm0 1c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9zm0-2.5c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5c2.969509 0 5.400504-2.3575119 5.497023-5.31714844.0090007-.27599565.2400359-.49243782.5160315-.48343711.2759957.0090007.4924378.2400359.4834371.51603155-.114093 3.4985237-2.9869632 6.284554-6.4964916 6.284554zm-.29090657-12.99359748c.27587424-.01216621.50937715.20161139.52154336.47748563.01216621.27587423-.20161139.50937715-.47748563.52154336-2.93195733.12930094-5.25315116 2.54886451-5.25315116 5.49456849 0 .27614237-.22385763.5-.5.5s-.5-.22385763-.5-.5c0-3.48142406 2.74307146-6.34074398 6.20909343-6.49359748zm1.13784138 8.04763908-1.2004882-1.20048821c-.19526215-.19526215-.19526215-.51184463 0-.70710678s.51184463-.19526215.70710678 0l1.20048821 1.2004882 1.6006509-4.00162734-4.50670359 1.80268144-1.80268144 4.50670359zm4.10281269-6.50378907-2.6692597 6.67314927c-.1016411.2541026-.3029834.4554449-.557086.557086l-6.67314927 2.6692597 2.66925969-6.67314926c.10164107-.25410266.30298336-.45544495.55708602-.55708602z" fill-rule="evenodd"></path></symbol><symbol id="icon-filter" viewBox="0 0 16 16"><path d="m14.9738641 0c.5667192 0 1.0261359.4477136 1.0261359 1 0 .24221858-.0902161.47620768-.2538899.65849851l-5.6938314 6.34147206v5.49997973c0 .3147562-.1520673.6111434-.4104543.7999971l-2.05227171 1.4999945c-.45337535.3313696-1.09655869.2418269-1.4365902-.1999993-.13321514-.1730955-.20522717-.3836284-.20522717-.5999978v-6.99997423l-5.69383133-6.34147206c-.3731872-.41563511-.32996891-1.0473954.09653074-1.41107611.18705584-.15950448.42716133-.2474224.67571519-.2474224zm-5.9218641 8.5h-2.105v6.491l.01238459.0070843.02053271.0015705.01955278-.0070558 2.0532976-1.4990996zm-8.02585008-7.5-.01564945.00240169 5.83249953 6.49759831h2.313l5.836-6.499z"></path></symbol><symbol id="icon-home" viewBox="0 0 18 18"><path d="m9 5-6 6v5h4v-4h4v4h4v-5zm7 6.5857864v4.4142136c0 .5522847-.4477153 1-1 1h-5v-4h-2v4h-5c-.55228475 0-1-.4477153-1-1v-4.4142136c-.25592232 0-.51184464-.097631-.70710678-.2928932l-.58578644-.5857864c-.39052429-.3905243-.39052429-1.02368929 0-1.41421358l8.29289322-8.29289322 8.2928932 8.29289322c.3905243.39052429.3905243 1.02368928 0 1.41421358l-.5857864.5857864c-.1952622.1952622-.4511845.2928932-.7071068.2928932zm-7-9.17157284-7.58578644 7.58578644.58578644.5857864 7-6.99999996 7 6.99999996.5857864-.5857864z" fill-rule="evenodd"></path></symbol><symbol id="icon-image" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm-3.49645283 10.1752453-3.89407257 6.7495552c.11705545.048464.24538859.0751995.37998328.0751995h10.60290092l-2.4329715-4.2154691-1.57494129 2.7288098zm8.49779013 6.8247547c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v13.98991071l4.50814957-7.81026689 3.08089884 5.33809539 1.57494129-2.7288097 3.5875735 6.2159812zm-3.0059397-11c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm0 1c-.5522847 0-1 .44771525-1 1s.4477153 1 1 1 1-.44771525 1-1-.4477153-1-1-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-info" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule="evenodd"></path></symbol><symbol id="icon-institution" viewBox="0 0 18 18"><path d="m7 16.9998189v-2.0003623h4v2.0003623h2v-3.0005434h-8v3.0005434zm-3-10.00181122h-1.52632364c-.27614237 0-.5-.22389817-.5-.50009056 0-.13995446.05863589-.27350497.16166338-.36820841l1.23156713-1.13206327h-2.36690687v12.00217346h3v-2.0003623h-3v-1.0001811h3v-1.0001811h1v-4.00072448h-1zm10 0v2.00036224h-1v4.00072448h1v1.0001811h3v1.0001811h-3v2.0003623h3v-12.00217346h-2.3695309l1.2315671 1.13206327c.2033191.186892.2166633.50325042.0298051.70660631-.0946863.10304615-.2282126.16169266-.3681417.16169266zm3-3.00054336c.5522847 0 1 .44779634 1 1.00018112v13.00235456h-18v-13.00235456c0-.55238478.44771525-1.00018112 1-1.00018112h3.45499992l4.20535144-3.86558216c.19129876-.17584288.48537447-.17584288.67667324 0l4.2053514 3.86558216zm-4 3.00054336h-8v1.00018112h8zm-2 6.00108672h1v-4.00072448h-1zm-1 0v-4.00072448h-2v4.00072448zm-3 0v-4.00072448h-1v4.00072448zm8-4.00072448c.5522847 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.4477153-1.00018112 1-1.00018112zm-12 0c.55228475 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.44771525-1.00018112 1-1.00018112zm5.99868798-7.81907007-5.24205601 4.81852671h10.48411203zm.00131202 3.81834559c-.55228475 0-1-.44779634-1-1.00018112s.44771525-1.00018112 1-1.00018112 1 .44779634 1 1.00018112-.44771525 1.00018112-1 1.00018112zm-1 11.00199236v1.0001811h2v-1.0001811z" fill-rule="evenodd"></path></symbol><symbol id="icon-location" viewBox="0 0 18 18"><path d="m9.39521328 16.2688008c.79596342-.7770119 1.59208152-1.6299956 2.33285652-2.5295081 1.4020032-1.7024324 2.4323601-3.3624519 2.9354918-4.871847.2228715-.66861448.3364384-1.29323246.3364384-1.8674457 0-3.3137085-2.6862915-6-6-6-3.36356866 0-6 2.60156856-6 6 0 .57421324.11356691 1.19883122.3364384 1.8674457.50313169 1.5093951 1.53348863 3.1694146 2.93549184 4.871847.74077492.8995125 1.53689309 1.7524962 2.33285648 2.5295081.13694479.1336842.26895677.2602648.39521328.3793207.12625651-.1190559.25826849-.2456365.39521328-.3793207zm-.39521328 1.7311992s-7-6-7-11c0-4 3.13400675-7 7-7 3.8659932 0 7 3.13400675 7 7 0 5-7 11-7 11zm0-8c-1.65685425 0-3-1.34314575-3-3s1.34314575-3 3-3c1.6568542 0 3 1.34314575 3 3s-1.3431458 3-3 3zm0-1c1.1045695 0 2-.8954305 2-2s-.8954305-2-2-2-2 .8954305-2 2 .8954305 2 2 2z" fill-rule="evenodd"></path></symbol><symbol id="icon-minus" viewBox="0 0 16 16"><path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-newsletter" viewBox="0 0 18 18"><path d="m9 11.8482489 2-1.1428571v-1.7053918h-4v1.7053918zm-3-1.7142857v-2.1339632h6v2.1339632l3-1.71428574v-6.41967746h-12v6.41967746zm10-5.3839632 1.5299989.95624934c.2923814.18273835.4700011.50320827.4700011.8479983v8.44575236c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-8.44575236c0-.34479003.1776197-.66525995.47000106-.8479983l1.52999894-.95624934v-2.75c0-.55228475.44771525-1 1-1h12c.5522847 0 1 .44771525 1 1zm0 1.17924764v3.07075236l-7 4-7-4v-3.07075236l-1 .625v8.44575236c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-8.44575236zm-10-1.92924764h6v1h-6zm-1 2h8v1h-8z" fill-rule="evenodd"></path></symbol><symbol id="icon-orcid" viewBox="0 0 18 18"><path d="m9 1c4.418278 0 8 3.581722 8 8s-3.581722 8-8 8-8-3.581722-8-8 3.581722-8 8-8zm-2.90107518 5.2732337h-1.41865256v7.1712107h1.41865256zm4.55867178.02508949h-2.99247027v7.14612121h2.91062487c.7673039 0 1.4476365-.1483432 2.0410182-.445034s1.0511995-.7152915 1.3734671-1.2558144c.3222677-.540523.4833991-1.1603247.4833991-1.85942385 0-.68545815-.1602789-1.30270225-.4808414-1.85175082-.3205625-.54904856-.7707074-.97532211-1.3504481-1.27883343-.5797408-.30351132-1.2413173-.45526471-1.9847495-.45526471zm-.1892674 1.07933542c.7877654 0 1.4143875.22336734 1.8798852.67010873.4654977.44674138.698243 1.05546001.698243 1.82617415 0 .74343221-.2310402 1.34447791-.6931277 1.80315511-.4620874.4586773-1.0750688.6880124-1.8389625.6880124h-1.46810075v-4.98745039zm-5.08652545-3.71099194c-.21825533 0-.410525.08444276-.57681478.25333081-.16628977.16888806-.24943341.36245684-.24943341.58071218 0 .22345188.08314364.41961891.24943341.58850696.16628978.16888806.35855945.25333082.57681478.25333082.233845 0 .43390938-.08314364.60019916-.24943342.16628978-.16628977.24943342-.36375592.24943342-.59240436 0-.233845-.08314364-.43131115-.24943342-.59240437s-.36635416-.24163862-.60019916-.24163862z" fill-rule="evenodd"></path></symbol><symbol id="icon-plus" viewBox="0 0 16 16"><path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-print" viewBox="0 0 18 18"><path d="m16.0049107 5h-14.00982141c-.54941618 0-.99508929.4467783-.99508929.99961498v6.00077002c0 .5570958.44271433.999615.99508929.999615h1.00491071v-3h12v3h1.0049107c.5494162 0 .9950893-.4467783.9950893-.999615v-6.00077002c0-.55709576-.4427143-.99961498-.9950893-.99961498zm-2.0049107-1v-2.00208688c0-.54777062-.4519464-.99791312-1.0085302-.99791312h-7.9829396c-.55661731 0-1.0085302.44910695-1.0085302.99791312v2.00208688zm1 10v2.0018986c0 1.103521-.9019504 1.9981014-2.0085302 1.9981014h-7.9829396c-1.1092806 0-2.0085302-.8867064-2.0085302-1.9981014v-2.0018986h-1.00491071c-1.10185739 0-1.99508929-.8874333-1.99508929-1.999615v-6.00077002c0-1.10435686.8926228-1.99961498 1.99508929-1.99961498h1.00491071v-2.00208688c0-1.10341695.90195036-1.99791312 2.0085302-1.99791312h7.9829396c1.1092806 0 2.0085302.89826062 2.0085302 1.99791312v2.00208688h1.0049107c1.1018574 0 1.9950893.88743329 1.9950893 1.99961498v6.00077002c0 1.1043569-.8926228 1.999615-1.9950893 1.999615zm-1-3h-10v5.0018986c0 .5546075.44702548.9981014 1.0085302.9981014h7.9829396c.5565964 0 1.0085302-.4491701 1.0085302-.9981014zm-9 1h8v1h-8zm0 2h5v1h-5zm9-5c-.5522847 0-1-.44771525-1-1s.4477153-1 1-1 1 .44771525 1 1-.4477153 1-1 1z" fill-rule="evenodd"></path></symbol><symbol id="icon-search" viewBox="0 0 22 22"><path d="M21.697 20.261a1.028 1.028 0 01.01 1.448 1.034 1.034 0 01-1.448-.01l-4.267-4.267A9.812 9.811 0 010 9.812a9.812 9.811 0 1117.43 6.182zM9.812 18.222A8.41 8.41 0 109.81 1.403a8.41 8.41 0 000 16.82z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-facebook" viewBox="0 0 24 24"><path d="m6.00368507 20c-1.10660471 0-2.00368507-.8945138-2.00368507-1.9940603v-12.01187942c0-1.10128908.89451376-1.99406028 1.99406028-1.99406028h12.01187942c1.1012891 0 1.9940603.89451376 1.9940603 1.99406028v12.01187942c0 1.1012891-.88679 1.9940603-2.0032184 1.9940603h-2.9570132v-6.1960818h2.0797387l.3114113-2.414723h-2.39115v-1.54164807c0-.69911803.1941355-1.1755439 1.1966615-1.1755439l1.2786739-.00055875v-2.15974763l-.2339477-.02492088c-.3441234-.03134957-.9500153-.07025255-1.6293054-.07025255-1.8435726 0-3.1057323 1.12531866-3.1057323 3.19187953v1.78079225h-2.0850778v2.414723h2.0850778v6.1960818z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-twitter" viewBox="0 0 24 24"><path d="m18.8767135 6.87445248c.7638174-.46908424 1.351611-1.21167363 1.6250764-2.09636345-.7135248.43394112-1.50406.74870123-2.3464594.91677702-.6695189-.73342162-1.6297913-1.19486605-2.6922204-1.19486605-2.0399895 0-3.6933555 1.69603749-3.6933555 3.78628909 0 .29642457.0314329.58673729.0942985.8617704-3.06469922-.15890802-5.78835241-1.66547825-7.60988389-3.9574208-.3174714.56076194-.49978171 1.21167363-.49978171 1.90536824 0 1.31404706.65223085 2.47224203 1.64236444 3.15218497-.60350999-.0198635-1.17401554-.1925232-1.67222562-.47366811v.04583885c0 1.83355406 1.27302891 3.36609966 2.96411421 3.71294696-.31118484.0886217-.63651445.1329326-.97441718.1329326-.2357461 0-.47149219-.0229194-.69466516-.0672303.47149219 1.5065703 1.83253297 2.6036468 3.44975116 2.632678-1.2651707 1.0160946-2.85724264 1.6196394-4.5891906 1.6196394-.29861172 0-.59093688-.0152796-.88011875-.0504227 1.63450624 1.0726291 3.57548241 1.6990934 5.66104951 1.6990934 6.79263079 0 10.50641749-5.7711113 10.50641749-10.7751859l-.0094298-.48894775c.7229547-.53478659 1.3516109-1.20250585 1.8419628-1.96190282-.6632323.30100846-1.3751855.50422736-2.1217148.59590507z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-youtube" viewBox="0 0 24 24"><path d="m10.1415 14.3973208-.0005625-5.19318431 4.863375 2.60554491zm9.963-7.92753362c-.6845625-.73643756-1.4518125-.73990314-1.803375-.7826454-2.518875-.18714178-6.2971875-.18714178-6.2971875-.18714178-.007875 0-3.7861875 0-6.3050625.18714178-.352125.04274226-1.1188125.04620784-1.8039375.7826454-.5394375.56084773-.7149375 1.8344515-.7149375 1.8344515s-.18 1.49597903-.18 2.99138042v1.4024082c0 1.495979.18 2.9913804.18 2.9913804s.1755 1.2736038.7149375 1.8344515c.685125.7364376 1.5845625.7133337 1.9850625.7901542 1.44.1420891 6.12.1859866 6.12.1859866s3.78225-.005776 6.301125-.1929178c.3515625-.0433198 1.1188125-.0467854 1.803375-.783223.5394375-.5608477.7155-1.8344515.7155-1.8344515s.18-1.4954014.18-2.9913804v-1.4024082c0-1.49540139-.18-2.99138042-.18-2.99138042s-.1760625-1.27360377-.7155-1.8344515z" fill-rule="evenodd"></path></symbol><symbol id="icon-subject-medicine" viewBox="0 0 18 18"><path d="m12.5 8h-6.5c-1.65685425 0-3 1.34314575-3 3v1c0 1.6568542 1.34314575 3 3 3h1v-2h-.5c-.82842712 0-1.5-.6715729-1.5-1.5s.67157288-1.5 1.5-1.5h1.5 2 1 2c1.6568542 0 3-1.34314575 3-3v-1c0-1.65685425-1.3431458-3-3-3h-2v2h1.5c.8284271 0 1.5.67157288 1.5 1.5s-.6715729 1.5-1.5 1.5zm-5.5-1v-1h-3.5c-1.38071187 0-2.5-1.11928813-2.5-2.5s1.11928813-2.5 2.5-2.5h1.02786405c.46573528 0 .92507448.10843528 1.34164078.31671843l1.13382424.56691212c.06026365-1.05041141.93116291-1.88363055 1.99667093-1.88363055 1.1045695 0 2 .8954305 2 2h2c2.209139 0 4 1.790861 4 4v1c0 2.209139-1.790861 4-4 4h-2v1h2c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2h-2c0 1.1045695-.8954305 2-2 2s-2-.8954305-2-2h-1c-2.209139 0-4-1.790861-4-4v-1c0-2.209139 1.790861-4 4-4zm0-2v-2.05652691c-.14564246-.03538148-.28733393-.08714006-.42229124-.15461871l-1.15541752-.57770876c-.27771087-.13885544-.583937-.21114562-.89442719-.21114562h-1.02786405c-.82842712 0-1.5.67157288-1.5 1.5s.67157288 1.5 1.5 1.5zm4 1v1h1.5c.2761424 0 .5-.22385763.5-.5s-.2238576-.5-.5-.5zm-1 1v-5c0-.55228475-.44771525-1-1-1s-1 .44771525-1 1v5zm-2 4v5c0 .5522847.44771525 1 1 1s1-.4477153 1-1v-5zm3 2v2h2c.5522847 0 1-.4477153 1-1s-.4477153-1-1-1zm-4-1v-1h-.5c-.27614237 0-.5.2238576-.5.5s.22385763.5.5.5zm-3.5-9h1c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-success" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm3.4860198 4.98163161-4.71802968 5.50657859-2.62834168-2.02300024c-.42862421-.36730544-1.06564993-.30775346-1.42283677.13301307-.35718685.44076653-.29927542 1.0958383.12934879 1.46314377l3.40735508 2.7323063c.42215801.3385221 1.03700951.2798252 1.38749189-.1324571l5.38450527-6.33394549c.3613513-.43716226.3096573-1.09278382-.115462-1.46437175-.4251192-.37158792-1.0626796-.31842941-1.4240309.11873285z" fill-rule="evenodd"></path></symbol><symbol id="icon-table" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587l-4.0059107-.001.001.001h-1l-.001-.001h-5l.001.001h-1l-.001-.001-3.00391071.001c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm-11.0059107 5h-3.999v6.9941413c0 .5572961.44630695 1.0058587.99508929 1.0058587h3.00391071zm6 0h-5v8h5zm5.0059107-4h-4.0059107v3h5.001v1h-5.001v7.999l4.0059107.001c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-12.5049107 9c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.22385763-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1.499-5h-5v3h5zm-6 0h-3.00391071c-.54871518 0-.99508929.44887827-.99508929 1.00585866v1.99414134h3.999z" fill-rule="evenodd"></path></symbol><symbol id="icon-tick-circle" viewBox="0 0 24 24"><path d="m12 2c5.5228475 0 10 4.4771525 10 10s-4.4771525 10-10 10-10-4.4771525-10-10 4.4771525-10 10-10zm0 1c-4.97056275 0-9 4.02943725-9 9 0 4.9705627 4.02943725 9 9 9 4.9705627 0 9-4.0294373 9-9 0-4.97056275-4.0294373-9-9-9zm4.2199868 5.36606669c.3613514-.43716226.9989118-.49032077 1.424031-.11873285s.4768133 1.02720949.115462 1.46437175l-6.093335 6.94397871c-.3622945.4128716-.9897871.4562317-1.4054264.0971157l-3.89719065-3.3672071c-.42862421-.3673054-.48653564-1.0223772-.1293488-1.4631437s.99421256-.5003185 1.42283677-.1330131l3.11097438 2.6987741z" fill-rule="evenodd"></path></symbol><symbol id="icon-tick" viewBox="0 0 16 16"><path d="m6.76799012 9.21106946-3.1109744-2.58349728c-.42862421-.35161617-1.06564993-.29460792-1.42283677.12733148s-.29927541 1.04903009.1293488 1.40064626l3.91576307 3.23873978c.41034319.3393961 1.01467563.2976897 1.37450571-.0948578l6.10568327-6.660841c.3613513-.41848908.3096572-1.04610608-.115462-1.4018218-.4251192-.35571573-1.0626796-.30482786-1.424031.11366122z" fill-rule="evenodd"></path></symbol><symbol id="icon-update" viewBox="0 0 18 18"><path d="m1 13v1c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-1h-1v-10h-14v10zm16-1h1v2c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-2h1v-9c0-.55228475.44771525-1 1-1h14c.5522847 0 1 .44771525 1 1zm-1 0v1h-4.5857864l-1 1h-2.82842716l-1-1h-4.58578644v-1h5l1 1h2l1-1zm-13-8h12v7h-12zm1 1v5h10v-5zm1 1h4v1h-4zm0 2h4v1h-4z" fill-rule="evenodd"></path></symbol><symbol id="icon-upload" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.85576936 4.14572769c.19483374-.19483375.51177826-.19377714.70556874.00001334l2.59099082 2.59099079c.1948411.19484112.1904373.51514474.0027906.70279143-.1932998.19329987-.5046517.19237083-.7001856-.00692852l-1.74638687-1.7800176v6.14827687c0 .2717771-.23193359.492096-.5.492096-.27614237 0-.5-.216372-.5-.492096v-6.14827641l-1.74627892 1.77990922c-.1933927.1971171-.51252214.19455839-.70016883.0069117-.19329987-.19329988-.19100584-.50899493.00277731-.70277808z" fill-rule="evenodd"></path></symbol><symbol id="icon-video" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-8.30912922 2.24944486 4.60460462 2.73982242c.9365543.55726659.9290753 1.46522435 0 2.01804082l-4.60460462 2.7398224c-.93655425.5572666-1.69578148.1645632-1.69578148-.8937585v-5.71016863c0-1.05087579.76670616-1.446575 1.69578148-.89375851zm-.67492769.96085624v5.5750128c0 .2995102-.10753745.2442517.16578928.0847713l4.58452283-2.67497259c.3050619-.17799716.3051624-.21655446 0-.39461026l-4.58452283-2.67497264c-.26630747-.15538481-.16578928-.20699944-.16578928.08477139z" fill-rule="evenodd"></path></symbol><symbol id="icon-warning" viewBox="0 0 18 18"><path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-checklist-banner" viewBox="0 0 56.69 56.69"><path style="fill:none" d="M0 0h56.69v56.69H0z"></path><clipPath id="b"><use xlink:href="#a" style="overflow:visible"></use></clipPath><path d="M21.14 34.46c0-6.77 5.48-12.26 12.24-12.26s12.24 5.49 12.24 12.26-5.48 12.26-12.24 12.26c-6.76-.01-12.24-5.49-12.24-12.26zm19.33 10.66 10.23 9.22s1.21 1.09 2.3-.12l2.09-2.32s1.09-1.21-.12-2.3l-10.23-9.22m-19.29-5.92c0-4.38 3.55-7.94 7.93-7.94s7.93 3.55 7.93 7.94c0 4.38-3.55 7.94-7.93 7.94-4.38-.01-7.93-3.56-7.93-7.94zm17.58 12.99 4.14-4.81" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round"></path><path d="M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5m14.42-5.2V4.86s0-2.93-2.93-2.93H4.13s-2.93 0-2.93 2.93v37.57s0 2.93 2.93 2.93h15.01M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round;stroke-linejoin:round"></path></symbol><symbol id="icon-chevron-down" viewBox="0 0 16 16"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 1)"></path></symbol><symbol id="icon-eds-i-arrow-right-medium" viewBox="0 0 24 24"><path d="m12.728 3.293 7.98 7.99a.996.996 0 0 1 .281.561l.011.157c0 .32-.15.605-.384.788l-7.908 7.918a1 1 0 0 1-1.416-1.414L17.576 13H4a1 1 0 0 1 0-2h13.598l-6.285-6.293a1 1 0 0 1-.082-1.32l.083-.095a1 1 0 0 1 1.414.001Z"></path></symbol><symbol id="icon-eds-i-check-circle-medium" viewBox="0 0 24 24"><path d="M12 1c6.075 0 11 4.925 11 11s-4.925 11-11 11S1 18.075 1 12 5.925 1 12 1Zm0 2a9 9 0 1 0 0 18 9 9 0 0 0 0-18Zm5.125 4.72a1 1 0 0 1 .156 1.405l-6 7.5a1 1 0 0 1-1.421.143l-3-2.5a1 1 0 0 1 1.28-1.536l2.217 1.846 5.362-6.703a1 1 0 0 1 1.406-.156Z"></path></symbol><symbol id="icon-eds-i-chevron-down-medium" viewBox="0 0 16 16"><path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-chevron-down-small" viewBox="0 0 16 16"><path d="M13.692 5.278a1 1 0 0 1 .03 1.414L9.103 11.51a1.491 1.491 0 0 1-2.188.019L2.278 6.692a1 1 0 0 1 1.444-1.384L8 9.771l4.278-4.463a1 1 0 0 1 1.318-.111l.096.081Z"></path></symbol><symbol id="icon-eds-i-chevron-right-medium" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-eds-i-chevron-right-small" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-eds-i-chevron-up-medium" viewBox="0 0 16 16"><path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-close-medium" viewBox="0 0 16 16"><path d="m2.29679575 12.2772478c-.39658757.3965876-.39438847 1.0328109-.00062148 1.4265779.39651227.3965123 1.03246768.3934888 1.42657791-.0006214l4.27724782-4.27724787 4.2772478 4.27724787c.3965876.3965875 1.0328109.3943884 1.4265779.0006214.3965123-.3965122.3934888-1.0324677-.0006214-1.4265779l-4.27724787-4.2772478 4.27724787-4.27724782c.3965875-.39658757.3943884-1.03281091.0006214-1.42657791-.3965122-.39651226-1.0324677-.39348875-1.4265779.00062148l-4.2772478 4.27724782-4.27724782-4.27724782c-.39658757-.39658757-1.03281091-.39438847-1.42657791-.00062148-.39651226.39651227-.39348875 1.03246768.00062148 1.42657791l4.27724782 4.27724782z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-copy-link" viewBox="0 0 24 24"><path fill-rule="evenodd" clip-rule="evenodd" d="M19.4594 8.57015C19.0689 8.17963 19.0689 7.54646 19.4594 7.15594L20.2927 6.32261C20.2927 6.32261 20.2927 6.32261 20.2927 6.32261C21.0528 5.56252 21.0528 4.33019 20.2928 3.57014C19.5327 2.81007 18.3004 2.81007 17.5404 3.57014L16.7071 4.40347C16.3165 4.794 15.6834 4.794 15.2928 4.40348C14.9023 4.01296 14.9023 3.3798 15.2928 2.98927L16.1262 2.15594C17.6673 0.614803 20.1659 0.614803 21.707 2.15593C23.2481 3.69705 23.248 6.19569 21.707 7.7368L20.8737 8.57014C20.4831 8.96067 19.85 8.96067 19.4594 8.57015Z"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M18.0944 5.90592C18.4849 6.29643 18.4849 6.9296 18.0944 7.32013L16.4278 8.9868C16.0373 9.37733 15.4041 9.37734 15.0136 8.98682C14.6231 8.59631 14.6231 7.96314 15.0136 7.57261L16.6802 5.90594C17.0707 5.51541 17.7039 5.5154 18.0944 5.90592Z"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M13.5113 6.32243C13.9018 6.71295 13.9018 7.34611 13.5113 7.73664L12.678 8.56997C12.678 8.56997 12.678 8.56997 12.678 8.56997C11.9179 9.33006 11.9179 10.5624 12.6779 11.3224C13.438 12.0825 14.6703 12.0825 15.4303 11.3224L16.2636 10.4891C16.6542 10.0986 17.2873 10.0986 17.6779 10.4891C18.0684 10.8796 18.0684 11.5128 17.6779 11.9033L16.8445 12.7366C15.3034 14.2778 12.8048 14.2778 11.2637 12.7366C9.72262 11.1955 9.72266 8.69689 11.2637 7.15578L12.097 6.32244C12.4876 5.93191 13.1207 5.93191 13.5113 6.32243Z"></path><path d="M8 20V22H19.4619C20.136 22 20.7822 21.7311 21.2582 21.2529C21.7333 20.7757 22 20.1289 22 19.4549V15C22 14.4477 21.5523 14 21 14C20.4477 14 20 14.4477 20 15V19.4549C20 19.6004 19.9426 19.7397 19.8408 19.842C19.7399 19.9433 19.6037 20 19.4619 20H8Z"></path><path d="M4 13H2V19.4619C2 20.136 2.26889 20.7822 2.74705 21.2582C3.22434 21.7333 3.87105 22 4.5451 22H9C9.55228 22 10 21.5523 10 21C10 20.4477 9.55228 20 9 20H4.5451C4.39957 20 4.26028 19.9426 4.15804 19.8408C4.05668 19.7399 4 19.6037 4 19.4619V13Z"></path><path d="M4 13H2V4.53808C2 3.86398 2.26889 3.21777 2.74705 2.74178C3.22434 2.26666 3.87105 2 4.5451 2H9C9.55228 2 10 2.44772 10 3C10 3.55228 9.55228 4 9 4H4.5451C4.39957 4 4.26028 4.05743 4.15804 4.15921C4.05668 4.26011 4 4.39633 4 4.53808V13Z"></path></symbol><symbol id="icon-eds-i-download-medium" viewBox="0 0 16 16"><path d="m12.9975267 12.999368c.5467123 0 1.0024733.4478567 1.0024733 1.000316 0 .5563109-.4488226 1.000316-1.0024733 1.000316h-9.99505341c-.54671233 0-1.00247329-.4478567-1.00247329-1.000316 0-.5563109.44882258-1.000316 1.00247329-1.000316zm-4.9975267-11.999368c.55228475 0 1 .44497754 1 .99589209v6.80214418l2.4816273-2.48241149c.3928222-.39294628 1.0219732-.4006883 1.4030652-.01947579.3911302.39125371.3914806 1.02525073-.0001404 1.41699553l-4.17620792 4.17752758c-.39120769.3913313-1.02508144.3917306-1.41671995-.0000316l-4.17639421-4.17771394c-.39122513-.39134876-.39767006-1.01940351-.01657797-1.40061601.39113012-.39125372 1.02337105-.3931606 1.41951349.00310701l2.48183446 2.48261871v-6.80214418c0-.55001601.44386482-.99589209 1-.99589209z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-info-filled-medium" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-institution-medium" viewBox="0 0 24 24"><g><path fill-rule="evenodd" clip-rule="evenodd" d="M11.9967 1C11.6364 1 11.279 1.0898 10.961 1.2646C10.9318 1.28061 10.9035 1.29806 10.8761 1.31689L2.79765 6.87C2.46776 7.08001 2.20618 7.38466 2.07836 7.76668C1.94823 8.15561 1.98027 8.55648 2.12665 8.90067C2.42086 9.59246 3.12798 10 3.90107 10H4.99994V16H4.49994C3.11923 16 1.99994 17.1193 1.99994 18.5V19.5C1.99994 20.8807 3.11923 22 4.49994 22H19.4999C20.8807 22 21.9999 20.8807 21.9999 19.5V18.5C21.9999 17.1193 20.8807 16 19.4999 16H18.9999V10H20.0922C20.8653 10 21.5725 9.59252 21.8667 8.90065C22.0131 8.55642 22.0451 8.15553 21.9149 7.7666C21.7871 7.38459 21.5255 7.07997 21.1956 6.86998L13.1172 1.31689C13.0898 1.29806 13.0615 1.28061 13.0324 1.2646C12.7143 1.0898 12.357 1 11.9967 1ZM4.6844 8L11.9472 3.00755C11.9616 3.00295 11.9783 3 11.9967 3C12.015 3 12.0318 3.00295 12.0461 3.00755L19.3089 8H4.6844ZM16.9999 16V10H14.9999V16H16.9999ZM12.9999 16V10H10.9999V16H12.9999ZM8.99994 16V10H6.99994V16H8.99994ZM3.99994 18.5C3.99994 18.2239 4.2238 18 4.49994 18H19.4999C19.7761 18 19.9999 18.2239 19.9999 18.5V19.5C19.9999 19.7761 19.7761 20 19.4999 20H4.49994C4.2238 20 3.99994 19.7761 3.99994 19.5V18.5Z"></path></g></symbol><symbol id="icon-eds-i-mail-medium" viewBox="0 0 24 24"><path d="m19.462 0c1.413 0 2.538 1.184 2.538 2.619v12.762c0 1.435-1.125 2.619-2.538 2.619h-16.924c-1.413 0-2.538-1.184-2.538-2.619v-12.762c0-1.435 1.125-2.619 2.538-2.619zm.538 5.158-7.378 6.258a2.549 2.549 0 0 1 -3.253-.008l-7.369-6.248v10.222c0 .353.253.619.538.619h16.924c.285 0 .538-.266.538-.619zm-.538-3.158h-16.924c-.264 0-.5.228-.534.542l8.65 7.334c.2.165.492.165.684.007l8.656-7.342-.001-.025c-.044-.3-.274-.516-.531-.516z"></path></symbol><symbol id="icon-eds-i-menu-medium" viewBox="0 0 24 24"><path d="M21 4a1 1 0 0 1 0 2H3a1 1 0 1 1 0-2h18Zm-4 7a1 1 0 0 1 0 2H3a1 1 0 0 1 0-2h14Zm4 7a1 1 0 0 1 0 2H3a1 1 0 0 1 0-2h18Z"></path></symbol><symbol id="icon-eds-i-search-medium" viewBox="0 0 24 24"><path d="M11 1c5.523 0 10 4.477 10 10 0 2.4-.846 4.604-2.256 6.328l3.963 3.965a1 1 0 0 1-1.414 1.414l-3.965-3.963A9.959 9.959 0 0 1 11 21C5.477 21 1 16.523 1 11S5.477 1 11 1Zm0 2a8 8 0 1 0 0 16 8 8 0 0 0 0-16Z"></path></symbol><symbol id="icon-eds-i-user-single-medium" viewBox="0 0 24 24"><path d="M12 1a5 5 0 1 1 0 10 5 5 0 0 1 0-10Zm0 2a3 3 0 1 0 0 6 3 3 0 0 0 0-6Zm-.406 9.008a8.965 8.965 0 0 1 6.596 2.494A9.161 9.161 0 0 1 21 21.025V22a1 1 0 0 1-1 1H4a1 1 0 0 1-1-1v-.985c.05-4.825 3.815-8.777 8.594-9.007Zm.39 1.992-.299.006c-3.63.175-6.518 3.127-6.678 6.775L5 21h13.998l-.009-.268a7.157 7.157 0 0 0-1.97-4.573l-.214-.213A6.967 6.967 0 0 0 11.984 14Z"></path></symbol><symbol id="icon-eds-i-warning-filled-medium" viewBox="0 0 18 18"><path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-expand-image" viewBox="0 0 18 18"><path d="m7.49754099 11.9178212c.38955542-.3895554.38761957-1.0207846-.00290473-1.4113089-.39324695-.3932469-1.02238878-.3918247-1.41130883-.0029047l-4.10273549 4.1027355.00055454-3.5103985c.00008852-.5603185-.44832171-1.006032-1.00155062-1.0059446-.53903074.0000852-.97857527.4487442-.97866268 1.0021075l-.00093318 5.9072465c-.00008751.553948.44841131 1.001882 1.00174994 1.0017946l5.906983-.0009331c.5539233-.0000875 1.00197907-.4486389 1.00206646-1.0018679.00008515-.5390307-.45026621-.9784332-1.00588841-.9783454l-3.51010549.0005545zm3.00571741-5.83449376c-.3895554.38955541-.3876196 1.02078454.0029047 1.41130883.393247.39324696 1.0223888.39182478 1.4113089.00290473l4.1027355-4.10273549-.0005546 3.5103985c-.0000885.56031852.4483217 1.006032 1.0015506 1.00594461.5390308-.00008516.9785753-.44874418.9786627-1.00210749l.0009332-5.9072465c.0000875-.553948-.4484113-1.00188204-1.0017499-1.00179463l-5.906983.00093313c-.5539233.00008751-1.0019791.44863892-1.0020665 1.00186784-.0000852.53903074.4502662.97843325 1.0058884.97834547l3.5101055-.00055449z" fill-rule="evenodd"></path></symbol><symbol id="icon-github" viewBox="0 0 100 100"><path fill-rule="evenodd" clip-rule="evenodd" d="M48.854 0C21.839 0 0 22 0 49.217c0 21.756 13.993 40.172 33.405 46.69 2.427.49 3.316-1.059 3.316-2.362 0-1.141-.08-5.052-.08-9.127-13.59 2.934-16.42-5.867-16.42-5.867-2.184-5.704-5.42-7.17-5.42-7.17-4.448-3.015.324-3.015.324-3.015 4.934.326 7.523 5.052 7.523 5.052 4.367 7.496 11.404 5.378 14.235 4.074.404-3.178 1.699-5.378 3.074-6.6-10.839-1.141-22.243-5.378-22.243-24.283 0-5.378 1.94-9.778 5.014-13.2-.485-1.222-2.184-6.275.486-13.038 0 0 4.125-1.304 13.426 5.052a46.97 46.97 0 0 1 12.214-1.63c4.125 0 8.33.571 12.213 1.63 9.302-6.356 13.427-5.052 13.427-5.052 2.67 6.763.97 11.816.485 13.038 3.155 3.422 5.015 7.822 5.015 13.2 0 18.905-11.404 23.06-22.324 24.283 1.78 1.548 3.316 4.481 3.316 9.126 0 6.6-.08 11.897-.08 13.526 0 1.304.89 2.853 3.316 2.364 19.412-6.52 33.405-24.935 33.405-46.691C97.707 22 75.788 0 48.854 0z"></path></symbol><symbol id="icon-springer-arrow-left"><path d="M15 7a1 1 0 000-2H3.385l2.482-2.482a.994.994 0 00.02-1.403 1.001 1.001 0 00-1.417 0L.294 5.292a1.001 1.001 0 000 1.416l4.176 4.177a.991.991 0 001.4.016 1 1 0 00-.003-1.42L3.385 7H15z"></path></symbol><symbol id="icon-springer-arrow-right"><path d="M1 7a1 1 0 010-2h11.615l-2.482-2.482a.994.994 0 01-.02-1.403 1.001 1.001 0 011.417 0l4.176 4.177a1.001 1.001 0 010 1.416l-4.176 4.177a.991.991 0 01-1.4.016 1 1 0 01.003-1.42L12.615 7H1z"></path></symbol><symbol id="icon-submit-open" viewBox="0 0 16 17"><path d="M12 0c1.10457 0 2 .895431 2 2v5c0 .276142-.223858.5-.5.5S13 7.276142 13 7V2c0-.512836-.38604-.935507-.883379-.993272L12 1H6v3c0 1.10457-.89543 2-2 2H1v8c0 .512836.38604.935507.883379.993272L2 15h6.5c.276142 0 .5.223858.5.5s-.223858.5-.5.5H2c-1.104569 0-2-.89543-2-2V5.828427c0-.530433.210714-1.039141.585786-1.414213L4.414214.585786C4.789286.210714 5.297994 0 5.828427 0H12Zm3.41 11.14c.250899.250899.250274.659726 0 .91-.242954.242954-.649606.245216-.9-.01l-1.863671-1.900337.001043 5.869492c0 .356992-.289839.637138-.647372.637138-.347077 0-.647371-.285256-.647371-.637138l-.001043-5.869492L9.5 12.04c-.253166.258042-.649726.260274-.9.01-.242954-.242954-.252269-.657731 0-.91l2.942184-2.951303c.250908-.250909.66127-.252277.91353-.000017L15.41 11.14ZM5 1.413 1.413 5H4c.552285 0 1-.447715 1-1V1.413ZM11 3c.276142 0 .5.223858.5.5s-.223858.5-.5.5H7.5c-.276142 0-.5-.223858-.5-.5s.223858-.5.5-.5H11Zm0 2c.276142 0 .5.223858.5.5s-.223858.5-.5.5H7.5c-.276142 0-.5-.223858-.5-.5s.223858-.5.5-.5H11Z" fill-rule="nonzero"></path></symbol></svg>
</div>
</footer>




    

    

<div class="c-site-messages message u-hide u-hide-print c-site-messages--nature-briefing c-site-messages--nature-briefing-email-variant c-site-messages--nature-briefing-redesign-2020 sans-serif c-site-messages--nature-briefing-cancer" data-component-id="nature-briefing-banner" data-component-expirydays="30" data-component-trigger-scroll-percentage="15" data-track="in-view" data-track-action="in-view" data-track-category="nature briefing" data-track-label="Briefing banner visible: Cancer">

    
    <div class="c-site-messages__banner-large">

        
<div class="c-site-messages__close-container">
    <button class="c-site-messages__close" data-track="click" data-track-category="nature briefing" data-track-label="Briefing banner dismiss: Cancer">
        <svg width="25px" height="25px" focusable="false" aria-hidden="true" viewBox="0 0 25 25" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
            <title>Close banner</title>
            <defs></defs>
            <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd">
                <rect opacity="0" x="0" y="0" width="25" height="25"></rect>
                <path d="M6.29679575,16.2772478 C5.90020818,16.6738354 5.90240728,17.3100587 6.29617427,17.7038257 C6.69268654,18.100338 7.32864195,18.0973145 7.72275218,17.7032043 L12,13.4259564 L16.2772478,17.7032043 C16.6738354,18.0997918 17.3100587,18.0975927 17.7038257,17.7038257 C18.100338,17.3073135 18.0973145,16.671358 17.7032043,16.2772478 L13.4259564,12 L17.7032043,7.72275218 C18.0997918,7.32616461 18.0975927,6.68994127 17.7038257,6.29617427 C17.3073135,5.89966201 16.671358,5.90268552 16.2772478,6.29679575 L12,10.5740436 L7.72275218,6.29679575 C7.32616461,5.90020818 6.68994127,5.90240728 6.29617427,6.29617427 C5.89966201,6.69268654 5.90268552,7.32864195 6.29679575,7.72275218 L10.5740436,12 L6.29679575,16.2772478 Z" fill="#ffffff"></path>
            </g>
        </svg>
        <span class="visually-hidden">Close</span>
    </button>
</div>


        <div class="c-site-messages__form-container">

            <div class="grid grid-12 last">
                <div class="grid grid-4">
                    <img alt="Nature Briefing: Cancer" src="/static/images/logos/nature-briefing-logo-cancer-white-bc263e7d57.svg" width="373" height="40">
                    <p class="c-site-messages--nature-briefing__strapline extra-tight-line-height">Sign up for the <em>Nature Briefing: Cancer</em> newsletter — what matters in cancer research, free to your inbox weekly.</p>
                </div>
                <div class="grid grid-8 last">
                    <form action="https://www.nature.com/briefing/cancer" method="post" data-location="banner" data-track="signup_nature_briefing_banner" data-track-action="transmit-form" data-track-category="nature briefing" data-track-label="Briefing banner submit: Cancer">
                        <input id="briefing-banner-signup-form-input-track-originReferralPoint" type="hidden" name="track_originReferralPoint" value="CancerBriefingBanner">
                        <input id="briefing-banner-signup-form-input-track-formType" type="hidden" name="track_formType" value="DirectEmailBanner">

                        <input type="hidden" value="false" name="gdpr_tick" id="gdpr_tick_banner">
                        <input type="hidden" value="false" name="marketing" id="marketing_input_banner">
                        <input type="hidden" value="false" name="marketing_tick" id="marketing_tick_banner">
                        <input type="hidden" value="CancerBriefingBanner" name="brieferEntryPoint" id="brieferEntryPoint_banner">

                        <label class="nature-briefing-banner__email-label" for="emailAddress">Email address</label>

                        <div class="nature-briefing-banner__email-wrapper">
                            <input class="nature-briefing-banner__email-input box-sizing text14" type="email" id="emailAddress" name="emailAddress" value="" placeholder="e.g. jo.smith@university.ac.uk" required="" data-test-element="briefing-emailbanner-email-input">
                            
                            <input type="hidden" value="true" name="N:cancer" id="defaultNewsletter_banner">
                            <button type="submit" class="nature-briefing-banner__submit-button box-sizing text14" data-test-element="briefing-emailbanner-signup-button">Sign up</button>
                        </div>

                        <div class="nature-briefing-banner__checkbox-wrapper grid grid-12 last">
                            <input class="nature-briefing-banner__checkbox-checkbox" id="gdpr-briefing-banner-checkbox" type="checkbox" name="gdpr" value="true" data-test-element="briefing-emailbanner-gdpr-checkbox" required="">
                            <label class="nature-briefing-banner__checkbox-label box-sizing text13 sans-serif block tighten-line-height" for="gdpr-briefing-banner-checkbox">I agree my information will be processed in accordance with the <em>Nature</em> and Springer Nature Limited <a href="https://www.nature.com/info/privacy">Privacy Policy</a>.</label>
                        </div>
                    </form>
                </div>
            </div>

        </div>

    </div>

    
    <div class="c-site-messages__banner-small">

        
<div class="c-site-messages__close-container">
    <button class="c-site-messages__close" data-track="click" data-track-category="nature briefing" data-track-label="Briefing banner dismiss: Cancer">
        <svg width="25px" height="25px" focusable="false" aria-hidden="true" viewBox="0 0 25 25" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
            <title>Close banner</title>
            <defs></defs>
            <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd">
                <rect opacity="0" x="0" y="0" width="25" height="25"></rect>
                <path d="M6.29679575,16.2772478 C5.90020818,16.6738354 5.90240728,17.3100587 6.29617427,17.7038257 C6.69268654,18.100338 7.32864195,18.0973145 7.72275218,17.7032043 L12,13.4259564 L16.2772478,17.7032043 C16.6738354,18.0997918 17.3100587,18.0975927 17.7038257,17.7038257 C18.100338,17.3073135 18.0973145,16.671358 17.7032043,16.2772478 L13.4259564,12 L17.7032043,7.72275218 C18.0997918,7.32616461 18.0975927,6.68994127 17.7038257,6.29617427 C17.3073135,5.89966201 16.671358,5.90268552 16.2772478,6.29679575 L12,10.5740436 L7.72275218,6.29679575 C7.32616461,5.90020818 6.68994127,5.90240728 6.29617427,6.29617427 C5.89966201,6.69268654 5.90268552,7.32864195 6.29679575,7.72275218 L10.5740436,12 L6.29679575,16.2772478 Z" fill="#ffffff"></path>
            </g>
        </svg>
        <span class="visually-hidden">Close</span>
    </button>
</div>


        <div class="c-site-messages__content text14">
            <span class="c-site-messages--nature-briefing__strapline strong">Get what matters in cancer research, free to your inbox weekly.</span>
            <a class="nature-briefing__link text14 sans-serif" data-track="click" data-track-category="nature briefing" data-track-label="Small-screen banner CTA to site" data-test-element="briefing-banner-link" target="_blank" rel="noreferrer noopener" href="/briefing/cancer/?brieferEntryPoint=CancerBriefingBanner">Sign up for Nature Briefing: Cancer
            </a>
        </div>

    </div>

</div>

    




<noscript>
    <img hidden src="https://verify.nature.com/verify/nature.png" width="0" height="0" style="display: none" alt="">
</noscript>




<script src="//content.readcube.com/ping?doi=10.1038/s41591-022-01976-z&amp;format=js&amp;last_modified=2022-09-12" async=""></script>

<ufu-rrzzrjgufssl></ufu-rrzzrjgufssl><div data-cc-ghost="" style="height: 352px;"></div><script type="text/javascript" id="fetch-contextual-ads-campaign-data" charset="">(function(){var g=function(a){a=new CustomEvent("campaignDataLoaded",{detail:a});document.dispatchEvent(a)},b=google_tag_manager["rm"]["50443292"](18);if(b){var k=1500;b=google_tag_manager["rm"]["50443292"](19);b="link"===b?google_tag_manager["rm"]["50443292"](20):google_tag_manager["rm"]["50443292"](21);var m=function(a,c){var h=!1,l=setTimeout(function(){h=!0;c(null)},k),d=new XMLHttpRequest;d.onload=function(){var e=null,f=[];if(200===d.status){try{e=JSON.parse(d.responseText)}catch(p){e={}}f=e.campaigns||[]}h||(clearTimeout(l),c(f.length?f.join(","):null))};d.open("GET",
"/platform/contextual?doi\x3d"+a);d.send()},n=function(a,c){a&&-1===a.indexOf("not set")?m(a,c):setTimeout(c,1)};n(b,function(a){window.campaignsForContextualAds=a;g(a);window.dataLayer.push({content:{article:{campaignID:a}}})})}else window.campaignsForContextualAds="",g(null)})();</script>
<script type="text/javascript" id="gtm-setup-accessdetailsloaded-handler" charset="">document.addEventListener("accessdetailsloaded",function(a){a=a.detail||{};var b={event:"update-access-details"};a.institutional_business_partner_ids&&a.resolved_by||console.log("BPID data could not be retrieved from /exposed-details");a.logged_in_to_sn_profile||console.log("logged_in_to_sn_profile could not be retrieved from /exposed-details");var c=a.institutional_business_partner_ids&&a.institutional_business_partner_ids.join?a.institutional_business_partner_ids.join(";"):"",d=a.resolved_by&&a.resolved_by.join?
a.resolved_by.join(";"):"",e=a.personal_business_partner_id_found,f=a.logged_in_to_sn_profile,g=a.snid;b.user={};b.user.profile={};b.user.profile.profileInfo={resolvedBy:d||null,bpid:c||null,personal:e||null,logged_in_to_sn_profile:f,snid:g||null};b.session={};b.session.authentication={};b.session.authentication.token=a.token||null;b.session.authentication.legacy={};window.dataLayer.push(b);window.idpUserDataLoaded=!0},!1);window.dataLayer.push({event:"accessdetailsloaded-handler-added"});
window.accessDetailsLoadedHandlerAdded=!0;</script><script type="text/javascript" id="gtm-mediatrust" charset="">var s=document.getElementsByTagName("script")[0],p=document.createElement("script");p.async="async";p.src="https://scripts.webcontentassessor.com/scripts/93dabb8d80079a87fec7bb6f67b807fce90e1688f8957ad7ad152bfd58ea01c2";s.parentNode.insertBefore(p,s);</script><script id="crossmark-script" text="" charset="" type="text/javascript" src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script><script type="text/javascript" id="polyfill-matches" charset="">Element.prototype.matches||(Element.prototype.matches=Element.prototype.matchesSelector||Element.prototype.mozMatchesSelector||Element.prototype.msMatchesSelector||Element.prototype.oMatchesSelector||Element.prototype.webkitMatchesSelector||function(a){a=(this.document||this.ownerDocument).querySelectorAll(a);for(var b=a.length;0<=--b&&a.item(b)!==this;);return-1<b});</script><script type="text/javascript" id="fetch-idp-user-data" charset="">(function(a){if("function"===typeof window.CustomEvent)return!1;var c=function(d,b){b=b||{};var e=document.createEvent("CustomEvent");e.initCustomEvent(d,b.bubbles||!1,b.cancelable||!1,b.detail||a);return e};c.prototype=window.Event.prototype;window.CustomEvent=c})();var parse=function(a,c){try{return 200===a?JSON.parse(c):null}catch(d){return null}},dispatch=function(a){a=new CustomEvent("accessdetailsloaded",{detail:a});document.dispatchEvent(a)},site=google_tag_manager["rm"]["50443292"](59),idpUrl;
switch(site){case "nature":idpUrl=-1<window.location.hostname.indexOf("local-www")||-1<window.location.hostname.indexOf("test-www")?"https://staging-idp.nature.com/exposed-details":"https://idp.nature.com/exposed-details";break;case "link":idpUrl=-1<window.location.hostname.indexOf("link-qa")?"https://staging-idp.springer.com/exposed-details":"https://idp.springer.com/exposed-details";break;case "springer":idpUrl=-1<window.location.hostname.indexOf("local-www")||-1<window.location.hostname.indexOf("test-www")?
"https://staging-idp.springer.com/exposed-details":"https://idp.springer.com/exposed-details"}if(void 0!==idpUrl){var transport=new XMLHttpRequest;transport.open("GET",idpUrl,!0);transport.withCredentials=!0;transport.onreadystatechange=function(){4===transport.readyState&&dispatch(parse(transport.status,transport.responseText))};transport.send()}else dispatch(null);</script><script src="https://verify.nature.com/verify/nature.min.js"></script><script type="text/javascript" id="create-ad-slots" charset="">function createAndLoadAds(){function h(b){"nature"===a&&google_tag_manager["rm"]["50443292"](87)(b);"bmc"!==a&&"springeropen"!==a||google_tag_manager["rm"]["50443292"](99)(b);("link"===a&&"oscar"===google_tag_manager["rm"]["50443292"](100)||"springer"===a||"link"===a&&!0===google_tag_manager["rm"]["50443292"](101))&&google_tag_manager["rm"]["50443292"](126)(b);"link"===a&&"bunsen"===google_tag_manager["rm"]["50443292"](127)&&google_tag_manager["rm"]["50443292"](152)(b);"link"===a&&"Core"===google_tag_manager["rm"]["50443292"](153)&&google_tag_manager["rm"]["50443292"](165)(b)}window.googletag=window.googletag||{cmd:[]};var a=google_tag_manager["rm"]["50443292"](166),e=google_tag_manager["rm"]["50443292"](168);
if(-1===window.location.search.indexOf("hide_ads\x3dtrue"))if(window.adSlots&&0!==Object.keys(window.adSlots).length)console.log("Ads previously loaded. Will not update ad slots until next page load.");else{window.adSlots||(window.adSlots={});window.getAd=function(b,f){for(var c in window.adSlots)if(-1<c.indexOf(b)){if("object"===f)return adSlots[c];if("slot"===f)return adSlots[c].slot}};googletag.cmd.push(function(){googletag.pubads().setPrivacySettings({limitedAds:e});console.log("limitedAds is ",
e);googletag.pubads().setRequestNonPersonalizedAds(google_tag_manager["rm"]["50443292"](170));googletag.pubads().enableSingleRequest();googletag.pubads().disableInitialLoad()});for(var g=document.querySelectorAll("[data-gpt]"),d=0;g[d];++d)h(g[d]);googletag.cmd.push(function(){googletag.enableServices()})}}createAndLoadAds();</script>
</body></html>